

(19)



(11)

EP 1 511 768 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:

11.04.2007 Bulletin 2007/15

(21) Application number: **03757056.1**

(22) Date of filing: **06.06.2003**

(51) Int Cl.:

C07K 14/315 ^(2006.01) **A61K 39/385** ^(2006.01)
C12N 5/10 ^(2006.01) **C12N 15/62** ^(2006.01)
C12N 15/63 ^(2006.01) **A61K 38/16** ^(2006.01)

(86) International application number:

PCT/EP2003/006096

(87) International publication number:

WO 2003/104272 (18.12.2003 Gazette 2003/51)

(54) **IMMUNOGENIC COMPOSITIONS**

IMMUNOGENE ZUSAMMENSETZUNGEN

COMPOSITIONS IMMUNOGENES

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR**

Designated Extension States:

LT LV

(30) Priority: **11.06.2002 GB 0213365**

15.01.2003 GB 0300914

(43) Date of publication of application:

09.03.2005 Bulletin 2005/10

(73) Proprietors:

- **GlaxoSmithKline Biologicals s.a.**
1330 Rixensart Brussels (BE)
- **GLAXO GROUP LIMITED**
Greenford, Middlesex UB6 ONN (GB)

(72) Inventors:

- **CABEZON SILVA, T.E.V.,**
GlaxoSmithKline Biolog. SA
1330 Rixensart Brussels (BE)
- **ELLIS, Jonathan H.,**
GlaxoSmithKline
Stevenage,
Hertfordshire SG1 2NY (GB)
- **GERARD, C.M.G.,**
GlaxoSmithKline Biologicals s.a.
1330 Rixensart Brussels (BE)
- **HAMBLIN, Paul A.,**
GlaxoSmithKline
Stevenage,
Hertfordshire SG1 2NY (GB)

- **PALMANTIER, R.M.,**
GlaxoSmithKline Biologicals s.a.
1330 Rixensart Brussels (BE)
- **VINALS Y DE BASSOLS, C.,**
GlaxoSmithKline Biolog.sa
1330 Rixensart Brussels (BE)

(74) Representative: **Lovatt, Victoria Jayne et al**

GlaxoSmithKline,
Corporate Intellectual Property CN925.1,
980 Great West Road
Brentford,
Middlesex TW8 9GS (GB)

(56) References cited:

WO-A-99/67293 **US-A- 6 090 388**

- **SANCHEZ-PUELLES J M ET AL:**
"IMMOBILIZATION AND SINGLE-STEP
PURIFICATION OF FUSION PROTEINS USING
DEAE-CELLULOSE" EUROPEAN JOURNAL OF
BIOCHEMISTRY, vol. 203, no. 1-2, 1992, pages
153-160, XP001155694 ISSN: 0014-2956
- **CAUBIN J ET AL: "Choline-binding domain as a**
novel affinity tag for purification of fusion
proteins produced in Pichia pastoris"
BIOTECHNOLOGY AND BIOENGINEERING, vol.
74, no. 2, 20 July 2001 (2001-07-20), pages
164-171, XP001155696 ISSN: 0006-3592

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 511 768 B1

- KJERRULF M ET AL: "TANDEM REPEATS OF T HELPER EPITOPES ENHANCE IMMUNOGENICITY OF FUSION PROTEINS BY PROMOTING PROCESSING AND PRESENTATION" MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 34, no. 8/9, June 1997 (1997-06), pages 599-608, XP000857056 ISSN: 0161-5890
- ASTORI M ET AL: "RECOMBINATION FUSION PEPTIDES CONTAINING SINGLE OR MULTIPLE REPEATS OF A UBIQUITOUS T-HELPER EPITOPE ARE HIGHLY IMMUNOGENIC" MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 33, no. 13, 1996, pages 1017-1024, XP001028964 ISSN: 0161-5890
- OLSZEWSKA WIESLAWA ET AL: "Protection against measles virus-induced encephalitis by anti-mimotope antibodies: The role of antibody affinity" VIROLOGY, vol. 272, no. 1, 30 June 2000 (2000-06-30), pages 98-105, XP002259121 ISSN: 0042-6822

Description

[0001] The present invention relates to fusion partners which act as immunological fusion partners, as expression enhancers, and preferably to fusion partners having both functions. The invention also relates to fusion proteins containing them, to their manufacture, to their use in vaccines and to their use in medicines. In particular fusion partners are provided that contain a so-called choline binding domain, for example fusions comprising LytA from *Streptococcus pneumoniae*, or the pneumococcal phage CP1 lysozyme (CPL1) wherein the choline binding domain is modified to include a heterologous T-helper epitope. Such fusion partners are shown to improve the expression level of the heterologous protein attached thereto and also find particular utility when fused to poorly immunogenic proteins or peptides that are otherwise useful as vaccine antigens. More particularly, such fusion partners are useful in constructs comprising self-antigens, eg tumour specific or tissue specific antigens.

Background to the invention

[0002] *Streptococcus pneumoniae* synthesises an N acetyl-L-alanine amidase, LytA, an autolysin that specifically degrades the peptidoglycan backbone of the cell wall eventually leading to cell lysis. Its polypeptide chain has two domains. The N-terminal domain is responsible for the catalytic activity, whereas the C-terminal domain of LytA is responsible for the affinity to choline and anchorage to the cell wall. This C-terminal domain is known to bind to choline and choline analogues, and will also bind to tertiary amines such as DEAE (diethyl amino ethyl) commonly used in chromatography.

[0003] LytA is a 318 amino acid protein, and the C-terminal part comprises a tandem of six imperfect repeats of 20 or 21 amino acids and a short COOH-terminal tail. The repeats are located at the following positions:

R1: 177-191

R2: 192-212

R3: 213-234

R4: 235-254

R5: 255-275

R6: 276-298

[0004] These repeats are predicted to be in a beta-turn conformation. The C-terminus is responsible for binding choline. Likewise the C-terminus of CPL1 is responsible for binding affinity and the aromatic residues in the repeat contribute to such binding. These proteins have been used as affinity tags to allow for rapid purification (Sanchez Puelles, Eur J Biochem. 1992, 203, 153-9).

[0005] Other proteins with a choline-binding domain have also been studied in *Streptococcus pneumoniae*.

[0006] One of them PspA (or Pneumococcal Surface Protein A), is a virulence factor (Yother J and Briles (1992) J Bacteriol 174(2) p 601). This protein is antigenic and immunogenic. It has a C-terminal domain consisting of 10 repeats of 20 amino acids, homologous with repeats of LytA.

[0007] CbpA (or Choline-Binding Protein A) is involved in the adherence of the pneumococcus to human cells (Rosenow et al (1997) Mol Microbiol 25 (5) p 819). It shows 10 repeats of 20 amino acids in the C-terminal domain which are almost identical to those of PspA.

[0008] LytB and LytC have a different modular organisation from the above-mentioned proteins as their choline-binding domain, made up of 15 repeats and 11 repeats respectively, is situated at the N-terminal end, not at the C-terminal end (Garcia P Mol Microbiol (1999) 31 (4) p1275 and Garcia P et al (1999) Mol Microbiol 33(1) p128). Sequence comparison shows LytB to have glucosamidase activity. LytC shows in vitro a lysozyme-type activity.

Additionally, three genes called PepA, PepB and PepC were cloned in 1995. Although their function is unknown, these genes also have a variable number of repeats homologous to those of LytA.

[0009] In their infection cycle, phages synthesise murein hydrolases facilitating their passage into the bacterium. These hydrolases have a choline-binding domain.

The muramidase CPL1 of the phage Cp-1 has been well studied. It shows 6 repeats of 20 amino acids at the C-terminus involved in the specific recognition of choline (Garica J. L. J. Virol 61 (8) p2573-80; (1987) and Garcia E Prol Natl Acad Sci (1988) p914). A comparison of the LytA and CPL1 repeats enables an initial consensus of those repeats to be made.

[0010] The murein hydrolases of phages Dp-1 (Garcia P et al (1983) J Gen Microbiol 129 (2) p489, Cpl-9 (Garcia P et al (1989) Biochem Biophys Res Commun 158(1) p 251, HB-3 Romero et al 1990 J Bacteriol 172 (9) p 5064-5070) and EJ-1 Diaz (1992) J Bacteriol 174 (17) p 5516), also show the characteristics of choline-binding domains.

[0011] This property is also shared by the lysozyme encoded by CP-1 a pneumococcal phage.

WO 99/10375 describes *inter alia*, human papilloma virus proteins E6, or E7 linked to a His tag and the C-terminal portion of LytA (herein (C-LytA) and the purification of the proteins by differential affinity chromatography.

WO 99/40188 describes *inter alia* fusion proteins comprising MAGE antigens with a His tails and a C-LytA portion at the N-terminus of the molecule.

[0012] It has now been surprisingly found that fusion partners according to the present invention, when fused to a heterologous protein were capable of enhancing the immunogenicity of the heterologous proteins attached thereto. It has also been found that the expression level of the heterologous proteins attached thereto can be enhanced. The present invention accordingly provides in a preferred embodiment an improved immunological fusion partner which can also act as an expression enhancer.

Summary of the invention

[0013] Accordingly the present invention comprises a fusion partner molecule comprising a choline binding domain or a fragment thereof or an analogue thereof, and a heterologous promiscuous T helper epitope, preferably a promiscuous MHC Class II T-epitope. Said fusion partner shows a capability of acting as both an immunological fusion partner, or as an expression enhancer and preferably as both an immunological partner and expression enhancer. A promiscuous T-helper epitope is an epitope that binds to more than one MHC Class II allele, preferably more than 3 MHC Class II alleles. In particular such epitopes are capable of eliciting helper T cell response in large numbers of individuals expressing diverse MHC haplotypes. Optionally, the fusion protein may retain its capability to bind to choline.

[0014] In a preferred embodiment the choline binding moiety is derived from the C terminus of LytA. Preferably the C-LytA or derivatives comprises at least four repeats of any of the repeats R1 to R6 set forth in figure 1 (SEQ ID NO:1 to 6). In a most preferred embodiment, the C-LytA extends from amino acid 177-298 which contains a portion of the first repeat and the complete five others.

[0015] In a further aspect of the invention, there is provided a fusion partner as herein defined further comprising a heterologous protein. The heterologous protein may be either chemically conjugated or fused to the fusion partner. Preferably the heterologous protein is a tumour-associated antigen or immunogenic fragment thereof.

[0016] In a further aspect of the invention there is provided a nucleic acid sequence encoding the proteins as herein defined. There is also provided an expression vector comprising said nucleic acid, and a host transformed with said nucleic acid or vector.

[0017] In a further aspect of the invention there is provided an immunogenic composition comprising a protein or a nucleic acid sequence as herein described, and a pharmaceutically acceptable excipient, diluent or carrier. Preferably the immunogenic composition further comprises a Th-1 inducing adjuvant.

[0018] In yet a further embodiment, the invention provides the immunogenic composition or protein and nucleic acids for use in medicine. In particular, there is provided a protein or a nucleic acid of the invention, in the manufacture of a medicament for eliciting an immune response in a patient, or for use in the treatment or prophylaxis of infectious diseases or cancer diseases.

[0019] The invention further provides for methods of treating a patient suffering from an infectious disease or a cancer disease, particularly carcinoma of the breast, lung (particularly non - small cell lung carcinoma), colorectal, ovarian, prostate, gastric and other GI (gastrointestinal) by the administration of a safe and effective amount of a composition or nucleic acid as herein described.

[0020] In yet a further embodiment the invention provides a method of producing an immunogenic composition as herein described by admixing a nucleic acid or protein of the invention with a pharmaceutically acceptable excipient, diluent or carrier.

Detailed description of the invention

[0021] As described therein, in one embodiment of the present invention the modified choline binding domain (fusion partner) has a capability of acting as an expression enhancer with the resulting fusion protein will be expressed at a higher yield in a host cell as compared to the unfused protein, preferably at a yield greater than about 100% (2-fold higher) or 150% or more, as measured by SDS-PAGE followed by Coomassie blue staining or silver staining, optionally followed by gel scanning. The modified choline binding domain according to the invention has also the capability of acting as an immunological partner with the resulting fusion protein with a heterologous protein will be more immunogenic in a host as compared to the unfused heterologous protein.

[0022] In another embodiment of the present invention, the modified choline binding domain has the capability to act as an immunological fusion partner, allowing an enhanced immune response to be obtained with the fusion protein as compared to the heterologous protein alone.

[0023] In a preferred embodiment, the modified choline binding domain has a dual function, having the capability to act as both an immunological fusion partner and as an expression enhancer.

[0024] In a preferred embodiment the choline binding moiety is derived from the C terminus of LytA. Preferably the C-LytA or derivatives comprises at least two repeats, preferably at least four repeats. In this context, C-LytA derivatives

refer to a variant of C-LytA according to the present invention, that is to say variants which have retained both the capability of acting as an immunological partner and an expression enhancer. Preferred variants include, for example, peptides comprising an amino acid sequence having at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, most preferably at least 97-99% identity, to any of the repeats R1 to R6 set forth in figure 1 (SEQ ID NO:1 to 6), or a peptide comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids from the amino acid sequence set forth in figure 1 (SEQ ID NO:1 to 8).

[0025] Accordingly, in one aspect of the invention there is provided a fusion partner protein comprising a modified choline binding domain and a heterologous promiscuous T helper epitope, wherein the choline binding domain is selected from the group comprising:

- a) the C-terminal domain of LytA as set forth in SEQ ID NO:7;
- b) the sequence of SEQ ID NO:8;
- c) a peptide sequence comprising an amino acid sequence having at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, most preferably at least 97-99% identity, to any of SEQ ID NO:1 to 6;
- d) a peptide sequence comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids from the amino acid sequence of SEQ ID NO:7 or SEQ ID NO:8.

In a most preferred embodiment, the C-LytA extends from amino acid 177-298 which contains a portion of the first repeat and the complete five others, as set forth in figure 1.

[0026] The second component of the fusion partner, the heterologous T-cell epitope is preferably selected from the group of epitopes that will bind to a number of individuals expressing more than one MHC II molecules in humans. For example, epitopes that are specifically contemplated are P2 and P30 epitopes from tetanus toxoid, Panina - Bordignon Eur. J. Immunol 19 (12), 2237 (1989). In a preferred embodiment the heterologous T-cell epitope is P2 or P30 from Tetanus toxin.

[0027] The P2 epitope has the sequence QYIKANSKFIGITE and corresponds to amino acids 830-843 of the Tetanus toxin. The P30 epitope (residues 947-967 of Tetanus Toxin) has the sequence FNNFTVSFWLRVPKVSASHLE. The FNNFTV sequence may optionally be deleted. Other universal T epitopes can be derived from the circumsporozoite protein from *Plasmodium falciparum* - in particular the region 378-398 having the sequence DIEKKIAKMEKASSVFNWNS (Alexander J, (1994) Immunity 1 (9), p 751-761). Another epitope is derived from Measles virus fusion protein at residue 288-302 having the sequence LSEIKGVIVHRLEGV (Partidos CD, 1990, J. Gen. Virol 71(9) 2099-2105). Yet another epitope is derived from hepatitis B virus surface antigen, in particular amino acids, having the sequence FFLL-TRILTIPQSLD. Another set of epitopes is derived from diphtheria toxin. Four of these peptides (amino acids 271-290, 321-340, 331-350, 351-370) map within the T domain of fragment B of the toxin, and the remaining 2 map in the R domain (411-430, 431-450):

PVFAGANYAAWAVNVAQVI
VHHNTEEIVAQSIALSSLMV
QSIALSSLMVAQAIPLVGEL
VDIGFAAYNFVESII NLFQV
QGESGHDIKITAENTPLPIA
GVLLPTIPGKLDVNSKSTHI

(Raju R., Navaneetham D., Okita D., Diethelm-Okita B., McCormick D., Conti-Fine B. M. (1995) Eur. J. Immunol. 25: 3207-14.)

[0028] The heterologous T-epitope is preferably fused to C-LytA containing at least 4 repeats, preferably repeat 2 -5 inclusive. One or more subsequent repeats may optionally be fused to the C-terminus of the T-epitope. Alternatively, the heterologous T-epitope is preferably inserted between two consecutive repeats of C-LytA containing a total of at least 4 repeats, or inserted into one of the repeats of C-LytA containing a total of at least 4 repeats. More preferably, the C-LytA contains 6 repeats and the heterologous epitope is inserted within and at the beginning of the sixth repeat of C-LytA.

[0029] The present invention further provides, in other aspects, fusion proteins that comprise at least one polypeptide as described above, as well as polynucleotides encoding such fusion proteins, typically in the form of pharmaceutical compositions, e.g., vaccine compositions, comprising a physiologically acceptable carrier and/or an immunostimulant. Thus a self-protein or other poorly immunogenic protein may be fused to either the N or C terminal end of the resulting fusion partner. Alternatively the self protein or poorly immunogenic protein may be inserted into the fusion partner. In an optional embodiment a histidine tag or at least four, preferably more than 6 histidine residues, may be fused to the alternative end of the poorly immunogenic protein. This would allow for the protein to be purified by affinity chromatography steps, as a histidine tail, typically comprising at least four, preferably six or more residues binds to metal ions and

therefore is suitable for metal immobilised metal ion affinity chromatography (IMAC).

Typical constructs would therefore comprise:

- Poorly-immunogenic protein - C-LytA repeats₁₋₄-P₂ epitope (inserted in or replacing C-LytA repeat₅)-C-LytA repeats
- 5 - C-LytA repeats₁₋₄-P₂ epitope (inserted in or replacing C-LytA repeat₅) - C-LytA repeat₆-Poorly immunogenic protein
- Poorly immunogenic protein - C-LytA repeat₂₋₅-P₂ epitope (inserted into C-LytA repeat₆)
- C-LytA₂₋₅-P₂ epitope (inserted into C-LytA repeat₆)- Poorly immunogenic protein.
- Poorly immunogenic protein C-LytA repeats₁₋₅-P₂ epitope- inserted in C-LytA repeat₆
- C-LytA repeats₁₋₅-P₂ epitope- inserted in C-LytA repeat₆- Poorly immunogenic protein
- 10 - Poorly immunogenic protein- P₂ epitope inserted into C-LytA repeat₁-C-LytA repeats₂₋₅
- P₂ epitope inserted into C-LytA repeat₁-C-LytA repeats₂₋₅- Poorly immunogenic protein
- Poorly immunogenic protein- P₂ epitope inserted into C-LytA repeat₁-C-LytA repeats₂₋₆
- P₂ epitope inserted into C-LytA repeat₁-C-LytA repeats₂₋₆- Poorly immunogenic protein
- Poorly immunogenic protein-C-LytA repeat₁-P₂ epitope inserted into C-LytA repeat₂-C-LytA repeats₃₋₆
- 15 - C-LytA repeat₁-P₂ epitope inserted into C-LytA repeat₂-C-LytA repeats₃₋₆- Poorly immunogenic protein;

where "inserted into" means at any place into the repeat for example between residue 1 and 2, or between 2 and 3, etc.

[0030] The promiscuous T helper epitope may be inserted within a repeat region for example C-LytA repeats₂₋₅ - C-LytA repeat_{6a}-P₂ epitope - C-LytA repeat_{6b}, where the P₂ epitope is inserted within the sixth repeat (see figure 2).

20 **[0031]** In other preferred embodiments the C-terminal end of CPL1 (C-CPL1) may be used as an alternative to C-LytA.

[0032] Alternatively, the P₂ epitope in the above constructs may be replaced by other promiscuous T epitopes, for example P30. In an embodiment of the invention, two or more promiscuous epitopes are part of the fusion construct. It is however preferred to keep the fusion partner as small as possible, thus limiting the number of potentially interfering CD8+ and B epitopes. Thus the fusion partner is preferably no bigger than 100-140 amino acids, preferably no bigger

25 than 120 amino acids, typically about 100 amino acid.

[0033] The antigen to which the fusion partner is fused may be from bacterial, viral, protozoan, fungal or mammalian, including human, sources.

[0034] The fusion partner of the present invention are preferably fused to a self antigen such as a tumour associated or tissue specific antigens such as those for prostate, breast, colorectal, lung, pancreatic, ovarian, renal or melanoma

30 cancers. Fragments of said self or tumour antigens are expressly contemplated to be fused to the fusion partner of the invention. Typically the fragment will contain at least 20, preferably 50, more preferably 100 contiguous amino acids of the full-length sequence. Typically such fragments will be devoid of one or more transmembrane domains or may have N-terminal or C-terminal deletions of about 3, 5, 8, 10, 15, 20, 28, 33, 50, 54 amino acids. Such fragments will, when suitably presented, be able to generate immune responses that recognise the full length protein. Particularly illustrative

35 polypeptides of the present invention comprise a sequence of at least 10 contiguous amino acids, preferably 20, more preferably 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180 amino acids of a tumour associated or tissue specific protein fused to the fusion partner.

[0035] The polypeptides of the invention are immunogenic, i.e., they react detectably within an immunoassay (such as an ELISA or T-cell stimulation assay) with antisera and/or T-cells from a patient with crypto expressing cancer.

40 Screening for immunogenic activity can be performed using techniques well known to the skilled artisan. For example, such screens can be performed using methods such as those described in Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988. In one illustrative example, a polypeptide may be immobilised on a solid support and contacted with patient sera to allow binding of antibodies within the sera to the immobilised polypeptide. Unbound sera may then be removed and bound antibodies detected using, for example, ¹²⁵I-labeled Protein A. As would

45 be recognised by the skilled artisan, immunogenic portions of tumour associated or tumour specific antigen are also encompassed by the present invention. An "immunogenic portion" as used herein, is a fragment that itself is immunologically reactive (i.e., specifically binds) with the B-cells and/or T-cell surface antigen receptors that recognize the polypeptide. Immunogenic portions may generally be identified using well known techniques, such as those summarized in Paul, *Fundamental Immunology*, 3rd ed., 243-247 (Raven Press, 1993) and references cited therein. Such techniques

50 include screening polypeptides for the ability to react with antigen-specific antibodies, antisera and/or T-cell lines or clones. As used herein, antisera and antibodies are "antigen-specific" if they specifically bind to an antigen (i.e., they react with the protein in an ELISA or other immunoassay, and do not react detectably with unrelated proteins). Such antisera and antibodies may be prepared as described herein, and using well-known techniques. In one preferred embodiment, an immunogenic portion of a polypeptide is a portion that reacts with antisera and/or T-cells at a level that

55 is not substantially less than the reactivity of the full-length polypeptide (e.g., in an ELISA and/or T-cell reactivity assay). Preferably, the level of immunogenic activity of the immunogenic portion is at least about 50%, preferably at least about 70% and most preferably greater than about 90% of the immunogenicity for the full-length polypeptide. In some instances, preferred immunogenic portions will be identified that have a level of immunogenic activity greater than that of the

corresponding full-length polypeptide, e.g., having greater than about 100% or 150% or more immunogenic activity.

[0036] In certain other embodiments, illustrative immunogenic portions may include peptides in which an N-terminal leader sequence and/or transmembrane domain have been deleted. Other illustrative immunogenic portions will contain a small N- and/or C-terminal deletion (e.g., about 1-50 amino acids, preferably about 1-30 amino acids, more preferably about 5-15 amino acids), relative to the mature protein.

[0037] Exemplary antigens or fragments derived therefrom include MAGE 1, Mage 3 and MAGE 4 or other MAGE antigens such as disclosed in WO 99/40188, PRAME (WO 96/10577), BAGE, RAGE, LAGE 1 (WO 98/32855), LAGE 2 (also known as NY-ESO-1, WO 98/14464), XAGE (Liu et al, Cancer Res, 2000, 60:4752-4755; WO 02/18584) SAGE, and HAGE (WO 99/53061) or GAGE (Robbins and Kawakami, 1996, Current Opinions in Immunology 8, pps 628-636; Van den Eynde et al., International Journal of Clinical & Laboratory Research (submitted 1997); Correale et al. (1997), Journal of the National Cancer Institute 89, p293. Indeed these antigens are expressed in a wide range of tumour types such as melanoma, lung carcinoma, sarcoma and bladder carcinoma.

[0038] In a preferred embodiment prostate antigens are utilised, such as Prostate specific antigen (PSA), PAP, PSCA (PNAS 95(4) 1735 -1740 1998), PSMA or the antigen known as prostase.

[0039] In a particularly preferred embodiment, the prostate antigen is P501S or a fragment thereof. P501S, also named prostein (Xu et al., Cancer Res. 61, 2001, 1563-1568), is known as SEQ ID NO. 113 of WO98/37814 and is a 553 amino acid protein. Immunogenic fragments and portions thereof comprising at least 20, preferably 50, more preferably 100 contiguous amino acids as disclosed in the above referenced patent application and are specifically contemplated by the present invention. Preferred fragments are disclosed in WO 98/50567 (PS108 antigen) and as prostate cancer-associated protein (SEQ ID NO: 9 of WO 99/67384). Other preferred fragments are amino acids 51-553, 34-553 or 55-553 of the full-length P501S protein. In particular, construct 1, 2 and 3 (see figure 2, SEQ ID NOs. 27-32) are expressly contemplated, and can be expressed in yeast systems, for example DNA sequences encoding such polypeptides can be expressed in yeast system.

[0040] Prostase is a prostate-specific serine protease (trypsin-like), 254 amino acid-long, with a conserved serine protease catalytic triad H-D-S and a amino-terminal pre-propeptide sequence, indicating a potential secretory function (P. Nelson, Lu Gan, C. Ferguson, P. Moss, R. Linas, L. Hood & K. Wand, "Molecular cloning and characterisation of prostase, an androgen-regulated serine protease with prostate restricted expression, In Proc. Natl. Acad. Sci. USA (1999) 96, 3114-3119). A putative glycosylation site has been described. The predicted structure is very similar to other known serine proteases, showing that the mature polypeptide folds into a single domain. The mature protein is 224 amino acids-long, with one A2 epitope shown to be naturally processed. Prostase nucleotide sequence and deduced polypeptide sequence and homologous are disclosed in Ferguson, et al. (Proc. Natl. Acad. Sci. USA 1999, 96, 3114-3119) and in International Patent Applications No. WO 98/12302 (and also the corresponding granted patent US 5,955,306), WO 98/20117 (and also the corresponding granted patents US 5,840,871 and US 5,786,148) (prostate-specific kallikrein) and WO 00/04149 (P703P).

[0041] Other prostate specific antigens are known from WO98/37418, and WO/004149. Another is STEAP (PNAS 96 14523 14528 7 -12 1999).

[0042] Other tumour associated antigens useful in the context of the present invention include: Plu -1 J Biol. Chem 274 (22) 15633 -15645, 1999, HASH -1, HASH -2 (Alders, M. et al., Hum. Mol. Genet. 1997, 6, 859-867). Cripto (Salomon et al Bioessays 199, 21 61 -70, US patent 5654140), CASB616 (WO 00/53216), Criptin (US 5,981,215). Additionally, antigens particularly relevant for vaccines in the therapy of cancer also comprise tyrosinase, telomerase, P53, NY-Br1.1 (WO 01/47959) and fragments thereof such as disclosed in WO 00/43420, B726 (WO 00/60076, SEQ ID nos 469 and 463; WO 01/79286, SEQ ID nos 474 and 475), P510 (WO 01/34802 SEQ ID nos 537 and 538) and survivin.

[0043] The present invention is also useful in combination with breast cancer antigens such as Her-2/neu, mammaprotein (US patent 5,668,267), B305D (WO 00/61753 SEQ ID nos 299, 304, 305 and 315), or those disclosed in WO 00/52165, WO 99/33869, WO 99/19479, WO 98/45328. Her-2/neu antigens are disclosed inter alia, in US patent 5,801,005. Preferably the Her-2/neu comprises the entire extracellular domain (comprising approximately amino acid 1-645) or fragments thereof and at least an immunogenic portion of or the entire intracellular domain approximately the C terminal 580 amino acids. In particular, the intracellular portion should comprise the phosphorylation domain or fragments thereof. Such constructs are disclosed in WO 00/44899. A particularly preferred construct is known as ECD-PhD, a second is known as ECD deltaPhD (see WO 00/44899). The Her-2/neu as used herein can be derived from rat, mouse or human.

[0044] Certain tumour antigens are small peptide antigens (ie less than about 50 amino acids). These antigens can be chemically conjugated to the modified choline binding protein of the present invention.

[0045] Exemplary peptides included Mucin derived peptides such as MUC-1 (see for example US 5,744,144; US 5,827,666; WO 88/05054, US 4,963,484). Specifically contemplated are MUC-1 derived peptides that comprise at least one repeat unit of the MUC-1 peptide, preferably at least two such repeats and which is recognised by the SM3 antibody (US 6,054,438). Other mucin derived peptides include peptide from MUC-5.

[0046] Alternatively, said antigen is an interleukin such as IL13 and IL14, which are preferred. Or said antigen maybe

a self peptide hormone such as whole length Gonadotrophin hormone releasing hormone (GnRH, WO 95/20600), a short 10 amino acid long peptide, useful in the treatment of many cancers, or in immunocastration.

[0047] Other tumour-specific antigens are suitable to be coupled with the modified Choline binding protein of the present invention include, but are not restricted to tumour-specific gangliosides such as GM2, and GM3.

[0048] The covalent coupling of the peptide to modified choline binding protein can be carried out in a manner well known in the art. Thus, for example, for direct covalent coupling it is possible to utilise a carbodiimide, glutaraldehyde or (N-[γ -maleimidobutyryloxy] succinimide ester, utilising common commercially available heterobifunctional linkers such as CDAP and SPDP (using manufacturers instructions). After the coupling reaction, the immunogen can easily be isolated and purified by means of a dialysis method, a gel filtration method, a fractionation method etc.

[0049] The antigen may also be derived from sources which are pathogenic to humans, such as Human Immunodeficiency virus HIV-1 (such as tat, nef, reverse transcriptase, gag, gp120 and gp160), human herpes simplex viruses, such as gD or derivatives thereof or Immediate Early protein such as ICP27 from HSV1 or HSV2, cytomegalovirus ((esp Human)(such as gB or derivatives thereof), Rotavirus (including live-attenuated viruses), Epstein Barr virus (such as gp350 or derivatives thereof), Varicella Zoster Virus (such as gpl, II and IE63), or from a hepatitis virus such as hepatitis B virus (for example Hepatitis B Surface antigen or a derivative thereof), hepatitis A virus, hepatitis C virus and hepatitis E virus, or from other viral pathogens, such as paramyxoviruses: Respiratory Syncytial virus (such as F and G proteins or derivatives thereof), parainfluenza virus, measles virus, mumps virus, human papilloma viruses (for example HPV6, 11, 16, 18, ...), flaviviruses (e.g. Yellow Fever Virus, Dengue Virus, Tick-borne encephalitis virus, Japanese Encephalitis Virus) or Influenza virus (whole live or inactivated virus, split influenza virus, grown in eggs or MDCK cells, or whole flu viroosomes (as described by R. Gluck, Vaccine, 1992, 10, 915-920) or purified or recombinant proteins thereof, such as HA, NP, NA, or M proteins, or combinations thereof), or derived from bacterial pathogens such as *Neisseria* spp, including *N. gonorrhea* and *N. meningitidis* (for example capsular polysaccharides and conjugates thereof, transferrin-binding proteins, lactoferrin binding proteins, PIIC, adhesins); *S. pyogenes* (for example M proteins or fragments thereof, C5A protease, lipoteichoic acids), *S. agalactiae*, *S. mutans*; *H. ducreyi*; *Moraxella* spp, including *M. catarrhalis*, also known as *Branhamella catarrhalis* (for example high and low molecular weight adhesins and invasins); *Bordetella* spp, including *B. pertussis* (for example pertactin, pertussis toxin or derivatives thereof, filamentous hemagglutinin, adenylate cyclase, fimbriae), *B. parapertussis* and *B. bronchiseptica*; *Mycobacterium* spp., including *M. tuberculosis* (for example ESAT6, Antigen 85A, -B or -C), *M. bovis*, *M. leprae*, *M. avium*, *M. paratuberculosis*, *M. smegmatis*; *Legionella* spp, including *L. pneumophila*; *Escherichia* spp, including enterotoxigenic *E. coli* (for example colonization factors, heat-labile toxin or derivatives thereof, heat-stable toxin or derivatives thereof), enterohemorrhagic *E. coli*, enteropathogenic *E. coli* (for example shiga toxin-like toxin or derivatives thereof); *Vibrio* spp, including *V. cholera* (for example cholera toxin or derivatives thereof); *Shigella* spp, including *S. sonnei*, *S. dysenteriae*, *S. flexnerii*; *Yersinia* spp, including *Y. enterocolitica* (for example a Yop protein), *Y. pestis*, *Y. pseudotuberculosis*; *Campylobacter* spp, including *C. jejuni* (for example toxins, adhesins and invasins) and *C. coli*, *Salmonella* spp, including *S. typhi*, *S. paratyphi*, *S. choleraesuis*, *S. enteritidis*; *Listeria* spp., including *L. monocytogenes*; *Helicobacter* spp, including *H. pylori* (for example urease, catalase, vacuolating toxin); *Pseudomonas* spp, including *P. aeruginosa*; *Staphylococcus* spp., including *S. aureus*, *S. epidermidis*; *Enterococcus* spp., including *E. faecalis*, *E. faecium*; *Clostridium* spp., including *C. tetani* (for example tetanus toxin and derivative thereof), *C. botulinum* (for example botulinum toxin and derivative thereof), *C. difficile* (for example clostridium toxins A or B and derivatives thereof); *Bacillus* spp., including *B. anthracis* (for example botulinum toxin and derivatives thereof); *Corynebacterium* spp., including *C. diphtheriae* (for example diphtheria toxin and derivatives thereof); *Borrelia* spp., including *B. burgdorferi* (for example OspA, OspC, DbpA, DbpB), *B. garinii* (for example OspA, OspC, DbpA, DbpB), *B. afzelii* (for example OspA, OspC, DbpA, DbpB), *B. andersonii* (for example OspA, OspC, -DbpA, DbpB), *B. hermsii*, *Ehrlichia* spp., including *E. equi* and the agent of the Human Granulocytic Ehrlichiosis; *Rickettsia* spp, including *R. rickettsii*; *Chlamydia* spp., including *C. trachomatis* (for example MOMP, heparin-binding proteins), *C. pneumoniae* (for example MOMP, heparin-binding proteins), *C. psittaci*; *Leptospira* spp., including *L. interrogans*; *Treponema* spp., including *T. pallidum* (for example the rare outer membrane proteins), *T. denticola*, *T. hyodysenteriae*; or derived from parasites such as *Plasmodium* spp., including *P. falciparum*, *Toxoplasma* spp., including *T. gondii* (for example SAG2, SAG3, Tg34); *Entamoeba* spp., including *E. histolytica*; *Babesia* spp., including *B. microti*; *Trypanosoma* spp., including *T. cruzi*; *Giardia* spp., including *G. lamblia*; *Leshmania* spp., including *L. major*; *Pneumocystis* spp., including *P. carinii*; *Trichomonas* spp., including *T. vaginalis*; *Schistosoma* spp., including *S. mansoni*, or derived from yeast such as *Candida* spp., including *C. albicans*; *Cryptococcus* spp., including *C. neoformans*.

[0050] Other preferred specific antigens for *M. tuberculosis* are for example Tb Ral2, Tb H9, Tb Ra35, Tb38-1, Erd 14, DPV, MTI, MSL, mTTC2 and hTCC1 (WO 99/51748). Proteins for *M. tuberculosis* also include fusion proteins and variants thereof where at least two, preferably three polypeptides of *M. tuberculosis* are fused into a larger protein. Preferred fusions include Ra12-TbH9-Ra35, Erd14-DPV-MTI, DPV-MTI-MSL, Erd14-DPV-MTI-MSL-mTCC2, Erd14-DPV-MTI-MSL, DPV-MTI-MSL-mTCC2, TbH9-DPV-MTI (WO 99/51748).

[0051] Most preferred antigens for Chlamydia include for example the High Molecular Weight Protein (HWMP) (WO 99/17741), ORF3 (EP 366 412), and putative membrane proteins (Pmps). Other Chlamydia antigens of the vaccine

formulation can be selected from the group described in WO 99/28475.

[0052] Preferred bacterial antigens are derived from *Streptococcus* spp, including *S. pneumoniae* (for example capsular polysaccharides and conjugates thereof, PsaA, PspA, streptolysin, choline-binding proteins) and the protein antigen Pneumolysin (Biochem Biophys Acta, 1989, 67, 1007; Rubins et al., Microbial Pathogenesis, 25, 337-342), and mutant detoxified derivatives thereof (WO 90/06951; WO 99/03884). Other preferred bacterial antigens are derived from *Haemophilus* spp., including *H. influenzae* type B (for example PRP and conjugates thereof), *non typeable H. influenzae*, for example OMP26, high molecular weight adhesins, P5, P6, protein D and lipoprotein D, and fimbrin and fimbrin derived peptides (US 5,843,464) or multiple copy variants or fusion proteins thereof.

[0053] Derivatives of Hepatitis B Surface antigen are well known in the art and include, inter alia, those PreS1, PreS2 S antigens set forth described in European Patent applications EP-A-414 374; EP-A-0304 578, and EP 198-474. In one preferred The HBV antigen is HBV polymerase (Ji Hoon Jeong et al, 1996, BBRC 223, 264-271; Lee H.J. et al, Biotechnol. Lett. 15, 821-826). In another preferred aspect the antigen within the fusion is a HIV-1 antigen, gp120, especially when expressed in CHO cells. In a further embodiment, antigen comprises gD2t as hereinabove defined.

[0054] In a preferred embodiment of the present invention fusions comprise an antigen derived from the Human Papilloma Virus (HPV 6a, 6b, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68), in particular those HPV serotypes considered to be responsible for genital warts (HPV 6 or HPV 11 and others), and the HPV viruses responsible for cervical cancer (HPV16, HPV18 and others).

[0055] Suitable HPV antigens are E1, E2, E4, E5, E6, E7, L1 and L2. Particularly preferred forms of genital wart prophylactic, or therapeutic, fusions comprise L1 particles or capsomers, and fusion proteins comprising one or more antigens selected from the HPV 6 and HPV 11 proteins E6, E7, L1, and L2.

[0056] The most preferred forms of fusion protein are: L2E7 as disclosed in WO 96/26277, and proteinD(1/3)-E7 disclosed in GB 9717953.5 (PCT/EP98/05285).

[0057] A preferred HPV cervical infection or cancer, prophylaxis or therapeutic vaccine, composition may comprise HPV 16 or 18 antigens. For example, L1 or L2 antigen monomers, or L1 or L2 antigens presented together as a virus like particle (VLP) or the L1 alone protein presented alone in a VLP or capsomer structure. Such antigens, virus like particles and capsomer are per se known. See for example WO94/00152, WO94/20137, WO94/05792, and WO93/02184.

[0058] Additional early proteins may be included alone or as fusion proteins such as E7, E2 or preferably E5 for example; particularly preferred embodiments of this includes a VLP comprising L1 E7 fusion proteins (WO 96/11272). Particularly preferred HPV 16 antigens comprise the early proteins E6 or E7 in fusion with a protein D carrier to form Protein D - E6 or E7 fusions from HPV 16, or combinations thereof; or combinations of E6 or E7 with L2 (WO 96/26277). Alternatively the HPV 16 or 18 early proteins E6 and E7, may be presented in a single molecule, preferably a Protein D- E6/E7 fusion. Other fusions optionally contain either or both E6 and E7 proteins from HPV 18, preferably in the form of a Protein D - E6 or Protein D - E7 fusion protein or Protein D E6/E7 fusion protein. Fusions may comprise antigens from other HPV strains, preferably from strains HPV 31 or 33.

[0059] Fusions according to the present invention comprise antigens derived from parasites that cause Malaria. For example, preferred antigens from *Plasmodia falciparum* include RTS,S and TRAP. RTS is a hybrid protein comprising substantially all the C-terminal portion of the circumsporozoite (CS) protein of *P. falciparum* linked via four amino acids of the preS2 portion of Hepatitis B surface antigen to the surface (S) antigen of hepatitis B virus. Its full structure is disclosed in the International Patent Application No. PCT/EP92/02591, published under Number WO 93/10152 claiming priority from UK patent application No.9124390.7. When expressed in yeast RTS is produced as a lipoprotein particle, and when it is co-expressed with the S antigen from HBV it produces a mixed particle known as RTS,S. TRAP antigens are described in the International Patent Application No. PCT/GB89/00895, published under WO 90/01496. A preferred embodiment of the present invention is a fusion wherein the antigenic preparation comprises a combination of the RTS, S and TRAP antigens. Other plasmodia antigens that are likely candidates to be components of the fusion are *P. faciparum* MSP1, AMA1, MSP3, EBA, GLURP, RAP1, RAP2, Sequestin, PfEMP1, Pf332, LSA1, LSA3, STARP, SALSA, PfEXP1, Pfs25, Pfs28, PFS27/25, Pfs16, Pfs48/45, Pfs230 and their analogues in *Plasmodium* spp.

[0060] The present invention also provides a polynucleotide encoding the fusion partner according to the present invention. The invention further relates a polynucleotide that hybridise to the polynucleotide sequence provided herein in figure 1 (SEQ ID NO:9 to 16). In this regard, the invention especially relates to polynucleotides that hybridise under stringent conditions to the polynucleotide described herein. As herein used, the terms "stringent conditions" and "stringent hybridisation conditions" mean hybridisation occurring only if there is at least 95% and preferably at least 97% identity between the sequences. A specific example of stringent hybridization conditions is overnight incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml of denatured, sheared salmon sperm DNA, followed by washing the hybridisation support in 0.1x SSC at about 65°C. Hybridisation and wash conditions are well known and exemplified in Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), particularly Chapter 11 therein. Solution hybridisation may also be used with the polynucleotide sequences provided by the invention.

[0061] The present invention also provides a polynucleotide encoding the polypeptide comprising the fusion partner according to the present invention fused to a tumour associated antigen or fragment thereof. In particular, the present invention provides for polynucleotide sequences encoding a fusion partner protein comprising a choline binding domain and a heterologous promiscuous T heper epitope, preferably wherein the choline binding domain is derived from the C terminus of LytA. In a more preferred embodiment, the C-LytA moiety of the polynucleotides according to the invention comprise at least four repeats of any of SEQ ID NO.9-14, more preferably comprise the sequence of SEQ ID NO.15, still more preferably the sequence of SEQ ID NO.16. In other related embodiments, the present invention provides for polynucleotide variants having substantial identity to the sequences disclosed herein in SEQ ID NOs.9-16, for example those comprising at least 70% sequence identity, preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher, sequence identity compared to a polynucleotide sequence of this invention using conventional methods, e.g., BLAST analysis using standard parameters. In a still further embodiment the polynucleotide as claimed further comprises a heterologous protein.

[0062] Such polynucleotide sequences can be inserted into a suitable expression vector and expressed in a suitable host. Vectors may be provided which encode the modified choline binding protein of the invention and which contain a suitable restriction site into which a DNA encoding a poorly immunogenic protein can be inserted to produce a fusion protein.

In other embodiments of the invention, polynucleotide sequences or fragments thereof which encode polypeptide fusions of the invention, may be used in recombinant DNA molecules to direct expression of a polypeptide in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences that encode substantially the same or a functionally equivalent amino acid sequence may be produced and these sequences may be used to clone and express a given polypeptide.

[0063] As will be understood by those of skill in the art, it may be advantageous in some instances to produce polypeptide-encoding nucleotide sequences possessing non-naturally occurring codons. The DNA code has 4 letters (A, T, C and G) and uses these to spell three letter "codons" which represent the amino acids the proteins encodes in an organism's genes. The linear sequence of codons along the DNA molecule is translated into the linear sequence of amino acids in the protein(s) encoded by those genes. The code is highly degenerate, with 61 codons coding for the 20 natural amino acids and 3 codons representing "stop" signals. Thus, most amino acids are coded for by more than one codon - in fact several are coded for by four or more different codons.

[0064] Where more than one codon is available to code for a given amino acid, it has been observed that the codon usage patterns of organisms are highly non-random. Different species show a different bias in their codon selection and, furthermore, utilisation of codons may be markedly different in a single species between genes which are expressed at high and low levels. This bias is different in viruses, plants, bacteria and mammalian cells, and some species show a stronger bias away from a random codon selection than others. For example, humans and other mammals are less strongly biased than certain bacteria or viruses. For these reasons, there is a significant probability that a mammalian gene expressed in *E.coli* or a viral gene expressed in mammalian cells will have an inappropriate distribution of codons for efficient expression. It is believed that the presence in a heterologous DNA sequence of clusters of codons which are rarely observed in the host in which expression is to occur, is predictive of low heterologous expression levels in that host.

[0065] In consequence, codons preferred by a particular prokaryotic (for example *E. coli* or yeast) or eukaryotic host can be optimised, that is selected to increase the rate of protein expression, to produce a recombinant RNA transcript having desirable properties, such as for example a half-life which is longer than that of a transcript generated from the naturally occurring sequence, or to optimise the immune response in humans. The process of codon optimisation may include any sequence, generated either manually or by computer software, where some or all of the codons of the native sequence are modified. Several methods have been published (Nakamura et.al., Nucleic Acids Research 1996, 24: 214-215; WO98/34640). One preferred method according to this invention is Syngene method, a modification of Calgene method (R. S. Hale and G Thompson (Protein Expression and Purification Vol. 12 pp.185-188 (1998)).

[0066] Accordingly in a preferred embodiment the DNA sequence of the protein has a RSCU (Relative synonymous Codon useage (also known as Codon Index CI)) of at least 0.65 and have less than 85% identity to the corresponding wild type region.

[0067] This process of codon optimisation and the resulting constructs are advantageous as they may have some or all of the following benefits: 1) to improve expression of the gene product by replacing rare or infrequently used codons with more frequently used codons, 2) to remove or include restriction enzyme sites to facilitate downstream cloning and 3) to reduce the potential for homologous recombination between the insert sequence in the DNA vector and genomic sequences and 4) to improve the immune response in humans by raising a cellular and/or an antibody response (preferably both responses) against the target antigen. The sequences of the present invention advantageously have reduced recombination potential, but express to at least the same level as the wild type sequences. Due to the nature of the algorithms used by the SynGene programme to generate a codon optimised sequence, it is possible to generate an extremely large number of different codon optimised sequences which will perform a similar function. In brief, the codons

are assigned using a statistical method to give synthetic gene having a codon frequency closer to that found naturally in highly expressed E.coli and human genes. In brief, the codons are assigned using a statistical method to give synthetic gene having a codon frequency closer to that found naturally in highly expressed human genes such as β -Actin. Illustrative, although non limiting, examples of suitable codon-optimised sequences are given in SEQ ID NOs:19-22 and SEQ ID NOs:24-26.

[0068] In the polynucleotides of the present invention, the codon usage pattern is altered from that typical of the target antigen to more closely represent the codon bias of a highly expressed gene in a target organism, for example human 6-actin. The "codon usage coefficient" is a measure of how closely the codon pattern of a given polynucleotide sequence resembles that of a target species. Codon frequencies can be derived from literature sources for the highly expressed genes of many species (see e.g. Nakamura et.al. Nucleic Acids Research 1996, 24:214-215). The codon frequencies for each of the 61 codons (expressed as the number of occurrences occurrence per 1000 codons of the selected class of genes) are normalised for each of the twenty natural amino acids, so that the value for the most frequently used codon for each amino acid is set to 1 and the frequencies for the less common codons are scaled to lie between zero and 1. Thus each of the 61 codons is assigned a value of 1 or lower for the highly expressed genes of the target species. In order to calculate a codon usage coefficient for a specific polynucleotide, relative to the highly expressed genes of that species, the scaled value for each codon of the specific polynucleotide are noted and the geometric mean of all these values is taken (by dividing the sum of the natural logs of these values by the total number of codons and take the anti-log). The coefficient will have a value between zero and 1 and the higher the coefficient the more codons in the polynucleotide are frequently used codons. If a polynucleotide sequence has a codon usage coefficient of 1, all of the codons are "most frequent" codons for highly expressed genes of the target species.

[0069] According to the present invention, the codon usage pattern of the polynucleotide will preferably exclude codons representing < 10% of the codons used for a particular amino acid. A relative synonymous codon usage (RSCU) value is the observed number of codons divided by the number expected if all codons for that amino acid were used equally frequently. A polynucleotide of the present invention will preferably exclude codons with an RSCU value of less than 0.2 in highly expressed genes of the target organism. A polynucleotide of the present invention will generally have a codon usage coefficient for highly expressed human genes of greater than 0.6, preferably greater than 0.65, most preferably greater than 0.7. Codon usage tables for human can also be found in Genbank.

[0070] In comparison, a highly expressed beta actin gene has a RSCU of 0.747.

[0071] The codon usage table (Table 1) for a homo sapiens is set out below:

Table 1. Codon usage for human (highly expressed) genes 1/24/91 (human_high.cod)

AmAcid	Codon	Number	/1000	Fraction
Gly	GGG	905.00	18.76	0.24
Gly	GGA	525.00	10.88	0.14
Gly	GGT	441.00	9.14	0.12
Gly	GGC	1867.00	38.70	0.50
Glu	GAG	2420.00	50.16	0.75
Glu	GAA	792.00	16.42	0.25
Asp	GAT	592.00	12.27	0.25
Asp	GAC	1821.00	37.75	0.75
Val	GTG	1866.00	38.68	0.64
Val	GTA	134.00	2.78	0.05
Val	GTT	198.00	4.10	0.07
Val	GTC	728.00	15.09	0.25
Ala	GCG	652.00	13.51	0.17
Ala	GCA	488.00	10.12	0.13
Ala	GCT	654.00	13.56	0.17
Ala	GCC	2057.00	42.64	0.53
Arg	AGG	512.00	10.61	0.18
Arg	AGA	298.00	6.18	0.10
Ser	AGT	354.00	7.34	0.10

EP 1 511 768 B1

			(continued)		
	AmAcid	Codon	Number	/1000	Fraction
	Ser	AGC	1171.00	24.27	0.34
5	Lys	AAG	2117.00	43.88	0.82
	Lys	AAA	471.00	9.76	0.18
	Asn	AAT	314.00	6.51	0.22
	Asn	AAC	1120.00	23.22	0.78
10	Met	ATG	1077.00	22.32	1.00
	Ile	ATA	88.00	1.82	0.05
	Ile	ATT	315.00	6.53	0.18
	Ile	ATC	1369.00	28.38	0.77
15	Thr	ACG	405.00	8.40	0.15
	Thr	ACA	373.00	7.73	0.14
	Thr	ACT	358.00	7.42	0.14
20	Thr	ACC	1502.00	31.13	0.57
	Trp	TGG	652.00	13.51	1.00
	End	TGA	109.00	2.26	0.55
25	Cys	TGT	325.00	6.74	0.32
	Cys	TGC	706.00	14.63	0.68
	End	TAG	42.00	0.87	0.21
	End	TAA	46.00	0.95	0.23
30	Tyr	TAT	360.00	7.46	0.26
	Tyr	TAC	1042.00	21.60	0.74
	Leu	TTG	313.00	6.49	0.06
	Leu	TTA	76.00	1.58	0.02
35	Phe	TTT	336.00	6.96	0.20
	Phe	TTC	1377.00	28.54	0.80
	Ser	TCG	325.00	6.74	0.09
40	Ser	TCA	165.00	3.42	0.05
	Ser	TCT	450.00	9.33	0.13
	Ser	TCC	958.00	19.86	0.28
	Arg	CGG	611.00	12.67	0.21
45	Arg	CGA	183.00	3.79	0.06
	Arg	CGT	210.00	4.35	0.07
	Arg	CGC	1086.00	22.51	0.37
50	Gln	CAG	2020.00	41.87	0.88
	Gln	CAA	283.00	5.87	0.12
	His	CAT	234.00	4.85	0.21
	His	CAC	870.00	18.03	0.79
55	Leu	CTG	2884.00	59.78	0.58
	Leu	CTA	166.00	3.44	0.03
	Leu	CTT	238.00	4.93	0.05

(continued)

	AmAcid	Codon	Number	/1000	Fraction
	Leu	CTC	1276.00	26.45	0.26
5	Pro	CCG	482.00	9.99	0.17
	Pro	CCA	456.00	9.45	0.16
	Pro	CCT	568.00	11.77	0.19
10	Pro	CCC	1410.00	29.23	0.48

[0072] A DNA sequence encoding the fusion proteins or modified choline binding protein of the present invention can be synthesised using standard DNA synthesis techniques, such as by enzymatic ligation as described by D.M. Roberts *et al.* in Biochemistry 1985, 24, 5090-5098, by chemical synthesis, by *in vitro* enzymatic polymerisation, or by PCR technology utilising for example a heat stable polymerase, or by a combination of these techniques.

[0073] Enzymatic polymerisation of DNA may be carried out *in vitro* using a DNA polymerase such as DNA polymerase I (Klenow fragment) or Taq polymerase in an appropriate buffer containing the nucleoside triphosphates dATP, dCTP, dGTP and dTTP as required at a temperature of 10°-37°C, generally in a volume of 50µl or less. Enzymatic ligation of DNA fragments may be carried out using a DNA ligase such as T4 DNA ligase in an appropriate buffer, such as 0.05M Tris (pH 7.4), 0.01 M MgCl₂, 0.01 M dithiothreitol, 1mM spermidine, 1mM ATP and 0.1 mg/ml bovine serum albumin, at a temperature of 4°C to ambient, generally in a volume of 50 µl or less. The chemical synthesis of the DNA polymer or fragments may be carried out by conventional phosphotriester, phosphate or phosphoramidite chemistry, using solid phase techniques such as those described in 'Chemical and Enzymatic Synthesis of Gene Fragments - A Laboratory Manual' (ed. H.G. Gassen and A. Lang), Verlag Chemie, Weinheim (1982), or in other scientific publications, for example M.J. Gait, H.W.D. Matthes, M. Singh, B.S. Sproat, and R.C. Titmas, Nucleic Acids Research, 1982, 10, 6243; B.S. Sproat, and W. Bannwarth, Tetrahedron Letters, 1983, 24, 5771; M.D. Matteucci and M.H. Caruthers, Tetrahedron Letters, 1980, 21, 719; M.D. Matteucci and M.H. Caruthers, Journal of the American Chemical Society, 1981, 103, 3185; S.P. Adams *et al.*, Journal of the American Chemical Society, 1983, 105, 661; N.D. Sinha, J. Biemat, J. McMannus, and H. Koester, Nucleic Acids Research, 1984, 12, 4539; and H.W.D. Matthes *et al.*, EMBO Journal, 1984, 3, 801.

[0074] The process of the invention may be performed by conventional recombinant techniques such as described in Maniatis *et al.*, Molecular Cloning - A Laboratory Manual; Cold Spring Harbor, 1982-1989.

[0075] In particular, the process may comprise the steps of :

- i) preparing a replicable or integrating expression vector capable, in a host cell, of expressing a DNA polymer comprising a nucleotide sequence that encodes the protein or an immunogenic derivative thereof
- ii) transforming a host cell with said vector
- iii) culturing said transformed host cell under conditions permitting expression of said DNA polymer to produce said protein; and
- iv) recovering said protein

[0076] The term 'transforming' is used herein to mean the introduction of foreign DNA into a host cell. This can be achieved for example by transformation, transfection or infection with an appropriate plasmid or viral vector using e.g. conventional techniques as described in Genetic Engineering; Eds. S.M. Kingsman and A.J. Kingsman; Blackwell Scientific Publications; Oxford, England, 1988. The term 'transformed' or 'transformant' will hereafter apply to the resulting host cell containing and expressing the foreign gene of interest.

[0077] The expression vectors are novel and also form part of the invention.

[0078] The replicable expression vectors may be prepared in accordance with the invention, by cleaving a vector compatible with the host cell to provide a linear DNA segment having an intact replicon, and combining said linear segment with one or more DNA molecules which, together with said linear segment encode the desired product, such as the DNA polymer encoding the protein of the invention, or derivative thereof, under ligating conditions.

[0079] Thus, the DNA polymer may be performed or formed during the construction of the vector, as desired.

[0080] The choice of vector will be determined in part by the host cell, which may be prokaryotic or eukaryotic but are preferably *E. coli*, yeast or CHO cells. Suitable vectors include plasmids, bacteriophages, cosmids and recombinant viruses. Expression and cloning vectors preferably contain a selectable marker such that only the host cells expressing the marker will survive under selective conditions. Selection genes include but are not limited to the one encoding protein that confer a resistance to ampicillin, tetracyclin or kanamycin. Expression vectors also contain control sequences which are compatible with the designated host. For example, expression control sequences for *E. coli*, and more generally for prokaryotes, include promoters and ribosome binding sites. Promoter sequences may be naturally occurring, such as

the β -lactamase (penicillinase) (Weissman 1981, *In Interferon 3* (ed. L. Gresser), lactose (lac) (Chang et al. Nature, 1977, 198: 1056) and tryptophan (trp) (Goeddel et al. Nucl. Acids Res. 1980, 8, 4057) and lambda-derived P_L promoter system. In addition, synthetic promoters which do not occur in nature also function as bacterial promoters. This is the case for example for the tac synthetic hybrid promoter which is derived from sequences of the trp and lac promoters

(De Boer et al., Proc. Natl Acad Sci. USA 1983, 80, 21-26). These systems are particularly suitable with *E. coli*.
[0081] Yeast compatible vectors also carry markers that allow the selection of successful transformants by conferring prototrophy to auxotrophic mutants or resistance to heavy metals on wild-type strains. Expression control sequences for yeast vectors include promoters for glycolytic enzymes (Hess et al., J. Adv. Enzyme Reg. 1968, 7, 149), PH05 gene encoding acid phosphatase, CUP1 gene, ARG3 gene, GAL genes promoters and synthetic promoter sequences. Other control elements useful in yeast expression are terminators and mRNA leader sequences. The 5' coding sequence is particularly useful since it typically encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. Suitable signal sequences can be encoded by genes for secreted yeast proteins such as the yeast invertase gene and the α -factor gene, acid phosphatase, killer toxin, the alpha-mating factor gene and recently the heterologous inulinase signal sequence derived from INU1A gene of *Kluyveromyces marxianus*. Suitable vectors have been developed for expression in *Pichia pastoris* and *Saccharomyces cerevisiae*.

[0082] A variety of *P. pastoris* expression vectors are available based on various inducible or constitutive promoters (Cereghino and Cregg, FEMS Microbiol. Rev. 2000, 24:45-66). For the production of cytosolic and secreted proteins, the most commonly used *P. pastoris* vectors contain the very strong and tightly regulated alcohol oxidase (AOX1) promoter. The vectors also contain the *P. pastoris* histidinol dehydrogenase (HIS4) gene for selection in his4 hosts. Secretion of foreign protein require the presence of a signal sequence and the *S. cerevisiae* prepro alpha mating factor signal sequence has been widely and successfully used in *Pichia* expression system. Expression vectors are integrated into the *P. pastoris* genome to maximize the stability of expression strains. As in *S. cerevisiae*, cleavage of a *P. pastoris* expression vector within a sequence shared by the host genome (AOX1 or HIS4) stimulates homologous recombination events that efficiently target integration of the vector to that genomic locus. In general, a recombinant strain that contains multiple integrated copies of an expression cassette can yield more heterologous protein than single-copy strain. The most effective way to obtain high copy number transformants requires the transformation of *Pichia* recipient strain by the sphaeroplast technique (Cregg et al 1985, Mol.Cell.Biol. 5: 3376-3385).

[0083] The preparation of the replicable expression vector may be carried out conventionally with appropriate enzymes for restriction, polymerisation and ligation of the DNA, by procedures described in, for example, Maniatis *et al.* cited above.

[0084] The recombinant host cell is prepared, in accordance with the invention, by transforming a host cell with a replicable expression vector of the invention under transforming conditions. Suitable transforming conditions are conventional and are described in, for example, Maniatis *et al.* cited above, or "DNA Cloning" Vol. II, D.M. Glover ed., IRL Press Ltd, 1985.

[0085] The choice of transforming conditions depends upon the choice of the host cell to be transformed. For example, in vivo transformation using a live viral vector as the transforming agent for the polynucleotides of the invention is described above. Bacterial transformation of a host such as *E. coli* may be done by direct uptake of the polynucleotides (which may be expression vectors containing the desired sequence) after the host has been treated with a solution of CaCl₂ (Cohen *et al.*, Proc. Nat. Acad. Sci., 1973, 69, 2110) or with a solution comprising a mixture of rubidium chloride (RbCl), MnCl₂, potassium acetate and glycerol, and then with 3-[N-morpholino]-propane-sulphonic acid, RbCl and glycerol or by electroporation. Transformation of lower eukaryotic organisms such as yeast cells in culture by direct uptake may be carried out for example by using the method of Hinnen *et al* (Proc. Natl. Acad. Sci. 1978, 75 : 1929-1933). Mammalian cells in culture may be transformed using the calcium phosphate coprecipitation of the vector DNA onto the cells (Graham & Van der Eb, Virology 1978, 52, 546). Other methods for introduction of polynucleotides into mammalian cells include dextran mediated transfection, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) into liposomes, and direct microinjection of the polynucleotides into nuclei.

[0086] The invention also extends to a host cell transformed with a nucleic acid encoding the protein of the invention or a replicable expression vector of the invention.

[0087] Culturing the transformed host cell under conditions permitting expression of the DNA polymer is carried out conventionally, as described in, for example, Maniatis *et al.* and "DNA Cloning" cited above. Thus, preferably the cell is supplied with nutrient and cultured at a temperature below 50°C, preferably between 25°C and 42°C, more preferably between 25°C and 35°C, most preferably at 30°C. The incubation time may vary from a few minutes to a few hours, according to the proportion of the polypeptide in the bacterial cell, as assessed by SDS-PAGE or Western blot.

[0088] The product may be recovered by conventional methods according to the host cell and according to the localisation of the expression product (intracellular or secreted into the culture medium or into the cell periplasm). Thus, where the host cell is bacterial, such as *E. coli* it may, for example, be lysed physically, chemically or enzymatically and the protein product isolated from the resulting lysate. Where the host cell is mammalian, the product may generally be isolated from the nutrient medium or from cell free extracts. Where the host cell is a yeast such as *Saccharomyces cerevisiae* or *Pichia pastoris*, the product may generally be isolated from from lysed cells or from the culture medium,

and then further purified using conventional techniques. The specificity of the expression system may be assessed by western blot or by ELISA using an antibody directed against the polypeptide of interest.

[0089] Conventional protein isolation techniques include selective precipitation, adsorption chromatography, and affinity chromatography including a monoclonal antibody affinity column. When the proteins of the present invention are expressed with a histidine tail (His tag), they can easily be purified by affinity chromatography using an ion metal affinity chromatography column (IMAC) column. The metal ion, may be any suitable ion for example zinc, nickel, iron, magnesium or copper, but is preferably zinc or nickel. Preferably the IMAC buffer contains detergent, preferably an anionic detergent such as SDS, more preferably a non-ionic detergent such as Tween 80, or a zwitterionic detergent such as Empigen BB, as this may result in lower levels of endotoxin in the final product.

[0090] Further chromatographic steps include for example a Q-Sepharose step that may be operated either before or after the IMAC column. Preferably the pH is in the range of 7.5 to 10, more preferably from 7.5 to 9.5, optimally between 8 and 9.

[0091] The proteins of the invention can thus be purified according to the following protocol. After cell disruption, cell extracts containing the protein can be solubilised in a pH 8.5 Tris buffer containing urea (8.0 M for example), and SDS (from 0.5% to 1% for example). After centrifugation, the resulting supernatant may then be loaded onto to an IMAC (Nickel) Sepharose FF column equilibrated with a pH 8.5 Tris buffer. The column may then be washed with a high salt containing buffer (eg 0.75 - 1.5M NaCl, 15 mM pH 8.5 Tris buffer). The column may optionally then be washed again with phosphate buffer without salt. The proteins of the invention may be eluted from the column with an imidazole-containing buffered solution. The proteins can then be submitted to an additional chromatographic step, such as to an anion exchange chromatography (Q Sepharose for example).

[0092] The proteins of the present invention are provided either soluble in a liquid form or in a lyophilised form, which is the preferred form. It is generally expected that each human dose will comprise 1 to 1000 µg of protein, and preferably 30-300 µg. The purification process can also include a carboxyamidation step whereby the protein is first reduced in the presence of Glutathion and then carboxymethylated in the presence of iodoacetamide. This step offers the advantage of controlling the oxidative aggregation of the molecule with itself or with host cell protein contaminants through covalent bridging with disulphide bonds.

[0093] The present invention also provides pharmaceutical and immunogenic compositions comprising a protein of the present invention in a pharmaceutically acceptable excipient.

A preferred vaccine composition comprises at least a protein according to the invention. Said protein has, preferably, blocked thiol groups and is highly purified, e.g. has less than 5% host cell contamination. Such vaccine may optionally contain one or more other tumour-associated antigen and derivatives. For example, suitable other associated antigen include prostate, PAP-1, PSA (prostate specific antigen), PSMA (prostate-specific membrane antigen), PSCA (Prostate Stem Cell Antigen), STEAP.

[0094] In another embodiment, illustrative immunogenic compositions, such as for example vaccine compositions, of the present invention comprise DNA encoding one or more of the fusion polypeptides as described above, such that the fusion polypeptide is generated *in situ*. As noted above, the polynucleotide may be administered within any of a variety of delivery systems known to those of ordinary skill in the art. Indeed, numerous gene delivery techniques are well known in the art, such as those described by Rolland, *Crit. Rev. Therap. Drug Carrier Systems* 15:143-198, 1998, and references cited therein. Appropriate polynucleotide expression systems will, of course, contain the necessary regulatory DNA regulatory sequences for expression in a patient (such as a suitable promoter and terminating signal). Alternatively, bacterial delivery systems may involve the administration of a bacterium (such as *Bacillus-Calmette-Guerrin*) that expresses an immunogenic portion of the polypeptide on its cell surface or secretes such an epitope.

[0095] Therefore, in certain embodiments, polynucleotides encoding immunogenic polypeptides described herein are introduced into suitable mammalian host cells for expression using any of a number of known viral-based systems. In one illustrative embodiment, retroviruses provide a convenient and effective platform for gene delivery systems. A selected nucleotide sequence encoding a polypeptide of the present invention can be inserted into a vector and packaged in retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to a subject. A number of illustrative retroviral systems have been described (e.g., U.S. Pat. No. 5,219,740; Miller and Rosman (1989) *BioTechniques* 7:980-990; Miller, A. D. (1990) *Human Gene Therapy* 1:5-14; Scarpa et al. (1991) *Virology* 180: 849-852; Bums et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:8033-8037; and Boris-Lawrie and Temin (1993) *Cur. Opin. Genet. Develop.* 3:102-109.

[0096] In addition, a number of illustrative adenovirus-based systems have also been described. Unlike retroviruses which integrate into the host genome, adenoviruses persist extrachromosomally thus minimizing the risks associated with insertional mutagenesis (Haj-Ahmad and Graham (1986) *J. Virol.* 57:267-274; Bett et al. (1993) *J. Virol.* 67: 5911-5921; Mittereder et al. (1994) *Human Gene Therapy* 5:717-729; Seth et al. (1994) *J. Virol.* 68:933-940; Barr et al. (1994) *Gene Therapy* 1:51-58; Berkner, K. L. (1988) *BioTechniques* 6:616-629; and Rich et al. (1993) *Human Gene Therapy* 4:461-476). Since humans are sometimes infected by common human adenovirus serotypes such as AdHu5, a significant proportion of the population have a neutralizing antibody response to the adenovirus, which is likely to effect

the immune response to a heterologous antigen in a recombinant vaccine based system. Non-human primate adenoviral vectors such as the chimpanzee adenovirus 68 (AdC68, Fitzgerald et al. (2003) J. Immunol 170(3):1416-22)) are may offer an alternative adenoviral system without the disadvantage of a pre-existing neutralising antibody response.

[0097] Various adeno-associated virus (AAV) vector systems have also been developed for polynucleotide delivery. AAV vectors can be readily constructed using techniques well known in the art. See, e.g., U.S. Pat. Nos. 5,173,414 and 5,139,941; International Publication Nos. WO 92/01070 and WO 93/03769; Lebkowski et al. (1988) Molec. Cell. Biol. 8: 3988-3996; Vincent et al. (1990) Vaccines 90 (Cold Spring Harbor Laboratory Press); Carter, B. J. (1992) Current Opinion in Biotechnology 3:533-539; Muzyczka, N. (1992) Current Topics in Microbiol. and Immunol. 158:97-129; Kotin, R. M. (1994) Human Gene Therapy 5:793-801; Shelling and Smith (1994) Gene Therapy 1:165-169; and Zhou et al. (1994) J. Exp. Med. 179:1867-1875.

[0098] Additional viral vectors useful for delivering the nucleic acid molecules encoding polypeptides of the present invention by gene transfer include those derived from the pox family of viruses, such as vaccinia virus and avian poxvirus. By way of example, vaccinia virus recombinants expressing the novel molecules can be constructed as follows. The DNA encoding a polypeptide is first inserted into an appropriate vector so that it is adjacent to a vaccinia promoter and flanking vaccinia DNA sequences, such as the sequence encoding thymidine kinase (TK). This vector is then used to transfect cells which are simultaneously infected with vaccinia. Homologous recombination serves to insert the vaccinia promoter plus the gene encoding the polypeptide of interest into the viral genome. The resulting TK^{sup}(-) recombinant can be selected by culturing the cells in the presence of 5-bromodeoxyuridine and picking viral plaques resistant thereto.

[0099] A vaccinia-based infection/transfection system can be conveniently used to provide for inducible, transient expression or coexpression of one or more polypeptides described herein in host cells of an organism. In this particular system, cells are first infected in vitro with a vaccinia virus recombinant that encodes the bacteriophage T7 RNA polymerase. This polymerase displays exquisite specificity in that it only transcribes templates bearing T7 promoters. Following infection, cells are transfected with the polynucleotide or polynucleotides of interest, driven by a T7 promoter. The polymerase expressed in the cytoplasm from the vaccinia virus recombinant transcribes the transfected DNA into RNA which is then translated into polypeptide by the host translational machinery. The method provides for high level, transient, cytoplasmic production of large quantities of RNA and its translation products. See, e.g., Elroy-Stein and Moss, Proc. Natl. Acad. Sci. USA (1990) 87:6743-6747; Fuerst et al. Proc. Natl. Acad. Sci. USA (1986) 83:8122-8126.

[0100] Alternatively, avipoxviruses, such as the fowlpox and canarypox viruses, can also be used to deliver the coding sequences of interest. Recombinant avipox viruses, expressing immunogens from mammalian pathogens, are known to confer protective immunity when administered to non-avian species. The use of an Avipox vector is particularly desirable in human and other mammalian species since members of the Avipox genus can only productively replicate in susceptible avian species and therefore are not infective in mammalian cells. Methods for producing recombinant Avipoxviruses are known in the art and employ genetic recombination, as described above with respect to the production of vaccinia viruses. See, e.g., WO 91/12882; WO 89/03429; and WO 92/03545.

[0101] Any of a number of alphavirus vectors can also be used for delivery of polynucleotide compositions of the present invention, such as those vectors described in U.S. Patent Nos. 5,843,723; 6,015,686; 6,008,035 and 6,015,694. Certain vectors based on Venezuelan Equine Encephalitis (VEE) can also be used, illustrative examples of which can be found in U.S. Patent Nos. 5,505,947 and 5,643,576.

[0102] The compositions of the present invention can be delivered by a number of routes such as intramuscularly, subcutaneously, intraperitoneally or intravenously.

[0103] In another embodiment of the invention, a polynucleotide is administered/delivered as "naked" DNA, for example as described in Ulmer et al., *Science* 259:1745-1749, 1993 and reviewed by Cohen, *Science* 259:1691-1692, 1993. The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are efficiently transported into the cells. In a preferred embodiment, the composition is delivered intradermally. In particular, the composition is delivered by means of a gene gun (particularly particle bombardment) administration techniques which involve coating the vector on to a bead (eg gold) which are then administered under high pressure into the epidermis; such as, for example, as described in Haynes et al, *J Biotechnology* 44: 37-42 (1996).

[0104] In one illustrative example, gas-driven particle acceleration can be achieved with devices such as those manufactured by Powderject Pharmaceuticals PLC (Oxford, UK) and Powderject Vaccines Inc. (Madison, WI), some examples of which are described in U.S. Patent Nos. 5,846,796; 6,010,478; 5,865,796; 5,584,807; and EP Patent No. 0500 799. This approach offers a needle-free delivery approach wherein a dry powder formulation of microscopic particles, such as polynucleotide, are accelerated to high speed within a helium gas jet generated by a hand held device, propelling the particles into a target tissue of interest, typically the skin. The particles are preferably gold beads of a 0.4 - 4.0 μm , more preferably 0.6 - 2.0 μm diameter and the DNA conjugate coated onto these and then encased in a cartridge or cassette for placing into the "gene gun".

[0105] In a related embodiment, other devices and methods that may be useful for gas-driven needle-less injection of compositions of the present invention include those provided by Bioject, Inc. (Portland, OR), some examples of which are described in U.S. Patent Nos. 4,790,824; 5,064,413; 5,312,335; 5,383,851; 5,399,163; 5,520,639 and 5,993,412.

[0106] It is possible for the immunogen component comprising the nucleotide sequence encoding the antigenic peptide, to be administered on a once off basis or to be administered repeatedly, for example, between 1 and 7 times, preferably between 1 and 4 times, at intervals between about 1 day and about 18 months. However, this treatment regime will be significantly varied depending upon the size of the patient, the disease which is being treated/protected against, the amount of nucleotide sequence administered, the route of administration, and other factors which would be apparent to a skilled medical practitioner.

[0107] It is therefore another aspect of the present invention to provide for the use of a protein or a DNA encoding said protein, as described herein, in the manufacture of an immunogenic composition for eliciting an immune response in a patient. Preferably the immune response is to be elicited by sequential administration of i) the said protein followed by the said DNA sequence; or ii) the said DNA sequence followed by the said protein. More preferably the DNA sequence is coated onto biodegradable beads or delivered via a particle bombardment approach. Still more preferably the protein is adjuvanted, preferably with a TH-1 inducing adjuvant, preferably with a CpG/QS21 based adjuvant formulation.

[0108] The vectors which comprise the nucleotide sequences encoding antigenic peptides are administered in such amount as will be prophylactically or therapeutically effective. The quantity to be administered, is generally in the range of one picogram to 16 milligram, preferably 1 picogram to 10 micrograms for particle-mediated delivery, and 10 micrograms to 16 milligram for other routes of nucleotide per dose. The exact quantity may vary considerably depending on the weight of the patient being immunised and the route of administration.

[0109] Suitable techniques for introducing the naked polynucleotide or vector into a patient also include topical application with an appropriate vehicle. The nucleic acid may be administered topically to the skin, or to mucosal surfaces for example by intranasal, oral, intravaginal or intrarectal administration. The naked polynucleotide or vector may be present together with a pharmaceutically acceptable excipient, such as phosphate buffered saline (PBS). DNA uptake may be further facilitated by use of facilitating agents such as bupivacaine, either separately or included in the DNA formulation. Other methods of administering the nucleic acid directly to a recipient include ultrasound, electrical stimulation, electroporation and microseeding which is described in US 5,697,901.

[0110] Uptake of nucleic acid constructs may be enhanced by several known transfection techniques, for example those including the use of transfection agents. Examples of these agents includes cationic agents, for example, calcium phosphate and DEAE-Dextran and lipofectants, for example, lipofectam and transfectam. The dosage of the nucleic acid to be administered can be altered.

[0111] The fusion proteins and encoding polypeptides according to the invention can also be formulated as a pharmaceutical/immunogenic composition, e.g. as a vaccine. Accordingly therefore, the present invention also provides for a pharmaceutical/immunogenic composition comprising a fusion protein of the present invention in a pharmaceutically acceptable excipient. Accordingly there is also provided a process for the preparation of an immunogenic composition according to the present invention, comprising admixing the fusion protein of the invention or the encoding polynucleotide with a suitable adjuvant, diluent or other pharmaceutically acceptable carrier.

[0112] The fusion proteins of the present invention are provided preferably at least 80% pure more preferably 90% pure as visualised by SDS PAGE. Preferably the proteins appear as a single band by SDS PAGE.

[0113] Vaccine preparation is generally described in Vaccine Design ("The subunit and adjuvant approach" (eds. Powell M.F. & Newman M.J). (1995) Plenum Press New York). Encapsulation within liposomes is described by Fullerton, US Patent 4,235,877.

[0114] The fusion proteins of the present invention and encoding polynucleotides are preferably adjuvanted in the vaccine formulation of the invention. Certain adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatised polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF, interleukin-2, -7, -12, and other like growth factors, may also be used as adjuvants.

[0115] Within certain embodiments of the invention, the adjuvant composition is preferably one that induces an immune response predominantly of the Th1 type. High levels of Th1-type cytokines (e.g., IFN- γ , TNF α , IL-2 and IL-12) tend to favor the induction of cell mediated immune responses to an administered antigen. In contrast, high levels of Th2-type cytokines (e.g., IL-4, IL-5, IL-6 and IL-10) tend to favor the induction of humoral immune responses. Following application of a vaccine as provided herein, a patient will support an immune response that includes Th1- and Th2-type responses. Within a preferred embodiment, in which a response is predominantly Th1-type, the level of Th1-type cytokines will increase to a greater extent than the level of Th2-type cytokines. The levels of these cytokines may be readily assessed using standard assays. For a review of the families of cytokines, see Mosmann and Coffman, *Ann. Rev. Immunol.* 7: 145-173, 1989.

[0116] Preferred TH-1 inducing adjuvants are selected from the group of adjuvants comprising: 3D-MPL, QS21, a mixture of QS21 and cholesterol, and a CpG oligonucleotide or a mixture of two or more said adjuvants. Certain preferred adjuvants for eliciting a predominantly Th1-type response include, for example, a combination of monophosphoryl lipid

A, preferably 3-de-O-acylated monophosphoryl lipid A, together with an aluminum salt. MPL[®] adjuvants are available from Corixa Corporation (Seattle, WA; see, for example, US Patent Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094). CpG-containing oligonucleotides (in which the CpG dinucleotide is unmethylated) also induce a predominantly Th1 response. Such oligonucleotides are well known and are described, for example, in WO 96/02555, WO 99/33488 and U.S. Patent Nos. 6,008,200 and 5,856,462. Immunostimulatory DNA sequences are also described, for example, by Sato et al., *Science* 273:352, 1996. Another preferred adjuvant comprises a saponin, such as Quil A, or derivatives thereof, including QS21 and QS7 (Aquila Biopharmaceuticals Inc., Framingham, MA); Escin; Digitonin; or *Gypsophila* or *Chenopodium quinoa* saponins. Other preferred formulations include more than one saponin in the adjuvant combinations of the present invention, for example combinations of at least two of the following group comprising QS21, QS7, Quil A, β -escin, or digitonin.

[0117] Alternatively the saponin formulations may be combined with vaccine vehicles composed of chitosan or other polycationic polymers, polylactide and polylactide-co-glycolide particles, poly-N-acetyl glucosamine-based polymer matrix, particles composed of polysaccharides or chemically modified polysaccharides, liposomes and lipid-based particles, particles composed of glycerol monoesters, etc. The saponins may also be formulated in the presence of cholesterol to form particulate structures such as liposomes or ISCOMs. Furthermore, the saponins may be formulated together with a polyoxyethylene ether or ester, in either a non-particulate solution or suspension, or in a particulate structure such as a paucilamellar liposome or ISCOM. The saponins may also be formulated with excipients such as Carbopol[®] to increase viscosity, or may be formulated in a dry powder form with a powder excipient such as lactose.

[0118] In one preferred embodiment, the adjuvant system includes the combination of a monophosphoryl lipid A and a saponin derivative, such as the combination of QS21 and 3D-MPL[®] adjuvant, as described in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol, as described in WO 96/33739. Other preferred formulations comprise an oil-in-water emulsion and tocopherol. Another particularly preferred adjuvant formulation employing QS21, 3D-MPL[®] adjuvant and tocopherol in an oil-in-water emulsion is described in WO 95/17210.

[0119] Another enhanced adjuvant system involves the combination of a CpG-containing oligonucleotide and a saponin derivative particularly the combination of CpG and QS21 as disclosed in WO 00/09159 and in WO 00/62800. Preferably the formulation additionally comprises an oil in water emulsion and tocopherol.

[0120] In a yet further embodiment the present invention provides an immunogenic composition comprising a fusion protein according to the invention, and further comprising D3-MPL, a saponin preferably QS21 and a CpG oligonucleotide, optionally formulated in an oil in water emulsion.

[0121] Additional illustrative adjuvants for use in the pharmaceutical compositions of the invention include Montanide ISA 720 (Seppic, France), SAF (Chiron, California, United States), ISCOMS (CSL), MF-59 (Chiron), the SBAS series of adjuvants (e.g., SBAS-2 or SBAS-4, available from SmithKline Beecham, Rixensart, Belgium), Detox (Enhancyn[®] (Corixa, Hamilton, MT), RC-529 (Corixa, Hamilton, MT) and other aminoalkyl glucosaminide 4-phosphates (AGPs), such as those described in pending U.S. Patent Application Serial Nos. 08/853,826 and 09/074,720, the disclosures of which are incorporated herein by reference in their entireties, and polyoxyethylene ether adjuvants such as those described in WO 99/52549A1.

[0122] Other preferred adjuvants include adjuvant molecules of the general formula (I): $\text{HO}(\text{CH}_2\text{CH}_2\text{O})_n\text{-A-R}$, wherein, n is 1-50, A is a bond or -C(O)-, R is C_{1-50} alkyl or Phenyl C_{1-50} alkyl. One embodiment of the present invention consists of a vaccine formulation comprising a polyoxyethylene ether of general formula (I), wherein n is between 1 and 50, preferably 4-24, most preferably 9; the R component is C_{1-50} , preferably $\text{C}_4\text{-C}_{20}$ alkyl and most preferably C_{12} alkyl, and A is a bond. The concentration of the polyoxyethylene ethers should be in the range 0.1-20%, preferably from 0.1-10%, and most preferably in the range 0.1-1%. Preferred polyoxyethylene ethers are selected from the following group: polyoxyethylene-9-lauryl ether, polyoxyethylene-9-stearyl ether, polyoxyethylene-8-stearyl ether, polyoxyethylene-4-lauryl ether, polyoxyethylene-35-lauryl ether, and polyoxyethylene-23-lauryl ether. Polyoxyethylene ethers such as polyoxyethylene lauryl ether are described in the Merck index (12th edition: entry 7717). These adjuvant molecules are described in WO 99/52549. The polyoxyethylene ether according to the general formula (I) above may, if desired, be combined with another adjuvant. For example, a preferred adjuvant combination is preferably with CpG as described in the pending UK patent application GB 9820956.2.

[0123] It is an embodiment of the invention that the antigens, including nucleic acid vector, of the invention be utilised with immunostimulatory agent. Preferably the immunostimulatory agent is administered at the same time as the antigens of the invention and in preferred embodiments are formulated together. It is another embodiment of the invention that the antigen and immunostimulatory agent (or vice versa) are administered sequentially to the same or adjacent sites, separated in time by periods of between 0-100 hours. Such immunostimulatory agents include but are not limited to: synthetic imidazoquinolines such as imiquimod [S-26308, R-837], (Harrison, et al., Vaccine 19: 1820-1826, 2001; and resiquimod [S-28463, R-848] (Vasilakos, et al., Cellular immunology 204: 64-74, 2000.; Schiff bases of carbonyls and amines that are constitutively expressed on antigen presenting cell and T-cell surfaces, such as tucaresol (Rhodes, J. et al., Nature 377: 71-75, 1995), cytokine, chemokine and co-stimulatory molecules as either protein or peptide, including for example pro-inflammatory cytokines such as Interferon, GM-CSF, IL-1 alpha, IL-1 beta, TGF- alpha and TGF - beta,

Th1 inducers such as interferon gamma, IL-2, IL-12, IL-15, IL-18 and IL-21, Th2 inducers such as IL-4, IL-5, IL-6, IL-10 and IL-13 and other chemokine and co-stimulatory genes such as MCP-1, MIP-1 alpha, MIP-1 beta, RANTES, TCA-3, CD80, CD86 and CD40L, other immunostimulatory targeting ligands such as CTLA-4 and L-selectin, apoptosis stimulating proteins and peptides such as Fas, (49), synthetic lipid based adjuvants, such as vaxfectin, (Reyes et al., Vaccine 19: 3778-3786, 2001) squalene, alpha- tocopherol, polysorbate 80, DOPC and cholesterol, endotoxin, [LPS], (Beutler, B., Current Opinion in Microbiology 3: 23-30, 2000); CpG oligo- and di-nucleotides (Sato, Y. et al., Science 273 (5273): 352-354, 1996; Hemmi, H. et al., Nature 408: 740-745, 2000) and other potential ligands that trigger Toll receptors to produce Th1-inducing cytokines, such as synthetic Mycobacterial lipoproteins, Mycobacterial protein p19, peptidoglycan, teichoic acid and lipid A.

[0124] Other suitable adjuvant include CT (cholera toxin, subunits A and B) and LT (heat labile enterotoxin from E. coli, subunits A and B), heat shock protein family (HSPs), and LLO (listeriolysin O; WO 01/72329).

[0125] Where the immunostimulatory agent is a protein, the agent may be administered either as a protein or as a polynucleotide encoding the protein.

[0126] Other suitable delivery systems include microspheres wherein the antigenic material is incorporated into or conjugated to biodegradable polymers/microspheres so that the antigenic material can be mixed with a suitable pharmaceutical carrier and used as a vaccine. The term "microspheres" is generally employed to describe colloidal particles which are substantially spherical and have a diameter in the range 10 nm to 2 mm. Microspheres made from a very wide range of natural and synthetic polymers have found use in a variety of biomedical applications. This delivery system is especially advantageous for proteins having short half-lives in vivo requiring multiple treatments to provide efficacy, or being unstable in biological fluids or not fully absorbed from the gastrointestinal tract because of their relatively high molecular weights. Several polymers have been described as a matrix for protein release. Suitable polymers include gelatin, collagen, alginates, dextran. Preferred delivery systems include biodegradable poly(DL-lactic acid) (PLA), poly(lactide-co-glycolide) (PLG), poly(glycolic acid) (PGA), poly(ϵ -caprolactone) (PCL), and copolymers poly(DL-lactic-co-glycolic acid) (PLGA). Other preferred systems include heterogeneous hydrogels such as poly(ether ester) multiblock copolymers, containing repeating blocks based on hydrophilic poly-(ethylene glycol) (PEG) and hydrophobic poly(butylene terephthalate) (PBT), or poly(ethylene glycol)-terephthalate/poly(butylene terephthalate) (PEGT/PBT) (Sohier et al. Eur. J. Pharm and Biopharm, 2003, 55, 221-228). Systems are preferred which provide a sustained release for 1 to 3 months such as PLGA, PLA and PEGT/PBT.

[0127] It is possible for the immunogenic or vaccine composition to be administered on a once off basis or, preferably, to be administered repeatedly, as many times as necessary, for example, between 1 and 7 times, preferably between 1 and 4 times, at intervals between about 1 day and about 18 months, preferably one month. This may be optionally followed by dosing at regular intervals of between 1 and 12 months for a period up to the remainder of the patient's life. In a preferred embodiment the patient receives the antigen in different forms in a "prime boost" regime. Thus for example the antigen, the fusion protein, is first administered as a protein adjuvant base formulation and then subsequently administered as a DNA based vaccine. This administration mode is preferred. The preferred adjuvant is a combination of a CpG-containing oligonucleotide and a saponin derivative, particularly the combination of CpG and QS21 as disclosed in WO 00/09159 and in WO 00/62800. The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are efficiently transported into the cells. Alternatively the DNA can be delivered via a particle bombardment approach, for example, gas-driven particle acceleration with devices such as those manufactured by Powderject Pharmaceuticals PLC (Oxford, UK) and Powderject Vaccines Inc. (Madison, WI) as taught herein. This approach offers a needle-free delivery approach wherein a dry powder formulation of microscopic particles, such as polynucleotide or polypeptide particles, are accelerated to high speed within a helium gas jet generated by a hand held device, propelling the particles into a target tissue of interest.

[0128] In another preferred embodiment, the DNA based vaccine will be administered first, followed by the protein adjuvant base formulation. Still another embodiment will concern the delivery of the DNA construct by means of specialised delivery vectors, preferably by the means of viral system, most preferably by the means of adenoviral-based systems. Other suitable viral-based systems of DNA delivery include retroviral, lentiviral, adeno-associated viral, herpes viral and vaccinia-viral based systems.

[0129] In another preferred embodiment, the protein adjuvant base formulation and DNA based vaccine may be co-administered at adjacent or overlapping sites. Dependent upon the nature of the DNA vaccine formulation, this can be achieved by mixing the DNA and protein adjuvant formulations prior to administration or by simultaneously administration of the DNA and protein adjuvant formulation.

[0130] The treatment regime will be significantly varied depending upon the size and species of patient concerned, the amount of nucleic acid vaccine and / or protein composition administered, the route of administration, the potency and dose of any adjuvant compounds used and other factors which would be apparent to a skilled medical practitioner.

[0131] Within further aspects, the present invention provides methods for stimulating an immune response in a patient, preferably a T cell response in a human patient, comprising administering a pharmaceutical composition described herein. The patient may be afflicted with lung or colon cancer or colorectal cancer or breast cancer, in which case the

methods provide treatment for the disease, or patient considered at risk for such a disease may be treated prophylactically.

[0132] Within further aspects, the present invention provides methods for inhibiting the development of a cancer in a patient, comprising administering to a patient a pharmaceutical composition as recited above. The patient may be afflicted with, for example, sarcoma, prostate, ovarian, bladder, lung, colon, colorectal or breast cancer, in which case the methods provide treatment for the disease, or patient considered at risk for such a disease may be treated prophylactically.

[0133] The present invention further provides, within other aspects, methods for removing tumour cells from a biological sample, comprising contacting a biological sample with T cells that specifically react with a polypeptide of the present invention, wherein the step of contacting is performed under conditions and for a time sufficient to permit the removal of cells expressing the protein from the sample.

[0134] Within related aspects, methods are provided for inhibiting the development of a cancer in a patient, comprising administering to a patient a biological sample treated as described above.

[0135] Methods are further provided, within other aspects, for stimulating and/or expanding T cells specific for a polypeptide of the present invention, comprising contacting T cells with one or more of: (i) a polypeptide as described above; (ii) a polynucleotide encoding such a polypeptide; and/or (iii) an antigen presenting cell that expresses such a polypeptide; under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells. Isolated T cell populations comprising T cells prepared as described above are also provided.

[0136] Within further aspects, the present invention provides methods for inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of a T cell population as described above.

The present invention further provides methods for inhibiting the development of a cancer in a patient, comprising the steps of: (a) incubating CD4+ and/or CD8+ T cells isolated from a patient with one or more of: (i) a polypeptide disclosed herein; (ii) a polynucleotide encoding such a polypeptide; and (iii) an antigen-presenting cell that expressed such a polypeptide; and (b) administering to the patient an effective amount of the proliferated T cells, and thereby inhibiting the development of a cancer in the patient. Proliferated cells may, but need not, be cloned prior to administration to the patient.

[0137] According to another embodiment of this invention, an immunogenic composition described herein is delivered to a host via antigen presenting cells (APCs), such as dendritic cells, macrophages, B cells, monocytes and other cells that may be engineered to be efficient APCs. Such cells may, but need not, be genetically modified to increase the capacity for presenting the antigen, to improve activation and/or maintenance of the T cell response, to have anti-tumor effects *per se* and/or to be immunologically compatible with the receiver (*i.e.*, matched HLA haplotype). APCs may generally be isolated from any of a variety of biological fluids and organs, including tumor and peritumoral tissues, and may be autologous, allogeneic, syngeneic or xenogeneic cells.

[0138] Certain preferred embodiments of the present invention use dendritic cells or progenitors thereof as antigen-presenting cells. Dendritic cells are highly potent APCs (Banchereau and Steinman, *Nature* 392:245-251, 1998) and have been shown to be effective as a physiological adjuvant for eliciting prophylactic or therapeutic antitumor immunity (see Timmerman and Levy, *Ann. Rev. Med.* 50:507-529, 1999). In general, dendritic cells may be identified based on their typical shape (stellate *in situ*, with marked cytoplasmic processes (dendrites) visible *in vitro*), their ability to take up, process and present antigens with high efficiency and their ability to activate naïve T cell responses. Dendritic cells may, of course, be engineered to express specific cell-surface receptors or ligands that are not commonly found on dendritic cells *in vivo* or *ex vivo*, and such modified dendritic cells are contemplated by the present invention. As an alternative to dendritic cells, secreted vesicles antigen-loaded dendritic cells (called exosomes) may be used within a vaccine (see Zitvogel et al., *Nature Med.* 4:594-600, 1998).

[0139] Dendritic cells and progenitors may be obtained from peripheral blood, bone marrow, tumor-infiltrating cells, peritumoral tissues-infiltrating cells, lymph nodes, spleen, skin, umbilical cord blood or any other suitable tissue or fluid. For example, dendritic cells may be differentiated *ex vivo* by adding a combination of cytokines such as GM-CSF, IL-4, IL-13 and/or TNF α to cultures of monocytes harvested from peripheral blood. Alternatively, CD34 positive cells harvested from peripheral blood, umbilical cord blood or bone marrow may be differentiated into dendritic cells by adding to the culture medium combinations of GM-CSF, IL-3, TNF α , CD40 ligand, LPS, flt3 ligand and/or other compound(s) that induce differentiation, maturation and proliferation of dendritic cells.

[0140] Dendritic cells are conveniently categorized as "immature" and "mature" cells, which allows a simple way to discriminate between two well characterized phenotypes. However, this nomenclature should not be construed to exclude all possible intermediate stages of differentiation. Immature dendritic cells are characterized as APC with a high capacity for antigen uptake and processing, which correlates with the high expression of Fc γ receptor and mannose receptor. The mature phenotype is typically characterized by a lower expression of these markers, but a high expression of cell surface molecules responsible for T cell activation such as class I and class II MHC, adhesion molecules (*e.g.*, CD54 and CD11) and costimulatory molecules (*e.g.*, CD40, CD80, CD86 and 4-1 BB).

[0141] APCs may generally be transfected with a polynucleotide of the invention (or portion or other variant thereof) such that the encoded polypeptide, or an immunogenic portion thereof, is expressed on the cell surface. Such transfection may take place *ex vivo*, and a pharmaceutical composition comprising such transfected cells may then be used for

therapeutic purposes, as described herein. Alternatively, a gene delivery vehicle that targets a dendritic or other antigen presenting cell may be administered to a patient, resulting in transfection that occurs *in vivo*. *In vivo* and *ex vivo* transfection of dendritic cells, for example, may generally be performed using any methods known in the art, such as those described in WO 97/24447, or the gene gun approach described by Mahvi et al., *Immunology and cell Biology* 75:456-460, 1997.

Antigen loading of dendritic cells may be achieved by incubating dendritic cells or progenitor cells with the tumor polypeptide, DNA (naked or within a plasmid vector) or RNA; or with antigen-expressing recombinant bacterium or viruses (e.g., vaccinia, fowlpox, adenovirus or lentivirus vectors). Prior to loading, the polypeptide may be covalently conjugated to an immunological partner that provides T cell help (e.g., a carrier molecule). Alternatively, a dendritic cell may be pulsed with a non-conjugated immunological partner, separately or in the presence of the polypeptide.

Definitions

[0142] Also provided by the invention are methods for the analysis of character sequences or strings, particularly genetic sequences or encoded protein sequences. Preferred methods of sequence analysis include, for example, methods of sequence homology analysis, such as identity and similarity analysis, DNA, RNA and protein structure analysis, sequence assembly, cladistic analysis, sequence motif analysis, open reading frame determination, nucleic acid base calling, codon usage analysis, nucleic acid base trimming, and sequencing chromatogram peak analysis.

[0143] A computer based method is provided for performing homology identification. This method comprises the steps of: providing a first polynucleotide sequence comprising the sequence of a polynucleotide of the invention in a computer readable medium; and comparing said first polynucleotide sequence to at least one second polynucleotide or polypeptide sequence to identify homology. A computer based method is also provided for performing homology identification, said method comprising the steps of: providing a first polypeptide sequence comprising the sequence of a polypeptide of the invention in a computer readable medium; and comparing said first polypeptide sequence to at least one second polynucleotide or polypeptide sequence to identify homology.

[0144] "Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as the case may be, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" can be readily calculated by known methods, including but not limited to those described in (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heine, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48: 1073 (1988). Methods to determine identity are designed to give the largest match between the sequences tested. Moreover, methods to determine identity are codified in publicly available computer programs. Computer program methods to determine identity between two sequences include, but are not limited to, the GAP program in the GCG program package (Devereux, J., et al., *Nucleic Acids Research* 12(1): 387 (1984)), BLASTP, BLASTN (Altschul, S.F. et al., *J. Molec. Biol.* 215: 403-410 (1990), and FASTA(Pearson and Lipman Proc. Natl. Acad. Sci. USA 85: 2444-2448 (1988). The BLAST family of programs is publicly available from NCBI and other sources (*BLAST Manual*, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al., *J. Mol. Biol.* 215: 403-410 (1990). The well known Smith Waterman algorithm may also be used to determine identity.

[0145] Parameters for polypeptide sequence comparison include the following:

Algorithm: Needleman and Wunsch, J. Mol Biol. 48: 443-453 (1970)

Comparison matrix: BLOSSUM62 from Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA. 89:10915-10919 (1992)

Gap Penalty: 8

Gap Length Penalty: 2

A program useful with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison WI. The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps).

[0146] Parameters for polynucleotide comparison include the following:

Algorithm: Needleman and Wunsch, J. Mol Biol. 48: 443-453 (1970)

Comparison matrix: matches = +10, mismatch = 0

Gap Penalty: 50

Gap Length Penalty: 3

Available as: The "gap" program from Genetics Computer Group, Madison WI. These are the default parameters for nucleic acid comparisons.

[0147] A preferred meaning for "identity" for polynucleotides and polypeptides, as the case may be, are provided in (1) and (2) below.

(1) Polynucleotide embodiments further include an isolated polynucleotide comprising a polynucleotide sequence having at least a 50, 60, 70, 80, 85, 90, 95, 97 or 100% identity to any of the reference sequences of SEQ ID NO: 9 to SEQ ID NO:16, wherein said polynucleotide sequence may be identical to any the reference sequences of SEQ ID NO:9 to SEQ ID NO:16 or may include up to a certain integer number of nucleotide alterations as compared to the reference sequence, wherein said alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence, and wherein said number of nucleotide alterations is determined by multiplying the total number of nucleotides in any of SEQ ID NO:9 to SEQ ID NO:16 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of nucleotides in any of SEQ ID NO:9 to SEQ ID NO:16, or:

$$n_n \leq x_n - (x_n \cdot y),$$

wherein n_n is the number of nucleotide alterations, x_n is the total number of nucleotides in any of SEQ ID NO:9 to SEQ ID NO:16, y is 0.50 for 50%, 0.60 for 60%, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, 0.97 for 97% or 1.00 for 100%, and \cdot is the symbol for the multiplication operator, and wherein any non-integer product of x_n and y is rounded down to the nearest integer prior to subtracting it from x_n . Alterations of polynucleotide sequences encoding the polypeptides of any of SEQ ID NO:1 to SEQ ID NO:8 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations.

By way of example, a polynucleotide sequence of the present invention may be identical to any of the reference sequences of SEQ ID NO:9 to SEQ ID NO:16, that is it may be 100% identical, or it may include up to a certain integer number of nucleic acid alterations as compared to the reference sequence such that the percent identity is less than 100% identity. Such alterations are selected from the group consisting of at least one nucleic acid deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleic acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of nucleic acid alterations for a given percent identity is determined by multiplying the total number of nucleic acids in any of SEQ ID NO:9 to SEQ ID NO:16 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of nucleic acids in any of SEQ ID NO:9 to SEQ ID NO:16, or:

$$n_n \leq x_n - (x_n \cdot y),$$

wherein n_n is the number of nucleic acid alterations, x_n is the total number of nucleic acids in any of SEQ ID NO:9 to SEQ ID NO:16, y is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., \cdot is the symbol for the multiplication operator, and wherein any non-integer product of x_n and y is rounded down to the nearest integer prior to subtracting it from x_n .

(2) Polypeptide embodiments further include an isolated polypeptide comprising a polypeptide having at least a 50,60, 70, 80, 85, 90, 95, 97 or 100% identity to the polypeptide reference sequence of any of SEQ ID NO:1 to SEQ ID NO:8, wherein said polypeptide sequence may be identical to any of the reference sequence of SEQ ID NO: to SEQ ID NO:8 or may include up to a certain integer number of amino acid alterations as compared to the reference sequence, wherein said alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in

one or more contiguous groups within the reference sequence, and wherein said number of amino acid alterations is determined by multiplying the total number of amino acids in any of SEQ ID NO:1 to SEQ ID NO:8 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of amino acids in any of SEQ ID NO:1 to SEQ ID NO:8, or:

5

$$n_a \leq x_a - (x_a \cdot y).$$

10 wherein n_a is the number of amino acid alterations, x_a is the total number of amino acids in SEQ ID NO:2, y is 0.50 for 50%, 0.60 for 60%, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, 0.97 for 97% or 1.00 for 100%, and \cdot is the symbol for the multiplication operator, and wherein any non-integer product of x_a and y is rounded down to the nearest integer prior to subtracting it from x_a .

15 **[0148]** By way of example, a polypeptide sequence of the present invention may be identical to the reference sequence of any of SEQ ID NO:1 to SEQ ID NO:8, that is it may be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the percent identity is less than 100% identity. Such alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, inter-
20 spersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in any of SEQ ID NO:1 to SEQ ID NO:8 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of amino acids in any of SEQ ID NO:1 to SEQ ID NO:8, or:

25

$$n_a \leq x_a - (x_a \cdot y).$$

wherein n_a is the number of amino acid alterations, x_a is the total number of amino acids in any of SEQ ID NO:1 to SEQ ID NO:8, y is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and \cdot is the symbol for the multiplication operator,
30 and wherein any non-integer product of x_a and y is rounded down to the nearest integer prior to subtracting it from x_a .

Figure legends

[0149]

35

Figure 1: Sequence information for C-LytA. Each repeat has been defined on the basis of both multiple sequence alignment and secondary structure prediction using the following alignment programs: 1) MatchBox (Depiereux E et al. (1992) Comput Applic Biosci 8:501-9); 2) ClustalW (Thompson JD et al. (1994) Nucl Acid Res 22:4673-80);
3) Block-Maker (Henikoff S et al (1995) Gene 163:gc17-26)

40 Figure 2: CPC and native Constructs (SEQ ID NOs. 27-36)

Figure 3: Schematic structure of CPC-p501 His fusion protein expressed in *S. cerevisiae*

Figure 4: Primary structure of CPC-P501 His fusion protein (SEQ ID NO.41)

Figure 5: Nucleotide sequence of CPC P501 His(pRIT15201) (SEQ ID NO.42)

Figure 6: Cloning strategy for generation of plasmid pRIT 15201

45 Figure 7: Plasmid map of pRIT15201

Figure 8: Comparative expression of CPC P501 and P501 in *S.cerevisiae* strain DC5

Figure 9: Production of CPC-P501S HIS (Y1796) at small scale. Fig. 9A represents the antigen productivity as estimated by SDS-PAGE with silver staining; Fig. 9B represents the antigen productivity as estimated by western blot.

Figure 10: Purification scheme of CPC-P501-His produced by Y1796.

50 Figure 11: Pattern of CPC P501 His purified protein (4-12% Novex Nu-Page polyacrylamide precasted gels).

Figure 12: Native full-length P501 S sequence (SEQ ID NO: 17)

Figure 13: Sequence of the CPC-P501 S expression cassette of JNW735 (SEQ ID NO:18)

Figure 14: Two codon optimised P501S sequences (SEQ ID NO:19-20)

Figure 15: Re-engineered codon optimised sequence 19 (SEQ ID NO:21)

55 Figure 16: Re-engineered codon optimised sequence 20 (SEQ ID NO:22)

Figure 17: The starting sequence for the optimisation of CPC (SEQ ID NO:23)

Figure 18: Representative codon optimised CPC sequences (SEQ ID NO:24-25)

Figure 19: Engineered CPC codon optimised sequence (SEQ ID NO:26)

Figure 20: P501S CPC fusion candidate constructs and sequences (SEQ ID NOs. 37-40 & 45-48)

Figure 21: Western blot analysis of CHO cells following transient transfection with P501 S (JNW680), CPC-P501S (JNW735) and empty vector control.

Figure 22: Anti-P501S antibody responses following immunisation at day0, 21 & 42 with pVAC-P501S (JNW680, mice B1-9) or Empty vector (pVAC, mice A1-6). A pre-bleed was taken at day -1. Subsequently bleeds were taken at day 28 and day 49 (mice A1-3, B1-3) and day 56 (mice A4-6, B4-9). All sera was tested at 1/100 dilution. The results for the pVAC immunised mice were averaged. The results for the individual pVAC-P501 S immunised mice are shown. As a positive control, sera from Adeno-P501 S immunised mice (Corixa Corp, diluted 1/100) is included.

Figure 23: Peptide library screen using C57BL/6 mice immunised at day 0, 21, 42, and 70 with pVAC-P501 S (JNW680). All peptides were used at a final concentration of 50µg/ml. Peptides 1-50 are overlapping 15-20mers obtained from Corixa. Peptides 51-70 are predicted 8-9mer Kb and Db epitopes and were ordered from Mimotopes (UK). Samples 71-72 and 73-78 are DMSO controls and no peptide controls respectively. Graph A shows the IFN-γ responses whilst Graph B shows the IL-2 responses. Peptides selected for use in subsequent immunoassays are shown in black.

Figure 24: Cellular responses by ELISPOT at day 77 following PMID immunisation at day 0, 21, 42, and 70 with pVAC-P501S (JNW680, B6-9) and pVAC empty (A4-6). Peptide 18, 22 & 48 were used at 50µg/ml. CPC-P501 S protein was used at 20µg/ml. Graph A shows the IFN-γ responses whilst Graph B shows the IL-2 responses.

Figure 25: Comparison of P501 S and CPC-P501 S. Cellular responses were measured by IL-2 ELISPOT using peptide 22 (10µg/ml) at day 28. Mice were immunised by PMID at day 0 and 21 with pVAC empty (control), pVAC-P501 S (JNW680) and CPC-P501 S (JNW735).

Figure 26: Immune response (lymphoproliferation on spleen cells) following protein immunisation with CPC-P501 S.

Figure 27: Evaluation of the immune response to different CPC-P501 S constructs. Cellular responses were measured by IL-2 ELISPOT at day 28. Mice were immunised by PMID at day 0 and 21 with p7313-ie empty (control), JNW735 and CPC-P501S constructs (JNW770, 771 and 773)

Figure 28: MUC-1 CPC sequences (SEQ ID NOs. 49 & 50)

Figure 29: ss-CPC-MUC-1 sequences (SEQ ID NOs. 51 & 52)

[0150] The invention will be further described by reference to the following examples:

EXAMPLE I: Preparation of the recombinant Yeast strain Y1796 expressing P501 Fusion Protein containing a C-LytA-P2-C-LytA (CPC) as fusion partner

1. - Protein design

[0151] The structure of the fusion protein C-P2-C-p501 (alternatively named CPC-P501) to be expressed in *S. cerevisiae* is depicted in figure 3. This fusion contains the C-terminal region of gene LytA (residues 187 to 306), in which the P2 fragment of tetanus toxin (residues 830-843) has been inserted. The P2 fragment is placed between the residues 277 and 278 of C-Lyt-A. The C-lytA fragment containing the P2 insertion is followed by P501 (residues amino acid 51 to 553) and by the His tail.

[0152] The primary structure of the resulting fusion protein has the sequence described in figure 4 and the coding sequence corresponding to the above protein design is in figure 5.

2. - Cloning strategy for the generation of a yeast plasmid expressing CPC-P501 (51-553)-His fusion protein

[0153]

- The starting material is the yeast vector pRIT15068 (UK patent application 0015619.0).
- This vector contains the yeast Cup1 promoter, the yeast alpha prepro signal coding sequence and the coding sequence corresponding to residues 55 to 553 of P501S followed by His tail.
- The cloning strategy outlined in figure 6 include the following steps:

a) The first step is the insertion of P2 sequence (codon-optimised for yeast expression) in frame, inside the C-lytA coding sequence. The C-lytA coding sequence is harbored by plasmid pRIT 14662 (PCT/EP99/00660). The insertion is done using an adaptor formed by two complementary oligonucleotides named P21 and P22 into the plasmid pRIT 14662 previously open by NcoI

The sequence of P21 and P22 is:

P21 5' catgcaatacatcaaggctaactctaagttcattggtatcactgaaggcgt 3'
 P22 3' gttatgtagttccgattgagattcaagtaaccatagtgactccgcagttac 5'

After ligation and transformation of *E. coli* and transformant characterization, the plasmid named pRIT15199 is obtained.

b) The second step is the preparation of C-lytA-P2-C-lytA DNA fragment by PCR amplification. The amplification is performed using pRIT15199 as template and the oligonucleotides named C-LytANOTATG and C-LytA-aa55. The sequence of both oligonucleotides being:

C-LytANOTATG

=5'aaaaccatggcggccgcttacgtacattccgacggctctatccaaaagacaag 3'

C-LytA-aa55 =5'aaacatgtacatgaacttttctggcctgtctgccagtttc 3'

The amplified fragment is treated with the restriction enzymes NcoI and Afl III to generate the respective cohesive ends.

c) The next step is the ligation of the above fragment with vector pRIT15068 (largest fragment obtained after NcoI treatment) to generate the complete fusion protein coding sequence. After ligation and *E. coli* transformation the plasmid named pRIT15200 is obtained. In this plasmid the remaining unique NcoI site contains the ATG coding for the start codon.

d) In the next step a NcoI fragment containing the CUP1 promoter and a portion of 2 μ plasmid sequences is prepared from plasmid pRIT 15202. Plasmid pRIT 15202 is a yeast 2 μ derivative containing the CUP1 promoter with an NcoI site at ATG (ATG sequence: AAACC ATG)

e) The NcoI fragment isolated from pRIT 15202 is ligated to pRIT15200, previously open with NcoI, in the right orientation, in such a way the pCUP1 promoter is at the 5' side of the coding sequence. This results in the generation of a final expression plasmid named pRIT15201 (see figure 7).

3. - Preparation of the recombinant yeast strain Y1796 (RIX4440)

[0154] The plasmid pRIT 15201 is used to transform the *S. cerevisiae* strain DC5 (ATCC 20820). After selection and characterisation of the yeast transformants containing the plasmid pRIT 15201 a recombinant yeast strain named Y1796 expressing CPC-P501-His fusion protein is obtained. The protein after reduction and carboxyamidation, is isolated and purified by affinity chromatography (IMAC) followed by anion exchange chromatography (Q Sepharose FF).

Example II

[0155] In analogous fashion proteins constructs as depicted in figure 2 may be expressed utilising the corresponding DNA sequences shown therein. In particular, yeast strain SC333 (construct 2) corresponds to Y1796 strain but expressing P501₅₅₋₅₅₃ devoid of the CPC fusion partner. Yeast strain Y1800 (construct 3) corresponds to Y1796 strain but additionally comprises the native sequence signal for P501 S (aa1-aa34), while yeast strain Y1802 (construct 4) comprises the alpha pre signal sequence upstream CPC-P501S sequence. Yeast strain Y1790 (construct 5) is expressing a P501S construct devoid of CPC and having the alpha prepro signal sequence.

Example III. Preparation of purified CPC-P501

1. - Production of CPC-P501S HIS (Y1796) at small scale

[0156] For Y1796, in minimal medium supplemented with histidine, expression is induced in log phase by addition of CuSO₄ ranging from 100 to 500 μ M, and culture is maintained at 30°. Cells are harvested after 8 or 24h induction. Copper is added just before use and not mixed with medium in advance.

[0157] For SDS PAGE analysis, yeast cells extraction is performed in citrate phosphate buffer pH4.0 + 130 mM NaCl. Extraction is performed with glass beads for small cell quantity and with French press for higher cells quantity, and then mixed with sample buffer and SDS-PAGE analysed. Results of comparative analysis on SDS PAGE of the different constructs are depicted in figure 8 and summarised in Table 2 below.

As shown in Table 1 below, the level of expression of the culture is much higher for Y1796 strain as compared to the expression level of parent strain SC333, a strain expressing the corresponding P501S-His devoid of CPC partner. Likewise, the presence of a signal sequence (alpha pre) does not affect the results discussed above: the level of

expression of the culture is much higher for Y1802 strain as compared to the expression level of corresponding strain Y1790, a strain expressing the corresponding P501S-His devoid of CPC partner.

Table 2

Recombinant Strain	Plasmid	Promotor	Signal sequence	Fusion Partner	P501 aa sequences	Expressio n level
SC333	Ma333	CUP1	-	-	55-553-His	⊖ND
Y1796	pRIT 15201	CUP 1	-	CPC	51-553- His	+++
Y1802	pRIT 15219	CUP 1	α pre	CPC	51-553- His	++++
Y1790	pRIT 15068	CUP 1	α prepro	-	55-553- His	+
CPC = clyta P2 clyta						
ND= not detectable, even in western blot						
+ = detectable in western blot						
+++ / ++++ = detectable in western blot and visible in silver stained gels						

2. - Fermentation of Y1796 (RIX4440) at larger scale

[0158] 100 μ l of the working seed are spread on solid medium and grown for approximately 24h at 30°C. This solid pre-culture is then used to inoculate a liquid pre-culture in shake flasks.

[0159] This liquid pre-culture is grown for 20h at 30°C and transferred into a 20L fermenter. The fed-batch fermentation includes a growth phase of about 44h and an induction phase of about 22h.

[0160] The carbon source (glucose) was supplemented to the culture by a continuous feeding. The residual glucose concentration was maintained very low (≤ 50 mg/L) in order to minimise the ethanol production by fermentation. This was realised by limiting the development of the micro-organism by limited glucose feed rate.

At the end of the growth phase, CUP1 promoter is induced by adding CuSO₄ in order to produce the antigen.

[0161] The absence of contaminations was checked by inoculating 10⁶ cells into standard TSB and TH1 vials supplemented with nystatine and incubated respectively for 14 days at 20-25°C and at 30-35°C. No growth was observed as expected.

3. - Antigen characterisation and productivity

[0162] Cell homogenates were prepared by French pressing of fermentation samples harvested at different times during the induction phase and analysed by SDS-PAGE and Western Blot. It was shown that the major part of the protein of interest was located in the insoluble fraction obtained from the cell homogenate after centrifugation. The SDS-PAGE and Western Blot analyses shown in the Figures below were realised on the pellets obtained after centrifugation of these cell homogenates.

[0163] Figures 8 A and B show a kinetics of the antigen production during the induction phase for culture PR0127. It appears that no antigen expression occurred during the growth phase. The specific antigen productivity seems to increase from the beginning of the induction phase up to 6h and then remained quite stable up to the end. But the volumetric productivity increased by a factor 1.5 to 2 due to biomass accumulation observed during the same period of time. The antigen productivity was estimated at about 500 mg per litre of fermentation broth by comparing purified reference of the antigen and crude extracts on SDS-PAGE with silver staining (figure 9A) and WB analyses using an anti-P501 S antibody (a murine ascite directed against P501S aa439-aa459 used at a dilution of 1/1000) (figure 9B).

Example IV. Purification of CPC-P501 (51-553)-His fusion protein produced by Y1796

[0164] After the cell breakage, the protein is associated with the pellet fraction. A carbamido-methylation of the molecule has been introduced in the process in order to cope with the oxidative aggregation of the molecule with itself or with host cell protein contaminants through covalent bridging with disulphide bonds. The use of detergents has also been required to manage the hydrophobic character of this protein (12 trans-membrane domains predicted).

[0165] The purification protocol, developed for the scale of 1 L of culture OD (optical density) 120, is described in figure 10. All the operations are performed at room temperature (RT).

According to DOC TCA BCA protein assay, the global purification yield is 30 - 70 mg of purified antigen / L of culture OD 120. The yield is linked to the level of expression of the culture and is higher as compared to the purification yield

of parent strain expressing unfused P501 S-His.

The protein assay is performed as followed: proteins are first precipitated using TCA (trichloroacetic acid) in the presence of DOC (deoxycholate) then dissolved in a alkaline medium in the presence of SDS. The proteins then react with BCA (bicinchoninic acid) (Pierce) to form a soluble purple complex presenting a high adsorbance at 562 nm, which is proportional to the amount of proteins present in the sample.

SDS-PAGE analysis of 3 purified bulks (figure 11) shows no difference in reducing and non reducing conditions (cf. lanes 2, 3 and 4 versus lanes 5, 6 and 7). The pattern consists of a major band at 70 kDa, a smear of higher MW and faint degradation bands. All the bands are detected by a specific anti P501 S monoclonal antibody.

Example V. Vaccine preparation using CPC- P501S His protein

[0166] The protein of Example 3 or 4 can be formulated into a vaccine containing QS21 and 3D-MPL in an oil in water emulsion.

1. - Vaccine preparation:

[0167] The antigen produced as shown in Example 1 to 3 a C-LytA - P2 - P501 S His. As an adjuvant, the formulation comprises a mixture of 3 de -O-acylated monophosphoryl lipid A (3D-MPL) and QS21 in an oil/water emulsion. The adjuvant system SBAS2 has been previously described WO 95/17210.

[0168] **3D-MPL:** is an immunostimulant derived from the lipopolysaccharide (LPS) of the Gram-negative bacterium *Salmonella minnesota*. MPL has been deacylated and is lacking a phosphate group on the lipid A moiety. This chemical treatment dramatically reduces toxicity while preserving the immunostimulant properties (Ribi, 1986). Ribi Immunochemistry produces and supplies MPL to SB-Biologicals.

Experiments performed at Smith Kline Beecham Biologicals have shown that

3D-MPL combined with various vehicles strongly enhances both the humoral and a TH1 type of cellular immunity.

[0169] **QS21:** is a natural saponin molecule extracted from the bark of the South American tree *Quillaja saponaria* Molina. A purification technique developed to separate the individual saponins from the crude extracts of the bark, permitted the isolation of the particular saponin, QS21, which is a triterpene glycoside demonstrating stronger adjuvant activity and lower toxicity as compared with the parent component. QS21 has been shown to activate MHC class I restricted CTLs to several subunit Ags, as well as to stimulate Ag specific lymphocytic proliferation (Kensil, 1992). Aquila (formally Cambridge Biotech Corporation) produces and supplies QS21 to SB-Biologicals.

Experiments performed at SmithKline Beecham Biologicals have demonstrated a clear synergistic effect of combinations of MPL and QS21 in the induction of both humoral and TH1 type cellular immune responses.

[0170] **The oil/water emulsion** is composed an organic phase made of of 2 oils (a tocopherol and squalene), and an aqueous phase of PBS containing Tween 80 as emulsifier. The emulsion comprised 5% squalene 5% tocopherol 0.4% Tween 80 and had an average particle size of 180 nm and is known as SB62 (see WO 95/17210).

Experiments performed at SmithKline Beecham Biologicals have proven that the adjunction of this O/W emulsion to 3D-MPL/QS21 (SBAS2) further increases the immunostimulant properties of the latter against various subunit antigens.

2. - Preparation of emulsion SB62 (2 fold concentrate):

[0171] Tween 80 is dissolved in phosphate buffered saline (PBS) to give a 2% solution in the PBS. To provide 100 ml two fold concentrate emulsion 5g of DL alpha tocopherol and 5ml of squalene are vortexed to mix thoroughly. 90ml of PBS/Tween solution is added and mixed thoroughly. The resulting emulsion is then passed through a syringe and finally microfluidised by using an M110S microfluidics machine. The resulting oil droplets have a size of approximately 180 nm.

3. - Formulations:

[0172] A typical formulation containing 3D-MPL and QS21 in an oil/water emulsion is performed as follows: 20µg - 25 µg C-LytA P2-P501S are diluted in 10 fold concentrated of PBS pH 6.8 and H₂O before consecutive addition of SB62 (50µl), MPL (20µg), QS21 (20µg), optionally comprising CpG oligonucleotide (100 µg) and 1 µg/ml thiomersal as preservative. The amount of each component may vary as necessary. All incubations are carried out at room temperature with agitation.

Example VI. Codon-optimised P501S sequences**1. - Generation of the control recombinant plasmids:**

[0173] Full-length P501S sequence was cloned into pVAC (Thomsen, Immunology, 1998; 95:510P105), generating expression plasmid JNW680. SEQ ID NO:17 represents human P501S expression cassette in the plasmid JNW680 and is illustrated in Figure 12. The protein sequence of SEQ ID NO:17 is shown in single letter format, the start and stop codons being shown in bold. The Kozak sequence is denoted by the hash symbols. The codon usage index of the human P501 S sequence (SEQ ID NO:17) is 0.618, as calculated by the SynGene programme.

SynGene programme

[0174] Basically, the codons are assigned using a statistical method to give synthetic gene having a codon frequency closer to that found naturally in highly expressed *E. coli* and human genes.

[0175] SynGene is an updated version of the Visual Basic program called CalcGene, written by R. S. Hale and G. Thompson (Protein Expression and Purification Vol. 12 pp.185-188 (1998)). For each amino acid residue in the original sequence, a codon was assigned based on the probability of it appearing in highly expressed *E. coli* genes. Details of the CalcGene program, which works under Microsoft Windows 3.1, can be obtained from the authors. Because the program applies a statistical method to assign codons to the synthetic gene, not all resulting codons are the most frequently used in the target organism. Rather, the proportion of frequently and infrequently used codons of the target organism is reflected in the synthetic sequence by assigning codons in the correct proportions. However, as there is no hard-and-fast rule assigning a particular codon to a particular position in the sequence, each time it is run the program will produce a different synthetic gene - although each will have the same codon usage pattern and each will encode the same amino acid sequence. If the program is run several times for a given amino acid sequence and a given target organism, several different nucleotide sequences will be produced which may differ in the number, type and position of restriction sites, intron splice signals etc., some of which may be undesirable. The skilled artisan will be able to select an appropriate sequence for use in expression of the polypeptide on the basis of these features.

[0176] Furthermore, since the codons are randomly assigned on a statistical basis, it is possible (although perhaps unlikely) that two or more codons which are relatively rarely used in the target organism might be clustered in close proximity. It is believed that such clusters may upset the machinery of translation and result in particularly low expression rates, so the algorithm for choosing the codons in the optimized gene excludes any codons with an RSCU value of less than 0.2 for highly expressed genes in order to prevent any rare codon clusters being fortuitously selected. The distribution of the remaining codons is then allocated according to the frequencies for highly expressed *E. coli* to give an overall distribution within the synthetic gene that is typical such genes (coefficient = 0.85) and also for highly expressed human genes (coefficient = 0.50).

Syngene (Peter Ertl, unpublished), an updated version of the CalcGene program, allows exclusion of rare codons to be optional, and is also used to allocate codons according to the codon frequency pattern of highly expressed human genes.

[0177] The sequence of the CPC-P501 S cassette cloned from the vector pRIT15201 (see Figure 7) into pVAC, thereby generating plasmid JNW735, is set forth in SEQ ID NO:18 and is illustrated in Figure 13. This sequence is identical to the pRIT15201 sequence with the exception of the removal of the His tag and the addition of a Kozak sequence (GCCACC) and appropriate restriction enzyme sites. The amino acid sequence of SEQ ID NO:18 is shown in single letter format, the start and stop codons are shown in bold. The boxed residues are the P2 helper epitope of tetanus toxoid. The underlined residues are the Clyta purification tag. The Kozak sequence is denoted by the hash symbols.

2. - Generation of the recombinant plasmids with P501S codon optimised sequences:

[0178] Although the codon coefficient index (CI) of P501S native sequence is already high (0.618), it is possible increase the CI value further. This will have two potential benefits - to improve the antigen expression and/or immunogenicity and to reduce the possibility for recombination between the P501 S vector and genomic sequences.

[0179] Using the Syngene programme, a selection (SEQ ID NO:19 to SEQ ID NO:20) of codon optimised sequences was obtained (Figure 14). Table 3 below shows a comparison of the codon coefficient index for the starting P501 S sequence and the two representative codon optimised sequences, selected on the basis of a suitable restriction enzyme site profile and a good CI index.

Table 3 - Comparison of the codon coefficient indices of two codon optimised P501 S genes

Sequence	Codon coefficient index (CI)
P501 S	0.618

(continued)

Sequence	Codon coefficient index (CI)
SEQ ID NO:19	0.725
SEQ ID NO:20	0.755

3. Further evaluation of the codon-optimised sequences

Sequence SEQ ID NO:19

[0180] Although SEQ ID NO: 19 has a good CI index (0.725), it contains a doublet of rare codons at amino acids position 202 and 203. These codons were manually substituted with more frequent codons by changing the DNA sequence from TTGTTG to CTGCTG. To facilitate cloning and expression, restriction enzyme sites and a Kozak sequence were added. The final engineered sequence (SEQ ID NO:21) is shown in Figure 15. The Syngene programme was used to fragment this sequence into oligonucleotides with a minimum overlap of 19-20 bases. Therefore, Figure 15 shows the re-engineered P501S codon optimised SEQ ID NO. 19. Restriction enzyme sites are underlined, Kozak sequence is bolded, re-engineered DNA sequence to remove a rare codon doublet is boxed.

[0181] Using a two-step PCR protocol, the overlapping primers generated by the Syngene programme were first assembled using a PCR Assembly protocol (detailed below). The assembly reaction generates a diverse population of fragments. The correct full-length fragment was recovered/amplified using the PCR recovery protocol and the terminal primers. The resulting PCR fragment was excised from an agarose gel, purified, restricted with NheI and XhoI and cloned into pVAC. Positive clones were identified by restriction enzyme analysis and confirmed by double-stranded sequencing. This generates plasmid JNW766, which, due to the error-prone nature of the PCR process, contained a single silent mutation (C to T at position 360 of SEQ ID NO: 21).

1. Assembly reaction - PCR conditions, generic protocol

[0182] Reaction mix (total volume = 50 μ l):

- 1 x Reaction buffer (Pfx or Proofstart)
- 1 μ l Oligo pool (equal mix of all overlapping oligos)
- 0.5mM dNTPs
- DNA polymerase (Pfx or Proofstart, 2.5-5U)
- +/-1mM MgSO₄
- +/-1x enhancer solution (Pfx enhancer or Proofstart buffer Q)

1. 94°C for 120s (Proofstart only)
2. 94°C for 30s
3. 40°C for 120s
4. 72°C for 10s
5. 94°C for 15s
6. 40°C for 30s
7. 72°C for 20s + 3s/cycle
8. Cycle to step 5, 25 times
9. Hold at 4°C

2. Recovery reaction - PCR conditions (generic protocol)

[0183] Reaction mix (total volume = 50 μ l):

- 1 x Reaction buffer (Pfx or Proofstart)
- 5-10 μ l assembly reaction mix
- 0.3-0.75mM dNTPs
- 50pmol primer (5' terminal primer, sense orientation)
- 50pmol primer (3' terminal primer, anti-sense orientation)
- DNA polymerase (Pfx or Proofstart, 2.5-5U)
- +/-1 mM MgSO₄

- +/-1x enhancer solution (Pfx enhancer or Proofstart buffer Q)

1. 94°C 120s (Proofstart only)
2. 94°C 45s
3. 60°C 30s
4. 72°C 120s
5. Cycle to step 2, 25 times
6. 72°C 240s
7. Hold at 4°C

Sequence SEQ ID NO:20

[0184] Although SEQ ID NO: 20 has a very good CI index (0.755), it was noticed that it contained a doublet of rare codons at amino acids position 131 and 132. These codons were manually substituted with more frequent codons by changing the DNA sequence from TTGTTG to CTGCTG. To facilitate cloning, an internal BamHI site was removed by mutating G to C (see the double-underlined nucleotide in Figure 16). To facilitate cloning and expression, restriction enzyme sites and a Kozak sequence were added. The final engineered sequence (SEQ ID NO:22) is shown in Figure 16. The Syngene programme was used to fragment this sequence into oligonucleotides with a minimum overlap of 19-20 bases.

Figure 16 therefore shows the re-engineered P501S codon optimised sequence 20 (SEQ ID NO:22). Restriction enzyme sites are underlined, Kozak sequence is bolded, re-engineered DNA sequence to remove a rare codon doublet is boxed and a silent point mutation to remove a BamHI site is double-underlined.

[0185] Using a similar two-step PCR protocol to the one described above, full-length P501S fragment was amplified and cloned into pVAC. Positive clones were identified by restriction enzyme analysis and confirmed by double-stranded sequencing. This generates plasmid JNW764. The sequence of the P501S coding cassette is shown in Figure 16 (SEQ ID NO: 22).

DNA Sequence similarity

[0186] Pair distances following alignment by the ClustalV (weighted) method are shown in Table 3 below. Table 4 below shows percent similarity between the starting human P501S sequence and the two codon optimised sequences SEQ ID NO:21 and 22 selected for further investigation. The data confirms that the codon optimised DNA sequences are approximately 80% similar to the original P501 S sequence.

Table 4

SEQ ID NO:	% similarity with starting P501S sequence
21	79.6
22	79.4

Example VII. Codon-optimised CPC sequences

1.- Approach

[0187] Since the original CPC sequence was originally designed for optimal expression in yeast, this section describes the process of codon optimising for human expression.

2.- Sequence design

[0188] The starting sequence for the optimisation of CPC is shown in Figure 17 (SEQ ID NO: 23). This is derived entirely from the pRIT15201 and contains the entire coding sequence of CPC plus four amino acids of P501S to facilitate downstream cloning. Using the Syngene programme, a selection of codon optimised sequences were obtained, from which representative sequences are shown in Figure 18 (SEQ ID NO: 24-25). Table 5 below shows a comparison of the codon coefficient index for the starting CPC sequence and the two representative codon optimised sequences.

Table 5. Codon coefficient indices for two CPC optimised sequences

Sequence	Codon coefficient index (CI)
Original CPC = SEQ ID NO:23	0.506
SEQ ID NO:24	0.809
SEQ ID NO:25	0.800

[0189] In addition to the codon optimisation, all sequences were also screened for restriction enzyme cloning sites. On the basis of the highest CI value and a favourable restriction enzyme site profile, SEQ ID NO: 24 was selected for construction. To facilitate cloning and expression, 5' and 3' cloning sites were added and a Kozak sequence (GCCACC) was inserted 5' of the initiating ATG start codon. This engineered sequence is shown in Figure 19 (SEQ ID NO:26). This sequence includes four amino acids of P501 S (boxed), restriction enzyme cloning sites (NheI and XhoI, underlined), a Kozak sequence (Bold), a stop codon (italicised) and 4bp of flanking irrelevant DNA to facilitate cloning.

[0190] The Syngene programme was used to fragment this sequence into 50-60-mer oligonucleotides with a minimum overlap of 18-20 bases.

Using a similar two-step PCR protocol to the one described above, the correct fragment was recovered/amplified and cloned into pVAC. Positive clones were identified by restriction enzyme analysis and sequence verified generating vector JNW759.

4.- DNA similarity

[0191] Pair Distances following alignment ClustalV (Weighted) are shown in Table 6 below. The table shows percent similarity at the DNA level between the starting sequence of CPC and the codon optimised sequence and confirms that the codon optimised sequences are approximately 80% similar to the original CPC sequence.

Table 6

Sequence SEQ ID NO:	% similarity with starting CPC sequence
24	80.2
25	81.6

Example VIII. Construction of the P501S fusion candidate

[0192] All the candidates shown in the schematic below are codon optimised and constructed using overlapping PCR methodologies from plasmids JNW764 and JNW759 as templates (SEQ ID NO: 22 and SEQ ID NO: 26 respectively), and cloned into the expression vector p7313 ie.

[0193] The four candidates shown schematically below are based upon CPC-P501S. Codon optimised CPC-P501S is construct A. Candidates B, C, D also include the sequence encoding the N terminal 50 amino acids of P501S, positioned either at the N terminus of CPC-P501S (construct D), the C terminus of CPC-P501S (construct C), or between CPC and P501S (construct B). A schematic representation of the constructs is given in Figure 20.

The nucleotide and protein sequence for each of the four constructs is shown in SEQ ID NO: 37-40 for the nucleotide sequences, and SEQ ID NO. 45-48 for the corresponding polypeptide sequences. In constructs A, C and D, the underlined codon preferentially encodes tyrosine (either TAC or TAT) but the nucleotide sequence may be altered to encode threonine (either ACA, ACC, ACG or ACT). In construct B, the underlined codon preferentially encodes threonine (either ACA, ACC, ACG or ACT), but the nucleotide sequence may be altered to encode tyrosine (either TAC or TAT). In all constructs, the coding sequence is flanked by appropriate restriction enzyme cloning sites (in this case, NotI and BamHI), and a Kozak sequence immediately upstream of the initiating ATG. Table 7 below shows the plasmid identification for the constructs detailed above:

Table 7

Construct	Amino acid at underlined codon	Sequence of codon	Plasmid ID
A	Tyrosine	TAC	JNW771
B	Threonine	ACA	JNW773
B	Tyrosine	TAC	JNW770

(continued)

Construct	Amino acid at underlined codon	Sequence of codon	Plasmid ID
C	Tyrosine	TAC	JNW777
D	Tyrosine	TAC	JNW769

[0194] The cellular responses following immunisation with p7313-ie (empty vector), pVAC-P501 S (JNW735), JNW770, JNW771 and JNW773 were assessed by ELISPOT following a primary immunisation by PMID at day 0 and three boosts at day 21, 42 and 70. Assays were carried out 7 days post boost. Figure 27 shows that good IL-2 ELISPOT responses were detected in mice immunised with JNW770, JNW771 and JNW773.

Example IX. Immunogenicity experiments using particle-mediated intra-dermal delivery (PMID) studies

[0195] Full-length P501 S, when delivered by particle mediated intra-dermal delivery (PMID), generates good antibody & cellular responses. These data demonstrate that the PMID is a very effective delivery route. Furthermore, comparison of P501 S and CPC-P501 S confirms that CPC-P501S induces a stronger immune response as determined by peptide ELISPOT.

1.- Materials & Methods

1.1. Cutaneous gene gun immunisation

[0196] Plasmid DNA was precipitated onto 2µm diameter gold beads using calcium chloride and spermidine. Loaded beads were coated onto Tefzel tubing as described (Eisenbraun et al, 1993; Pertmer et al, 1996). Particle bombardment was performed using the Accell gene delivery system (PCT WO 95/19799). For each plasmid, female C57BU6 mice were immunised on days 0, 21, 42 and 70. Each administration consisted of two bombardments with DNA/gold, providing a total dose of approximately 4-5 µg of plasmid.

1.2. ELISPOT assays for T cell responses to the P501S gene product

a) Preparation of splenocytes

[0197] Spleens were obtained from immunised animals at 7-14 days post boost. Spleens were processed by grinding between glass slides to produce a cell suspension. Red blood cells were lysed by ammonium chloride treatment and debris was removed to leave a fine suspension of splenocytes. Cells were resuspended at a concentration of 8×10^8 /ml in RPMI complete media for use in ELISPOT assays.

b) Screening of peptide library

[0198] A peptide library covering a majority of the P501 S sequence was obtained from Corixa Corp. The library contained fifty 15-20mer peptides overlapping by 4-11 amino acids peptides. The peptides are numbered 1-50. In addition, a prediction programme (H-G. Rammensee, et al.: Immunogenetics, 1999, 50: 213-219) (<http://syfpeithi.bmi-heidelberg.com/>) was used to predict putative Kb and Db epitopes from the P501 S sequence. The ten best epitopes for Kb and Db were ordered from Mimotopes (UK) and included in the library (peptides 51-70). For screening of the peptide library, peptides were used at a final concentration of 50µg/ml (approx. 25-50µM) in IFNγ and IL-2 ELISPOTS using the protocol described below. For IFNγ ELISPOTS, IL-2 was added to the assays at 10ng/ml. Splenocytes used for the screening were taken at day 84 from C57BU6 mice immunised at day 0, 21, 42 and 70. Three peptides were identified from the library screen - Peptides 18 (HCRQAYSVYAFMISLGGCLG), 22 (GLSAPSLSPHCCPCRARLAF) and 48 (VCLAAGITYVPPLLLEGVG). These peptides were subsequently used in the ELISPOT assays

c) ELISPOT assay

[0199] Plates were coated with 15µg/ml (in PBS) rat anti mouse IFNγ or rat anti mouse IL-2 (Pharmingen). Plates were coated overnight at +4°C. Before use the plates were washed three times with PBS. Splenocytes were added to the plates at 4×10^5 cells/well. Peptides identified in the library screen were re-ordered from Genemed Synthesis and used at a final concentration of 50µg/ml. CPC-P501S protein (GSKBio) was used in the assay at 20µg/ml. ELISPOT assays were carried out in the presence of either IL-2 (10ng/ml), IL-7 (10ng/ml) or no cytokine. Total volume in each

well was 200µl. Plates containing peptide stimulated cells were incubated for 16 hours in a humidified 37°C incubator.

e) Development of ELISPOT assay plates.

[0200] Cells were removed from the plates by washing once with water (with 10 minute soak to ensure lysis of cells) and three times with PBS. Biotin conjugated rat anti mouse IFNγ or IL-2 (Pharmingen) was added at 1µg/ml in PBS. Plates were incubated with shaking for 2 hours at room temperature. Plates were then washed three times with PBS before addition of Streptavidin alkaline phosphatase (Caltag) at 1/1000 dilution. Following three washes in PBS spots were revealed by incubation with BCIP substrate (Biorad) for 15-45 mins. Substrate was washed off using water and plates were allowed to dry. Spots were enumerated using an image analysis system devised by Brian Hayes, Asthma Cell Biology unit, GSK.

1.3. ELISA assay for antibodies to the P501 S gene product

[0201] Serum samples were obtained from the animals by venepuncture on days -1, 28, 49 and 56, and assayed for the presence of anti-P501S antibodies. ELISA was performed using Nunc Maxisorp plates coated overnight at 4°C with 0.5µg/ml of CPC-P501S protein (GSKBio) in sodium bicarbonate buffer. After washing with TBS-Tween (Tris-buffered saline, pH 7.4 containing 0.05 % of Tween 20) the plates were blocked with Blocking buffer (3% BSA in TBS-Tween buffer) for 2hrs at room temperature. All sera were incubated at 1:100 dilution for 1 hr at RT in Blocking buffer. Antibody binding was detected using HRP-conjugated rabbit anti-mouse immunoglobulins (#P0260, Dako) at 1:2000 dilution in Blocking buffer. Plates were washed again and bound conjugate detected using Fast OPD colour reagents (Sigma, UK). The reaction was stopped by the addition of 3M sulphuric acid, and the OPD product quantitated by measuring the absorbance at 490nm.

1.4. Transient transfection assays

[0202] Human P501 S expression from various DNA constructs was analysed by transient transfection of the plasmids into CHO (Chinese hamster ovary) cells followed by Western blotting on total cell protein. Transient transfections were performed with the Transfectam reagent (Promega) according to the manufacturer's guidelines. In brief, 24-well tissue culture plates were seeded with 5x10⁴ CHO cells per well in 1 ml DMEM complete medium (DMEM, 10% FCS, 2mM L-glutamine, penicillin 100IU/ml, streptomycin 100µg/ml) and incubated for 16 hours at 37°C. 0.5µg DNA was added to 25µl of 0.3M NaCl (sufficient for one well) and 2µl of Transfectam was added to 25µl of Milli-Q. The DNA and Transfectam solutions were mixed gently and incubated at room temperature for 15 minutes. During this incubation step, the cells were washed once in PBS and covered with 150µl of serum free medium (DMEM, 2mM L-glutamine). The DNA-Transfectam solution was added drop wise to the cells, the plate gently shaken and incubated at 37°C for 4-6 hours. 500µl of DMEM complete medium was added and the cells incubated for a further 48-72 hours at 37°C.

2. Western blot analysis of CHO cells transiently transfected with P501S plasmids

[0203] The transiently transfected CHO cells were washed with PBS and treated with a Versene (1:5000)/0.025% trypsin solution to transfer the cells into suspension. Following trypsinisation, the CHO cells were pelleted and resuspended in 50µl of PBS. An equal volume of 2x NP40 lysis buffer was added and the cells incubated on ice for 30 minutes. 100µl of 2x TRIS-Glycine SDS sample buffer (Invitrogen) containing 50mM DTT was added and the solution heated to 95°C for 5 minutes. 1-20µl of sample was loaded onto a 4-20% TRIS-Glycine Gel 1.5mm (Invitrogen) and electrophoresed at constant voltage (125V) for 90 minutes in 1x TRIS-Glycine buffer (Invitrogen). A pre-stained broad range marker (New England Biolabs, #P7708S) was used to size the samples. Following electrophoresis, the samples were transferred to Immobilon-P PVDF membrane (Millipore), pre-wetted in methanol, using an Xcell III Blot Module (Invitrogen), 1x Transfer buffer (Invitrogen) containing 20% methanol and a constant voltage of 25V for 90 minutes. The membrane was blocked overnight at 4°C in TBS-Tween (Tris-buffered saline, pH 7.4 containing 0.05 % of Tween 20) containing 3% dried skimmed milk (Marvel). The primary antibody (10E3) was diluted 1:1000 and incubated with the membrane for 1 hour at room temperature. Following extensive washing in TBS-Tween, the secondary antibody (HRP-conjugated rabbit anti-mouse immunoglobulins (#P0260, Dako)) was diluted 1:2000 in TBS-Tween containing 3% dried skimmed milk and incubated with the membrane for one hour at room temperature. Following extensive washing, the membrane was incubated with Supersignal West Pico Chemiluminescent substrate (Pierce) for 5 minutes. Excess liquid was removed and the membrane sealed between two sheets of cling film, and exposed to Hyperfilm ECL film (Amersham-PharmaciaBiotech) for 1-30 minutes.

3. Generation of the Full-length human P501S expression cassette

[0204] The starting point for the construction of a P501S expression cassette was the plasmid pcDNA3.1-P501 S (Corixa Corp), which has a pcDNA3.1 backbone (Invitrogen) containing a full-length human P501 S cDNA cassette cloned between the EcoRI and NotI sites. This vector is also termed JNW673. The presence of P501S was confirmed by fluorescent sequencing. The sequence of the cDNA cassette is given by the NCBI/Genbank sequence (accession number AY033593). Human P501 S was PCR amplified from JNW673 template DNA, restricted with XbaI and SalI and cloned into the NheI/XhoI sites of pVAC generating vector JNW680. The correct orientation of the fragment relative to the CMV promoter was confirmed by PCR and by DNA sequencing. The sequence of the expression cassette is shown in Figure 12 (SEQ ID NO: 17).

To construct a CPC-P501 S expression cassette, CPC-P501 S was PCR amplified from the vector pRIT15201 (see Figure 7), restricted with XbaI and SalI and cloned into the NheI and XhoI sites of pVAC, generating plasmid JNW735. The correct orientation was confirmed by PCR and sequencing. The sequence of the CPC-P501 S expression cassette is shown in Figure 13 (SEQ ID NO:18).

4. Expression of human P501S from plasmids JNW680 and JNW735

[0205] The P501S expression plasmids were transiently transfected into CHO cells and a total cell lysate prepared as described in methods. A Western blot of a total cell lysate identified single bands of approximately 55kDa and 62kDa for samples transfected with JNW680 and JNW735 respectively (Figure 21). This is consistent with the predicted molecular weights of 59.3kDa and 63.3kDa for P501 S and CPC-P501 S respectively. The addition of the CPC tag does not adversely affect the expression of P501 S.

5. Results

5.1. Antibody responses to human P501S following PMID immunisation

[0206] The antibody responses following immunisation with pVAC (empty vector) and pVAC-P501S (JNW680) were assessed by ELISA following a primary immunisation by PMID at day 0 and three boosts at day 21 and day 42 and day 70. Figure 22 shows the antibody responses from sera taken at day -1, day 28 and day 49 (mice A1-3, B1-3) and day 56 (mice A4-6, B4-9). Whilst there were some non-specific responses to the pVAC empty vector, specific responses to the P501 S construct were seen in 5 of 9 mice.

5.2. Identification of novel T cell epitopes from human P501S in C57BU6 mice by screening of a P501S peptide library

[0207] Following immunisation with JNW680 (pVAC-P501S) by PMID at day 0 and three boosts at day 21 and day 42 and day 70, ELISPOT assays were carried out at day 84. Peptides from the P501 S library were tested at 50µg/ml final concentration. From this initial screen, three peptides were found to stimulate IFN-γ and/or IL-2 secretion. Peptides 18, 22 and 48 (Figure 23). These peptides were used in subsequent cellular assays.

5.3. Cellular responses to pVAC-P501S (JNW680) following PMID immunisation

[0208] The cellular responses following immunisation with pVAC (empty vector) and pVAC-P501 S were assessed by ELISPOT following a primary immunisation by PMID at day 0 and three boosts at day 21, 42 and 70. Assays were carried out 7 days post boost. Two different assay conditions were used: 1) Peptides 18, 22 and 48 identified in the peptide library screen used at 50µg/ml final concentration and 2) CPC-P501S protein used at 20µg/ml final concentration. Figure 24A shows that whilst there were no P501 S-specific responses to the empty vector (A4-6), the pVAC-P501 S construct induced specific IFN-γ responses to Peptides 18 and 22 in all mice (B6-9) whilst one mouse (B7) also showed an IFN-γ response to Peptide 48. Figure 24B shows that all mice showed specific IL-2 responses to Peptides 18, 22 and 48. Furthermore, pVAC-P501 S immunised mice (B6-9) also showed moderate IL-2 responses to CPC-P501S, whereas the empty vector immunised mice (A4-6) showed no responses.

5.4. Comparison of cellular responses to P501S and CPC-P501S following PMID immunisation.

[0209] The cellular responses following immunisation with pVAC (empty vector), pVAC-P501S (JNW680) and CPC-P501S (JNW735) were assessed by ELISPOT following a primary immunisation by PMID at day 0 and boosts at day 21 and 42. Assays were carried out 7 days post boost. Two different assay conditions were used: 1) Peptides 18, 22

and 48 identified in the peptide library screen used at 50 µg/ml final concentration and 2) CPC-P501 S protein used at 20 µg/ml final concentration. Figure 25 shows that at day 28, CPC-P501 S induced good IL-2 responses to 10 µg/ml of peptide 22, whilst there were no P501 S-specific responses to either the empty vector or the pVAC-P501 S. These results were also seen using CPC-P501 S protein to re-stimulated the splenocytes. At day 49 (post 2nd boost), the responses induced by P501 S and CPC-P501 S were equivalent. These data suggest that the addition of the CPC tag improves the kinetics and/or magnitude of the response to P501 S.

Example IX. Immunogenicity experiments in mice using P501S Protein + adjuvant studies

1. Design and adjuvant formulation

[0210] The immune response induced by vaccination using the recombinant purified CPC-P501 S protein formulated in adjuvants is characterized in experiments performed in mice.

Groups of 5 to 10, eight weeks old female C57BL/6 mice are vaccinated, 2-6 times intramuscularly at 2 weeks intervals with 10 µg of the CPC-P501S protein formulated in different adjuvant systems. The volume administered corresponds to 1/10th of a human dose (50 µl).

The serology (total Ig response) and cellular response (T cell lymphoproliferation and cytokine production) are analyzed on spleen cells, 6-14 days after the last vaccination using standard protocols as described in Gérard, c. et al, 2001, Vaccine 19, 2583-2589.

[0211] The data of one representative experiment is shown. It included 5 groups of eight C57BL/6 female mice which received 4 intramuscular injections of CPC P501 (10 µg) + adjuvant (A, B, C) at days 0, 14, 28, 42. Example V provides an experimental protocol of how to carry out the formulations. Briefly the adjuvant formulations are as follows (quantities given for one dose of 100 µl):

- **Adjuvant A:** QS21 (10 µg), MPL (10 µg) and CpG7909 (100 µg) made according to the method disclosed in WO 00/62800;
- **Adjuvant B:** formulation of QS21 (20 µg), MPL (20 µg), CpG7909 (100 µg) and 50 µl SB62 oil-in-water emulsion (WO 95/17210);
- **Adjuvant C:** formulation of QS21 (10 µg), MPL (10 µg), CpG7909 (100 µg) and 10 µl SB62 oil-in-water emulsion (WO 99/12565).

2. Serology

[0212] The total Ig response induced by vaccination was measured by ELISA using either the CPC-P501 or RA12-P501 (C term, which is a truncated form of the P501 protein corresponding to the C terminus of the protein fused at its N terminus, to a TB derived protein RA12 - Ra12 is derived from MTB32A antigen described in Skeiky et al., Infection and Immun. (1999) 67:3998-4007).

The adjuvanted CPC-P501 S proteins give a good antibody response after vaccination.

3. Cellular response

3.1. Lymphoproliferation

[0213] 7 days after the latest vaccine, lymphoproliferation was performed on spleen cells individually. 2.10⁵ spleen cells were plated in quadruplicate, in 96 well microplate, in RPMI medium containing 1% normal mice serum. After 72 hours of re-stimulation with either the immunogen (CPC-P501) or the truncated protein (RA12 P501) at different concentration, 1 µCi 3H thymidine (Amersham 5Ci/ml) was added. After 16 hours, cells were harvested onto filter plates. Incorporated radioactivity was counted in a β counter. Results are expressed in CPM or as stimulation indexes* (geomean CPM in cultures with antigen / geomean CPM in cultures without antigen).

Re-stimulation with ConA (2 µg/ml) as positive control was included as positive control.

[0214] As shown in Figure 26, a P501 specific lymphoproliferation is seen in the spleen of all groups of mice receiving the adjuvanted protein after in vitro re-stimulation with either the immunogen or another P501 protein made in another expression system (*E coli*), indicating that T cells have been primed in vivo by the vaccination.

3.2. IFNγ production measured by intracellular staining of spleen cells

[0215] Bone Marrow Dendritic Cells (BMDC) obtained after culture of mouse PBL for 7 days in the presence of GM-CSF. 7 days after the latest vaccine, spleen or PBL are collected and a cell suspension prepared. 10⁶ cells (1 pool per group)

were incubated +/-18hrs with 10e5 BMDC pulsed overnight with 10µg/ml of either the CPCp501 protein or the RA12. After a treatment with the 2.4.G.2 antibody, spleen cells were stained with fluorescent anti CD4 and CD8 antibodies. (anti CD4-APC and an anti CDBPerCP). After a permeabilization and fixation step, cells were stained with a fluorescent anti IFNg-FITC antibody.

[0216] In mice vaccinated with CPC P501 in different adjuvant, both CD4 and CD8 T cells are shown to produce IFNg in response to DC pulsed with either the immunogen and the C-term p501 made in *E coli* (as shown by intracellular straining of spleen and PBLs). There is an increase of 4-10X in the % of cells making this cytokine in the groups receiving the adjuvanted CPC-P501 S compared to the protein alone, and between 0.1 to 10% of CD4 or CD8 T cells are shown to produce IFNg.

[0217] In conclusion, these data allow to conclude that the adjuvanted CPC-P501 protein is immunogenic in mice. Both a P501 specific humoral and cellular responses including IFNg production by CD4 and CD8 T cells can be detected after several intramuscular vaccination with CPC P501 in adjuvants.

Example X. CPC-MUC-1 constructs and sequences

[0218] CPC sequence is taken from nucleotide SEQ ID NO. 28.
MUC1 sequence is available from Genbank database (accession number NM_002456).

1. MUC1-CPC construct

[0219] Due to the presence of a signal sequence in MUC1 that is cleaved post-translationally, the CPC motif was placed at the C-terminus. The resulting MUC1-CPC DNA sequence is depicted in SEQ ID NO. xx (figure 28A) and the corresponding MUC1-CPC protein sequence in SEQ ID NO. yy (figure 28B).

2. ss-CPC-MUC1 construct

[0220] Due to the presence of a signal sequence in MUC1 that is cleaved post-translationally, the MUC1 signal sequence was replaced by a heterologous leader sequence (from the human immunoglobulin heavy chain) and the CPC motif was inserted between the heterologous leader sequence and the MUC1 sequence, generating a sequence termed ss-CPC-MUC1 as depicted in figure 29.

SEQUENCE LISTING

[0221]

<110> GlaxosmithKline Biologicals sa
Glaxo Group Ltd

<120> Immunogenic compositions

<130> B45311

<160> 52

<170> FastSEQ for Windows version 4.0

<210> 1

<211> 15

<212> PRT

<213> Streptococcus pneumoniae

<400> 1

Gly Trp Gln Lys Asn Asp Thr Gly Tyr Trp Tyr Val His Ser Asp
1 5 10 15

<210> 2

<211> 21
 <212> PRT
 <213> Streptococcus pneumoniae

5 <400> 2

Gly Ser Tyr Pro Lys Asp Lys Phe Glu Lys Ile Asn Gly Thr Trp Tyr
 1 5 10 15
 Tyr Phe Asp Ser Ser
 20

15 <210> 3
 <211> 22
 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 3

20 Gly Tyr Met Leu Ala Asp Arg Trp Arg Lys His Thr Asp Gly Asn Trp
 1 5 10 15
 Tyr Trp Phe Asp Asn Ser
 20

25 <210> 4
 <211> 20
 <212> PRT
 <213> Streptococcus pneumoniae
 30 <400> 4

35 Gly Glu Met Ala Thr Gly Trp Lys Lys Ile Ala Asp Lys Trp Tyr Tyr
 1 5 10 15
 Phe Asn Glu Glu
 20

40 <210> 5
 <211> 21
 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 5

45 Gly Ala Met Lys Thr Gly Trp Val Lys Tyr Lys Asp Thr Trp Tyr Tyr
 1 5 10 15
 Leu Asp Ala Lys Glu
 20

50 <210> 6
 <211> 23
 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 6

Gly Ala Met Val Ser Asn Ala Phe Ile Gln Ser Ala Asp Gly Thr Gly
 1 5 10 15
 Trp Tyr Tyr Leu Lys Pro Asp
 20

<210> 7

<211> 142

<212> PRT

<213> Streptococcus pneumoniae

<400> 7

Gly Trp Gln Lys Asn Asp Thr Gly Tyr Trp Tyr Val His Ser Asp Gly
 1 5 10 15
 Ser Tyr Pro Lys Asp Lys Phe Glu Lys Ile Asn Gly Thr Trp Tyr Tyr
 20 25 30
 Phe Asp Ser Ser Gly Tyr Met Leu Ala Asp Arg Trp Arg Lys His Thr
 35 40 45
 Asp Gly Asn Trp Tyr Trp Phe Asp Asn Ser Gly Glu Met Ala Thr Gly
 50 55 60
 Trp Lys Lys Ile Ala Asp Lys Trp Tyr Tyr Phe Asn Glu Glu Gly Ala
 65 70 75 80
 Met Lys Thr Gly Trp Val Lys Tyr Lys Asp Thr Trp Tyr Tyr Leu Asp
 85 90 95
 Ala Lys Glu Gly Ala Met Val Ser Asn Ala Phe Ile Gln Ser Ala Asp
 100 105 110
 Gly Thr Gly Trp Tyr Tyr Leu Lys Pro Asp Gly Thr Leu Ala Asp Arg
 115 120 125
 Pro Glu Phe Thr Val Glu Pro Asp Gly Leu Ile Thr Val Lys
 130 135 140

<210> 8

<211> 112

<212> PRT

<213> Streptococcus pneumoniae

<400> 8

Tyr Val His Ser Asp Gly Ser Tyr Pro Lys Asp Lys Phe Glu Lys Ile
 1 5 10 15
 Asn Gly Thr Trp Tyr Tyr Phe Asp Ser Ser Gly Tyr Met Leu Ala Asp
 20 25 30
 Arg Trp Arg Lys His Thr Asp Gly Asn Trp Tyr Trp Phe Asp Asn Ser
 35 40 45
 Gly Glu Met Ala Thr Gly Trp Lys Lys Ile Ala Asp Lys Trp Tyr Tyr
 50 55 60
 Phe Asn Glu Glu Gly Ala Met Lys Thr Gly Trp Val Lys Tyr Lys Asp
 65 70 75 80
 Thr Trp Tyr Tyr Leu Asp Ala Lys Glu Gly Ala Met Val Ser Asn Ala
 85 90 95
 Phe Ile Gln Ser Ala Asp Gly Thr Gly Trp Tyr Tyr Leu Lys Pro Asp
 100 105 110

EP 1 511 768 B1

<210> 9
 <211> 45
 <212> DNA
 <213> Streptococcus pneumoniae
 5
 <400> 9
 ggctggcaga agaatgacac tggctactgg tacgtacatt cagac 45
 <210> 10
 10 <211> 63
 <212> DNA
 <213> Streptococcus pneumoniae
 <400> 10
 15
 ggctcttatc caaaagacaa gtttgagaaa atcaatggca cttggtacta ctttgacagt 60
 tca 63
 <210> 11
 20 <211> 66
 <212> DNA
 <213> Streptococcus pneumoniae
 <400> 11
 25
 ggctatatgc ttgcagaccg ctggaggaag cacacagacg gcaactggta ctggttcgac 60
 aactca 66
 <210> 12
 30 <211> 60
 <212> DNA
 <213> Streptococcus pneumoniae
 <400> 12
 35
 ggcgaaatgg ctacaggctg gaagaaaatc gctgataagt ggtactattt caacgaagaa 60
 <210> 13
 40 <211> 63
 <212> DNA
 <213> Streptococcus pneumoniae
 <400> 13
 45
 ggtgccatga agacaggctg ggtcaagtac aaggacactt ggtactactt agacgctaaa 60
 gaa 63
 <210> 14
 50 <211> 69
 <212> DNA
 <213> Streptococcus pneumoniae
 <400> 14
 55

ggcgccatgg tatcaaatgc ctttatccag tcagcggacg gaacaggctg gtactacctc 60

5

aaaccagac

69

<210> 15

<211> 429

10

<212> DNA

<213> Streptococcus pneumoniae

<400> 15

15

```

ggctggcaga agaatgacac tggctactgg tacgtacatt cagacggctc ttatccaaaa 60
gacaagtttg agaaaatcaa tggcacttgg tactactttg acagttcagg ctatatgctt 120
gcagaccgct ggaggaagca cacagacggc aactgggtact ggttcgacaa ctcaggcgaa 180
atggctacag gctggaagaa aatcgctgat aagtgggtact atttcaacga agaagggtgcc 240
atgaagacag gctgggtcaa gtacaaggac acttgggtact acttagacgc taaagaaggc 300
gccatgggtat caaatgcctt tatccagtca gcggacggaa caggctggta ctacctcaaa 360
ccagacggaa cactggcaga caggccagaa ttcacagtag agccagatgg cttgattaca 420
gtaaaataa 429

```

25

<210> 16

<211> 336

<212> DNA

<213> Streptococcus pneumoniae

30

<400> 16

35

```

tacgtacatt ccgacggctc ttatccaaaa gacaagtttg agaaaatcaa tggcacttgg 60
tactactttg acagttcagg ctatatgctt gcagaccgct ggaggaagca cacagacggc 120
aactgggtact ggttcgacaa ctcaggcgaa atggctacag gctggaagaa aatcgctgat 180
aagtgggtact atttcaacga agaagggtgcc atgaagacag gctgggtcaa gtacaaggac 240
acttgggtact acttagacgc taaagaaggc gccatgggtat caaatgcctt tatccagtca 300
gcggacggaa caggctggta ctacctcaaa ccagac 336

```

40

<210> 17

<211> 1674

<212> DNA

<213> Homo sapiens

45

<400> 17

50

55

gccacccatgg tccagaggct gtgggtgagc cgcctgctgc ggcaccggaa agcccagctc 60
 ttgctgggtca acctgctaac ctttggcctg gaggtgtgtt tggccgcagg catcacctat 120
 gtgccgcctc tgctgctgga agtgggggta gaggagaagt tcatgacctt ggtgctgggc 180
 attggtccag tgctgggcct ggtctgtgtc ccgctcctag gctcagccag tgaccactgg 240
 5 cgtggacgct atggccgccc cggcccttc atctgggcac tgtccttggg catcctgctg 300
 agcctctttc tcatcccaag ggcgggctgg ctacgagggc tgetgtgccc ggatcccagg 360
 cccctggagc tggcactgct catcctgggc gtggggctgc tggacttctg tggccagggtg 420
 tgcttcactc cactggaggc cctgctctct gacctcttcc gggaccgcga ccactgtcgc 480
 caggcctact ctgtctatgc cttcatgatc agtcttgggg gctgcctggg ctacctcctg 540
 10 cctgccattg actgggacac cagtgccttg gcccctacc tgggcaccca ggaggagtgc 600
 ctctttggcc tgctcaccct catcttcttc acctgcgtag cagccacact gctggtggct 660
 gaggaggcag cgctgggccc caccgagcca gcagaagggc tgtcggcccc ctcttctgctg 720
 cccactgctg gtccatgccg gggccgcttg gctttccgga acctgggcgc cctgcttccc 780
 cggctgcacc agctgtgctg ccgcatgccc cgcacctgc gccggctctt cgtggtgag 840
 15 ctgtgcagct ggatggcact catgaccttc acgctgtttt acacggattt cgtgggcgag 900
 gggctgtacc agggcgctgc cagagctgag ccgggcaccg agggccggag acactatgat 960
 gaaggcgctt ggatgggcag cctggggctg ttctgcagt gcgccatctc cctggtcttc 1020
 tctctggtea tggaccggct ggtgcagcga ttccggcactc gagcagtcta tttggccagt 1080
 gtggcagctt tccctgtggc tgccgggtgc acatgcctgt cccacagtgt ggcctggtg 1140
 20 acagcttcag ccgccctcac cgggttcacc ttctcagccc tgcagatcct gccctacaca 1200
 ctggcctccc tctaccaccg ggagaagcag gtgttcctgc ccaaataccg aggggacact 1260
 ggaggtgcta gcagtgagga cagcctgatg accagcttcc tgccaggccc taagcctgga 1320
 gctcccttcc ctaatggaca cgtgggtgct ggaggcagtg gcctgctccc acctccccc 1380
 gcgctctgcg gggcctctgc ctgtgatgtc tccgtacgtg tgggtggtggg tgagcccacc 1440
 25 gaggccaggg tggttccggg ccggggcacc tgccctggacc tcgccatcct ggatagtgcc 1500

ttctgtctgt cccaggtggc cccatccctg tttatgggct ccattgtcca gctcagccag 1560
 tctgtcactg cctatatggt gtctgccgca ggcctgggtc tggtcgccat ttactttgct 1620
 30 acacaggtag tatttgacaa gagcgacttg gccaaatact cagcgtaggt cgag 1674

<210> 18

<211> 1947

<212> DNA

35 <213> Artificial Sequence

<220>

<223> Hybrid gene between St. pneum. C-LytA, P2 T helper epitope and human P501S.

40 <400> 18

45

50

55

EP 1 511 768 B1

gccacatgg cgcccgctta cgtacattcc gacggctctt atccaaaaga caagtttgag 60
 aaaatcaatg gcacttggtg ctactttgac agttcaggct atatgcttgc agaccgctgg 120
 aggaagcaca cagacggcaa ctggtactgg ttcgacaact caggcgaaat ggctacaggc 180
 5 tgggaagaaa tcgctgataa gtggtactat ttcaacgaag aagggtgccaat gaagacaggc 240
 tgggtcaagt acaaggacac ttggtactac ttagacgcta aagaaggcgc catgcaatac 300
 atcaaggcta actctaagtt cattgggtatc actgaaggcg tcatgggtatc aaatgccttt 360
 atccagttag cggaaggaaac aggtggttac tacctcaaac cagacggaac actggcagac 420
 agggcagaaa agttcatgta catggtgctg ggcattgggtc cagtgtctggg cctgggtctgt 480
 10 gtcccgctcc taggctcagc cagtgtaccac tggcgtggac gctatggccg ccgcccggccc 540
 ttcatctggg cactgtcctt gggcatcctg ctgagcctct ttctcatccc aaggggccggc 600
 tggctagcag ggctgctgtg cccggatccc agggccctgg agctggcact gctcatcctg 660
 ggcgtggggc tgctggactt ctgtggccag gtgtgcttca ctccactgga ggccctgtct 720
 tctgacctct tccgggaccc ggaccactgt cggcctgcca actctgtcta tgccttcag 780
 atcagtctgt ggggctgcct gggctacctc ctgacctgcca ttgactggga caccagtgtc 840
 15 ctggcccccct acctgggcac ccaggaggag tgccctcttg gctgtctcac cctcatcttc 900
 ctcacctgag tagcagccac actgctggtg gctgaggagg cagcgtctggg cccaccagag 960
 ccagcagaag ggctgtcggc cccctccttg tggcccccact gctgtccatg ccggggccgc 1020
 ttggctttcc ggaacctggg cgcctgctt ccccggtgc accagctgtg ctgcccagatg 1080
 ccccgacccc tgcgcccggc ctctgctggc gagctgtgca gctggatggc actcatgacc 1140
 20 ttacgctgt ttacacgga ttctgctggc gaggggctgt accaggcggt gccagagct 1200
 gagccgggca ccgagggccc gagacactat gatgaaggcg ttccgatggg cagcctgggg 1260
 ctgttctctg agtgcccac ctccctggtc ttctctctgg tcatggaccg gctgggtgag 1320
 cgattcggca ctcgagcagt ctatttggcc agtgtggcag ctttccctgt ggctgcccgt 1380
 gccacatgcc tgtcccacag tgtggccgtg gtgacagctt cagccgccct caccgggttc 1440
 25 accttctcag ccctgcagat cctgccctac acactggcct ccctctacca ccgggagaag 1500
 caggtgttcc tgcccaaata ccgaggggac actggagggtg ctacagtgta ggacagcctg 1560
 atgaccagct tcctgccagg ccctaagcct ggagctccct tccctaattg acacgtgggt 1620
 gctggaggca gtggcctgct cccacctcca cccgcctct gcggggcctc tgccctgtat 1680
 gtctccgtac gtgtggtggt ggggtgagccc accgaggcca ggggtggtcc gggccggggc 1740
 30 atctgectgg acctcgccat cctggatagt gccttctctg tgtcccaggt gggcccatcc 1800
 ctgtttatgg gctccattgt ccagctcagc cagctctgtc ctgctatat ggtgtctgcc 1860
 gcaggcctgg gtctggtcgc catttacttt gctacacagg tagtatttga caagagcgac 1920
 ttggccaaat actcagcgta ggtcgag 1947

35 <210> 19
 <211> 1662
 <212> DNA
 <213> Artificial Sequence

40 <220>
 <223> Codon optimised human P501S

400> 19

45 atggtgcagc ggctctgggt gagccgcctc ctgcccagtc gcaaggccca gctcctgctg 60
 gtgaatctgc tcacattcgg cctggagggt tgccctggccg ccggcatcac ctactgtccc 120
 cccctcctgc tggagggtggg agtcgaggag aagttcatga ccatgggtgct gggcattggg 180
 cccgtcctgg gcctcgtgtg cgtgcctctc ctccgagcg cttccgacca ttggcgccgc 240

50

55

5 cggtatggcc gcaggagacc cttcatctgg gctctgagtc tcggcatcct gctgagcctg 300
 ttcttgatcc ctccggccgg ctggctggcc gggtgctgt gcccgatcc tcggccctg 360
 gagctggccc tgctgaccc ctggctggcc ctgctggact tctgcccga ggtgtgcttc 420
 acgcccctgg aggcactgct gagcgacctg ttccgggacc ccgaccattg ccgccaggcg 480
 tacagcgtgt acgccttcat gatctccctg ggaggctgcc tgggctacct gctccccgcc 540
 atcgattggg acaccagcgc actcgcctcc tatctcggaa cacaggagga atgcctgttc 600
 ggattgttga cgtcatctt cctcacgtgc gtccgggcca ccctgttggg ggccgaggag 660
 gccgcccctg ggcccaccga gccggccgag ggactgagcg ccccgagcct gattccacac 720
 10 tgctgccctt gccggggccg cctggccttc cgtaatctgg gcgccctcct gcctcggctc 780
 catcagctgt gttgcagaat gcctaggacg ctgcggcgcc tgttcgtcgc tgagtgtgac 840
 tcctggatgg ctctcatgac cttcacctg tttatacgg acttcgtcgg ggagggcctg 900
 taccaggggg tgccgcgcgc cgagcccggg acagaggcgc gccgccacta cgacgaggga 960
 gtgcgtatgg gctccctggg cctcttcttg cagtgcgcca tcagtctggg tttctctctg 1020
 15 gtcattggaca ggctggtgca gcgcttcgga acccgggcgg tgtacctggc gacgtggcc 1080
 gccttccccg tggctgccgg cgccacctgc ctctctcact cgggtggcct ggtcaccgcc 1140
 agcgcgcgcc tgaccgggtt cacttctctt gccctgcaga ttctgcctta caccctggcc 1200
 agcctgtacc atcgcgagaa acaggtgttt ctccccaaat acagaggcga caccgggggc 1260
 gcctccagcg aggacagcct catgacctcc ttctgcctg gccccaagcc cggcgccct 1320
 20 ttccccaacg ggcacgtggg cgccggcggg agtgggctcc tgccccccc tcctgcgctg 1380
 tgccggggcca gcgcctgca cgtgagcgtg cgcgtggtgg tgggcgagcc caccgaggcc 1440
 cgcgtggtgc cgggcagagg catttgtctg gacctggcca tcctcgactc cgccttcctc 1500
 ctccagccagg tggccccgtc cctcttcatg ggctctatcg tccagctgtc tcagagcgtc 1560
 accgcttaca tgggtgtccg tgctggactg ggcttggtgg ctatttattt cgccaccag 1620
 25 gtggtgttcg acaagagcga cctggccaaa tactccgcct ga 1662

<210> 20

<211> 1662

<212> DNA

30 <213> Artificial Sequence

<220>

<223> Codon optimised human P501S

35 <400> 20

40

45

50

55

atggtgcagc ggctgtgggt gtcccggtg ctgcgccata gaaaggccca gttgctgctg 60
 gtgaacctgc tgactttcgg actggaggtg tgcctggctg ccgggatcac gtacgtgcc 120
 cccctgctgc tggaggtggg cgtggaggag aagttcatga caatggtgct gggcatcggc 180
 cccgtccctgg gcctcgtgtg tgtgcccc ctcgggagtg cgtccgatca ttggcggggc 240
 5 cgctacggcc gccgcagacc gttcatctgg gccctgagcc tggggatcct gctctctctc 300
 ttctgatcc cccgggccgg ctggctggcc ggctgctgt gtcccgacc ccgccctctg 360
 gagctggccc tcctgatcct gggcgtgggc ttgttggact tctgcggcca ggtgtgtttc 420
 actccctgg aggtctctgt ctccgacctc ttccgcgacc ccgaccactg taggcaggct 480
 tacagcgtgt acgccttcat gatcagtctg gggggtatgc tgggctatct gctgcccgct 540
 10 atcgactggg acaccagcgc cctggcccc tacctgggga ctcaggagga gtgcctgttc 600
 ggctgctca ccttgatctt cctgacgtgc gtcccgcca ccctgctggt ggccgaggag 660
 gcggccctgg ggcccaccga gccgcgcgag ggctgagcg ctcccagct gagccccat 720
 tgctgcccgt gcagggttag gctgccttc aggaatctgg gcgctttgct gccccgctg 780
 catcagctgt gctgtcgcat gcctgcacc ctgcgcgcc ttgtcgtcgc tgagctctgt 840
 15 tcctggatgg ccctgatgac gttcacctc ttctacacc acttcgtggg ggagggcctg 900
 taccagggcg tgcccagggc cgagcccggc accgaggcta ggcgccatta cgacgagggc 960
 gtcaggatgg gctctctggg cctcttctc cagtgcgcca tcagtctggt gttctctctg 1020
 gtgatggacc ggctggtgca gccttcggc acccgggccg tgtacctgc ctctgtggcg 1080
 gctttccccg tcgcccgccg cgcgacctgc ctgtctcatt ctgtcgccgt ggtgaccgcc 1140
 20 agcgccgccc tgaccggctt caccttcagt gcgtccaga ttctgcccta caccctggcg 1200
 tctctgtacc atcgcgagaa gcaggtgttc ctgcccaagt accgcgggga cacaggggga 1260
 gcttctctcg aggacagcct gatgaccagc ttcttgccc gcccgaagcc gggggccct 1320
 ttccccaaag gccatgtcgg ggccggcgcc agcgccctgc tccctcccc ccccgccctg 1380
 tgccgcgcta gtgctgcga cgtgagcgtg cgggtggtgg tgggggagcc caccgaggct 1440
 25 agggctcgtgc ctggccgggg gatctgcctg gacctggcca tcctcgactc cgccttctctg 1500
 ctctcccagg tggcgcccag cctgttcatg ggcagtatcg tgcagctgag ccagagcgtg 1560
 accgcctaca tgggtgagcgc cgcggccctg gggttggtgg ccatctactt tgccaccag 1620

30 gtcgtgttcg acaagagcga tctcgccaag tatagcgct ga 1662

<210> 21

<211> 1688

35 <212> DNA

<213> Artificial Sequence

<220>

<223> Codon optimised human P501S

40

<400> 21

45

50

55

5 gacggctagc gccaccatgg tgcagcggct ctgggtgagc cgcctcctgc ggcacgcgaa 60
 ggcccagctc ctgctgggtga atctgctcac attcggcctg gaggtgtgcc tggccgcggg 120
 catcacctac gtgccccccc tctgctgga ggtgggagtc gaggagaagt tcatgaccat 180
 ggtgctgggc attgggcccg tctgggcct cgtgtgctg cctctcctcg gcagcgttc 240
 cgaccattgg cgcggccggt atggccgcag gagacccttc atctgggctc tgagtctcgg 300
 catcctgctg agcctgttcc tgatccctcg ggccggctgg ctggccgggc tgcgtgtccc 360
 cgatcctcgg cccctggagc tggccctgct gatcctcggc gtgggcctgc tggacttctg 420
 cggccagggtg tgcctcacgc cctggagggc actgctgagc gacctgttcc gggaccccca 480
 ccattgcccgc caggcgtaga gcgtgtacgc ctcatgata tccctgggag gctgcctggg 540
 ctacctgctc cccgccatcg attgggacac cagcgcactc gcccctatc tcggaacaca 600
 ggaggaatgc ctgttcggac tgcgtacgct catcttctc acgtgcgtcg cggccaccct 660
 gttggtggcc gaggaggccg cctgggggccc caccgagccg gccgagggac tgagcgcccc 720
 gagcctgagt ccacactgct gcccttgccg ggcccgctg gccctccgta atctgggcgc 780
 cctcctgect cggtccatc agctgtgttg cagaatgcct aggaacgtgc ggcgcctgtt 840
 15 cgctcgtgag ttgtgctcct ggatggctct catgaccttc accctgtttt atacggactt 900
 cgctggggag ggcctgtacc aggggggtgcc gcgcgccgag cccgggacag aggcgcgccg 960
 ccactacgac gagggagtgc gtatgggctc cctgggcctc ttcttgagc gcgccatcag 1020
 tctggttttc tctctgtca tggacaggct ggtgcagcgc ttccgaaccc gggcggtgta 1080
 cctggcgagc gtggccgctc tccccgtggc tggccggcgc acctgcctct ctcactcggt 1140
 20 ggccgtggtc accgccagcg ccgccctgac cgggttcacc ttctctgccc tgcagattct 1200
 gccctacacc ctggccagcc tgtaccatcg cgagaaacag gtgtttctcc ccaagtacag 1260
 aggcgacacc gggggcgccct ccagcgagga cagcctcatg acctccttcc tgccctggccc 1320
 caagcccggc gccctttcc ccaacgggca cgtgggcgcc ggccggagtg ggctcctgccc 1380
 cccccctcct gcgtgtgctg gggccagcgc ctgcgacgtg agcgtgcgcg tgggtgtggg 1440
 25 cgagcccacc gagggccgcg tgggtgccggg cagaggcatt tgtctggacc tggccatcct 1500
 cgactccgcc ttctcctca gccagggtggc cccgtccctc ttcatgggct ctatcgtcca 1560
 gctgtctcag agcgtcaccg cttacatggt gtccgctgct ggactgggct tgggtggctat 1620
 ttatttcgcc acccaggtgg tgttcgacaa gagcgacctg gccaaatact ccgcctgact 1680
 cgaggcag 1688

<210> 22

<211> 1688

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon optimised human P501S

<400> 22

45 gacggctagc gccaccatgg tgcagcggct gtgggtgtcc cggctgctgc gccatagaaa 60
 ggcccagttg ctgctgggtga acctgctgac ttccggactg gaggtgtgcc tggctgccgg 120
 gatcacgtac gtgccccccc tgctgctgga ggtgggcgtg gaggagaagt tcatgacaat 180
 ggtgctgggc atcgcccccg tctgggcct cgtgtgtgtg cccctcctcg ggagtgcgtc 240
 cgatcattgg cggggccgct acggccggc cagaccgttc atctgggccc tgagcctggg 300
 catcctgctc tctctcttcc tgatcccccg ggccggctgg ctggccggcc tgcgtgttcc 360
 cgacccccgc cctctggagc tggccctcct gatcctgggc gtgggcctgc tggacttctg 420
 cggccagggtg tgttcaactc ccctggagggc tctgctctcc gacctcttcc gccaccccca 480
 ccactgtagg caggcttaca gcgtgtacgc ctcatgata agtctggggg gatgcctggg 540
 50 ctatctgctg cccgctatcg actgggacac cagcgccctg gcccctacc tggggactca 600
 ggaggagtgc ctgttcggcc tgctcacctt gatcttctc acgtgcgtcg ccgccaccct 660

55

```

gctggtggcc gaggaggcgg cccctggggcc caccgagccc gccgagggcc tgagcgctcc 720
cagcctgagc ccccatgtgt gcccggtgcag ggctaggctc gccttcagga atctggggcg 780
tttgctgccc cgcctgcacg agctgtgtct tcgcatgcct cgcaccctgc gccgcctgtt 840
5 cgtcgctgag ctctgttcct ggatggccct gatgacgttc accctcttct acaccgactt 900
cgtgggggag ggctgtacc agggcgtgcc cagggccgag cccggcaccg aggctaggcg 960
ccattacgac gagggcgtca ggatgggctc tctgggcctc ttctgcagt gcgccatcag 1020
tctggtgttc tctctggtga tggaccggct ggtgcagcgc ttcggcaccc gggccgtgta 1080
cctcgccctc gtggcggctt tccccgtcgc cgcgggcgcg acctgcctgt ctcatctctgt 1140
10 cgcctgtgtg accgccagcg ccgccctgac cggcttcacc ttcagtgcgc tccagattct 1200
gccctacacc ctggcgtctc tgtaccatcg cgagaagcag gtgttcctgc ccaagtaccg 1260
cggggacaca gggggagctt cctctgagga cagcctgatg accagcttct tgcccggccc 1320
caagccgggg gcccttttcc ccaacggcca tgtcggggcg ggcggcagcg gcctgctccc 1380
tccccccccc gccctgtgcg gcgctagtgc ctgcgacgtg agcgtgcggg tgggtggtggg 1440
15 ggagcccacc gaggctaggg tcgtgcctgg ccgggggatc tgcctggacc tggccatcct 1500
cgactccgcc ttctgtctct cccaggtggc gccagcctg ttcatgggca gtatcgtgca 1560
gctgagccag agcgtgaccg cctacatggt gagcgccgcc ggccctgggt tgggtggccat 1620
ctactttgcc acccaggctg tgttcgacaa gagcgatctc gccaaagtata gcgcctgact 1680
cgaggcag                                     1688

<210> 23
<211> 435
<212> DNA
<213> Artificial Sequence

25 <220>
<223> Hybrid gene between St. pneum. C-LytA, P2 T helper epitope and a small portion of the 5' end of human P501S

<400> 23

30 atggcggccg cttacgtaca ttccgacggc tcttatccaa aagacaagtt tgagaaaatc 60
aatggcactt ggtactactt tgacagttca ggctatatgc ttgcagaccg ctggaggaag 120
cacacagacg gcaactggta ctgggttcgac aactcaggcg aaatggctac aggctggaag 180
35 aaaatcgctg ataagtggta ctatttcaac gaagaagggtg ccatgaagac aggctgggtc 240
aagtacaagg acacttggta ctacttagac gctaaagaag gcgccatgca atacatcaag 300
gctaactcta agttcattgg tatcactgaa ggcgatcatg tatcaaagtc ctttatccag 360
tcagcggacg gaacaggctg gtactacctc aaaccagacg gaacactggc agacaggcca 420
gaaaagttca tgtac                                     435

40 <210> 24
<211> 435
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Hybrid gene between St. pneum. C-LytA, P2 T helper epitope and a small portion of the 5' end of human
P501S - codon-optimised

50 <400> 24

55

```

EP 1 511 768 B1

atggccgccc cctacgtgca tagcgacggg agctacccca aggacaagtt cgagaagatc 60
 aacgggacat ggtactactt cgactcctcc ggctacatgc tcgccgaccg ctggcggaag 120
 cacaccgacg gcaactggta ctggttcgat aactcgggag agatggccac cggctggaag 180
 5 aagatcgccg acaagtggta ctatttcaac gaggagggcg ccatgaagac cggctgggtg 240
 aagtataagg acacctggta ctacctcgac gccaaaggagg gcgccatgca gtatatcaag 300
 gccaacagca agttcatcgg catcaccgag ggagtgatgg tcagcaacgc ctttatccag 360
 agcgcggacg gcaccggatg gtactacttg aagccggacg gcaccctcgc ggatcgccc 420
 gagaagttca tgtac 435

 10 <210> 25
 <211> 435
 <212> DNA
 <213> Artificial Sequence

 15 <220>
 <223> Hybrid gene between St. pneum. C-LytA, P2 T helper epitope and a small portion of the 5' end of human
 P501S - codon-optimised

 20 <400> 25

 atggccgccc cctacgtgca cagcgacggg tcctacccaa aggacaagtt cgagaagatc 60
 aacggcacgt ggtactatct cgacagcagc ggctacatgc tcgccgatcg ctggcgcaag 120
 25 cacaccgacg ggaactggta ctggttcgac aactctggcg agatggctac ggggtggaag 180
 aagatcgccg acaagtggta ctacttcaac gaggagggcg ccatgaagac cgggtgggtg 240
 aagtacaagg acacctggta ctacctggac gctaaggagg gcgccatgca gtacatcaag 300
 gccaaactcga agttcatcgg gatcaccgag ggcgatgatg tcagtaacgc tttcatccag 360
 agcgcggacg gcacaggctg gtattacctg aagcccgatg gcaccctggc ggacagacct 420
 gagaaattca tgtac 435

 30 <210> 26
 <211> 464
 <212> DNA
 35 <213> Artificial Sequence

 <220>
 <223> Hybrid gene between St. pneum. C-LytA, P2 T helper epitope and a small portion of the 5' end of human
 P501S - codon-optimised

 40 <400> 26

 gacggctagc gccaccatgg ccgccgccta cgtgcatagc gacgggagct accccaagga 60
 45 caagttcgag aagatcaacg ggacatggta ctacttcgac tcctccggct acatgctcgc 120
 cgaccgctgg cggaagcaca ccgacggcaa ctggtactgg ttcgataact cgggagagat 180
 ggccaccggc tgggaagaaga tcgcggacaa gtggtactat ttcaacgagg agggcgccat 240
 gaagaccggc tgggtgaagt ataaggacac ctggtactac ctcgacgcca aggagggcgc 300
 catgcagtat atcaaggcca acagcaagtt catcggcac accgagggag tgatgggtcag 360
 caacgccttt atccagagcg ccgacggcac cggatggtac tacttgaagc cggacggcac 420
 50 cctcgcggat cggccccgaga agttcatgta ctgactcgag gcag 464

 <210> 27
 <211> 652
 55 <212> PRT
 <213> Artificial Sequence

 <220>

EP 1 511 768 B1

<223> Hybrid protein between St. pneum. C-LytA, P2 T helper epitope and amino acids 51-553 of human P501S

<400> 27

5	Met	Ala	Ala	Ala	Tyr	Val	His	Ser	Asp	Gly	Ser	Tyr	Pro	Lys	Asp	Lys
	1				5					10					15	
	Phe	Glu	Lys	Ile	Asn	Gly	Thr	Trp	Tyr	Tyr	Phe	Asp	Ser	Ser	Gly	Tyr
				20					25					30		
10	Met	Leu	Ala	Asp	Arg	Trp	Arg	Lys	His	Thr	Asp	Gly	Asn	Trp	Tyr	Trp
			35					40					45			
	Phe	Asp	Asn	Ser	Gly	Glu	Met	Ala	Thr	Gly	Trp	Lys	Lys	Ile	Ala	Asp
		50					55					60				
	Lys	Trp	Tyr	Tyr	Phe	Asn	Glu	Glu	Gly	Ala	Met	Lys	Thr	Gly	Trp	Val
	65					70					75				80	
15	Lys	Tyr	Lys	Asp	Thr	Trp	Tyr	Tyr	Leu	Asp	Ala	Lys	Glu	Gly	Ala	Met
					85					90					95	

20

25

30

35

40

45

50

55

	Gln	Tyr	Ile	Lys	Ala	Asn	Ser	Lys	Phe	Ile	Gly	Ile	Thr	Glu	Gly	Val	
				100					105					110			
5	Met	Val	Ser	Asn	Ala	Phe	Ile	Gln	Ser	Ala	Asp	Gly	Thr	Gly	Trp	Tyr	
			115					120					125				
	Tyr	Leu	Lys	Pro	Asp	Gly	Thr	Leu	Ala	Asp	Arg	Pro	Glu	Lys	Phe	Met	
			130				135					140					
	Tyr	Met	Val	Leu	Gly	Ile	Gly	Pro	Val	Leu	Gly	Leu	Val	Cys	Val	Pro	
	145					150					155					160	
10	Leu	Leu	Gly	Ser	Ala	Ser	Asp	His	Trp	Arg	Gly	Arg	Tyr	Gly	Arg	Arg	
				165							170				175		
	Arg	Pro	Phe	Ile	Trp	Ala	Leu	Ser	Leu	Gly	Ile	Leu	Leu	Ser	Leu	Phe	
				180						185					190		
	Leu	Ile	Pro	Arg	Ala	Gly	Trp	Leu	Ala	Gly	Leu	Leu	Cys	Pro	Asp	Pro	
			195					200					205				
15	Arg	Pro	Leu	Glu	Leu	Ala	Leu	Leu	Ile	Leu	Gly	Val	Gly	Leu	Leu	Asp	
			210				215					220					
	Phe	Cys	Gly	Gln	Val	Cys	Phe	Thr	Pro	Leu	Glu	Ala	Leu	Leu	Ser	Asp	
	225					230					235					240	
	Leu	Phe	Arg	Asp	Pro	Asp	His	Cys	Arg	Gln	Ala	Tyr	Ser	Val	Tyr	Ala	
				245						250					255		
20	Phe	Met	Ile	Ser	Leu	Gly	Gly	Cys	Leu	Gly	Tyr	Leu	Leu	Pro	Ala	Ile	
				260						265					270		
	Asp	Trp	Asp	Thr	Ser	Ala	Leu	Ala	Pro	Tyr	Leu	Gly	Thr	Gln	Glu	Glu	
			275					280					285				
	Cys	Leu	Phe	Gly	Leu	Leu	Thr	Leu	Ile	Phe	Leu	Thr	Cys	Val	Ala	Ala	
25			290				295					300					
	Thr	Leu	Leu	Val	Ala	Glu	Glu	Ala	Ala	Leu	Gly	Pro	Thr	Glu	Pro	Ala	
	305					310					315					320	
	Glu	Gly	Leu	Ser	Ala	Pro	Ser	Leu	Ser	Pro	His	Cys	Cys	Pro	Cys	Arg	
				325						330					335		
30	Ala	Arg	Leu	Ala	Phe	Arg	Asn	Leu	Gly	Ala	Leu	Leu	Pro	Arg	Leu	His	
				340					345					350			
	Gln	Leu	Cys	Cys	Arg	Met	Pro	Arg	Thr	Leu	Arg	Arg	Leu	Phe	Val	Ala	
			355					360					365				
	Glu	Leu	Cys	Ser	Trp	Met	Ala	Leu	Met	Thr	Phe	Thr	Leu	Phe	Tyr	Thr	
			370				375					380					
35	Asp	Phe	Val	Gly	Glu	Gly	Leu	Tyr	Gln	Gly	Val	Pro	Arg	Ala	Glu	Pro	
	385					390					395					400	
	Gly	Thr	Glu	Ala	Arg	Arg	His	Tyr	Asp	Glu	Gly	Val	Arg	Met	Gly	Ser	
				405						410					415		
	Leu	Gly	Leu	Phe	Leu	Gln	Cys	Ala	Ile	Ser	Leu	Val	Phe	Ser	Leu	Val	
				420					425						430		
40	Met	Asp	Arg	Leu	Val	Gln	Arg	Phe	Gly	Thr	Arg	Ala	Val	Tyr	Leu	Ala	
			435					440					445				
	Ser	Val	Ala	Ala	Phe	Pro	Val	Ala	Ala	Gly	Ala	Thr	Cys	Leu	Ser	His	
			450				455					460					
	Ser	Val	Ala	Val	Val	Thr	Ala	Ser	Ala	Ala	Leu	Thr	Gly	Phe	Thr	Phe	
	465					470					475					480	
45	Ser	Ala	Leu	Gln	Ile	Leu	Pro	Tyr	Thr	Leu	Ala	Ser	Leu	Tyr	His	Arg	
				485						490					495		
	Glu	Lys	Gln	Val	Phe	Leu	Pro	Lys	Tyr	Arg	Gly	Asp	Thr	Gly	Gly	Ala	
				500					505						510		
	Ser	Ser	Glu	Asp	Ser	Leu	Met	Thr	Ser	Phe	Leu	Pro	Gly	Pro	Lys	Pro	
			515					520					525				
50	Gly	Ala	Pro	Phe	Pro	Asn	Gly	His	Val	Gly	Ala	Gly	Gly	Ser	Gly	Leu	
			530				535					540					
	Leu	Pro	Pro	Pro	Pro	Ala	Leu	Cys	Gly	Ala	Ser	Ala	Cys	Asp	Val	Ser	
	545					550					555					560	
	Val	Arg	Val	Val	Val	Gly	Glu	Pro	Thr	Glu	Ala	Arg	Val	Val	Pro	Gly	
				565						570					575		
55	Arg	Gly	Ile	Cys	Leu	Asp	Leu	Ala	Ile	Leu	Asp	Ser	Ala	Phe	Leu	Leu	

				580					585					590		
	Ser	Gln	Val	Ala	Pro	Ser	Leu	Phe	Met	Gly	Ser	Ile	Val	Gln	Leu	Ser
			595					600					605			
5	Gln	Ser	Val	Thr	Ala	Tyr	Met	Val	Ser	Ala	Ala	Gly	Leu	Gly	Leu	Val
			610				615					620				
	Ala	Ile	Tyr	Phe	Ala	Thr	Gln	Val	Val	Phe	Asp	Lys	Ser	Asp	Leu	Ala
	625					630					635					640
	Lys	Tyr	Ser	Ala	Gly	Gly	His	His	His	His	His	His				
10					645					650						

<210> 28

<211> 1959

15 <212> DNA

<213> Artificial Sequence

<220>

20 <223> DNA encoding the Hybrid protein between St. pneum. C-LytA, P2 T helper epitope and amino acids 51-553 of human P501S

<400> 28

25	atggcgcccg	cttacgtaca	ttccgacggc	tcttatccaa	aagacaagtt	tgagaaaatc	60
	aatggcactt	ggtactactt	tgacagttca	ggctatatgc	ttgcagaccg	ctggaggaag	120
	cacacagacg	gcaactggta	ctggttcgac	aactcaggcg	aaatggctac	aggctggaag	180
	aaaatcgctg	ataagtggta	ctatttcaac	gaagaagggtg	ccatgaagac	aggctgggtc	240
	aagtacaagg	acacttggta	ctacttagac	gctaaagaag	gcgccatgca	atacatcaag	300
30	gctaacteta	agttcattgg	tatcactgaa	ggcgtcatgg	tatcaaattgc	ctttatccag	360
	tcagcggacg	gaacaggctg	gtactacctc	aaaccagacg	gaacactggc	agacaggcca	420
	gaaaagtcca	tgtacatggg	gctggggcatt	gggccagtgc	tgggcctggg	ctgtgtcccg	480
	ctcctaggct	cagccagtga	ccactggcgt	ggacgctatg	gccgcgcgcg	gcccttcac	540
	tgggcactgt	ccttgggcat	cctgctgagc	ctctttctca	tcccaagggc	cggctggcta	600
	gcagggctgc	tgtgcccggg	tcccaggccc	ctggagctgg	cactgctcat	cctgggcgtg	660
35	gggctgctgg	acttctgtgg	ccagggtgtg	ttcactccac	tggaggccct	gctctctgac	720
	ctcttccggg	acccggacca	ctgtcgccag	gcctactctg	tctatgcctt	catgatcagt	780
	cttgggggct	gcctgggcta	cctcctgect	gccattgact	gggacaccag	tgccctggcc	840
	ccctacctgg	gcacccagga	ggagtgcctc	tttggcctgc	tcacctcat	cttcctcacc	900
	tgcgtagcag	ccacactgct	ggtggctgag	gaggcagcgc	tgggccccac	cgagccagca	960
40	gaagggtgtg	cggccccctc	cttgtcgccc	cactgctgtc	catgcccggc	ccgcttggct	1020
	ttccggaacc	tgggcgccct	gcttccccgg	ctgcaccagc	tgtgctgccg	catgccccgc	1080
	accctgcgcc	ggctcttcgt	ggctgagctg	tgcagctgga	tggcactcat	gaccttcacg	1140
	ctgttttaca	cggatttcgt	gggcgagggg	ctgtaccagg	gcgtgcccag	agctgagccg	1200
	ggcaccgagg	cccggagaca	ctatgatgaa	ggcgttcgga	tgggcagcct	ggggctgttc	1260
45	ctgcagtgcg	ccatctccct	ggtcttctct	ctggctcatg	accggtgggt	gcagcgattc	1320
	ggcactcgag	cagtctatct	ggccagtgtg	gcagctttcc	ctgtggctgc	cgggtgcaca	1380
	tgccctgtccc	acagtgtggc	cgtggtgaca	gcttcagccg	ccctcaccgg	gttcaccttc	1440
	tcagccctgc	agatcctgcc	ctacacactg	gcctccctct	accaccggga	gaagcaggtg	1500
	ttcctgcccc	aataccgagg	ggacactgga	gggtgtagca	gtgaggacag	cctgatgacc	1560
50	agcttctctg	caggccctaa	gcctggagct	cccttcccta	atggacacgt	gggtgctgga	1620
	ggcagtggcc	tgctcccacc	tccaccgcgc	ctctgcgggg	cctctgcctg	tgatgtctcc	1680
	gtacgtgtgg	tgggtgggtga	gcccaccgag	gccagggtgg	ttccggggccg	gggcatctgc	1740
	ctggacctcg	ccatcctgga	tagtgccctc	ctgctgtccc	aggtggcccc	atccctgttt	1800
	atgggtccca	ttgtccagct	cagccagctc	gtcactgcct	atatgggtgtc	tgccgcaggc	1860
55	ctgggtctgg	tcgccattta	ctttgtctaca	caggtagtat	ttgacaagag	cgacttggcc	1920
	aaatactcag	cgggtggaca	ccatcaccat	caccattaa			1959

<210> 29

EP 1 511 768 B1

<211> 507

<212> PRT

<213> Artificial Sequence

5

<220>

<223> Human P501S (amino acids 55-553) fused to 6 histidine residues

<400> 29

10

15

20

25

30

35

40

45

50

55

	Met	Val	Leu	Gly	Ile	Gly	Pro	Val	Leu	Gly	Leu	Val	Cys	Val	Pro	Leu
	1				5					10					15	
	Leu	Gly	Ser	Ala	Ser	Asp	His	Trp	Arg	Gly	Arg	Tyr	Gly	Arg	Arg	Arg
				20					25					30		
5	Pro	Phe	Ile	Trp	Ala	Leu	Ser	Leu	Gly	Ile	Leu	Leu	Ser	Leu	Phe	Leu
			35					40					45			
	Ile	Pro	Arg	Ala	Gly	Trp	Leu	Ala	Gly	Leu	Leu	Cys	Pro	Asp	Pro	Arg
		50					55					60				
10	Pro	Leu	Glu	Leu	Ala	Leu	Leu	Ile	Leu	Gly	Val	Gly	Leu	Leu	Asp	Phe
	65					70					75				80	
	Cys	Gly	Gln	Val	Cys	Phe	Thr	Pro	Leu	Glu	Ala	Leu	Leu	Ser	Asp	Leu
				85						90				95		
	Phe	Arg	Asp	Pro	Asp	His	Cys	Arg	Gln	Ala	Tyr	Ser	Val	Tyr	Ala	Phe
				100					105					110		
15	Met	Ile	Ser	Leu	Gly	Gly	Cys	Leu	Gly	Tyr	Leu	Leu	Pro	Ala	Ile	Asp
			115					120					125			
	Trp	Asp	Thr	Ser	Ala	Leu	Ala	Pro	Tyr	Leu	Gly	Thr	Gln	Glu	Glu	Cys
			130				135					140				
	Leu	Phe	Gly	Leu	Leu	Thr	Leu	Ile	Phe	Leu	Thr	Cys	Val	Ala	Ala	Thr
20						150					155					160
	Leu	Leu	Val	Ala	Glu	Glu	Ala	Ala	Leu	Gly	Pro	Thr	Glu	Pro	Ala	Glu
					165					170						175
	Gly	Leu	Ser	Ala	Pro	Ser	Leu	Ser	Pro	His	Cys	Cys	Pro	Cys	Arg	Ala
				180					185					190		
25	Arg	Leu	Ala	Phe	Arg	Asn	Leu	Gly	Ala	Leu	Leu	Pro	Arg	Leu	His	Gln
			195				200					205				
	Leu	Cys	Cys	Arg	Met	Pro	Arg	Thr	Leu	Arg	Arg	Leu	Phe	Val	Ala	Glu
			210				215					220				
	Leu	Cys	Ser	Trp	Met	Ala	Leu	Met	Thr	Phe	Thr	Leu	Phe	Tyr	Thr	Asp
					230						235					240
30	Phe	Val	Gly	Glu	Gly	Leu	Tyr	Gln	Gly	Val	Pro	Arg	Ala	Glu	Pro	Gly
				245						250					255	
	Thr	Glu	Ala	Arg	Arg	His	Tyr	Asp	Glu	Gly	Val	Arg	Met	Gly	Ser	Leu
				260					265					270		
	Gly	Leu	Phe	Leu	Gln	Cys	Ala	Ile	Ser	Leu	Val	Phe	Ser	Leu	Val	Met
35				275				280					285			
	Asp	Arg	Leu	Val	Gln	Arg	Phe	Gly	Thr	Arg	Ala	Val	Tyr	Leu	Ala	Ser
			290				295					300				
	Val	Ala	Ala	Phe	Pro	Val	Ala	Ala	Gly	Ala	Thr	Cys	Leu	Ser	His	Ser
					310						315					320
40	Val	Ala	Val	Val	Thr	Ala	Ser	Ala	Ala	Leu	Thr	Gly	Phe	Thr	Phe	Ser
					325					330					335	
	Ala	Leu	Gln	Ile	Leu	Pro	Tyr	Thr	Leu	Ala	Ser	Leu	Tyr	His	Arg	Glu
				340					345					350		
	Lys	Gln	Val	Phe	Leu	Pro	Lys	Tyr	Arg	Gly	Asp	Thr	Gly	Gly	Ala	Ser
45			355					360					365			
	Ser	Glu	Asp	Ser	Leu	Met	Thr	Ser	Phe	Leu	Pro	Gly	Pro	Lys	Pro	Gly
			370				375					380				
	Ala	Pro	Phe	Pro	Asn	Gly	His	Val	Gly	Ala	Gly	Gly	Ser	Gly	Leu	Leu
					390					395						400
50	Pro	Pro	Pro	Pro	Ala	Leu	Cys	Gly	Ala	Ser	Ala	Cys	Asp	Val	Ser	Val
					405					410					415	
	Arg	Val	Val	Val	Gly	Glu	Pro	Thr	Glu	Ala	Arg	Val	Val	Pro	Gly	Arg
				420					425					430		
	Gly	Ile	Cys	Leu	Asp	Leu	Ala	Ile	Leu	Asp	Ser	Ala	Phe	Leu	Leu	Ser
55			435					440					445			

Gln Val Ala Pro Ser Leu Phe Met Gly Ser Ile Val Gln Leu Ser Gln
 450 455 460
 Ser Val Thr Ala Tyr Met Val Ser Ala Ala Gly Leu Gly Leu Val Ala
 465 470 475 480
 Ile Tyr Phe Ala Thr Gln Val Val Phe Asp Lys Ser Asp Leu Ala Lys
 485 490 495
 Tyr Ser Ala Gly Gly His His His His His His
 500 505

10 <210> 30
 <211> 1524
 <212> DNA
 <213> Artificial Sequence

15 <220>
 <223> DNA encoding Human P501S (amino acids 55-553) fused to 6 histidine residues

20 <400> 30

25 atggtgctgg gcattggtcc agtgctgggc ctggtctgtg tcccgtctct aggctcagcc 60
 agtgaccact ggcgtagacg ctatggccgc cgccggccct tcatctgggc actgtccttg 120
 ggcatcctgc tgagcctctt tctcatccca agggccggtt ggctagcagg gctgctgtgc 180
 ccggatccca ggcccctgga gctggcactg ctcatcctgg gcgtggggct gctggacttc 240
 tgtggccagg tgtgcttcac tccactggag gccctgctct ctgacctctt ccgggacccg 300
 gaccactgtc gccaggccta ctctgtctat gccttcatga tcagtcttgg ggggtgcctg 360
 ggctacctcc tgccctgcat tgactgggac accagtggcc tggcccccta cctgggcacc 420
 caggaggagt gcctcttttg cctgtctacc ctcatcttcc tcacctgcgt agcagccaca 480
 ctgctggtgg ctgaggaggc agcgtgggc cccaccgagc cagcagaagg gctgtcgccc 540
 cctcctctgt cgcccactg ctgtccatgc cgggccgctt tggctttccg gaacctgggc 600
 gccctgcttc cccggtgca ccagctgtgc tgccgcatgc ccgcaccct gcgcgggtc 660
 ttcgtggctg agctgtgcag ctggatggca ctcatgacct tcacgctgtt ttacacggat 720
 ttcgtgggag aggggctgta ccaggcgctg cccagagctg agccgggcac cgaggcccgg 780
 agacactatg atgaaggcgt tcggatgggc agcctggggc tgttcttgca gtgcgccatc 840
 35 tccctggtct tctctctggt catggaccgg ctggtgcagc gattcgggac tcgagcagtc 900
 tatttgcca gtgtggcagc tttccctgtg gctgccggtg ccacatgcct gtcccacagt 960
 gtggccgtgg tgacagcttc agccgccttc accgggttca ccttctcagc cctgcagatc 1020
 ctgccctaca cactggcctc cctctaccac cgggagaagc aggtgttctt gcccaaatac 1080
 cgaggggaca ctggaggtgc tagcagttag gacagcctga tgaccagctt cctgcccaggc 1140
 40 cctaagcctg gagctccctt ccctaattga cacgtgggtg ctggaggcag tggcctgctc 1200
 ccacctccac ccgcgctctg cggggcctct gcctgtgatg tctccgtacg tgtggtggtg 1260
 ggtgagccca ccgaggccag ggtggttccg ggccggggca tctgcctgga cctcgccatc 1320
 ctggatagtg ccttctctgt gtcccagggt gccccatccc tgtttatggg ctccattgtc 1380
 cagctcagcc agtctgtcac tgccatatag gtgtctgccg caggcctggg tctggctgcc 1440
 45 atttactttg ctacacaggt agtatattgac aagagcgact tggccaaata ctcagcgggt 1500
 ggacaccatc accatcacca ttaa 1524

50 <210> 31
 <211> 685
 <212> PRT
 <213> Artificial Sequence

55 <220>
 <223> Human P501S (amino acids 1-34 fused to 55-553) fused to 6 histidine residues

<400> 31

EP 1 511 768 B1

Met	Ala	Ala	Val	Gln	Arg	Leu	Trp	Val	Ser	Arg	Leu	Leu	Arg	His	Arg
1				5					10					15	
Lys	Ala	Gln	Leu	Leu	Leu	Val	Asn	Leu	Leu	Thr	Phe	Gly	Leu	Glu	Val
			20					25					30		

5

10

15

20

25

30

35

40

45

50

55

	Cys	Leu	Ala	Ala	Ala	Tyr	Val	His	Ser	Asp	Gly	Ser	Tyr	Pro	Lys	Asp
			35					40					45			
5	Lys	Phe	Glu	Lys	Ile	Asn	Gly	Thr	Trp	Tyr	Tyr	Phe	Asp	Ser	Ser	Gly
		50					55					60				
	Tyr	Met	Leu	Ala	Asp	Arg	Trp	Arg	Lys	His	Thr	Asp	Gly	Asn	Trp	Tyr
	65					70					75				80	
	Trp	Phe	Asp	Asn	Ser	Gly	Glu	Met	Ala	Thr	Gly	Trp	Lys	Lys	Ile	Ala
				85						90					95	
10	Asp	Lys	Trp	Tyr	Tyr	Phe	Asn	Glu	Glu	Gly	Ala	Met	Lys	Thr	Gly	Trp
				100					105						110	
	Val	Lys	Tyr	Lys	Asp	Thr	Trp	Tyr	Tyr	Leu	Asp	Ala	Lys	Glu	Gly	Ala
		115						120					125			
	Met	Gln	Tyr	Ile	Lys	Ala	Asn	Ser	Lys	Phe	Ile	Gly	Ile	Thr	Glu	Gly
	130						135					140				
15	Val	Met	Val	Ser	Asn	Ala	Phe	Ile	Gln	Ser	Ala	Asp	Gly	Thr	Gly	Trp
	145					150					155				160	
	Tyr	Tyr	Leu	Lys	Pro	Asp	Gly	Thr	Leu	Ala	Asp	Arg	Pro	Glu	Lys	Phe
				165						170					175	
	Met	Tyr	Met	Val	Leu	Gly	Ile	Gly	Pro	Val	Leu	Gly	Leu	Val	Cys	Val
			180						185					190		
20	Pro	Leu	Leu	Gly	Ser	Ala	Ser	Asp	His	Trp	Arg	Gly	Arg	Tyr	Gly	Arg
		195						200					205			
	Arg	Arg	Pro	Phe	Ile	Trp	Ala	Leu	Ser	Leu	Gly	Ile	Leu	Leu	Ser	Leu
		210					215					220				
	Phe	Leu	Ile	Pro	Arg	Ala	Gly	Trp	Leu	Ala	Gly	Leu	Leu	Cys	Pro	Asp
	225					230					235				240	
25	Pro	Arg	Pro	Leu	Glu	Leu	Ala	Leu	Leu	Ile	Leu	Gly	Val	Gly	Leu	Leu
				245						250					255	
	Asp	Phe	Cys	Gly	Gln	Val	Cys	Phe	Thr	Pro	Leu	Glu	Ala	Leu	Leu	Ser
			260						265					270		
	Asp	Leu	Phe	Arg	Asp	Pro	Asp	His	Cys	Arg	Gln	Ala	Tyr	Ser	Val	Tyr
		275						280					285			
30	Ala	Phe	Met	Ile	Ser	Leu	Gly	Gly	Cys	Leu	Gly	Tyr	Leu	Leu	Pro	Ala
		290					295					300				
	Ile	Asp	Trp	Asp	Thr	Ser	Ala	Leu	Ala	Pro	Tyr	Leu	Gly	Thr	Gln	Glu
	305					310					315				320	
	Glu	Cys	Leu	Phe	Gly	Leu	Leu	Thr	Leu	Ile	Phe	Leu	Thr	Cys	Val	Ala
				325						330					335	
35	Ala	Thr	Leu	Leu	Val	Ala	Glu	Glu	Ala	Ala	Leu	Gly	Pro	Thr	Glu	Pro
			340					345						350		
	Ala	Glu	Gly	Leu	Ser	Ala	Pro	Ser	Leu	Ser	Pro	His	Cys	Cys	Pro	Cys
		355						360					365			
	Arg	Ala	Arg	Leu	Ala	Phe	Arg	Asn	Leu	Gly	Ala	Leu	Leu	Pro	Arg	Leu
		370					375					380				
40	His	Gln	Leu	Cys	Cys	Arg	Met	Pro	Arg	Thr	Leu	Arg	Arg	Leu	Phe	Val
	385					390					395				400	
	Ala	Glu	Leu	Cys	Ser	Trp	Met	Ala	Leu	Met	Thr	Phe	Thr	Leu	Phe	Tyr
				405						410					415	
	Thr	Asp	Phe	Val	Gly	Glu	Gly	Leu	Tyr	Gln	Gly	Val	Pro	Arg	Ala	Glu
			420						425					430		
45	Pro	Gly	Thr	Glu	Ala	Arg	Arg	His	Tyr	Asp	Glu	Gly	Val	Arg	Met	Gly
			435					440					445			
	Ser	Leu	Gly	Leu	Phe	Leu	Gln	Cys	Ala	Ile	Ser	Leu	Val	Phe	Ser	Leu
		450					455					460				
50	Val	Met	Asp	Arg	Leu	Val	Gln	Arg	Phe	Gly	Thr	Arg	Ala	Val	Tyr	Leu
	465					470					475				480	
	Ala	Ser	Val	Ala	Ala	Phe	Pro	Val	Ala	Ala	Gly	Ala	Thr	Cys	Leu	Ser
				485						490					495	
	His	Ser	Val	Ala	Val	Val	Thr	Ala	Ser	Ala	Ala	Leu	Thr	Gly	Phe	Thr
				500					505					510		
55	Phe	Ser	Ala	Leu	Gln	Ile	Leu	Pro	Tyr	Thr	Leu	Ala	Ser	Leu	Tyr	His

10

15

20

25

30

35

40

45

50

55

atggcgcccg tgcagaggct atgggtatcg agactgctaa gacaccgcaa agctcagttg 60
 ttgttgggta acttgttgac cttcgggctg gaagtctgtt tggcgccgc ttacgtacat 120
 tccgacggct cttatccaaa agacaagttt gagaaaatca atggcacttg gtactacttt 180
 5 gacagttcag gctatatgct tgcagaccgc tggaggaagc acacagacgg caactggtac 240
 tggttcgaca actcaggcga aatggctaca ggctggaaga aaatcgctga taagtggtag 300
 tatttcaacg aagaagggtc catgaagaca ggctgggtca agtacaagga cacttggtag 360
 tacttagacg ctaaagaagg cgccatgcaa tacatcaagg ctaactctaa gttcattggt 420
 atcactgaag gcgtcatggt atcaaatgcc tttatccagt cagcggacgg aacaggctgg 480
 10 tactacctca aaccagacgg aacactggca gacaggccag aaaagtccat gtacatggtg 540
 ctgggcattg gtccagtgtc gggcctgggc tgtgtcccgc tctaggctc agccagtgtg 600
 cactggcgtg gacgctatgg ccgccgccgg cccttcactc gggcactgtc cttgggcatc 660
 ctgctgagcc tctttctcat cccaagggcc ggctggctag cagggtgtgt gtgcccggat 720
 cccaggcccc tggagctggc actgtctcat ctgggcgtgg ggctgtgtga cttctgtggc 780
 caggtgtgtc tcaactccact ggaggccctg ctctctgacc tcttccggga cccggaccac 840
 15 tgtcgccagg cctactctgt ctatgccttc atgacagtc ttgggggctg cctgggctac 900
 ctctgcctg ccattgactg ggacaccagt gccctggccc cctacctggg caccaggag 960
 gagtgcctct ttggcctgct caccctcatc ttcctcactc gcgtagcagc cacactgtg 1020
 gtggctgagg aggcagcgtc gggccccacc gagccagcag aagggtgtgtc ggccccctcc 1080
 ttgtcgcccc actgtgttcc atgccggggc cgcttggctt tccggaacct gggcgccctg 1140
 20 cttccccggc tgcaccagct gtgctgccgc atgccccgca ccttgcgccg gctcttcgtg 1200
 gctgagctgt gcagctggat ggcactcatg accttcacgc tgttttacac ggatttcgtg 1260
 ggcgagggggc tgtaccaggc cgtgcccaga gctgagccgg gcaccgaggc ccggagacac 1320
 tatgatgaag gcgttcggat gggcagcctg gggctgttcc tgcagtgcgc catctccctg 1380
 gtcttctctc tggctcatgga ccggctgggt cagcgattcg gcactcgagc agtctatttg 1440
 25 gccagtgtg cagctttccc tgtggctgcc ggtgccacat gcctgtccca cagtgtggcc 1500
 gtgggtgacg cttcagccgc cctcaccggg ttcacctctc cagccctgca gatcctgccc 1560
 tacacactgg cctccctcta ccaccgggag aagcaggtgt tctgcccga ataccgaggg 1620
 gacactggag gtgctagcag tgaggacagc ctgatgacca gcttctgtcc aggccctaag 1680

30
 cctggagctc ccttccctaa tggacacgtg ggtgctggag gcagtggcct gctcccacct 1740
 ccaccgcgc tctgcggggc ctctgcctgt gatgtctccg tacgtgtggg ggtgggtgag 1800
 cccaccgagg ccagggtggg tccgggcccgg ggcactctgc tggacctcgc catcctggat 1860
 35 agtgccttcc tgcgtgtcca ggtggcccca tccctgttta tgggtcccat tgtccagctc 1920
 agccagtctg tcaactgccta tatgggtgtc gccgcaggcc tgggtctggg cgccatttac 1980
 tttgctacac aggtagtatt tgacaagagc gacttggcca aatactcagc ggggtggacac 2040
 catcaccatc accattaa 2058

40 <210> 33
 <211> 671
 <212> PRT
 <213> Artificial Sequence

45 <220>
 <223> St. pneum. C-LytA portion fused to P2 T helper epitope fused to Human P501S (amino acids 55-553) fused to 6 histidine residues downstream of yeast alphaprepro signal sequence

50 <400> 33

55

Met Ala Ala Arg Phe Pro Ser Ile Phe Thr Ala Val Leu Phe Ala Ala
 1 5 10 15
 Ser Ser Ala Leu Ala Ala Ala Tyr Val His Ser Asp Gly Ser Tyr Pro
 20 25 30
 Lys Asp Lys Phe Glu Lys Ile Asn Gly Thr Trp Tyr Tyr Phe Asp Ser
 35 40 45
 Ser Gly Tyr Met Leu Ala Asp Arg Trp Arg Lys His Thr Asp Gly Asn
 50 55 60
 Trp Tyr Trp Phe Asp Asn Ser Gly Glu Met Ala Thr Gly Trp Lys Lys
 65 70 75 80
 Ile Ala Asp Lys Trp Tyr Tyr Phe Asn Glu Glu Gly Ala Met Lys Thr
 85 90 95
 Gly Trp Val Lys Tyr Lys Asp Thr Trp Tyr Tyr Leu Asp Ala Lys Glu
 100 105 110
 Gly Ala Met Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr
 115 120 125
 Glu Gly Val Met Val Ser Asn Ala Phe Ile Gln Ser Ala Asp Gly Thr
 130 135 140
 Gly Trp Tyr Tyr Leu Lys Pro Asp Gly Thr Leu Ala Asp Arg Pro Glu
 145 150 155 160
 Lys Phe Met Tyr Met Val Leu Gly Ile Gly Pro Val Leu Gly Leu Val
 165 170 175
 Cys Val Pro Leu Leu Gly Ser Ala Ser Asp His Trp Arg Gly Arg Tyr
 180 185 190
 Gly Arg Arg Arg Pro Phe Ile Trp Ala Leu Ser Leu Gly Ile Leu Leu
 195 200 205
 Ser Leu Phe Leu Ile Pro Arg Ala Gly Trp Leu Ala Gly Leu Leu Cys
 210 215 220
 Pro Asp Pro Arg Pro Leu Glu Leu Ala Leu Leu Ile Leu Gly Val Gly
 225 230 235 240
 Leu Leu Asp Phe Cys Gly Gln Val Cys Phe Thr Pro Leu Glu Ala Leu
 245 250 255
 Leu Ser Asp Leu Phe Arg Asp Pro Asp His Cys Arg Gln Ala Tyr Ser
 260 265 270
 Val Tyr Ala Phe Met Ile Ser Leu Gly Gly Cys Leu Gly Tyr Leu Leu
 275 280 285
 Pro Ala Ile Asp Trp Asp Thr Ser Ala Leu Ala Pro Tyr Leu Gly Thr
 290 295 300
 Gln Glu Glu Cys Leu Phe Gly Leu Leu Thr Leu Ile Phe Leu Thr Cys
 305 310 315 320
 Val Ala Ala Thr Leu Leu Val Ala Glu Glu Ala Ala Leu Gly Pro Thr

325 330 335
 Glu Pro Ala Glu Gly Leu Ser Ala Pro Ser Leu Ser Pro His Cys Cys
 340 345 350
 5 Pro Cys Arg Ala Arg Leu Ala Phe Arg Asn Leu Gly Ala Leu Leu Pro
 355 360 365
 Arg Leu His Gln Leu Cys Cys Arg Met Pro Arg Thr Leu Arg Arg Leu
 370 375 380
 10 Phe Val Ala Glu Leu Cys Ser Trp Met Ala Leu Met Thr Phe Thr Leu
 385 390 395 400
 Phe Tyr Thr Asp Phe Val Gly Glu Gly Leu Tyr Gln Gly Val Pro Arg
 405 410 415
 Ala Glu Pro Gly Thr Glu Ala Arg Arg His Tyr Asp Glu Gly Val Arg
 420 425 430
 15 Met Gly Ser Leu Gly Leu Phe Leu Gln Cys Ala Ile Ser Leu Val Phe
 435 440 445
 Ser Leu Val Met Asp Arg Leu Val Gln Arg Phe Gly Thr Arg Ala Val
 450 455 460
 Tyr Leu Ala Ser Val Ala Ala Phe Pro Val Ala Ala Gly Ala Thr Cys
 465 470 475 480
 20 Leu Ser His Ser Val Ala Val Val Thr Ala Ser Ala Ala Leu Thr Gly
 485 490 495
 Phe Thr Phe Ser Ala Leu Gln Ile Leu Pro Tyr Thr Leu Ala Ser Leu
 500 505 510
 25 Tyr His Arg Glu Lys Gln Val Phe Leu Pro Lys Tyr Arg Gly Asp Thr
 515 520 525
 Gly Gly Ala Ser Ser Glu Asp Ser Leu Met Thr Ser Phe Leu Pro Gly
 530 535 540
 Pro Lys Pro Gly Ala Pro Phe Pro Asn Gly His Val Gly Ala Gly Gly
 545 550 555 560
 30 Ser Gly Leu Leu Pro Pro Pro Ala Leu Cys Gly Ala Ser Ala Cys
 565 570 575
 Asp Val Ser Val Arg Val Val Val Gly Glu Pro Thr Glu Ala Arg Val
 580 585 590
 35 Val Pro Gly Arg Gly Ile Cys Leu Asp Leu Ala Ile Leu Asp Ser Ala
 595 600 605
 Phe Leu Leu Ser Gln Val Ala Pro Ser Leu Phe Met Gly Ser Ile Val
 610 615 620
 Gln Leu Ser Gln Ser Val Thr Ala Tyr Met Val Ser Ala Ala Gly Leu
 625 630 635 640
 40 Gly Leu Val Ala Ile Tyr Phe Ala Thr Gln Val Val Phe Asp Lys Ser
 645 650 655
 Asp Leu Ala Lys Tyr Ser Ala Gly Gly His His His His His His
 660 665 670

45

<210> 34
 <211> 2477
 <212> DNA
 <213> Artificial Sequence

50

<220>
 <223> DNA encoding St. pneum. C-LytA portion fused to P2 T helper epitope fused to Human P501S (amino acids 55-553) fused to 6 histidine residues downstream of yeast alphaprepro signal sequence

55

<400> 34

tacgtacatt cgcacggctc ttatccaaaa gacaagtttg agaaaatcaa tggcacttgg 60
 tactactttg acagttcagg ctatatgctt gcagaccgct ggaggaagca cacagacggc 120
 aactggtact ggttcgacaa ctcaggcgaa atggctacag gctggaagaa aatcgctgat 180
 aagtgggtact atttcaacga agaagggtgcc atgaagacag gctgggtcaa gtacaaggac 240

acttgggtact acttagacgc taaagaaggc gccatgcaat acatcaaggc taactctaag 300
 ttcattggta tcaactgaagg cgtcatggta tcaaattgcct ttatccagtc agcggacgga 360
 acaggctggt actacctcaa accagacgga acactggcag acaggccaga aatggcgcc 420
 agatttcctt caattttttac tgcagtttta ttgcagcat cctccgcatt agcggccgct 480
 tacgtacatt cgcacggctc ttatccaaaa gacaagtttg agaaaatcaa tggcacttgg 540
 tactactttg acagttcagg ctatatgctt gcagaccgct ggaggaagca cacagacggc 600
 aactggtact ggttcgacaa ctcaggcgaa atggctacag gctggaagaa aatcgctgat 660
 aagtgggtact atttcaacga agaagggtgcc atgaagacag gctgggtcaa gtacaaggac 720
 acttgggtact acttagacgc taaagaaggc gccatgcaat acatcaaggc taactctaag 780
 ttcattggta tcaactgaagg cgtcatggta tcaaattgcct ttatccagtc agcggacgga 840
 acaggctggt actacctcaa accagacgga acactggcag acaggccaga agctggtatt 900
 acttacgttc caccattggt gttggaagtt ggtgttgaag aaaagttcat gtacatggtg 960
 ctgggcattg gtccagtgtc gggcctggtc tgtgtccgc tcctaggctc agccagtgc 1020
 cactggcggtg gacgctatgg ccgcccggc cccttcactt gggcactgtc cttgggcctc 1080
 ctgctgagcc tctttctcat cccaagggcc ggttggttag cagggctgct gtgcccggat 1140
 cccaggcccc tggagctggc actgctcatc ctgggcgtgg ggctgctgga cttctgtggc 1200
 caggtgtgct tcaactccact ggaggccctg ctctctgacc tcttccggga cccggaccac 1260
 tgtcgccagg cctactctgt ctatgcttca tgatcagtct tgggggctgc ctgggctacc 1320
 tcctgcctgc cattgactgg gacaccagtg ccctggcccc ctacctgggc acccaggagg 1380
 agtgccctct tggcctgctc accctcatct tcttcacctg cgtagcagcc acaactgtctg 1440
 tggctgagga ggcagcgctg ggccccaccg agccagcaga agggctgtcg gccccctct 1500
 tgtcgcccca ctgctgtcca tgcggggccc gcttggcttt ccggaacctg ggcgccctgc 1560
 ttccccggct gcaccagctg tgctgccca tgcctccgac cctgcgcccg ctcttctgtg 1620
 ctgagctgtg cagctggatg gcaactcatg ccttcacgct gttttacacg gatttctgtg 1680
 gcgaggggct gtaccagggc gtgcccagag ctgagccggg caccgaggcc cggagacact 1740
 atgatgaagg cgttcggatg ggcagcctgg ggctgttctt gcagtgcgcc atctccctgg 1800
 tcttctctct ggtcatggac cggctggtgc agcgattcgg cactcgagca gtctatttgg 1860
 ccagtgtggc agctttccct gtggctgccc gtgcccacat cctgtccac agtgtggccg 1920
 tgggtgacagc ttcagccgcc ctcaccgggt tcaccttctc agccctgcag atcctgccct 1980
 acacactggc ctccctctac caccgggaga agcaggtgtt cctgcccata taccgagggg 2040
 acactggagg tgctagcagt gaggacagcc tgatgaccag cttcctgcca ggccctaagc 2100
 ctggagctcc ctccctaat ggacacgtgg gtgctggagg cagtggcctg ctccacctc 2160
 caccgcgct ctgcccggcc tctgctgtg atgtctccgt acgtgtggtg gtgggtgagc 2220
 ccaccgaggc caggggtggt ccgggcccgg gcatctgcct ggacctgcc atcctggata 2280
 gtgcttctct gctgtcccag gtggcccat cctgtttat gggctccatt gtccagctca 2340
 gccagtctgt cactgcctat atggtgtctg ccgcaggcct gggctctggt gccatttact 2400
 ttgctacaca ggtagtattt gacaagagcg acttggccaa atactcagcg ggtggacacc 2460
 atccacatca ccattaa

<210> 35

<211> 595

<212> PRT

<213> Artificial Sequence

<220>

<223> Human P501S (amino acids 55-553) fused to 6 histidine residues downstream of yeast alphaprepro signal sequence

<400> 35

EP 1 511 768 B1

	Met	Ser	Phe	Leu	Asn	Phe	Thr	Ala	Val	Leu	Phe	Ala	Ala	Ser	Ser	Ala
	1				5					10					15	
	Leu	Ala	Ala	Pro	Val	Asn	Thr	Thr	Thr	Glu	Asp	Glu	Thr	Ala	Gln	Ile
				20					25					30		
5	Pro	Ala	Glu	Ala	Val	Ile	Gly	Tyr	Ser	Asp	Leu	Glu	Gly	Asp	Phe	Asp
			35				40						45			
	Val	Ala	Val	Leu	Pro	Phe	Ser	Asn	Ser	Thr	Asn	Asn	Gly	Leu	Leu	Phe
			50				55					60				
	Ile	Asn	Thr	Thr	Ile	Ala	Ser	Ile	Ala	Ala	Lys	Glu	Glu	Gly	Val	Ser
10	65					70					75				80	
	Leu	Glu	Lys	Arg	Glu	Ala	Glu	Ala	Met	Val	Leu	Gly	Ile	Gly	Pro	Val

15

20

25

30

35

40

45

50

55

EP 1 511 768 B1

				85				90				95	
	Leu	Gly	Leu	Val	Cys	Val	Pro	Leu	Leu	Gly	Ser	Ala	Ser
				100				105				110	Asp
5	Arg	Gly	Arg	Tyr	Gly	Arg	Arg	Pro	Phe	Ile	Trp	Ala	Leu
				115				120				125	Ser
	Gly	Ile	Leu	Leu	Ser	Leu	Phe	Leu	Ile	Pro	Arg	Ala	Gly
				130			135					140	Trp
	Gly	Leu	Leu	Cys	Pro	Asp	Pro	Arg	Pro	Leu	Glu	Leu	Ala
				145		150					155		Leu
10	Leu	Gly	Val	Gly	Leu	Leu	Asp	Phe	Cys	Gly	Gln	Val	Cys
				165						170			Phe
													Thr
	Leu	Glu	Ala	Leu	Leu	Ser	Asp	Leu	Phe	Arg	Asp	Pro	Asp
				180					185				His
	Gln	Ala	Tyr	Ser	Val	Tyr	Ala	Phe	Met	Ile	Ser	Leu	Gly
				195				200					Gly
15	Gly	Tyr	Leu	Leu	Pro	Ala	Ile	Asp	Trp	Asp	Thr	Ser	Ala
				210				215					Leu
													Ala
	Tyr	Leu	Gly	Thr	Gln	Glu	Glu	Cys	Leu	Phe	Gly	Leu	Leu
				225		230					235		Thr
													Leu
	Phe	Leu	Thr	Cys	Val	Ala	Ala	Thr	Leu	Leu	Val	Ala	Glu
20				245							250		Glu
													Ala
	Leu	Gly	Pro	Thr	Glu	Pro	Ala	Glu	Gly	Leu	Ser	Ala	Pro
				260				265					Ser
													Leu
	Pro	His	Cys	Cys	Pro	Cys	Arg	Ala	Arg	Leu	Ala	Phe	Arg
				275				280					Asn
													Leu
25	Ala	Leu	Leu	Pro	Arg	Leu	His	Gln	Leu	Cys	Cys	Arg	Met
				290			295					300	Pro
													Arg
	Leu	Arg	Arg	Leu	Phe	Val	Ala	Glu	Leu	Cys	Ser	Trp	Met
				305		310					315		Ala
													Leu
	Thr	Phe	Thr	Leu	Phe	Tyr	Thr	Asp	Phe	Val	Gly	Glu	Gly
				325						330			Leu
													Tyr
30	Gly	Val	Pro	Arg	Ala	Glu	Pro	Gly	Thr	Glu	Ala	Arg	Arg
				340					345				His
													Tyr
	Glu	Gly	Val	Arg	Met	Gly	Ser	Leu	Gly	Leu	Phe	Leu	Gln
				355				360					Cys
													Ala
	Ser	Leu	Val	Phe	Ser	Leu	Val	Met	Asp	Arg	Leu	Val	Gln
				370			375					380	Arg
35													Phe
	Thr	Arg	Ala	Val	Tyr	Leu	Ala	Ser	Val	Ala	Ala	Phe	Pro
				385		390					395		Val
													Ala
	Gly	Ala	Thr	Cys	Leu	Ser	His	Ser	Val	Ala	Val	Val	Thr
				405						410			Ala
													Ser
	Ala	Leu	Thr	Gly	Phe	Thr	Phe	Ser	Ala	Leu	Gln	Ile	Leu
				420					425				Pro
40													Tyr
	Leu	Ala	Ser	Leu	Tyr	His	Arg	Glu	Lys	Gln	Val	Phe	Leu
				435				440					Pro
													Lys
	Arg	Gly	Asp	Thr	Gly	Gly	Ala	Ser	Ser	Glu	Asp	Ser	Leu
				450		455					460		Met
													Thr
	Phe	Leu	Pro	Gly	Pro	Lys	Pro	Gly	Ala	Pro	Phe	Pro	Asn
45				465		470					475		Gly
													His
	Gly	Ala	Gly	Gly	Ser	Gly	Leu	Leu	Pro	Pro	Pro	Pro	Ala
				485						490			Leu
													Cys
	Ala	Ser	Ala	Cys	Asp	Val	Ser	Val	Arg	Val	Val	Val	Gly
				500					505				Glu
													Pro
50	Glu	Ala	Arg	Val	Val	Pro	Gly	Arg	Gly	Ile	Cys	Leu	Asp
				515				520					Leu
													Ala
	Leu	Asp	Ser	Ala	Phe	Leu	Leu	Ser	Gln	Val	Ala	Pro	Ser
				530			535					540	Leu
													Phe
	Gly	Ser	Ile	Val	Gln	Leu	Ser	Gln	Ser	Val	Thr	Ala	Tyr
				545		550					555		Met
													Val
55	Ala	Ala	Gly	Leu	Gly	Leu	Val	Ala	Ile	Tyr	Phe	Ala	Thr
				565						570			Gln
													Val

Phe Asp Lys Ser Asp Leu Ala Lys Tyr Ser Ala Gly Gly His His His
580 585 590
His His His
595

<210> 36
<211> 1788
<212> DNA
<213> Artificial Sequence

<220>
<223> DNA encoding Human P501S (amino acids 55-553) fused to 6 histidine residues downstream of yeast alphaprepro signal sequence

<400> 36

20	atgagtttcc	tcaattttac	tgcagtttta	ttcgcagcat	cctccgcatt	agctgctcca	60
	gtcaacacta	caacagaaga	tgaaacggca	caaattccgg	ctgaagctgt	catcggttac	120
	tcagatttag	aaggggattt	cgatgttgct	gttttgccat	tttccaacag	cacaaataac	180
	gggttattgt	ttataaatac	tactattgcc	agcattgctg	ctaaagaaga	aggggtatct	240
	ctcgagaaaa	gagaggctga	agccatggtg	ctgggcattg	gtccagtgtg	ggggcctggtc	300
	tgtgtcccg	tectaggctc	agccagtgac	cactggcgctg	gacgctatgg	ccgcgcgcgg	360
25	cccttcactc	gggcactgtc	cttgggcata	ctgctgagcc	tctttctcat	cccaagggcc	420
	ggctggctag	cagggtgctc	gtgcccggat	cccaggcccc	tggagctggc	actgctcatc	480
	ctgggcgtgg	ggctgctgga	cttctgtggc	cagggtgtgct	tcactccact	ggaggccctg	540
	ctctctgacc	tcttccggga	cccggaccac	tgtcgccagg	cctactctgt	ctatgccttc	600
	atgatcagtc	ttgggggctg	cctgggctac	ctcctgcctg	ccattgactg	ggacaccagt	660
30	gccctggccc	cctacctggg	cacccaggag	gagtgcctct	ttggcctgct	cacccctcatc	720
	ttcttcacct	gcgtagcagc	cacactgctg	gtggctgagg	aggcagcgct	gggccccacc	780
	gagccagcag	aagggtctgtc	ggccccctcc	ttgtcgcccc	actgctgtcc	atgcgcggcc	840
	cgcttggttt	tccggaacct	gggcgcctctg	cttccccggc	tgcaccagct	gtgtctgcgc	900
	atgccccgca	ccctgcgcgc	gctcttcgtg	gctgagctgt	gcagctggat	ggcactcatg	960
35	accttcacgc	tgttttacac	ggatttcgtg	ggcgaggggc	tgtaccaggg	cgtgcccaga	1020
	gctgagccgg	gcaccgaggg	ccggagacac	tatgatgaag	gcgttcggat	gggcagcctg	1080
	gggtctgttc	tgcagtgcgc	catctccctg	gtcttctctc	tggctatgga	ccggctgggtg	1140
	cagcgattcg	gcactcgagc	agtctatttg	gccagtggtg	cagctttccc	cttgcctgcc	1200
	gtgcccacat	gcctgtccca	cagtgtggcc	gtggtgacag	cttcagccgc	cctcaccggg	1260
40	ttcactctct	cagccctgca	gatcctgccc	tacacactgg	cctccctcta	ccaccgggag	1320
	aagcaggtgt	tcctgcccaa	ataccgaggg	gacactggag	gtgctagcag	tgaggacagc	1380
	ctgatgacca	gcttctctgc	aggccctaag	cctggagctc	ccttcccta	tggacacgtg	1440
	gggtctggag	gcagtggcct	gctcccacct	ccaccgcgcg	tctgcggggc	ctctgcttgt	1500
	gatgtctccg	tacgtgtggt	gggtgggtgag	cccaccgagg	ccagggtggt	tccggggccgg	1560
45	ggcatctgcc	tggacctcgc	catcctggat	agtgccttcc	tgctgtccca	gggtggcccca	1620
	tccttgttta	tgggctccat	tgtccagctc	agccagtcctg	tcactgacct	tatggtgtct	1680
	gccgcaggcg	tgggtctggg	cgccatttac	tttgctacac	aggtagtatt	tgacaagagc	1740
	gacttggcca	aatactcagc	gggtggacac	catcaccatc	accattaa		1788

<210> 37
<211> 1955
<212> DNA
<213> Artificial Sequence

<220>
<223> DNA encoding codon-optimised Human P501S (amino acids 51-553) fused to St.pneum. C-LytA P2 helper epitope C-LytA

<400> 37

5 gcggccgcgc caccatggcc gccgcctacg tgcatagcga cgggagctac cccaaggaca 60
 agttcgagaa gatcaacggg acatgggtact acttcgactc ctccggctac atgctcgccg 120

10 accgctggcg gaagcacacc gacggcaact ggtactgggt cgataactcg ggagagatgg 180
 ccaccggctg gaagaagatc gcggacaagt ggtactatct caacgaggag ggcgccatga 240
 agaccggctg ggtgaagtat aaggacacct ggtactacct cgacgccaaag gagggcgcca 300
 tgcagtatat caaggccaac agcaagttca tcggcatcac cgagggagtg atggtcagca 360
 acgcctttat ccagagcgcc gacggcaccg gatggtaata cttgaagccg gacggcaccc 420
 tcgcggatcg gcccagaaag ttcattgtaca tgggtgctggg catcggtccc gtctggggcc 480
 15 tcgtgtgtgt gcccctcttc gggagtgcgt ccgactattg gcggggccgc tacggccgcc 540
 gcagaccgtt catctggggc ctgagcctgg gcactcctgt ctctctcttc ctgaccccc 600
 gggccggctg gctggccggc ctgctgtgtc ccgacccccg cctctggag ctggccctcc 660
 tgatcctggg cgtgggcctg ctggacttct gcggccaggt gtgtttcact cccctggagg 720
 ctctgctctc cgacctcttc cgcgaccccc accactgtag gcaggcttac agcgtgtacg 780
 20 ccttcattgat cagtctgggg ggatgcctgg gctatctgct gcccgctatc gactgggaca 840
 ccagcgccct gggcccttac ctggggactc aggaggagtg cctgttcggc ctgctcacct 900
 tgatcttctt gacgtgcgtc gccgccaccc tgctgggtgg cgaggaggcg gccctggggc 960
 ccaccgagcc cgcgagggc ctgagcgctc ccagcctgag cccccattgc tgcccgtgca 1020
 gggctaggct cgccttcagg aatctggggc ctttgcctgc ccgcctgcat cagctgtgct 1080
 25 gtcgcattgc tcgcacctg cgcgcctgt tcgtcgtga gctctgttcc tggatggccc 1140
 tgatgacgtt caccctcttc tacaccgact tcgtggggga gggcctgtac cagggcgtgc 1200
 ccagggccga gcccggcacc gaggctaggc gccattacga cgagggcgtc aggatgggct 1260
 ctctgggctt cttcctgcag tcgcacctca gtctgggtgt ctctctgggt atggaccggc 1320
 tgggtgcagc cttcggcacc cgggcccgtg acctcgctc tgtggcggt tccccgctc 1380
 30 ccgcccggcg gacctgcctg tctcattctg tcgcctggt gaccgccagc gccgccctga 1440
 ccggtctcac cttcagtgcg ctccagattc tgccctacac cctggcgtct ctgtaccatc 1500
 gcgagaagca ggtgttctc cccaagtacc gcggggacac agggggagct tcctctgagg 1560
 acagcctgat gaccagcttc ttgcccggc ccaagccggg ggccccttcc cccaacggcc 1620
 atgtcggggc gggcggcagc ggcctgctcc ctccccccc cgccctgtgc ggcgctagt 1680
 35 cctgcgacgt gagcgtgcgg gtggtgggtg gggagccac cgaggctagg gtcgtgcctg 1740
 gccgggggat ctgcctggac ctggccatcc tcgactccgc cttcctgctc tcccaggtgg 1800
 cggccagcct gttcatgggc agtatcgtgc agctgagcca gagcgtgacc gcctacatgg 1860
 tgagcgccgc cggcctgggg ttggtggcca tctactttgc caccaggtc gtgttcgaca 1920
 agagcgatct cgccaagtat agcgccctgag gatec 1955

40 <210> 38
 <211> 2045
 <212> DNA
 <213> Artificial Sequence

45 <220>
 <223> DNA encoding codon-optimised Human P501S (amino acids 1-553) fused to St.pneum. C-LytA P2 helper epitope C-LytA

50 <400> 38

55

5 gcggccgcgc caccatggcc gccgcctacg tgcatagcga cgggagctac cccaaggaca 60
 agttcagaaa gatcaacggg acatgggtact acttcgactc ctccggctac atgctcgccg 120
 accgctggcg gaagcacacc gacggcaact ggtactggtt cgataactcg ggagagatgg 180
 ccaccggctg gaagaagatc gccgacaagt ggtactattt caacgaggag ggcgccatga 240
 agaccggctg ggtgaagtat aaggacacct ggtactacct cgacgccaag gagggcgcca 300
 tgcagtatat caaggccaac agcaagttca tcggcatcac cgagggagtg atggtcagca 360
 acgcctttat ccagagcgcc gacggcaccg gatggtacta cttgaagccg gacggcaccc 420
 tcgcggtatc gcccgagatg gtgcagcggc tgtgggtgtc ccggctgctg cgccatagaa 480
 agggccagtt gctgctggtg aacctgctga ctttcggact ggaggtgtgc ctggctgccg 540
 10 tgggtgctggg catcgccccc gtccctggggc tcgtgtgtgt gcccctcctc gggagtgcgt 600
 ccgatcattg gcggggccgc tacggccgcc gcagaccgtt catctgggcc ctgagcctgg 660
 gcacccctgt ctctctcttc ctgatccccc ggcccggtcg gctggccggc ctgctgtgtc 720
 ccgacccccg cctctcgag ctggccctcc tgatcctggg cgtgggacct ctggacttct 780
 gcggccaggt gtgtttcact cccctggagg ctctgtcttc cgacctctc cgcgaccccc 840
 15 accactgtag gcaggcttac agcgtgtacg ccttcattgat cagtctgggg ggatgcctgg 900
 gctatctgct gcccgctatc gactgggaca ccagcgccct ggccccctac ctgggggactc 960
 aggaggagtg cctgttcggc ctgctcacct tgatcttctt gacgtgcgtc gccgccaccc 1020
 tgctgggtggc cgaggaggcg gccctggggc ccaccgagcc cggcgagggc ctgagcgctc 1080
 ccagccttag ccccatctgc tgcccgtgca gggctaggct cgccttcagg aatctgggag 1140

20

25 ctttgetgcc ccgcctgcat cagctgtgct gtgcgatgcc tcgcaccctg cgcgcctgt 1200
 tcgtcgctga gctctgttcc tggatggccc tgatgacgtt caccctcttc tacaccgact 1260
 tcgtggggga gggcctgtac cagggcggtc ccagggccga gcccgccacc gaggctaggc 1320
 gccattacga cgagggcgctc aggatgggct ctctgggcct cttcctgcag tgcgccatca 1380
 gtctggtgtt ctctctgggt atggaccggc tgggtgcagcg cttcggcacc cgggcccgtg 1440
 acctcgcttc tgtggcgggt ttcccgtcg ccgcccggcg gacctgcctg tctcattctg 1500
 tcgcccgtgt gaccgcccag gccgcccctga ccggttcac cttcagtgcg ctccagattc 1560
 30 tgccctacac cctggcgtct ctgtaccatc gcgagaagca ggtgttctct cccaagtacc 1620
 gcggggacac agggggagct tcctctgagg acagcctgat gaccagcttc ttgcccggcc 1680
 ccaagccggg ggccccttcc cccaacggcc atgtcggggc gggcggcagc ggctgtctcc 1740
 ctcccccccc cgccctgtgc ggcgctagtg cctgcgacgt gagcgtgcgg gtggtggtgg 1800
 gggagcccac cgaggctagg gtctgtcctg gccgggggat ctgcctggac ctggccatcc 1860
 35 tcgactccgc cttcctgtct tcccagtggt cgcgcagcct gttcatgggc agtatcgtgc 1920
 agctgagcca gacgtgacc gcctacatgg tgagcgccgc cggcctgggg ttggtggcca 1980
 tctactttgc caccaggtc gtgttcgaca agagcgatct cgccaagtat agcgcctgag 2040
 gatcc 2045

40

<210> 39
 <211> 2105
 <212> DNA
 <213> Artificial Sequence

45

<220>
 <223> DNA encoding St.pneum. C-LytA P2 helper epitope C-Lyta fused to Human P501S (amino acids 51-553)
 fused to Human P501S (amino acids 1-50) - Codon-optimised

50

<400> 39

55

gcgggcgcgc caccatggcc gccgcctacg tgcatagcga cgggagctac cccaaggaca 60
 agttcgagaa gatcaacggg acatgggtact acttcgactc ctccggctac atgctcgccg 120
 accgctggcg gaagcacacc gacggcaact ggtactggtt cgataactcg ggagagatgg 180
 ccaccggctg gaagaagatc gccgacaagt ggtactatct caacgaggag ggcgccatga 240
 5 agaccggctg ggtgaagtat aaggacacct ggtactacct cgacgccaaag gagggcgcca 300
 tgcagtatat caaggccaac agcaagttca tcggcatcac cgagggagtg atggtcagca 360
 acgcctttat ccagagcgcc gacggcaccg gatggtacta cttgaagccg gacggcacc 420
 tcgcggatcg gcccgagaag ttcattgtaca tgggtgctggg catcgccccc gtcttgggccc 480
 tcgtgtgtgt gcccctcctc gggagtgctg ccgatcattg gcggggccgc tacggccgcc 540
 10 gcagaccggt catctgggccc ctgagcctgg gcacccctgt ctctctcttc ctgatccccc 600
 gggccggctg gctggccggc ctgctgtgtc ccgacccccg cctcttggag ctggccctcc 660
 tgatcctggg cgtgggcctg ctggacttc cggccagggt gtgtttcact cccctggagg 720
 ctctgtcttc cgacctcttc cgcgaccccc accactgtag gcaggcttac agcgtgtacg 780
 ccttcatgat cagtctgggg ggatgcctgg gctatctgct gcccgctatc gactgggaca 840
 15 ccagcgccct ggccccctac ctggggactc aggaggagtg cctgttcggc ctgctcacct 900
 tgatcttctt gacgtgcgtc gccgccaccc tgctggtggc cgaggaggcg gccctggggc 960
 ccaccgagcc cgcgaggggc ctgagcgctc ccagcctgag ccccatctgc tgcctgtgca 1020
 gggctaggct cgccctcagg aatctgggcg ctttgcctgc ccgcctgcat cagctgtgct 1080
 gtcgatgccc tcgcacctg cgcgcctgt tcgtcgctga gctctgttcc tggatggccc 1140
 20 tgatgacgtt caccctcttc tacaccgact tcgtggggga gggcctgtac cagggcgtgc 1200
 ccaggggcca gcccggcacc gaggctaggc gccattacga cgaggcgctc aggatgggct 1260
 ctctgggccc cttctgtcag tgcgccatca gtctggtgtt ctctctggtg atggaccggc 1320
 tgggtgcagc cttcggcacc cgggcctgtg acctcgctc tgtggcggct tcccccgctc 1380
 ccgcccgcgc gacctgcctg tctcattctg tcgccgtggt gaccgccagc gccgccctga 1440
 25 ccggcttcac cttcagtgcg ctccagattc tgccctacac cctggcgtct ctgtaccatc 1500
 gcgagaagca ggtgttcttg cccaagtacc gcggggacac agggggagct tcctctgagg 1560
 acagcctgat gaccagcttc ttgcccgccc ccaagccggg ggcccccttc cccaacggcc 1620
 atgtcggggc gggcggcagc ggcctgtctc ctcccccccc cgccctgtgc ggcctagtgc 1680
 cctgcgacgt gacgtgcgg gtggtggtgg gggagccac cgaggctagg gtcgtgctg 1740
 gccgggggat ctgctggac ctggccatcc tcgactccgc ctctctgtc tcccagggtg 1800
 30 cggccagcct gttcatgggc agtatcgtgc agctgagcca gacgtgacc gcctacatgg 1860
 tgagcgccgc cggcctgggg ttggtggcca tctactttgc caccaggctc gtgttcgaca 1920

35 agagcgatct cgccaagtat agcgccatgg tgcagcggct gtgggtgtcc cggctgctgc 1980
 gccatagaaa ggcccagttg ctgctggtga acctgctgac ttctcgactg gaggtgtgccc 2040
 tggctgcccg gatcacgtac gtgccccccc tgetgctgga ggtgggcgtg gaggagtgag 2100
 gatcc 2105

40 <210> 40
 <211> 2105
 <212> DNA
 <213> Artificial Sequence

45 <220>
 <223> DNA encoding Human P501S (amino acids 1-50) fused to St.pneum. C-LytA P2 helper epitope C-LytA fused
 to Human P501S (amino acids 51-553) - Codon-optimised

50 <400> 40

55

gcgggccgcgc caccatggtg cagcggtgtg ggtgtgcccg gctgctgcgc catagaaagg 60
 cccagttgct gctggtgaac ctgctgactt tggactgga ggtgtgctg gctgccggga 120
 tcacgtacgt gccccccctg ctgctggagg tggcggtgga ggagatggcc gccgcctacg 180
 5 tgcatagcga cgggagctac cccaaggaca agtcgagaa gatcaacggg acatgggtact 240
 acttcgactc ctccggctac atgctcgccg accgctggcg gaagcacacc gacggcaact 300
 ggtactggtt cgataactcg ggagagatgg ccaccggctg gaagaagatc gcggacaagt 360
 ggtactatct caacgaggag ggcgccatga agaccggctg ggtgaagtat aaggacacct 420
 ggtactacct cgacgccaag gagggcgcca tgcagtatat caaggccaac agcaagttca 480
 10 tcggcatcac cgagggagtg atggtcagca acgctttat ccagagcgcc gacggcaccg 540
 gatggtacta cttgaagccg gacggcaccc tcgcggtatc gcccgagaag ttcattgtaca 600
 tgggtgctggg catcgggccc gtcctggggc tcgtgtgtgt gcccctctc gggagtgcgt 660
 ccgatcattg gcggggccgc tacggccgcc gcagaccgtt catctggggc ctgagcctgg 720
 gcatcctgct ctctctcttc ctgaccccc ggccggctg gctggccggc ctgctgtgtc 780
 ccgacccccg cctctggag ctggccctcc tgatcctggg cgtgggcctg ctggacttct 840
 15 gcggccaggt gtgtttcact cccctggagg ctctgctctc cgacctctc cgcgaccccc 900
 accactgtag gcaggttac agcgtgtacg ccttcattgat cagtctgggg ggtgacctg 960
 gctatctgct gcccgctatc gactgggaca ccagcgccct ggccccctac ctggggactc 1020
 aggaggagtg cctgttcggc ctgctcacct tgatcttcct gacgtgcgtc gccgccaccc 1080
 tgctggtggc cgaggaggcg gccctggggc ccaccgagcc cgcgaggggc ctgagcgctc 1140
 20 ccagcctgag cccccattgc tggcctgca gggctaggct cgccttcagg aatctggggc 1200
 ctttctgctc ccgctgcat cagctgtgct gtccatgcc tcgcacctg cgcgcctgt 1260
 tctgctgga gctctgttc tggatggccc tgatgacgtt caccctctc tacaccgact 1320
 tctggggga gggcctgtac cagggcgctc ccagggccga gcccggcacc gaggctaggc 1380
 gccattacga cgaggcgctc aggatgggct ctctgggctt cttcctgcag tgcgccatca 1440
 25 gtctggtgtt ctctctggtg atggaccggc tgggtgcagc cttcggcacc cggggcgtgt 1500
 acctgcctc tgtggcggtt tccccgctc ccgccggcg gacctgcctg tctcattctg 1560
 tcgccgtggt gaccgccagc gcgcacctga ccggttcac cttcagtgcg ctccagattc 1620
 tgccctacac cctggcgtct ctgtaccatc gcgagaagca ggtgttcctg cccaagtacc 1680
 gcggggacac agggggagct tcctctgagg acagcctgat gaccagcttc ttgcccggcc 1740
 30 ccaagccggg ggcctcttc cccaacggcc atgtcggggc gggcggcagc ggcctgctcc 1800
 ctcccccccc cgcctgtgc ggcgtagtg cctgcgacgt gagcgtgcgg gtggtggtgg 1860
 gggagcccac cgaggctagg gtcgtgctg gccgggggat ctgctggac ctggccatcc 1920
 tcgactccgc cttcctgctc tcccaggtgg cgcacgctt gttcatgggc agtatcgtgc 1980
 agctgagcca gagegtgacc gcctacatgg tgagcgccgc cggcctgggg ttggtggcca 2040
 35 tctactttgc caccaggtc gtgttcgaca agagcgatct cgccaagtat agcgctgag 2100
 gatcc 2105

<210> 41

<211> 652

40 <212> PRT

<213> Artificial Sequence

<220>

<223> St.pneum. C-LytA P2 helper epitope C-Lyta fused to Human P501S

45

<400> 41

50

55

EP 1 511 768 B1

	Met	Ala	Ala	Ala	Tyr	Val	His	Ser	Asp	Gly	Ser	Tyr	Pro	Lys	Asp	Lys	
	1				5					10					15		
	Phe	Glu	Lys	Ile	Asn	Gly	Thr	Trp	Tyr	Tyr	Phe	Asp	Ser	Ser	Gly	Tyr	
				20					25					30			
5	Met	Leu	Ala	Asp	Arg	Trp	Arg	Lys	His	Thr	Asp	Gly	Asn	Trp	Tyr	Trp	
			35					40					45				
	Phe	Asp	Asn	Ser	Gly	Glu	Met	Ala	Thr	Gly	Trp	Lys	Lys	Ile	Ala	Asp	
		50					55					60					
	Lys	Trp	Tyr	Tyr	Phe	Asn	Glu	Glu	Gly	Ala	Met	Lys	Thr	Gly	Trp	Val	
10	65					70					75					80	
	Lys	Tyr	Lys	Asp	Thr	Trp	Tyr	Tyr	Leu	Asp	Ala	Lys	Glu	Gly	Ala	Met	
					85					90					95		
	Gln	Tyr	Ile	Lys	Ala	Asn	Ser	Lys	Phe	Ile	Gly	Ile	Thr	Glu	Gly	Val	
				100					105					110			
15	Met	Val	Ser	Asn	Ala	Phe	Ile	Gln	Ser	Ala	Asp	Gly	Thr	Gly	Trp	Tyr	
				115				120					125				
	Tyr	Leu	Lys	Pro	Asp	Gly	Thr	Leu	Ala	Asp	Arg	Pro	Glu	Lys	Phe	Met	
		130				135					140						
	Tyr	Met	Val	Leu	Gly	Ile	Gly	Pro	Val	Leu	Gly	Leu	Val	Cys	Val	Pro	
	145					150					155					160	
20	Leu	Leu	Gly	Ser	Ala	Ser	Asp	His	Trp	Arg	Gly	Arg	Tyr	Gly	Arg	Arg	
				165						170					175		
	Arg	Pro	Phe	Ile	Trp	Ala	Leu	Ser	Leu	Gly	Ile	Leu	Leu	Ser	Leu	Phe	
				180					185					190			
	Leu	Ile	Pro	Arg	Ala	Gly	Trp	Leu	Ala	Gly	Leu	Leu	Cys	Pro	Asp	Pro	
25			195				200						205				
	Arg	Pro	Leu	Glu	Leu	Ala	Leu	Leu	Ile	Leu	Gly	Val	Gly	Leu	Leu	Asp	
		210				215					220						
	Phe	Cys	Gly	Gln	Val	Cys	Phe	Thr	Pro	Leu	Glu	Ala	Leu	Leu	Ser	Asp	
	225					230					235					240	
30	Leu	Phe	Arg	Asp	Pro	Asp	His	Cys	Arg	Gln	Ala	Tyr	Ser	Val	Tyr	Ala	
				245						250					255		
	Phe	Met	Ile	Ser	Leu	Gly	Gly	Cys	Leu	Gly	Tyr	Leu	Leu	Pro	Ala	Ile	
			260						265					270			
	Asp	Trp	Asp	Thr	Ser	Ala	Leu	Ala	Pro	Tyr	Leu	Gly	Thr	Gln	Glu	Glu	
		275					280						285				
35	Cys	Leu	Phe	Gly	Leu	Leu	Thr	Leu	Ile	Phe	Leu	Thr	Cys	Val	Ala	Ala	
		290					295					300					
	Thr	Leu	Leu	Val	Ala	Glu	Glu	Ala	Ala	Leu	Gly	Pro	Thr	Glu	Pro	Ala	
	305					310					315					320	
40	Glu	Gly	Leu	Ser	Ala	Pro	Ser	Leu	Ser	Pro	His	Cys	Cys	Pro	Cys	Arg	
				325						330					335		
	Ala	Arg	Leu	Ala	Phe	Arg	Asn	Leu	Gly	Ala	Leu	Leu	Pro	Arg	Leu	His	
			340						345					350			
	Gln	Leu	Cys	Cys	Arg	Met	Pro	Arg	Thr	Leu	Arg	Arg	Leu	Phe	Val	Ala	
			355				360						365				
45	Glu	Leu	Cys	Ser	Trp	Met	Ala	Leu	Met	Thr	Phe	Thr	Leu	Phe	Tyr	Thr	
		370					375					380					
	Asp	Phe	Val	Gly	Glu	Gly	Leu	Tyr	Gln	Gly	Val	Pro	Arg	Ala	Glu	Pro	
	385					390					395					400	
	Gly	Thr	Glu	Ala	Arg	Arg	His	Tyr	Asp	Glu	Gly	Val	Arg	Met	Gly	Ser	
				405						410					415		
50	Leu	Gly	Leu	Phe	Leu	Gln	Cys	Ala	Ile	Ser	Leu	Val	Phe	Ser	Leu	Val	
				420					425					430			
	Met	Asp	Arg	Leu	Val	Gln	Arg	Phe	Gly	Thr	Arg	Ala	Val	Tyr	Leu	Ala	
			435				440						445				
55	Ser	Val	Ala	Ala	Phe	Pro	Val	Ala	Ala	Gly	Ala	Thr	Cys	Leu	Ser	His	
		450					455					460					

Ser Val Ala Val Val Thr Ala Ser Ala Ala Leu Thr Gly Phe Thr Phe
 465 470 475 480
 Ser Ala Leu Gln Ile Leu Pro Tyr Thr Leu Ala Ser Leu Tyr His Arg
 485 490 495
 Glu Lys Gln Val Phe Leu Pro Lys Tyr Arg Gly Asp Thr Gly Gly Ala
 500 505 510
 Ser Ser Glu Asp Ser Leu Met Thr Ser Phe Leu Pro Gly Pro Lys Pro
 515 520 525
 Gly Ala Pro Phe Pro Asn Gly His Val Gly Ala Gly Gly Ser Gly Leu
 530 535 540
 Leu Pro Pro Pro Pro Ala Leu Cys Gly Ala Ser Ala Cys Asp Val Ser
 545 550 555 560
 Val Arg Val Val Val Gly Glu Pro Thr Glu Ala Arg Val Val Pro Gly
 565 570 575
 Arg Gly Ile Cys Leu Asp Leu Ala Ile Leu Asp Ser Ala Phe Leu Leu
 580 585 590
 Ser Gln Val Ala Pro Ser Leu Phe Met Gly Ser Ile Val Gln Leu Ser
 595 600 605
 Gln Ser Val Thr Ala Tyr Met Val Ser Ala Ala Gly Leu Gly Leu Val
 610 615 620
 Ala Ile Tyr Phe Ala Thr Gln Val Val Phe Asp Lys Ser Asp Leu Ala
 625 630 635 640
 Lys Tyr Ser Ala Gly Gly His His His His His His
 645 650

<210> 42

<211> 1959

<212> DNA

<213> Artificial Sequence

<220>

<223> DNA encoding St.pneum. C-LytA P2 helper epitope C-Lyta fused to Human P501S (plus his tag)

<400> 42

atggcgccg cttacgtaca ttccgacggc tcttatccaa aagacaagtt tgagaaaatc 60
 aatggcactt ggtactactt tgacagttca ggctatatgc ttgcagaccg ctggaggaag 120
 cacacagacg gcaactggta ctgggtcgac aactcaggcg aaatggctac aggctggaag 180
 5 aaaatcgctg ataagtggta ctatttcaac gaagaagggtg ccatgaagac aggctgggtc 240
 aagtacaagg acacttggta ctacttagac gctaaagaag gcgccatgca ataatcaag 300
 gctaactcta agttcattgg tatcaactgaa ggctcatgg tatcaaatgc ctttatccag 360
 tcagcgacg gaacaggctg gtactacctc aaaccagacg gaacactggc agacaggcca 420
 gaaaagttca tgtacatggg gctgggcatt ggtccagtgc tgggcctggg ctgtgtcccg 480
 10 ctctaggct cagccagtga cactggcgt ggacgctatg gccgccgccg gcccttcac 540
 tgggcactgt ccttgggcat cctgctgagc ctctttctca tcccaaggcg cggctggcta 600
 gcagggtctg tgtgcccggg tcccaggccc ctggagctgg cactgctcat cctgggctg 660
 gggctgctgg acttctgtgg ccagggtgtg ttcactccac tggaggccct gctctctgac 720
 ctcttcggg acccggaacca ctgtcgccag gcctactctg tctatgcct catgatcagt 780
 cttgggggtg gcctgggcta cctcctgcct gccattgact gggacaccag tgccctggcc 840
 15 cctacactgg gcacccagga ggagtgcctc tttggcctgc tcaccctcat cttcctcacc 900
 tgcgtagcag ccacactgct ggtggctgag gaggcagcgc tgggccccac cgagccagca 960
 gaagggtctg cgccccctc cttgtcgccc cactgctgtc catgccgggc ccgcttggct 1020
 ttccggaacc tgggcgcctc gcttccccgg ctgcaccagc tgtgtgccg catgccccgc 1080
 accctgcgcc ggctcttctg ggctgagctg tgcagctgga tggcactcat gaccttcacg 1140
 20 ctgttttaca cggatttctg gggcgagggg ctgtaccagg gcgtgcccag agctgagccg 1200
 ggcaccgagg cccggagaca ctatgatgaa ggcgttcgga tgggcagcct ggggctgttc 1260
 ctgcagtgcg ccatctccct ggtcttctct ctggctcatg accggctggg gcagcgattc 1320
 ggcactcgag cagtctatct ggccagtgtg gcagctttcc ctgtggctgc cgggtgccaca 1380
 25 tgccgtgcc acagtgtggc cgtggtgaca gcttcagccg cctcaccgg gttcaccttc 1440
 tcagccctgc agatcctgcc ctacacactg gcctccctct accaccggga gaagcaggtg 1500

30 ttccctgccc aataccgagg ggacactgga ggtgctagca gtgaggacag cctgatgacc 1560
 agcttccctg caggccctaa gcctggagct ccctcccta atggacacgt ggggtgctgga 1620
 ggcagtggcc tgctcccacc tccaccgcg ctctgcgggg cctctgcctg tgatgtctcc 1680
 gtacgtgtgg tgggtgggtg gccaccgag gccagggtgg ttccggggcg gggcatctgc 1740
 ctggacctcg ccactcctga tagtgccctc ctgctgtccc aggtggcccc atccctgttt 1800
 atgggctcca ttgtccagct cagccagtct gtcactgcct atatggtgtc tgccgcaggc 1860
 35 ctgggtctgg tcgccattta ctttgctaca caggtagtat ttgacaagag cgacttggcc 1920
 aaatactcag cgggtggaca ccatcaccat caccattaa 1959

40 <210> 43
 <211> 553
 <212> PRT
 <213> Homo sapiens

45 <400> 43

50

55

Met Val Gln Arg Leu Trp Val Ser Arg Leu Leu Arg His Arg Lys Ala
 1 5 10 15
 Gln Leu Leu Leu Val Asn Leu Leu Thr Phe Gly Leu Glu Val Cys Leu
 20 25 30
 Ala Ala Gly Ile Thr Tyr Val Pro Leu Leu Leu Glu Val Gly Val
 35 40 45
 Glu Glu Lys Phe Met Thr Met Val Leu Gly Ile Gly Pro Val Leu Gly
 50 55 60
 Leu Val Cys Val Pro Leu Leu Gly Ser Ala Ser Asp His Trp Arg Gly
 65 70 75 80
 Arg Tyr Gly Arg Arg Arg Pro Phe Ile Trp Ala Leu Ser Leu Gly Ile
 85 90 95
 Leu Leu Ser Leu Phe Leu Ile Pro Arg Ala Gly Trp Leu Ala Gly Leu
 100 105 110
 Leu Cys Pro Asp Pro Arg Pro Leu Glu Leu Ala Leu Leu Ile Leu Gly
 115 120 125
 Val Gly Leu Leu Asp Phe Cys Gly Gln Val Cys Phe Thr Pro Leu Glu
 130 135 140
 Ala Leu Leu Ser Asp Leu Phe Arg Asp Pro Asp His Cys Arg Gln Ala
 145 150 155 160
 Tyr Ser Val Tyr Ala Phe Met Ile Ser Leu Gly Gly Cys Leu Gly Tyr
 165 170 175
 Leu Leu Pro Ala Ile Asp Trp Asp Thr Ser Ala Leu Ala Pro Tyr Leu
 180 185 190
 Gly Thr Gln Glu Glu Cys Leu Phe Gly Leu Leu Thr Leu Ile Phe Leu
 195 200 205
 Thr Cys Val Ala Ala Thr Leu Leu Val Ala Glu Glu Ala Ala Leu Gly
 210 215 220
 Pro Thr Glu Pro Ala Glu Gly Leu Ser Ala Pro Ser Leu Ser Pro His
 225 230 235 240
 Cys Cys Pro Cys Arg Ala Arg Leu Ala Phe Arg Asn Leu Gly Ala Leu
 245 250 255
 Leu Pro Arg Leu His Gln Leu Cys Cys Arg Met Pro Arg Thr Leu Arg
 260 265 270
 Arg Leu Phe Val Ala Glu Leu Cys Ser Trp Met Ala Leu Met Thr Phe
 275 280 285
 Thr Leu Phe Tyr Thr Asp Phe Val Gly Glu Gly Leu Tyr Gln Gly Val
 290 295 300
 Pro Arg Ala Glu Pro Gly Thr Glu Ala Arg Arg His Tyr Asp Glu Gly
 305 310 315 320
 Val Arg Met Gly Ser Leu Gly Leu Phe Leu Gln Cys Ala Ile Ser Leu
 325 330 335
 Val Phe Ser Leu Val Met Asp Arg Leu Val Gln Arg Phe Gly Thr Arg
 340 345 350
 Ala Val Tyr Leu Ala Ser Val Ala Ala Phe Pro Val Ala Ala Gly Ala
 355 360 365

Thr Cys Leu Ser His Ser Val Ala Val Val Thr Ala Ser Ala Ala Leu
 370 375 380
 5 Thr Gly Phe Thr Phe Ser Ala Leu Gln Ile Leu Pro Tyr Thr Leu Ala
 385 390 395 400
 Ser Leu Tyr His Arg Glu Lys Gln Val Phe Leu Pro Lys Tyr Arg Gly
 405 410 415
 Asp Thr Gly Gly Ala Ser Ser Glu Asp Ser Leu Met Thr Ser Phe Leu
 420 425 430
 10 Pro Gly Pro Lys Pro Gly Ala Pro Phe Pro Asn Gly His Val Gly Ala
 435 440 445
 Gly Gly Ser Gly Leu Leu Pro Pro Pro Ala Leu Cys Gly Ala Ser
 450 455 460
 15 Ala Cys Asp Val Ser Val Arg Val Val Val Gly Glu Pro Thr Glu Ala
 465 470 475 480
 Arg Val Val Pro Gly Arg Gly Ile Cys Leu Asp Leu Ala Ile Leu Asp
 485 490 495
 Ser Ala Phe Leu Leu Ser Gln Val Ala Pro Ser Leu Phe Met Gly Ser
 500 505 510
 20 Ile Val Gln Leu Ser Gln Ser Val Thr Ala Tyr Met Val Ser Ala Ala
 515 520 525
 Gly Leu Gly Leu Val Ala Ile Tyr Phe Ala Thr Gln Val Val Phe Asp
 530 535 540
 25 Lys Ser Asp Leu Ala Lys Tyr Ser Ala
 545 550

<210> 44

<211> 644

30 <212> PRT

<213> Artificial Sequence

<220>

35 <223> St.pneum. C-LytA P2 helper epitope C-Lyta fused to Human P501S

35 <400> 44

40

45

50

55

Met Ala Ala Ala Tyr Val His Ser Asp Gly Ser Tyr Pro Lys Asp Lys
 1 5 10 15
 Phe Glu Lys Ile Asn Gly Thr Trp Tyr Tyr Phe Asp Ser Ser Gly Tyr
 20 25 30
 Met Leu Ala Asp Arg Trp Arg Lys His Thr Asp Gly Asn Trp Tyr Trp
 35 40 45
 Phe Asp Asn Ser Gly Glu Met Ala Thr Gly Trp Lys Lys Ile Ala Asp
 50 55 60
 Lys Trp Tyr Tyr Phe Asn Glu Glu Gly Ala Met Lys Thr Gly Trp Val
 65 70 75 80
 Lys Tyr Lys Asp Thr Trp Tyr Tyr Leu Asp Ala Lys Glu Gly Ala Met
 85 90 95
 Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Gly Val
 100 105 110
 Met Val Ser Asn Ala Phe Ile Gln Ser Ala Asp Gly Thr Gly Trp Tyr
 115 120 125
 Tyr Leu Lys Pro Asp Gly Thr Leu Ala Asp Arg Pro Glu Lys Phe Met
 130 135 140
 Tyr Met Val Leu Gly Ile Gly Pro Val Leu Gly Leu Val Cys Val Pro
 145 150 155 160
 Leu Leu Gly Ser Ala Ser Asp His Trp Arg Gly Arg Tyr Gly Arg Arg
 165 170 175
 Arg Pro Phe Ile Trp Ala Leu Ser Leu Gly Ile Leu Leu Ser Leu Phe
 180 185 190
 Leu Ile Pro Arg Ala Gly Trp Leu Ala Gly Leu Leu Cys Pro Asp Pro

		195				200			205								
		Arg	Pro	Leu	Glu	Leu	Ala	Leu	Leu	Ile	Leu	Gly	Val	Gly	Leu	Leu	Asp
5		210				215			220								
		Phe	Cys	Gly	Gln	Val	Cys	Phe	Thr	Pro	Leu	Glu	Ala	Leu	Leu	Ser	Asp
		225				230			235								240
		Leu	Phe	Arg	Asp	Pro	Asp	His	Cys	Arg	Gln	Ala	Tyr	Ser	Val	Tyr	Ala
					245				250								255
10		Phe	Met	Ile	Ser	Leu	Gly	Gly	Cys	Leu	Gly	Tyr	Leu	Leu	Pro	Ala	Ile
					260				265								270
		Asp	Trp	Asp	Thr	Ser	Ala	Leu	Ala	Pro	Tyr	Leu	Gly	Thr	Gln	Glu	Glu
					275				280								285
		Cys	Leu	Phe	Gly	Leu	Leu	Thr	Leu	Ile	Phe	Leu	Thr	Cys	Val	Ala	Ala
					290				295								300
15		Thr	Leu	Leu	Val	Ala	Glu	Glu	Ala	Ala	Leu	Gly	Pro	Thr	Glu	Pro	Ala
		305				310											320
		Glu	Gly	Leu	Ser	Ala	Pro	Ser	Leu	Ser	Pro	His	Cys	Cys	Pro	Cys	Arg
					325				330								335
20		Ala	Arg	Leu	Ala	Phe	Arg	Asn	Leu	Gly	Ala	Leu	Leu	Pro	Arg	Leu	His
					340				345								350
		Gln	Leu	Cys	Cys	Arg	Met	Pro	Arg	Thr	Leu	Arg	Arg	Leu	Phe	Val	Ala
					355				360								365
		Glu	Leu	Cys	Ser	Trp	Met	Ala	Leu	Met	Thr	Phe	Thr	Leu	Phe	Tyr	Thr
					370				375								380
25		Asp	Phe	Val	Gly	Glu	Gly	Leu	Tyr	Gln	Gly	Val	Pro	Arg	Ala	Glu	Pro
		385				390											400
		Gly	Thr	Glu	Ala	Arg	Arg	His	Tyr	Asp	Glu	Gly	Val	Arg	Met	Gly	Ser
					405				410								415
30		Leu	Gly	Leu	Phe	Leu	Gln	Cys	Ala	Ile	Ser	Leu	Val	Phe	Ser	Leu	Val
					420				425								430
		Met	Asp	Arg	Leu	Val	Gln	Arg	Phe	Gly	Thr	Arg	Ala	Val	Tyr	Leu	Ala
					435				440								445
		Ser	Val	Ala	Ala	Phe	Pro	Val	Ala	Ala	Gly	Ala	Thr	Cys	Leu	Ser	His
					450				455								460
35		Ser	Val	Ala	Val	Val	Thr	Ala	Ser	Ala	Ala	Leu	Thr	Gly	Phe	Thr	Phe
		465				470											480
		Ser	Ala	Leu	Gln	Ile	Leu	Pro	Tyr	Thr	Leu	Ala	Ser	Leu	Tyr	His	Arg
					485				490								495
		Glu	Lys	Gln	Val	Phe	Leu	Pro	Lys	Tyr	Arg	Gly	Asp	Thr	Gly	Gly	Ala
					500				505								510
40		Ser	Ser	Glu	Asp	Ser	Leu	Met	Thr	Ser	Phe	Leu	Pro	Gly	Pro	Lys	Pro
					515				520								525
		Gly	Ala	Pro	Phe	Pro	Asn	Gly	His	Val	Gly	Ala	Gly	Gly	Ser	Gly	Leu
					530				535								540
45		Leu	Pro	Pro	Pro	Pro	Ala	Leu	Cys	Gly	Ala	Ser	Ala	Cys	Asp	Val	Ser
		545				550											560
		Val	Arg	Val	Val	Val	Gly	Glu	Pro	Thr	Glu	Ala	Arg	Val	Val	Pro	Gly
					565				570								575
		Arg	Gly	Ile	Cys	Leu	Asp	Leu	Ala	Ile	Leu	Asp	Ser	Ala	Phe	Leu	Leu
					580				585								590
50		Ser	Gln	Val	Ala	Pro	Ser	Leu	Phe	Met	Gly	Ser	Ile	Val	Gln	Leu	Ser
					595				600								605
		Gln	Ser	Val	Thr	Ala	Tyr	Met	Val	Ser	Ala	Ala	Gly	Leu	Gly	Leu	Val
					610				615								620
		Ala	Ile	Tyr	Phe	Ala	Thr	Gln	Val	Val	Phe	Asp	Lys	Ser	Asp	Leu	Ala
55		625				630											640
		Lys	Tyr	Ser	Ala												

EP 1 511 768 B1

<210> 45

<211> 644

<212> PRT

<213> Artificial Sequence

5

<220>

<223> Codon-optimised hybrid protein between St.pneum. C-LytA P2 helper epitope C-Lyta fused to Human P501S amino acids 51-553)

10

<400> 45

15

20

25

30

35

40

45

50

55

	Met	Ala	Ala	Ala	Tyr	Val	His	Ser	Asp	Gly	Ser	Tyr	Pro	Lys	Asp	Lys
	1				5					10					15	
	Phe	Glu	Lys	Ile	Asn	Gly	Thr	Trp	Tyr	Tyr	Phe	Asp	Ser	Ser	Gly	Tyr
5				20					25					30		
	Met	Leu	Ala	Asp	Arg	Trp	Arg	Lys	His	Thr	Asp	Gly	Asn	Trp	Tyr	Trp
		35						40					45			
	Phe	Asp	Asn	Ser	Gly	Glu	Met	Ala	Thr	Gly	Trp	Lys	Lys	Ile	Ala	Asp
	50						55					60				
10	Lys	Trp	Tyr	Tyr	Phe	Asn	Glu	Glu	Gly	Ala	Met	Lys	Thr	Gly	Trp	Val
	65					70					75				80	
	Lys	Tyr	Lys	Asp	Thr	Trp	Tyr	Tyr	Leu	Asp	Ala	Lys	Glu	Gly	Ala	Met
				85						90					95	
	Gln	Tyr	Ile	Lys	Ala	Asn	Ser	Lys	Phe	Ile	Gly	Ile	Thr	Glu	Gly	Val
				100					105						110	
15	Met	Val	Ser	Asn	Ala	Phe	Ile	Gln	Ser	Ala	Asp	Gly	Thr	Gly	Trp	Tyr
		115						120					125			
	Tyr	Leu	Lys	Pro	Asp	Gly	Thr	Leu	Ala	Asp	Arg	Pro	Glu	Lys	Phe	Met
		130					135					140				
20	Tyr	Met	Val	Leu	Gly	Ile	Gly	Pro	Val	Leu	Gly	Leu	Val	Cys	Val	Pro
	145				150						155				160	
	Leu	Leu	Gly	Ser	Ala	Ser	Asp	His	Trp	Arg	Gly	Arg	Tyr	Gly	Arg	Arg
				165						170					175	
	Arg	Pro	Phe	Ile	Trp	Ala	Leu	Ser	Leu	Gly	Ile	Leu	Leu	Ser	Leu	Phe
			180						185					190		
25	Leu	Ile	Pro	Arg	Ala	Gly	Trp	Leu	Ala	Gly	Leu	Leu	Cys	Pro	Asp	Pro
		195						200					205			
	Arg	Pro	Leu	Glu	Leu	Ala	Leu	Leu	Ile	Leu	Gly	Val	Gly	Leu	Leu	Asp
		210					215					220				
30	Phe	Cys	Gly	Gln	Val	Cys	Phe	Thr	Pro	Leu	Glu	Ala	Leu	Leu	Ser	Asp
	225					230					235				240	
	Leu	Phe	Arg	Asp	Pro	Asp	His	Cys	Arg	Gln	Ala	Tyr	Ser	Val	Tyr	Ala
				245						250					255	
	Phe	Met	Ile	Ser	Leu	Gly	Gly	Cys	Leu	Gly	Tyr	Leu	Leu	Pro	Ala	Ile
			260					265						270		
35	Asp	Trp	Asp	Thr	Ser	Ala	Leu	Ala	Pro	Tyr	Leu	Gly	Thr	Gln	Glu	Glu
		275						280						285		
	Cys	Leu	Phe	Gly	Leu	Leu	Thr	Leu	Ile	Phe	Leu	Thr	Cys	Val	Ala	Ala
		290					295					300				
	Thr	Leu	Leu	Val	Ala	Glu	Glu	Ala	Ala	Leu	Gly	Pro	Thr	Glu	Pro	Ala
	305					310					315				320	
40	Glu	Gly	Leu	Ser	Ala	Pro	Ser	Leu	Ser	Pro	His	Cys	Cys	Pro	Cys	Arg
				325						330					335	
	Ala	Arg	Leu	Ala	Phe	Arg	Asn	Leu	Gly	Ala	Leu	Leu	Pro	Arg	Leu	His
				340					345					350		
45	Gln	Leu	Cys	Cys	Arg	Met	Pro	Arg	Thr	Leu	Arg	Arg	Leu	Phe	Val	Ala
		355						360					365			
	Glu	Leu	Cys	Ser	Trp	Met	Ala	Leu	Met	Thr	Phe	Thr	Leu	Phe	Tyr	Thr
		370					375					380				
	Asp	Phe	Val	Gly	Glu	Gly	Leu	Tyr	Gln	Gly	Val	Pro	Arg	Ala	Glu	Pro
	385					390					395				400	
50	Gly	Thr	Glu	Ala	Arg	Arg	His	Tyr	Asp	Glu	Gly	Val	Arg	Met	Gly	Ser
				405						410					415	

Leu Gly Leu Phe Leu Gln Cys Ala Ile Ser Leu Val Phe Ser Leu Val
 420 425 430
 5 Met Asp Arg Leu Val Gln Arg Phe Gly Thr Arg Ala Val Tyr Leu Ala
 435 440 445
 Ser Val Ala Ala Phe Pro Val Ala Ala Gly Ala Thr Cys Leu Ser His
 450 455 460
 Ser Val Ala Val Val Thr Ala Ser Ala Ala Leu Thr Gly Phe Thr Phe
 465 470 475 480
 10 Ser Ala Leu Gln Ile Leu Pro Tyr Thr Leu Ala Ser Leu Tyr His Arg
 485 490 495
 Glu Lys Gln Val Phe Leu Pro Lys Tyr Arg Gly Asp Thr Gly Gly Ala
 500 505 510
 Ser Ser Glu Asp Ser Leu Met Thr Ser Phe Leu Pro Gly Pro Lys Pro
 515 520 525
 Gly Ala Pro Phe Pro Asn Gly His Val Gly Ala Gly Gly Ser Gly Leu
 530 535 540
 Leu Pro Pro Pro Pro Ala Leu Cys Gly Ala Ser Ala Cys Asp Val Ser
 545 550 555 560
 20 Val Arg Val Val Val Gly Glu Pro Thr Glu Ala Arg Val Val Pro Gly
 565 570 575
 Arg Gly Ile Cys Leu Asp Leu Ala Ile Leu Asp Ser Ala Phe Leu Leu
 580 585 590
 Ser Gln Val Ala Pro Ser Leu Phe Met Gly Ser Ile Val Gln Leu Ser
 595 600 605
 25 Gln Ser Val Thr Ala Tyr Met Val Ser Ala Ala Gly Leu Gly Leu Val
 610 615 620
 Ala Ile Tyr Phe Ala Thr Gln Val Val Phe Asp Lys Ser Asp Leu Ala
 625 630 635 640
 30 Lys Tyr Ser Ala

<210> 46

<211> 694

35 <212> PRT

<213> Artificial Sequence

<220>

40 <223> St.pneum. C-LytA P2 helper epitope C-Lyta fused to Human P501S (amino acids 1-553)- codon optimised

<400> 46

45

50

55

EP 1 511 768 B1

	Met	Ala	Ala	Ala	Tyr	Val	His	Ser	Asp	Gly	Ser	Tyr	Pro	Lys	Asp	Lys
	1				5					10					15	
	Phe	Glu	Lys	Ile	Asn	Gly	Thr	Trp	Tyr	Tyr	Phe	Asp	Ser	Ser	Gly	Tyr
				20					25					30		
5	Met	Leu	Ala	Asp	Arg	Trp	Arg	Lys	His	Thr	Asp	Gly	Asn	Trp	Tyr	Trp
			35					40					45			
	Phe	Asp	Asn	Ser	Gly	Glu	Met	Ala	Thr	Gly	Trp	Lys	Lys	Ile	Ala	Asp
		50					55					60				
10	Lys	Trp	Tyr	Tyr	Phe	Asn	Glu	Glu	Gly	Ala	Met	Lys	Thr	Gly	Trp	Val
	65					70					75				80	
	Lys	Tyr	Lys	Asp	Thr	Trp	Tyr	Tyr	Leu	Asp	Ala	Lys	Glu	Gly	Ala	Met
				85						90				95		
	Gln	Tyr	Ile	Lys	Ala	Asn	Ser	Lys	Phe	Ile	Gly	Ile	Thr	Glu	Gly	Val
				100					105					110		
15	Met	Val	Ser	Asn	Ala	Phe	Ile	Gln	Ser	Ala	Asp	Gly	Thr	Gly	Trp	Tyr
			115					120					125			
	Tyr	Leu	Lys	Pro	Asp	Gly	Thr	Leu	Ala	Asp	Arg	Pro	Glu	Met	Val	Gln
		130					135				140					
20	Arg	Leu	Trp	Val	Ser	Arg	Leu	Leu	Arg	His	Arg	Lys	Ala	Gln	Leu	Leu

EP 1 511 768 B1

	145				150				155			160				
	Leu	Val	Asn	Leu	Leu	Thr	Phe	Gly	Leu	Glu	Val	Cys	Leu	Ala	Ala	Gly
					165				170						175	
5	Ile	Thr	Tyr	Val	Pro	Pro	Leu	Leu	Leu	Glu	Val	Gly	Val	Glu	Glu	Lys
				180					185					190		
	Phe	Met	Thr	Met	Val	Leu	Gly	Ile	Gly	Pro	Val	Leu	Gly	Leu	Val	Cys
			195					200					205			
	Val	Pro	Leu	Leu	Gly	Ser	Ala	Ser	Asp	His	Trp	Arg	Gly	Arg	Tyr	Gly
		210					215					220				
10	Arg	Arg	Arg	Pro	Phe	Ile	Trp	Ala	Leu	Ser	Leu	Gly	Ile	Leu	Leu	Ser
	225					230					235					240
	Leu	Phe	Leu	Ile	Pro	Arg	Ala	Gly	Trp	Leu	Ala	Gly	Leu	Leu	Cys	Pro
				245						250					255	
	Asp	Pro	Arg	Pro	Leu	Glu	Leu	Ala	Leu	Leu	Ile	Leu	Gly	Val	Gly	Leu
				260					265					270		
15	Leu	Asp	Phe	Cys	Gly	Gln	Val	Cys	Phe	Thr	Pro	Leu	Glu	Ala	Leu	Leu
		275							280					285		
	Ser	Asp	Leu	Phe	Arg	Asp	Pro	Asp	His	Cys	Arg	Gln	Ala	Tyr	Ser	Val
		290				295						300				
	Tyr	Ala	Phe	Met	Ile	Ser	Leu	Gly	Gly	Cys	Leu	Gly	Tyr	Leu	Leu	Pro
	305					310					315					320
20	Ala	Ile	Asp	Trp	Asp	Thr	Ser	Ala	Leu	Ala	Pro	Tyr	Leu	Gly	Thr	Gln
				325							330					335
	Glu	Glu	Cys	Leu	Phe	Gly	Leu	Leu	Thr	Leu	Ile	Phe	Leu	Thr	Cys	Val
				340					345					350		
25	Ala	Ala	Thr	Leu	Leu	Val	Ala	Glu	Glu	Ala	Ala	Leu	Gly	Pro	Thr	Glu
			355					360					365			
	Pro	Ala	Glu	Gly	Leu	Ser	Ala	Pro	Ser	Leu	Ser	Pro	His	Cys	Cys	Pro
		370				375						380				
	Cys	Arg	Ala	Arg	Leu	Ala	Phe	Arg	Asn	Leu	Gly	Ala	Leu	Leu	Pro	Arg
	385					390					395					400
30	Leu	His	Gln	Leu	Cys	Cys	Arg	Met	Pro	Arg	Thr	Leu	Arg	Arg	Leu	Phe
				405							410				415	
	Val	Ala	Glu	Leu	Cys	Ser	Trp	Met	Ala	Leu	Met	Thr	Phe	Thr	Leu	Phe
			420						425					430		
	Tyr	Thr	Asp	Phe	Val	Gly	Glu	Gly	Leu	Tyr	Gln	Gly	Val	Pro	Arg	Ala
		435					440					445				
35	Glu	Pro	Gly	Thr	Glu	Ala	Arg	Arg	His	Tyr	Asp	Glu	Gly	Val	Arg	Met
		450				455					460					
	Gly	Ser	Leu	Gly	Leu	Phe	Leu	Gln	Cys	Ala	Ile	Ser	Leu	Val	Phe	Ser
	465					470					475					480
	Leu	Val	Met	Asp	Arg	Leu	Val	Gln	Arg	Phe	Gly	Thr	Arg	Ala	Val	Tyr
				485						490					495	
40	Leu	Ala	Ser	Val	Ala	Ala	Phe	Pro	Val	Ala	Ala	Gly	Ala	Thr	Cys	Leu
				500					505					510		
	Ser	His	Ser	Val	Ala	Val	Val	Thr	Ala	Ser	Ala	Ala	Leu	Thr	Gly	Phe
			515					520					525			
	Thr	Phe	Ser	Ala	Leu	Gln	Ile	Leu	Pro	Tyr	Thr	Leu	Ala	Ser	Leu	Tyr
		530				535						540				
45	His	Arg	Glu	Lys	Gln	Val	Phe	Leu	Pro	Lys	Tyr	Arg	Gly	Asp	Thr	Gly
	545					550					555					560
	Gly	Ala	Ser	Ser	Glu	Asp	Ser	Leu	Met	Thr	Ser	Phe	Leu	Pro	Gly	Pro
				565						570					575	
	Lys	Pro	Gly	Ala	Pro	Phe	Pro	Asn	Gly	His	Val	Gly	Ala	Gly	Gly	Ser
				580				585						590		
50	Gly	Leu	Leu	Pro	Pro	Pro	Pro	Ala	Leu	Cys	Gly	Ala	Ser	Ala	Cys	Asp
				595				600					605			
	Val	Ser	Val	Arg	Val	Val	Val	Gly	Glu	Pro	Thr	Glu	Ala	Arg	Val	Val
		610					615					620				
	Pro	Gly	Arg	Gly	Ile	Cys	Leu	Asp	Leu	Ala	Ile	Leu	Asp	Ser	Ala	Phe
55	625					630					635					640

Leu Leu Ser Gln Val Ala Pro Ser Leu Phe Met Gly Ser Ile Val Gln
 645 650 655
 5 Leu Ser Gln Ser Val Thr Ala Tyr Met Val Ser Ala Ala Gly Leu Gly
 660 665 670
 Leu Val Ala Ile Tyr Phe Ala Thr Gln Val Val Phe Asp Lys Ser Asp
 675 680 685
 Leu Ala Lys Tyr Ser Ala
 690

10

<210> 47

<211> 694

<212> PRT

15

<213> Artificial Sequence

<220>

<223> St.pneum. C-LytA P2 helper epitope C-Lyta fused to Human P501S (amino acids 51-553) fused to Human P501S (amino acids 1-50) - codon-optimised

20

<400> 47

25

30

35

40

45

50

55

EP 1 511 768 B1

[illegible]

Glu Gly Leu Ser Ala Pro Ser Leu Ser Pro His Cys Cys Pro Cys Arg
 325 330 335
 5 Ala Arg Leu Ala Phe Arg Asn Leu Gly Ala Leu Leu Pro Arg Leu His
 340 345 350
 Gln Leu Cys Cys Arg Met Pro Arg Thr Leu Arg Arg Leu Phe Val Ala
 355 360 365
 Glu Leu Cys Ser Trp Met Ala Leu Met Thr Phe Thr Leu Phe Tyr Thr
 370 375 380
 10 Asp Phe Val Gly Glu Gly Leu Tyr Gln Gly Val Pro Arg Ala Glu Pro
 385 390 395 400
 Gly Thr Glu Ala Arg Arg His Tyr Asp Glu Gly Val Arg Met Gly Ser
 405 410 415
 Leu Gly Leu Phe Leu Gln Cys Ala Ile Ser Leu Val Phe Ser Leu Val
 420 425 430
 15 Met Asp Arg Leu Val Gln Arg Phe Gly Thr Arg Ala Val Tyr Leu Ala
 435 440 445
 Ser Val Ala Ala Phe Pro Val Ala Ala Gly Ala Thr Cys Leu Ser His
 450 455 460
 20 Ser Val Ala Val Val Thr Ala Ser Ala Ala Leu Thr Gly Phe Thr Phe
 465 470 475 480
 Ser Ala Leu Gln Ile Leu Pro Tyr Thr Leu Ala Ser Leu Tyr His Arg
 485 490 495
 Glu Lys Gln Val Phe Leu Pro Lys Tyr Arg Gly Asp Thr Gly Gly Ala
 500 505 510
 25 Ser Ser Glu Asp Ser Leu Met Thr Ser Phe Leu Pro Gly Pro Lys Pro
 515 520 525
 Gly Ala Pro Phe Pro Asn Gly His Val Gly Ala Gly Gly Ser Gly Leu
 530 535 540
 30 Leu Pro Pro Pro Pro Ala Leu Cys Gly Ala Ser Ala Cys Asp Val Ser
 545 550 555 560
 Val Arg Val Val Val Gly Glu Pro Thr Glu Ala Arg Val Val Pro Gly
 565 570 575
 Arg Gly Ile Cys Leu Asp Leu Ala Ile Leu Asp Ser Ala Phe Leu Leu
 580 585 590
 35 Ser Gln Val Ala Pro Ser Leu Phe Met Gly Ser Ile Val Gln Leu Ser
 595 600 605
 Gln Ser Val Thr Ala Tyr Met Val Ser Ala Ala Gly Leu Gly Leu Val
 610 615 620
 40 Ala Ile Tyr Phe Ala Thr Gln Val Val Phe Asp Lys Ser Asp Leu Ala
 625 630 635 640
 Lys Tyr Ser Ala Met Val Gln Arg Leu Trp Val Ser Arg Leu Leu Arg
 645 650 655
 His Arg Lys Ala Gln Leu Leu Leu Val Asn Leu Leu Thr Phe Gly Leu
 660 665 670
 45 Glu Val Cys Leu Ala Ala Gly Ile Thr Tyr Val Pro Pro Leu Leu Leu
 675 680 685
 Glu Val Gly Val Glu Glu
 690

<210> 48

<211> 694

<212> PRT

<213> Artificial Sequence

<220>

<223> Human P501S (amino acids 1-50) fused to St.pneum. C-LytA P2 helper epitope C-Lyta fused to Human P501S (amino acids 51-553) - codon optimised

<400> 48

5

10

15

20

25

30

35

40

45

50

55

EP 1 511 768 B1

	Met	Val	Gln	Arg	Leu	Trp	Val	Ser	Arg	Leu	Leu	Arg	His	Arg	Lys	Ala
	1				5					10					15	
	Gln	Leu	Leu	Leu	Val	Asn	Leu	Leu	Thr	Phe	Gly	Leu	Glu	Val	Cys	Leu
5				20					25					30		
	Ala	Ala	Gly	Ile	Thr	Tyr	Val	Pro	Pro	Leu	Leu	Leu	Glu	Val	Gly	Val
			35					40					45			
	Glu	Glu	Met	Ala	Ala	Ala	Tyr	Val	His	Ser	Asp	Gly	Ser	Tyr	Pro	Lys
		50					55					60				
10	Asp	Lys	Phe	Glu	Lys	Ile	Asn	Gly	Thr	Trp	Tyr	Tyr	Phe	Asp	Ser	Ser
	65					70					75				80	
	Gly	Tyr	Met	Leu	Ala	Asp	Arg	Trp	Arg	Lys	His	Thr	Asp	Gly	Asn	Trp
				85						90					95	
	Tyr	Trp	Phe	Asp	Asn	Ser	Gly	Glu	Met	Ala	Thr	Gly	Trp	Lys	Lys	Ile
				100					105					110		
15	Ala	Asp	Lys	Trp	Tyr	Tyr	Phe	Asn	Glu	Glu	Gly	Ala	Met	Lys	Thr	Gly
			115					120					125			
	Trp	Val	Lys	Tyr	Lys	Asp	Thr	Trp	Tyr	Tyr	Leu	Asp	Ala	Lys	Glu	Gly
		130					135					140				
	Ala	Met	Gln	Tyr	Ile	Lys	Ala	Asn	Ser	Lys	Phe	Ile	Gly	Ile	Thr	Glu
	145					150					155					160
20	Gly	Val	Met	Val	Ser	Asn	Ala	Phe	Ile	Gln	Ser	Ala	Asp	Gly	Thr	Gly
				165						170					175	
	Trp	Tyr	Tyr	Leu	Lys	Pro	Asp	Gly	Thr	Leu	Ala	Asp	Arg	Pro	Glu	Lys
			180						185					190		
	Phe	Met	Tyr	Met	Val	Leu	Gly	Ile	Gly	Pro	Val	Leu	Gly	Leu	Val	Cys
		195					200						205			
25	Val	Pro	Leu	Leu	Gly	Ser	Ala	Ser	Asp	His	Trp	Arg	Gly	Arg	Tyr	Gly
		210				215						220				
	Arg	Arg	Arg	Pro	Phe	Ile	Trp	Ala	Leu	Ser	Leu	Gly	Ile	Leu	Leu	Ser
	225					230					235					240
	Leu	Phe	Leu	Ile	Pro	Arg	Ala	Gly	Trp	Leu	Ala	Gly	Leu	Leu	Cys	Pro
				245						250					255	
30	Asp	Pro	Arg	Pro	Leu	Glu	Leu	Ala	Leu	Leu	Ile	Leu	Gly	Val	Gly	Leu
			260					265					270			
	Leu	Asp	Phe	Cys	Gly	Gln	Val	Cys	Phe	Thr	Pro	Leu	Glu	Ala	Leu	Leu
		275						280				285				
	Ser	Asp	Leu	Phe	Arg	Asp	Pro	Asp	His	Cys	Arg	Gln	Ala	Tyr	Ser	Val
35		290					295					300				
	Tyr	Ala	Phe	Met	Ile	Ser	Leu	Gly	Gly	Cys	Leu	Gly	Tyr	Leu	Leu	Pro
	305					310					315					320
	Ala	Ile	Asp	Trp	Asp	Thr	Ser	Ala	Leu	Ala	Pro	Tyr	Leu	Gly	Thr	Gln
				325						330					335	
40	Glu	Glu	Cys	Leu	Phe	Gly	Leu	Leu	Thr	Leu	Ile	Phe	Leu	Thr	Cys	Val
			340						345					350		
	Ala	Ala	Thr	Leu	Leu	Val	Ala	Glu	Glu	Ala	Ala	Leu	Gly	Pro	Thr	Glu
		355						360					365			
	Pro	Ala	Glu	Gly	Leu	Ser	Ala	Pro	Ser	Leu	Ser	Pro	His	Cys	Cys	Pro
		370					375					380				
45	Cys	Arg	Ala	Arg	Leu	Ala	Phe	Arg	Asn	Leu	Gly	Ala	Leu	Leu	Pro	Arg
	385					390					395					400
	Leu	His	Gln	Leu	Cys	Arg	Met	Pro	Arg	Thr	Leu	Arg	Arg	Leu	Phe	
				405					410					415		
	Val	Ala	Glu	Leu	Cys	Ser	Trp	Met	Ala	Leu	Met	Thr	Phe	Thr	Leu	Phe
			420						425					430		
50	Tyr	Thr	Asp	Phe	Val	Gly	Glu	Gly	Leu	Tyr	Gln	Gly	Val	Pro	Arg	Ala
			435					440					445			
	Glu	Pro	Gly	Thr	Glu	Ala	Arg	Arg	His	Tyr	Asp	Glu	Gly	Val	Arg	Met
		450					455					460				
	Gly	Ser	Leu	Gly	Leu	Phe	Leu	Gln	Cys	Ala	Ile	Ser	Leu	Val	Phe	Ser
	465					470					475					480
55	Leu	Val	Met	Asp	Arg	Leu	Val	Gln	Arg	Phe	Gly	Thr	Arg	Ala	Val	Tyr

				485				490				495		
	Leu	Ala	Ser	Val	Ala	Ala	Phe	Pro	Val	Ala	Ala	Gly	Ala	Thr
				500					505				510	
5	Ser	His	Ser	Val	Ala	Val	Val	Thr	Ala	Ser	Ala	Ala	Leu	Thr
			515					520				525		
	Thr	Phe	Ser	Ala	Leu	Gln	Ile	Leu	Pro	Tyr	Thr	Leu	Ala	Ser
		530					535				540			
	His	Arg	Glu	Lys	Gln	Val	Phe	Leu	Pro	Lys	Tyr	Arg	Gly	Asp
10	545				550					555				560
	Gly	Ala	Ser	Ser	Glu	Asp	Ser	Leu	Met	Thr	Ser	Phe	Leu	Pro
				565						570				575
	Lys	Pro	Gly	Ala	Pro	Phe	Pro	Asn	Gly	His	Val	Gly	Ala	Gly
				580					585					590
15	Gly	Leu	Leu	Pro	Pro	Pro	Pro	Ala	Leu	Cys	Gly	Ala	Ser	Ala
				595				600						605
	Val	Ser	Val	Arg	Val	Val	Val	Gly	Glu	Pro	Thr	Glu	Ala	Arg
		610					615				620			
	Pro	Gly	Arg	Gly	Ile	Cys	Leu	Asp	Leu	Ala	Ile	Leu	Asp	Ser
20	625				630					635				640
	Leu	Leu	Ser	Gln	Val	Ala	Pro	Ser	Leu	Phe	Met	Gly	Ser	Ile
				645						650				655
	Leu	Ser	Gln	Ser	Val	Thr	Ala	Tyr	Met	Val	Ser	Ala	Ala	Gly
				660				665						670
25	Leu	Val	Ala	Ile	Tyr	Phe	Ala	Thr	Gln	Val	Val	Phe	Asp	Lys
			675					680					685	
	Leu	Ala	Lys	Tyr	Ser	Ala								
		690												

30 <210> 49
 <211> 1971
 <212> DNA
 <213> Artificial Sequence

35 <220>
 <223> DNA encoding Human MUC-1 fused to St.pneum. C-LytA P2 helper epitope C-Lyta

<400> 49

40

45

50

55

atgacaccgg gcacccagtc tectttcttc ctgctgctgc tectcacagt gcttacagtt 60
 gttacagggt ctggtcatgc aagctctacc ccagggtggag aaaaggagac ttcgggtacc 120
 cagagaagtt cagtgccag ctctactgag aagaatgctg tgagtatgac cagcagcgta 180
 5 ctctccagcc acagccccgg ttcaggctcc tccaccactc agggacagga tgtcactctg 240
 gccccggcca cggaaccagc ttcagggtca gctgccacct ggggacagga tgtcacctcg 300
 gtcccagtc acaagccagc cctgggctcc accaccocgc cagcccacga tgtcacctca 360
 gccccggaca ccaagccagc cccgggctcc accgcccccc cagcccacgg tgtcacctcg 420
 gccccggaca ccaagccagc cccgggctcc accgcccccc cagcccacgg tgtcacctcg 480
 10 gccccggaca ccaagccagc cccgggctcc accgcccccc cagcccacgg tgtcacctcg 540
 gccccggaca ccaagccagc cccgggctcc accgcccccc cagcccacgg tgtcacctcg 600
 gccccggaca acagggccgc cttggcgctc accgcccccc cagtccacaa tgtcacctcg 660
 gcctcagggt ctgcatcagg ctccagcttct actctgggtg acaacggcac ctctgccagg 720
 gctaccacaa ccccagccag caagagcact ccattctcaa tcccagcca ccaactctgat 780
 actcctacca cccttgccag ccatagcacc aagactgatg ccagtagcac tcaccatagc 840
 15 acggtacctc ctctcacctc ctccaatcac agcacttctc cccagttgtc tactgggggtc 900
 tctttctttt tctgtctttt tcacatttca aacctccagt ttaattcctc tctggaagat 960
 cccagcaccg actactacca agagctgcag agagacattt ctgaaatgtt tttgcagatt 1020
 tataaacaag ggggttttct gggcctctcc aatattaagt tcaggccagg atctgtgggtg 1080
 gtacaattga ctctggcctt ccgagaaggt accatcaatg tccacgacgt ggagacacag 1140
 20 ttcaatcagt ataaaacgga agcagcctct cgatataacc tgacgatctc agacgtcagc 1200
 gtgagtgatg tgccatttcc tttctctgcc cagtctgggg ctgggggtgc aggctggggc 1260
 atcgcgctgc tgggtgctgt ctgtgttctg gttgcgctgg ccattgtcta tctcattgcc 1320

 25
 ttggctgtct gtcagtgcg ccgaaagaac tacgggcagc tggacatctt tccagcccgg 1380
 gatacctacc atcctatgag cgagtacccc acctaccaca cccatgggcg ctatgtgccc 1440
 cctagcagta ccgatcgtag cccctatgag aaggtttctg caggtaatgg tggcagcagc 1500
 30 ctctcttaca caaaccagc agtggcagcc acttctgcca acttgatggc ggcgcttac 1560
 gtacattccg acggtcttta tccaaaagac aagtttgaga aaatcaatgg cacttgggtac 1620
 tactttgaca gttcaggcta tatgcttgca gaccgctgga ggaagcacac agacggcaac 1680
 tggtagtggt tcgacaactc aggcgaatg gctacaggct ggaagaaaat cgctgataag 1740
 tggtagtatt tcaacgaaga aggtgccatg aagacaggct ggggtcaagta caaggacact 1800
 tggtagtact tagacgctaa agaaggcgcc atgcaatata tcaaggctaa ctctaagttc 1860
 35 attgggtatca ctgaaggcgt catgggtatca aatgccttta tccagtcagc ggacgggaaca 1920
 ggctgggtact acctcaaacc agacggaaca ctggcagaca ggccagaatg a 1971

<210> 50

<211> 656

<212> PRT

<213> Artificial Sequence

<220>

<223> Human MUC-1 fused to St.pneum. C-LyA P2 helper epitope C-LyA

<400> 50

EP 1 511 768 B1

	Met	Thr	Pro	Gly	Thr	Gln	Ser	Pro	Phe	Phe	Leu	Leu	Leu	Leu	Leu	Thr
	1				5					10					15	
	Val	Leu	Thr	Val	Thr	Gly	Ser	Gly	His	Ala	Ser	Ser	Thr	Pro	Gly	
				20					25					30		
5	Gly	Glu	Lys	Glu	Thr	Ser	Ala	Thr	Gln	Arg	Ser	Ser	Val	Pro	Ser	Ser
			35					40					45			
	Thr	Glu	Lys	Asn	Ala	Val	Ser	Met	Thr	Ser	Ser	Val	Leu	Ser	Ser	His
		50					55					60				
	Ser	Pro	Gly	Ser	Gly	Ser	Ser	Thr	Thr	Gln	Gly	Gln	Asp	Val	Thr	Leu
10	65					70					75					80
	Ala	Pro	Ala	Thr	Glu	Pro	Ala	Ser	Gly	Ser	Ala	Ala	Thr	Trp	Gly	Gln
				85						90					95	
	Asp	Val	Thr	Ser	Val	Pro	Val	Thr	Arg	Pro	Ala	Leu	Gly	Ser	Thr	Thr
				100					105					110		
15	Pro	Pro	Ala	His	Asp	Val	Thr	Ser	Ala	Pro	Asp	Asn	Lys	Pro	Ala	Pro
			115					120					125			
	Gly	Ser	Thr	Ala	Pro	Pro	Ala	His	Gly	Val	Thr	Ser	Ala	Pro	Asp	Thr
		130					135					140				
	Arg	Pro	Pro	Pro	Gly	Ser	Thr	Ala	Pro	Pro	Ala	His	Gly	Val	Thr	Ser
20	145					150					155					160
	Ala	Pro	Asp	Thr	Arg	Pro	Pro	Pro	Gly	Ser	Thr	Ala	Pro	Ala	Ala	His
				165						170					175	
	Gly	Val	Thr	Ser	Ala	Pro	Asp	Thr	Arg	Pro	Ala	Pro	Gly	Ser	Thr	Ala
				180					185					190		
25	Pro	Pro	Ala	His	Gly	Val	Thr	Ser	Ala	Pro	Asp	Asn	Arg	Pro	Ala	Leu
			195					200					205			
	Ala	Ser	Thr	Ala	Pro	Pro	Val	His	Asn	Val	Thr	Ser	Ala	Ser	Gly	Ser
		210					215					220				
	Ala	Ser	Gly	Ser	Ala	Ser	Thr	Leu	Val	His	Asn	Gly	Thr	Ser	Ala	Arg
	225					230					235					240
30	Ala	Thr	Thr	Thr	Pro	Ala	Ser	Lys	Ser	Thr	Pro	Phe	Ser	Ile	Pro	Ser
				245						250					255	
	His	His	Ser	Asp	Thr	Pro	Thr	Thr	Leu	Ala	Ser	His	Ser	Thr	Lys	Thr
				260					265					270		
	Asp	Ala	Ser	Ser	Thr	His	His	Ser	Thr	Val	Pro	Pro	Leu	Thr	Ser	Ser
35			275					280					285			
	Asn	His	Ser	Thr	Ser	Pro	Gln	Leu	Ser	Thr	Gly	Val	Ser	Phe	Phe	Phe
		290				295						300				
	Leu	Ser	Phe	His	Ile	Ser	Asn	Leu	Gln	Phe	Asn	Ser	Ser	Leu	Glu	Asp

40

45

50

55

					305						310					315			320	
					Pro	Ser	Thr	Asp	Tyr	Tyr	Gln	Glu	Leu	Gln	Arg	Asp	Ile	Ser	Glu	Met
									325						330				335	
5					Phe	Leu	Gln	Ile	Tyr	Lys	Gln	Gly	Gly	Phe	Leu	Gly	Leu	Ser	Asn	Ile
								340					345						350	
					Lys	Phe	Arg	Pro	Gly	Ser	Val	Val	Val	Gln	Leu	Thr	Leu	Ala	Phe	Arg
								355				360					365			
					Glu	Gly	Thr	Ile	Asn	Val	His	Asp	Val	Glu	Thr	Gln	Phe	Asn	Gln	Tyr
10						370					375					380				
					Lys	Thr	Glu	Ala	Ala	Ser	Arg	Tyr	Asn	Leu	Thr	Ile	Ser	Asp	Val	Ser
					385					390						395				400
					Val	Ser	Asp	Val	Pro	Phe	Pro	Phe	Ser	Ala	Gln	Ser	Gly	Ala	Gly	Val
								405						410					415	
15					Pro	Gly	Trp	Gly	Ile	Ala	Leu	Leu	Val	Leu	Val	Cys	Val	Leu	Val	Ala
								420					425					430		
					Leu	Ala	Ile	Val	Tyr	Leu	Ile	Ala	Leu	Ala	Val	Cys	Gln	Cys	Arg	Arg
								435				440					445			
					Lys	Asn	Tyr	Gly	Gln	Leu	Asp	Ile	Phe	Pro	Ala	Arg	Asp	Thr	Tyr	His
20						450					455					460				
					Pro	Met	Ser	Glu	Tyr	Pro	Thr	Tyr	His	Thr	His	Gly	Arg	Tyr	Val	Pro
					465					470						475				480
					Pro	Ser	Ser	Thr	Asp	Arg	Ser	Pro	Tyr	Glu	Lys	Val	Ser	Ala	Gly	Asn
								485						490					495	
25					Gly	Gly	Ser	Ser	Leu	Ser	Tyr	Thr	Asn	Pro	Ala	Val	Ala	Ala	Thr	Ser
								500					505					510		
					Ala	Asn	Leu	Met	Ala	Ala	Ala	Tyr	Val	His	Ser	Asp	Gly	Ser	Tyr	Pro
								515				520					525			
					Lys	Asp	Lys	Phe	Glu	Lys	Ile	Asn	Gly	Thr	Trp	Tyr	Tyr	Phe	Asp	Ser
30						530					535					540				
					Ser	Gly	Tyr	Met	Leu	Ala	Asp	Arg	Trp	Arg	Lys	His	Thr	Asp	Gly	Asn
					545					550					555					560
					Trp	Tyr	Trp	Phe	Asp	Asn	Ser	Gly	Glu	Met	Ala	Thr	Gly	Trp	Lys	Lys
								565						570					575	
35					Ile	Ala	Asp	Lys	Trp	Tyr	Tyr	Phe	Asn	Glu	Glu	Gly	Ala	Met	Lys	Thr
								580					585					590		
					Gly	Trp	Val	Lys	Tyr	Lys	Asp	Thr	Trp	Tyr	Tyr	Leu	Asp	Ala	Lys	Glu

45

<210> 51
<211> 2037
<212> DNA
<213> Artificial Sequence

<220>
<223> DNA encoding St.pneum. C-LytA P2 helper epitope C-Lyta fused to Human MUC-1
<400> 51

EP 1 511 768 B1

atgggatgga gctgtatcat cctcttcttg gtagcaacag ctacaggtgt ccactcccag 60
 gtccaaatgg cggccgctta cgtacattcc gacggctctt atccaaaaga caagtttgag 120
 aaaatcaatg gcacttggtg ctactttgac agttcaggct atatgcttgc agaccgctgg 180
 5 aggaagcaca cagacggcaa ctggtactgg ttcgacaact caggcgaaat ggctacaggc 240
 tggaagaaaa tcgtgataa gtggtactat ttcaacgaag aaggtgccat gaagacaggc 300
 tgggtcaagt acaaggacac ttggtactac ttagacgcta aagaaggcgc catgcaatac 360

 10
 atcaaggcta actctaagtt catttggtatc actgaaggcg tcatggtatc aaatgccttt 420
 atccagtcag cggacggaac aggttggtac tacctcaaac cagacggaac actggcagac 480
 aggccagaaa tgacaccggg caccagctct cctttcttcc tgctgctgct cctcacagtg 540
 15 cttacagttg ttacagggtc tgggtcatgca agctctaccc cagggtggaga aaaggagact 600
 tcggctaccc agagaagttc agtggccagc tctactgaga agaattgctgt gagtatgacc 660
 agcagcgtac tctccagcca cagccccggt tcaggctcct ccaccactca gggacaggat 720
 gtcactctgg ccccgggccac ggaaccagct tcagggttcag ctggccacctg gggacaggat 780
 gtcacctcgg tccagtcac caggccagcc ctgggctcca ccaccccgcc agcccacgat 840
 gtcacctcag ccccggaaca caagccagcc ccgggctcca ccgccccccc agcccacggg 900
 20 gtcacctcgg ccccggaacac caggccgccc ccgggctcca ccgccccccc agcccacggg 960
 gtcacctcgg ccccggaacac caggccgccc ccgggctcca ccgccccccc agcccacggg 1020
 gtcacctcgg ccccggaacac caggccgccc ccgggctcca ccgccccccc agcccacggg 1080
 gtcacctcgg ccccggaaca caggcccgcc ttggcgctcca ccgccccctc agtccacaat 1140
 gtcacctcgg cctcaggctc tgcacaggc tcagcttcta ctctggtgca caacggcacc 1200
 25 tctgcccagg ctaccacaac cccagccagc aagagcactc cattctcaat tcccagccac 1260
 cactctgata ctctaccac ccttgccagc catagcacca agactgatgc cagtagcact 1320
 caccatagca cggtagctcc tctcacctcc tccaatcaca gcacttctcc ccagtttgtc 1380
 actggggtct ctttcttttt cctgtctttt cacatttcaa acctccagtt taattcctct 1440
 ctggaagatc ccagcaccga ctactacaa gagctgcaga gagacatttc tgaaatgttt 1500
 30 ttgcagattt ataaacaagg gggttttctg ggcctctcca atattaagt caggccagga 1560
 tctgtggtgg tacaattgac tctggccttc cgagaaggta ccatcaatgt ccacgacgtg 1620
 gagacacagt tcaatcagta taaaacggaa gcagcctctc gatataacct gacgatctca 1680
 gacgtcagcg tgagtgatgt gccatttcct ttctctgccc agtctggggc tggggtgcca 1740
 ggctggggca tcgcgtgct ggtgctggtc tgtgttctgg ttgcgtggc cattgtctat 1800
 35 ctcatgacct tggctgtctg tcagtgcgc cgaaagaact acgggcagct ggacatcttt 1860
 ccagcccggg atacctacca tcctatgagc gagtaccoca cctaccacac ccatgggcgc 1920
 tatgtgcccc ctacgagtac cgatcgtagc ccctatgaga aggtttctgc aggtaatggg 1980
 ggcagcagcc tctcttacac aaaccagca gtggcagcca cttctgcca cttgtag 2037

 40 <210> 52
 <211> 678
 <212> PRT
 <213> Artificial Sequence

 45 <220>
 <223> St.pneum. C-LytA P2 helper epitope C-LytA fused to Human MUC-1

 <400> 52

 50

 55

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly
 1 5 10 15
 Val His Ser Gln Val Gln Met Ala Ala Ala Tyr Val His Ser Asp Gly
 20 25 30
 Ser Tyr Pro Lys Asp Lys Phe Glu Lys Ile Asn Gly Thr Trp Tyr Tyr
 35 40 45
 Phe Asp Ser Ser Gly Tyr Met Leu Ala Asp Arg Trp Arg Lys His Thr
 50 55 60
 Asp Gly Asn Trp Tyr Trp Phe Asp Asn Ser Gly Glu Met Ala Thr Gly
 65 70 75 80
 Trp Lys Lys Ile Ala Asp Lys Trp Tyr Tyr Phe Asn Glu Glu Gly Ala
 85 90 95
 Met Lys Thr Gly Trp Val Lys Tyr Lys Asp Thr Trp Tyr Tyr Leu Asp
 100 105 110
 Ala Lys Glu Gly Ala Met Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile
 115 120 125
 Gly Ile Thr Glu Gly Val Met Val Ser Asn Ala Phe Ile Gln Ser Ala
 130 135 140
 Asp Gly Thr Gly Trp Tyr Tyr Leu Lys Pro Asp Gly Thr Leu Ala Asp
 145 150 155 160
 Arg Pro Glu Met Thr Pro Gly Thr Gln Ser Pro Phe Phe Leu Leu Leu
 165 170 175

	Leu	Leu	Thr	Val	Leu	Thr	Val	Val	Thr	Gly	Ser	Gly	His	Ala	Ser	Ser
				180					185					190		
5	Thr	Pro	Gly	Gly	Glu	Lys	Glu	Thr	Ser	Ala	Thr	Gln	Arg	Ser	Ser	Val
			195					200					205			
	Pro	Ser	Ser	Thr	Glu	Lys	Asn	Ala	Val	Ser	Met	Thr	Ser	Ser	Val	Leu
		210					215					220				
	Ser	Ser	His	Ser	Pro	Gly	Ser	Gly	Ser	Ser	Thr	Thr	Gln	Gly	Gln	Asp
	225					230					235					240
10	Val	Thr	Leu	Ala	Pro	Ala	Thr	Glu	Pro	Ala	Ser	Gly	Ser	Ala	Ala	Thr
				245						250					255	
	Trp	Gly	Gln	Asp	Val	Thr	Ser	Val	Pro	Val	Thr	Arg	Pro	Ala	Leu	Gly
			260						265					270		
	Ser	Thr	Thr	Pro	Pro	Ala	His	Asp	Val	Thr	Ser	Ala	Pro	Asp	Asn	Lys
			275					280					285			
15	Pro	Ala	Pro	Gly	Ser	Thr	Ala	Pro	Pro	Ala	His	Gly	Val	Thr	Ser	Ala
		290					295					300				
	Pro	Asp	Thr	Arg	Pro	Pro	Gly	Ser	Thr	Ala	Pro	Pro	Ala	His	Gly	
	305					310				315						320
	Val	Thr	Ser	Ala	Pro	Asp	Thr	Arg	Pro	Pro	Pro	Gly	Ser	Thr	Ala	Pro
				325						330					335	
20	Ala	Ala	His	Gly	Val	Thr	Ser	Ala	Pro	Asp	Thr	Arg	Pro	Ala	Pro	Gly
			340						345					350		
	Ser	Thr	Ala	Pro	Pro	Ala	His	Gly	Val	Thr	Ser	Ala	Pro	Asp	Asn	Arg
			355					360					365			
	Pro	Ala	Leu	Ala	Ser	Thr	Ala	Pro	Pro	Val	His	Asn	Val	Thr	Ser	Ala
		370					375					380				
25	Ser	Gly	Ser	Ala	Ser	Gly	Ser	Ala	Ser	Thr	Leu	Val	His	Asn	Gly	Thr
	385					390					395					400
	Ser	Ala	Arg	Ala	Thr	Thr	Pro	Ala	Ser	Lys	Ser	Thr	Pro	Phe	Ser	
				405						410				415		
	Ile	Pro	Ser	His	His	Ser	Asp	Thr	Pro	Thr	Thr	Leu	Ala	Ser	His	Ser
				420					425					430		
30	Thr	Lys	Thr	Asp	Ala	Ser	Ser	Thr	His	His	Ser	Thr	Val	Pro	Pro	Leu
			435					440					445			
	Thr	Ser	Ser	Asn	His	Ser	Thr	Ser	Pro	Gln	Leu	Ser	Thr	Gly	Val	Ser
		450					455				460					
	Phe	Phe	Phe	Leu	Ser	Phe	His	Ile	Ser	Asn	Leu	Gln	Phe	Asn	Ser	Ser
35	465					470				475					480	
	Leu	Glu	Asp	Pro	Ser	Thr	Asp	Tyr	Tyr	Gln	Glu	Leu	Gln	Arg	Asp	Ile
				485						490					495	
	Ser	Glu	Met	Phe	Leu	Gln	Ile	Tyr	Lys	Gln	Gly	Gly	Phe	Leu	Gly	Leu
			500						505					510		
	Ser	Asn	Ile	Lys	Phe	Arg	Pro	Gly	Ser	Val	Val	Val	Gln	Leu	Thr	Leu
40			515					520					525			
	Ala	Phe	Arg	Glu	Gly	Thr	Ile	Asn	Val	His	Asp	Val	Glu	Thr	Gln	Phe
		530					535					540				
	Asn	Gln	Tyr	Lys	Thr	Glu	Ala	Ala	Ser	Arg	Tyr	Asn	Leu	Thr	Ile	Ser
	545					550					555				560	
45	Asp	Val	Ser	Val	Ser	Asp	Val	Pro	Phe	Pro	Phe	Ser	Ala	Gln	Ser	Gly
				565						570					575	
	Ala	Gly	Val	Pro	Gly	Trp	Gly	Ile	Ala	Leu	Leu	Val	Leu	Val	Cys	Val
			580					585					590			
	Leu	Val	Ala	Leu	Ala	Ile	Val	Tyr	Leu	Ile	Ala	Leu	Ala	Val	Cys	Gln
			595					600					605			
50	Cys	Arg	Arg	Lys	Asn	Tyr	Gly	Gln	Leu	Asp	Ile	Phe	Pro	Ala	Arg	Asp
		610					615					620				
	Thr	Tyr	His	Pro	Met	Ser	Glu	Tyr	Pro	Thr	Tyr	His	Thr	His	Gly	Arg
	625					630					635				640	
	Tyr	Val	Pro	Pro	Ser	Ser	Thr	Asp	Arg	Ser	Pro	Tyr	Glu	Lys	Val	Ser
				645						650					655	
55	Ala	Gly	Asn	Gly	Gly	Ser	Ser	Leu	Ser	Tyr	Thr	Asn	Pro	Ala	Val	Ala

660
Ala Thr Ser Ala Asn Leu
675

665

670

Claims

1. A fusion partner protein comprising a choline binding domain and a heterologous promiscuous T helper epitope.
2. A fusion partner protein according to claim 1 wherein the choline binding domain is the C terminus of LytA or a derivative thereof in which the derivative of the C-terminus of LytA retains both the capability of acting as an immunological partner and an expression enhancer.
3. A fusion partner protein according to claim 2 wherein the C-LytA or derivative thereof comprises at least four repeats of any of SEQ ID NO:1 to 6.
4. A fusion partner protein according to any of claims 1 to 3, wherein the choline binding domain is selected from the group comprising:
 - a) the C-terminal domain of LytA as set forth in SEQ ID NO:7; or
 - b) the sequence of SEQ ID NO:8; or
 - c) a peptide sequence comprising an amino acid sequence having at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, most preferably at least 97-99% identity, to any of SEQ ID NO: 1 to 6; or
 - d) a peptide sequence comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids from the amino acid sequence of SEQ ID NO:7 or SEQ ID NO:8.
5. A fusion protein comprising a fusion partner protein as claimed in any of claims 1 to 4 and a heterologous protein.
6. A fusion protein as claimed in claim 5 wherein the heterologous protein is chemically conjugated to the fusion partner.
7. A fusion protein as claimed in claim 5 or 6 wherein the heterologous protein is derived from an organism selected from the following group: Human Immunodeficiency virus HIV-1, human herpes simplex viruses, cytomegalovirus, Rotavirus, Epstein Barr virus, Varicella Zoster Virus, from a hepatitis virus such as hepatitis B virus, hepatitis A virus, hepatitis C virus and hepatitis E virus, from Respiratory Syncytial virus, parainfluenza virus, measles virus, mumps virus, human papilloma viruses, flaviviruses or Influenza virus, from *Neisseria spp.*, *Moraxella spp.*, *Bordetella spp.*, *Mycobacterium spp.*, including *M. tuberculosis*; *Escherichia spp.*, including enterotoxigenic *E. coli*; *Salmonella spp.*; *Listeria spp.*; *Helicobacter spp.*; *Staphylococcus spp.*, including *S. aureus*, *S. epidermidis*; *Borrelia spp.*; *Chlamydia spp.*, including *C. trachomatis*, *C. pneumoniae*; *Plasmodium spp.*, including *P. falciparum*; *Toxoplasma spp.*, *Candida spp.*
8. A fusion protein as claimed in claim 5 or 6 wherein the heterologous protein is a tumour associated protein or tissue specific protein or immunogenic fragment thereof.
9. A fusion protein as claimed in claim 8 wherein the heterologous protein or fragment thereof is selected from MAGE 1, MAGE 3, MAGE 4, PRAME, BAGE, LAGE 1, LAGE 2, SAGE, HAGE, XAGE, PSA, PAP, PSCA, prostatein, P501S, HASH2, Cripto, B726, NY-BR1.1, P510, MUC-1, Prostase, STEAP, tyrosinase, telomerase, survivin, CASB616, P53, or her 2 neu.
10. A fusion protein as claimed in any of claims 6 to 9 further comprising an affinity tag of at least 4 histidine residues.
11. A nucleic acid sequence encoding a protein of claim 1 to 10.
12. An expression vector comprising a nucleic acid sequence of claim 11.
13. A host cell transformed with a nucleic acid sequence of claim 11 or with an expression vector of claim 12.

14. An immunogenic composition comprising a protein as claimed in any of claim 1 to 10 or a DNA sequence as claimed in claim 11 and a pharmaceutically acceptable excipient.
15. An immunogenic composition as claimed in claim 14 which additionally comprises a TH-1 inducing adjuvant.
16. An immunogenic composition as claimed in claim 15 in which the TH-1 inducing adjuvant is selected from the group of adjuvants comprising: 3D-MPL, QS21, a mixture of QS21 and cholesterol, a CpG oligonucleotide or a mixture of two or more of said adjuvants.
17. A process for the preparation of a immunogenic composition as claimed in any of claims 14 to 16, comprising admixing the fusion protein of any of claims 6 to 10 or the encoding polynucleotide of claim 11 with a suitable adjuvant, diluent or other pharmaceutically acceptable carrier.
18. A process for producing a fusion protein of any of claims 1 to 10 comprising culturing a host cell of claim 13 under conditions sufficient for the production of said fusion protein and recovering the fusion protein from the culture medium.
19. A protein of any of claims 1 to 10 or a DNA sequence of claim 11 for use in medicine.
20. Use of a protein as claimed in any of claim 1 to 10 or a DNA sequence of claim 11 in the manufacture of an immunogenic composition for eliciting an immune response in a patient.
21. Use according to claim 20, wherein said immune response is to be elicited by sequential administration of i) the said protein followed by the said DNA sequence; or ii) the said DNA sequence followed by the said protein.
22. Use according to claim 21 wherein said DNA sequence is coated onto biodegradable beads or delivered via a particle bombardment approach.
23. Use according to claim 21 or claim 22 wherein said protein is adjuvanted.
24. Use of a protein as claimed in any of claim 1 to 10 or a DNA sequence of claim 11 in the manufacture of an immunogenic composition for immunotherapeutically treating a patient suffering from or susceptible to cancer.
25. Use according to claim 24 wherein said cancer is prostate cancer, colon cancer, lung cancer, breast cancer or melanoma.

Patentansprüche

1. Fusionspartnerprotein, das eine Cholin-Bindungsdomäne und ein heterologes promiskues T-Helferepitop umfaßt.
2. Fusionspartnerprotein gemäß Anspruch 1, worin die Cholin-Bindungsdomäne der C-Terminus von LytA oder ein Derivat davon ist, worin das Derivat des C-Terminus von LytA sowohl die Fähigkeit zur Funktion als immunologischer Partner als auch als Expressionsverstärker bewahrt.
3. Fusionspartnerprotein gemäß Anspruch 2, worin das C-LytA oder Derivat davon wenigstens vier Repeats aus einem beliebigen aus SEQ ID NO: 1 bis 6 umfaßt.
4. Fusionspartnerprotein gemäß einem der Ansprüche 1 bis 3, worin die Cholin-Bindungsdomäne aus der Gruppe ausgewählt ist, die folgendes umfaßt:
 - a) die C-terminale Domäne von LytA wie in SEQ ID NO: 7 dargestellt; oder
 - b) die Sequenz von SEQ ID NO: 8; oder
 - c) eine Peptidsequenz, die eine Aminosäuresequenz mit wenigstens 85 % Identität, bevorzugt wenigstens 90 % Identität, besonders bevorzugt wenigstens 95 % Identität, am meisten bevorzugt wenigstens 97-99 % Identität mit einem beliebigen aus SEQ ID NO: 1 bis 6 umfaßt; oder
 - d) eine Peptidsequenz, die eine Aminosäuresequenz mit wenigstens 15, 20, 30, 40, 50 oder 100 zusammenhängenden Aminosäuren aus der Aminosäuresequenz von SEQ ID NO: 7 oder SEQ ID NO: 8 umfaßt.

5. Fusionsprotein, das ein Fusionspartnerprotein gemäß einem der Ansprüche 1 bis 4 und ein heterologes Protein umfaßt.
6. Fusionsprotein gemäß Anspruch 5, worin das heterologe Protein chemisch an den Fusionspartner konjugiert ist.
7. Fusionsprotein gemäß Anspruch 5 oder 6, worin das heterologe Protein aus einem Organismus stammt, der aus der folgenden Gruppe ausgewählt ist: humanes Immundefizienzvirus HIV-1, humane Herpes simplex-Viren, Cytomegalovirus, Rotavirus, Epstein-Barr-Virus, Varicella Zoster-Virus, aus einem Hepatitisvirus wie Hepatitis B-Virus, Hepatitis A-Virus, Hepatitis C-Virus und Hepatitis E-Virus, aus respiratorischem Synzytialvirus, Parainfluenzavirus, Masernvirus, Mumpsvirus, humane Papillomaviren, Flaviviren oder Influenzavirus, aus *Neisseria* spp., *Moraxella* spp., *Bordetella* spp., *Mycobacterium* spp., einschließlich *M. tuberculosis*; *Escherichia* spp., einschließlich enterotoxisches *E. coli*; *Salmonella* spp.; *Listeria* spp.; *Helicobacter* spp.; *Staphylococcus* spp.; einschließlich *S. aureus*, *S. epidermidis*; *Borrelia* spp.; *Chlamydia* spp., einschließlich *C. trachomatis*, *C. pneumoniae*; *Plasmodium* spp., einschließlich *P. falciparum*; *Toxoplasma* spp., *Candida* spp.
8. Fusionsprotein gemäß Anspruch 5 oder 6, worin das heterologe Protein ein Tumor-assoziiertes Protein oder gewebespezifisches Protein oder immunogenes Fragment davon ist.
9. Fusionsprotein gemäß Anspruch 8, worin das heterologe Protein oder Fragment davon ausgewählt ist aus MAGE 1, MAGE 3, MAGE 4, PRAME, BAGE, LAGE 1, LAGE 2, SAGE, HAGE, XAGE, PSA, PAP, PSCA, Prostein, P501S, HASH2, Cripto, B726, NY-BR1.1, P510, MUC-1, Prostase, STEAP, Tyrosinase, Telomerase, Survivin, CASB616, P53 oder her 2 neu.
10. Fusionsprotein gemäß einem der Ansprüche 6 bis 9, das ferner einen Affinitätsmarker mit wenigstens 4 Histidinresten umfaßt.
11. Nukleinsäuresequenz, die ein Protein gemäß Anspruch 1 bis 10 codiert.
12. Expressionsvektor, der eine Nukleinsäuresequenz gemäß Anspruch 11 umfaßt.
13. Wirtszelle, die mit einer Nukleinsäuresequenz gemäß Anspruch 11 oder mit einem Expressionsvektor gemäß Anspruch 12 transformiert ist.
14. Immunogene Zusammensetzung, die ein Protein gemäß einem der Ansprüche 1 bis 10 oder eine DNA-Sequenz gemäß Anspruch 11 und einen pharmazeutisch akzeptablen Exzipienten umfaßt.
15. Immunogene Zusammensetzung gemäß Anspruch 14, die zusätzlich einen TH-1-induzierenden Hilfsstoff umfaßt.
16. Immunogene Zusammensetzung gemäß Anspruch 15, worin der TH-1-induzierende Hilfsstoff aus der Gruppe von Hilfsstoffen ausgewählt ist, die 3D-MPL, QS21, eine Mischung aus QS21 und Cholesterol, ein CpG-Oligonukleotid oder eine Mischung aus zwei oder mehreren der Hilfsstoffe umfaßt.
17. Verfahren zur Herstellung einer immunogenen Zusammensetzung gemäß einem der Ansprüche 14 bis 16, das das Vermischen des Fusionsproteins gemäß einem der Ansprüche 6 bis 10 oder des codierenden Polynukleotids gemäß Anspruch 11 mit einem geeigneten Hilfsstoff, Verdünnungsmittel oder anderen pharmazeutisch akzeptablen Träger umfaßt.
18. Verfahren zur Herstellung eines Fusionsproteins gemäß einem der Ansprüche 1 bis 10, das das Kultivieren einer Wirtszelle gemäß Anspruch 13 unter Bedingungen, die ausreichend zur Herstellung des Fusionsproteins sind, und das Gewinnen des Fusionsproteins aus dem Kulturmedium umfaßt.
19. Protein gemäß einem der Ansprüche 1 bis 10 oder DNA-Sequenz gemäß Anspruch 11 zur Verwendung in der Medizin.
20. Verwendung eines Proteins gemäß einem der Ansprüche 1 bis 10 oder einer DNA-Sequenz gemäß Anspruch 11 in der Herstellung einer immunogenen Zusammensetzung zum Hervorrufen einer Immunreaktion in einem Patienten.
21. Verwendung gemäß Anspruch 20, worin die Immunreaktion durch aufeinanderfolgende Verabreichung i) des Pro-

teins, gefolgt von der DNA-Sequenz; oder ii) der DNA-Sequenz, gefolgt vom Protein hervorgerufen wird.

22. Verwendung gemäß Anspruch 21, worin die DNA-Sequenz auf biologisch abbaubaren Perlen aufgetragen ist oder über einen Partikelbombardierungsansatz übertragen wird.

23. Verwendung gemäß Anspruch 21 oder 22, worin das Protein mit Hilfsstoff versetzt ist.

24. Verwendung eines Proteins gemäß einem der Ansprüche 1 bis 10 oder einer DNA-Sequenz gemäß Anspruch 11 in der Herstellung einer immunogenen Zusammensetzung zur immuntherapeutischen Behandlung eines Patienten, der an Krebs leidet oder dafür anfällig ist.

25. Verwendung gemäß Anspruch 24, worin der Krebs Prostatakrebs, Darmkrebs, Lungenkrebs, Brustkrebs oder Melanom ist.

Revendications

1. Protéine partenaire de fusion comprenant un domaine de liaison à la choline et un épitope de lymphocyte T auxiliaire multivalent.

2. Protéine partenaire de fusion selon la revendication 1, dans laquelle le domaine de liaison à la choline est l'extrémité C-terminale de LytA ou un dérivé de celle-ci, où le dérivé de l'extrémité C-terminale de LytA conserve la capacité d'agir à la fois en tant que partenaire immunogène et stimulateur de l'expression.

3. Protéine partenaire de fusion selon la revendication 2, dans laquelle le C-LytA ou un dérivé de celle-ci comprend au moins quatre répétitions de l'une quelconque des SEQ ID N° 1 à 6.

4. Protéine partenaire de fusion selon l'une quelconque des revendications 1 à 3, dans laquelle le domaine de liaison à la choline est sélectionné dans le groupe consistant en :

a) le domaine C-terminal de LytA tel que représenté par SEQ ID N° 7 ; ou

b) la séquence de SEQ ID N° 8 ; ou

c) une séquence peptidique comprenant une séquences d'acides aminés ayant au moins 85 % d'identité, de préférence au moins 90 % d'identité, de manière plus préférée au moins 95 % d'identité, et de la manière la plus préférée entre toutes au moins 97-99 % d'identité, avec l'une quelconque des SEQ ID N° 1 à 6 ; ou

d) une séquence peptidique comprenant une séquence d'acides aminés ayant au moins 15, 20, 30, 40, 50 ou 100 acides aminés contigus de la séquence d'acides aminés de SEQ ID N° 7 ou SEQ ID N° 8.

5. Protéine de fusion comprenant une protéine partenaire de fusion selon l'une quelconque des revendications 1 à 4, et une protéine hétérologue.

6. Protéine de fusion selon la revendication 5, dans laquelle la protéine hétérologue est chimiquement conjuguée au partenaire de fusion.

7. Protéine de fusion selon la revendication 5 ou 6, dans laquelle la protéine hétérologue est dérivée d'un organisme sélectionné dans le groupe suivant: virus de l'immunodéficience humaine HIV-1, virus herpès simplex humains, cytomégalovirus, rotavirus, virus d'Epstein-Barr, virus varicelle-zona, à partir d'un virus de l'hépatite tel que le virus de l'hépatite B, virus de l'hépatite A, virus de l'hépatite C et virus de l'hépatite E, à partir d'un virus respiratoire syncytial, virus parainfluenza, virus de la rougeole, virus des oreillons, des virus du papillome humain, des flavivirus ou virus de la grippe, à partir des espèces *Neisseria*, espèces *Moraxella*, espèces *Bordetella* ; espèces *Mycobacterium*, comprenant *M. tuberculosis*; des espèces *Escherichia*, comprenant *E. coli* entérotoxique; espèces *Salmonella*; espèces *Listeria*; espèces *Helicobacter*; espèces *Staphylococcus*; comprenant *S. aureus*, *S. epidermidis* ; espèces *Borrelia* ; espèces *Chlamydia*, comprenant *C. trachomatis*, *C. pneumoniae* ; espèces *Plasmodium*, comprenant *P. falciparum* ; espèces *Toxoplasma*, espèces *Candida*.

8. Protéine de fusion selon la revendication 5 ou 6, dans laquelle la protéine hétérologue est une protéine associée à une tumeur ou une protéine spécifique à un tissu ou un fragment immunogène de celle-ci.

9. Protéine de fusion selon la revendication 8, dans laquelle la protéine hétérologue, ou un fragment de celle-ci, est sélectionnée parmi MAGE 1, MAGE 3, MAGE 4, PRAME, BAGE, LAGE 1, LAGE 2, SAGE, HAGE, XAGE, PSA, PAP, PSCA, prostéine, P501S, HASH2, Cripto, B726, NY-BR1.1, P510, MUC-1, Prostase, STEAP, tyrosinase, télomérase, survivine, CASB616, P53, ou her 2 neu.
10. Protéine de fusion selon l'une quelconque des revendications 6 à 9 comprenant en outre un marqueur d'affinité d'au moins 4 résidus histidine.
11. Séquence d'acide nucléique codant pour une protéine selon la revendication 1 à 10.
12. Vecteur d'expression comprenant une séquence d'acide nucléique selon la revendication 11.
13. Cellule hôte transformée avec une séquence d'acide nucléique selon la revendication 11 ou avec un vecteur d'expression selon la revendication 12.
14. Composition immunogène comprenant une protéine selon l'une quelconque des revendications 1 à 10 ou une séquence ADN selon la revendication 11 et un excipient pharmaceutiquement acceptable.
15. Composition immunogène selon la revendication 14 qui comprend en outre un adjuvant induisant TH-1.
16. Composition immunogène selon la revendication 15, dans laquelle l'adjuvant induisant TH-1 est sélectionné parmi le groupe d'adjuvants comprenant : 3D-MPL, QS21, un mélange de QS21 et de cholestérol, un oligonucléotide CpG ou un mélange de deux ou plusieurs desdits adjuvants.
17. Procédé pour la préparation d'une composition immunogène selon l'une quelconque des revendications 14 à 16, comprenant un mélange de la protéine de fusion selon l'une quelconque des revendications 6 à 10, ou du polynucléotide codant selon la revendication 11, avec un adjuvant approprié, un diluant ou autre transporteur pharmaceutiquement acceptable.
18. Procédé de production d'une protéine de fusion selon l'une quelconque des revendications 1 à 10 comprenant la mise en culture d'une cellule hôte selon la revendication 13 dans des conditions suffisantes pour produire ladite protéine de fusion et récupérer la protéine de fusion dans le milieu de culture.
19. Protéine selon l'une quelconque des revendications 1 à 10 ou une séquence ADN selon la revendication 11 destinée à une utilisation en médecine.
20. Utilisation d'une protéine selon l'une quelconque des revendications 1 à 10 ou une séquence ADN selon la revendication 11 dans la fabrication d'une composition immunogène pour provoquer une réponse immunitaire chez un patient.
21. Utilisation selon la revendication 20, dans laquelle ladite réponse immunitaire doit être provoquée par une administration séquentielle de i) ladite protéine suivie par ladite séquence ADN ; ou ii) ladite séquence ADN suivie par ladite protéine.
22. Utilisation selon la revendication 21, dans laquelle ladite séquence ADN est enrobée sur des microsphères biodégradables ou est délivrée par une approche de bombardement particulaire.
23. Utilisation selon la revendication 21 ou la revendication 22, dans laquelle ladite protéine est associée à un adjuvant.
24. Utilisation d'une protéine selon l'une quelconque des revendications 1 à 10 ou une séquence ADN selon la revendication 11 dans la fabrication d'une composition immunogène pour un traitement d'immunothérapie chez un patient présentant un cancer ou étant susceptible de présenter un cancer.
25. Utilisation selon la revendication 24, dans laquelle ledit cancer est le cancer de la prostate, le cancer du côlon, le cancer du sein ou le mélanome.

Fig. 1 – Sequence information for C-LytA.

SEQ ID NO:1 – amino acid sequence of C-LytA repeat 1

GWQKNDTGYWYVHSD 15

SEQ ID NO:2 – amino acid sequence of C-LytA repeat 2

GSYPKDKFEKINGTWYYFDSS 21

SEQ ID NO:3 – amino acid sequence of C-LytA repeat 3

GYMLADRWRKHTDGNWYWF DNS 22

SEQ ID NO:4 – amino acid sequence of C-LytA repeat 4

GEMATGWKKIADKWYFNEE 20

SEQ ID NO:5 – amino acid sequence of C-LytA repeat 5

GAMKTGWVKYKDTWYYLDAKE 21

SEQ ID NO:6 – amino acid sequence of C-LytA repeat 6

GAMVSNAFIQSADGTGWYYLKPD 23

SEQ ID NO:7 – amino acid sequence of C-LytA cholin-binding domain

GWQKNDTGYW YVHSDGSYPK DKFEKINGTW YYFDSSGYML ADRWRKHTDG NWYWF DNSGE 60
MATGWKKIAD KWYFNEEGA MKTGWVKYKD TWYYLDAKEG AMVSNAFIQS ADGTGWYYLK 120
PDGTLADRPE FTVEPDGLIT VK 142

SEQ ID NO:8 – amino acid sequence of C-LytA domain from truncated repeat 1 to repeat 6 (as part of our constructs shown in figure 2)

YVHSDGSYPKDKFEKINGTWYYFDSSGYMLADRWRKHTDGNWYWF DNSGEMATGWKKIADKWYFNEEGAMKT
GWVKYKDTWYYLDAKEGAMVSNAFIQSADGTGWYYLKPD

SEQ ID NO:9 – DNA sequence encoding the amino acid sequence of SEQ ID NO:1

ggctggcaga agaatgacac tggctactgg tacgtacatt cagac

SEQ ID NO:10 – DNA sequence encoding the amino acid sequence of SEQ ID NO:2

ggctcttata caaaagacaa gtttgagaaa atcaatggca cttggtacta ctttgacagt tca

SEQ ID NO:11 – DNA sequence encoding the amino acid sequence of SEQ ID NO:3

ggctatatgc ttgcagaccg ctggaggaag cacacagacg gcaactggta ctggttcgac aactca

SEQ ID NO:12 – DNA sequence encoding the amino acid sequence of SEQ ID NO:4

ggcgaaatgg ctacaggctg gaagaaaatc gctgataagt ggtactatct caacgaagaa

SEQ ID NO:13 – DNA sequence encoding the amino acid sequence of SEQ ID NO:5

Ggtgccatga agacaggctg ggtcaagtac aaggacactt ggtactactt agacgctaaa gaa

SEQ ID NO:14 – DNA sequence encoding the amino acid sequence of SEQ ID NO:6

Ggcgccatgg tatcaaatgc ctttatccag tcagcggacg gaacaggctg gtactacctc
aaaccagac

SEQ ID NO:15 – DNA sequence encoding the amino acid sequence of SEQ ID NO:7

ggctggcaga agaatgacac tggctactgg tacgtacatt cagacggctc ttatccaaaa 60
gacaagtttg agaaaatcaa tggcacttgg tactactttg acagttcagg ctatatgctt 120
gcagaccgct ggaggaagca cacagacggc aactgggtact ggttcgacaa ctcaggcgaa 180
atggctacag gctggaagaa aatcgctgat aagtgggtact atttcaacga agaaggtgcc 240
atgaagacag gctgggtcaa gtacaaggac acttgggtact acttagacgc taaagaaggc 300
gccatggtat caaatgcctt tatccagtca gcggacggaa caggctggta ctacctcaaa 360
ccagacggaa cactggcaga caggccagaa ttcacagtag agccagatgg cttgattaca 420
gtaaaataa 429

SEQ ID NO:16 – DNA sequence encoding the amino acid sequence of SEQ ID NO:8

TACGTACATTCGACGGCTCTTATCCAAAAGACAAGTTTGAGAAAATCAATGGCACTTGGTACTACTTTGACA
GTTTCAGGCTATATGCTTGACAGACCGCTGGAGGAAGCACACAGACGGCAACTGGTACTGGTTCGACAACTCAGG
CGAAATGGCTACAGGCTGGAAGAAAATCGCTGATAAGTGGTACTATTTCAACGAAGAAGTGCCATGAAGACA
GGCTGGGTCAAGTACAAGGACACTTGGTACTACTTAGACGCTAAAGAAGGCGCCATGGTATCAAATGCCTTTA
TCCAGTCAGCGGACGGAACAGGCTGGTACTACCTCAAACCAGAC

FIG. 2. CPC and native Constructs

Construct 1 – coding sequence of CPC-P501₅₁₋₅₅₃ (see plasmid of figure 7 -Y1796)

Protein sequence (SEQ ID NO:27)

MAAA^{R1}YVHSDGSYPKDKFEKINGTWYYFDSSGYMLADRWRKHTDGNWYWFDNSGEMATG^{R2}
^{R3}WKKIADKWYYFNEEGAMKTGWVKYKDTWYYLDAKEGAM^{R4}MOYIKANSKEFIGITEGV^{R5}MVSNAFIQS^{R6}
ADGTGWYYLKPDGTLADRPEKFMVMVLGIGPVLGLVCVPLLGSASDHWRGRYGRRRPFIWALS
 GILLSLFLIPRAGWLAGLLCPDPRLELALLILGVLLDFCGQVCFTPLEALLSDLFRDPDHCRAYSV
 YAFMISLGGCLGYLLPAIDWDTSALAPYLGTEECFLGLLTLIFLTCVAATLLVAEEAALGPTEPAEG
 LSAPSLSPHCCPCRARLAFRNLGALLPRLHQLCCRMPTLRRLFVAELCSWMALMTFTLFYTDVGE
 GLYQGVPRAEPTARRHYDEGVRMGSGLFLQCAISLVFSLVMDRLVQRFQTRAVYLASVAAFPV
 AAGATCLSHSVAVVTASAALTGFTFSALQILPYTLASLYHREKQVFLPKYRGDTGGASSEDLSMTSF
 LPGPKPGAPFPNGHVGAGGSGLPPPALCGASACDVSVRVVVGEPTEARVVPGRGICLDLAILDSAF
 LLSQVAPSLFMGSIVQLSQSVTAYMVSAAGLGLVAIYFATQVVFDKSDLAKYSAGGHHHHHH

R1 (plain): aa5-9 (fragment) R4 (bold): aa53-72 P2 (underline): 97-110

R2 (bold): aa10-30 R5 (plain): aa73-93

R3 (plain): aa31-52 R6a (bold): aa94-95 R6b (bold): 113-133

Nucleotide sequence (SEQ ID NO:28)

ATGgeggccgctTACGTACATTCCGACGGCTCTTATCCAAAAGACAAGTTTGAGAAAATCAATGGCACTTGGT
 ACTACTTTTGACAGTTTCAAGGCTATATGCTTGACAGCCGCTGGAGGAAGCACACAGACGGCAACTGGTACTGGTT
 CGACAACTCAGGCGAAATGGCTACAGGCTGGAAGAAAATCGCTGATAAGTGGTACTATTTCAACGAAGAAGGT
 GCCATGAAGACAGGCTGGGTCAAGTACAAGGACACTTGGTACTACTTAGACGCTAAAGAAGGCGCCatgcaat
 acatcaaggctaactctaagttcattggtatcactgaaggcgctcATGGTATCAAATGCCTTTATCCAGTCAGC
 GGACGGAACAGGCTGGTACTACCTCAAACCAGACGGAACACTGGCAGACAGGCCAGAAaagttcatgtaCatg
 GTGCTGGGCATTGGTCCAGTGCTGGGCCTGGTCTGTGTCCCGCTCCTAGGCTCAGCCAGTGACCACTGGCGTG
 GACGCTATGGCCGCCGCCGCTTCATCTGGGCACTGTCTTGGGCATCCTGCTGAGCCTCTTTCTCATCCC
 AAGGGCCGGCTGGCTAGCAGGGCTGCTGTGCCCCGATCCCAGGCCCCCTGGAGCTGGCACTGCTCATCTGGGC
 GTGGGGCTGCTGGACTTCTGTGGCCAGGTGTGCTTCACTCCACTGGAGGCCCTGCTCTGACCTCTTCCGGG
 ACCCGGACCCTGTGCGCCAGGCCTACTCTGTCTATGCCTTCATGATCAGTCTTGGGGCTGCCTGGGCTACCT
 CCTGCCTGCCATTGACTGGGACACCAGTGCCCTGGCCCCCTACCTGGGCACCCAGGAGGAGTGCTCTTTGGC
 CTGCTCACCTCATCTTCTCACCTGCGTAGCAGCCACACTGCTGGTGGCTGAGGAGGCAGCGCTGGGCCCCA
 CCGAGCCAGCAGAAGGGCTGTGCGCCCCCTCCTGTGCGCCCCACTGCTGTCCATGCCGGGCCGCTTGGCTTT

CCGGAACCTGGGGCGCCCTGCTTCCCCGGCTGCACCAGCTGTGCTGCCGCATGCCCCGCACCCTGCGCCGGCTC
 TTCGTGGCTGAGCTGTGCAGCTGGATGGCACTCATGACCTTCACGCTGTTTTACACGGATTTTCGTGGGCGAGG
 GGCTGTACCAGGGCGTGCCAGAGCTGAGCCGGGCACCGAGGCCCGGAGACACTATGATGAAGGCGTTCGGAT
 GGGCAGCCTGGGGCTGTTCTCAGTGCGCCATCTCCCTGGTCTTCTCTCTGGTCATGGACCGGCTGGTGCAG
 CGATTCCGGCACTCGAGCAGTCTATTTGGCCAGTGTGGCAGCTTTCCTGTGGCTGCCGGTGCCACATGCCTGT
 CCCACAGTGTGGCCGTGGTGACAGCTTCAGCCGCCCTCACCGGGTTCACCTTCTCAGCCCTGCAGATCCTGCC
 CTACACACTGGCCCTCCCTCTACCACCGGGAGAAGCAGGTGTTCTCGCCCAAATACCGAGGGGACACTGGAGGT
 GCTAGCAGTGAGGACAGCCTGATGACCAGCTTCCTGCCAGGCCCTAAGCCTGGAGCTCCCTTCCCTAATGGAC
 ACGTGGGTGCTGGAGGCAGTGGCCTGCTCCACCTCCACCCGCGCTCTGCGGGGCCTCTGCCTGTGAtGTCTC
 CGTACGTGTGGTGGTGGGTGAGCCACCGAGGCCAGGGTGGTTCCGGGCCGGGGCATCTGCCCTGGACCTCGCC
 ATCCTGGATAGTGCCTTCTCTGTGTCCCAGTGGCCCCATCCCTGTTTATGGGCTCCATTGTCCAGCTCAGCC
 AGTCTGTCACTGCCTATATGGTGTCTGCCGAGGCCTGGGTCTGGTCCCATTTACTTTGCTACACAGGTAGT
 ATTTGACAAGAGCGACTTGGCCAAATACTCAGCGggtggacaccatcaccatcaccattaa

Construct 2 – Coding sequence of P501₅₅₋₅₅₃ HIS (control) (yeast strain SC333)

Protein sequence (SEQ ID NO:29)

MVLGIGPVLG LVCVPLLGS A SDHWRGRYGR RRPFIWALS L GILLSLFLIP RAGWLAGLLC 60
 PDPRPLELAL LILGVLLDF CGQVCFTPLE ALLSDLFRDP DHCRAQYSVY AFMISLGGCL 120
 GYLLPAIDWD TSALAPYLGT QEELFGLLT LIFLTCVAAT LLVAEEAALG PTEPAEGLSA 180
 PSLSPHCCPC RARLAFRNLG ALLPRLHQLC CRMPRTLRL FVAELCSWMA LMTFTLFYTD 240
 FVGEGLYQGV PRAEPGTEAR RHYDEGVRMG SLGLFLQCAI SLVFSLVMDR LVQRFGTRAV 300
 YLASVAAPFV AAGATCLSHS VAVVTASAAL TGFTFSALQI LPYTLASLYH REKQVFLPKY 360
 RGDGTGGASSE DSLMTSFLPG PKPGAPFPNG HVGAGGSGLL PPPALCGAS ACDVSVRVVV 420
 GEPTARVVP GRGICLDLAI LDSAFLLSQV APSLFMGSIV QLSQSVTAYM VSAAGLGLVA 480
 IYFATQVVFD KSDLAKYSAG GHHHHHH 507

Nucleotide sequence (SEQ ID NO:30)

atgGTGCTGG GCATTGGTCC AGTGCTGGGC CTGGTCTGTG TCCGCTCCT AGGCTCAGCC 60
 AGTGACCACT GCGGTGGACG CTATGGCCGC CGCCGGCCCT TCATCTGGGC ACTGTCCCTG 120
 GGCATCCTGC TGAGCCTCTT TCTCATCCCA AGGGCCGGCT GGCTAGCAGG GCTGCTGTGC 180
 CCGGATCCCA GGCCCTTGA GCTGGCACTG CTCATCCTGG GCGTGGGGCT GCTGGACTTC 240
 TGTGGCCAGG TGTGCTTAC TCCACTGGAG GCCCTGCTCT CTGACCTCTT CCGGGACCCG 300
 GACCACTGTC GCCAGGCCTA CTCTGTCTAT GCCTTCATGA TCAGTCTTGG GGGCTGCCTG 360
 GGCTACCTCC TGCTGCCAT TGACTGGGAC ACCAGTGCCC TGGCCCCCTA CCTGGGCACC 420
 CAGGAGGAGT GCCTCTTTGG CCTGCTCACC CTCATCTTCC TCACCTGCGT AGCAGCCACA 480
 CTGCTGGTGG CTGAGGAGGC AGCGCTGGGC CCCACCGAGC CAGCAGAAGG GCTGTGGGCC 540
 CCTCCTTGT CGCCCCACTG CTGTCCATGC CGGGCCCGCT TGGCTTTCCG GAACCTGGGC 600

```

GCCCTGCTTC CCCGGCTGCA CCAGCTGTGC TGCCGCATGC CCCGCACCCT GCGCCGGCTC 660
TTCGTGGCTG AGCTGTGCAG CTGGATGGCA CTCATGACCT TCACGCTGTT TTACACGGAT 720
TTCGTGGGCG AGGGGCTGTA CCAGGGCGTG CCCAGAGCTG AGCCGGGCAC CGAGGCCCCG 780
AGACACTATG ATGAAGGCGT TCGGATGGGC AGCCTGGGGC TGTTCCTGCA GTGCGCCATC 840
TCCCTGGTCT TCTCTCTGGT CATGGACCGG CTGGTGCAGC GATTCGGCAC TCGAGCAGTC 900
TATTTGGCCA GTGTGGCAGC TTCCCTGTG GCTGCCGGTG CCACATGCCT GTCCACAGT 960
GTGGCCGTGG TGACAGCTTC AGCCGCCCTC ACCGGGTTC CCTTCTCAGC CCTGCAGATC 1020
CTGCCCTACA CACTGGCCTC CCTCTACCAC CGGGAGAAGC AGGTGTTCTT GCCCAAATAC 1080
CGAGGGGACA CTGGAGGTGC TAGCAGTGAG GACAGCCTGA TGACCAGCTT CCTGCCAGGC 1140
CCTAAGCCTG GAGCTCCCTT CCCTAATGGA CACGTGGGTG CTGGAGGCAG TGGCCTGCTC 1200
CCACCTCCAC CCGCGCTCTG CGGGGCCTCT GCCTGTGAtG TCTCCGTACG TGTGGTGGTG 1260
GGTGAAGCCA CCGAGGCCAG GGTGGTTCCG GGCCGGGGCA TCTGCCTGGA CCTCGCCATC 1320
CTGGATAGTG CCTTCCTGCT GTCCAGGTG GCCCCATCCC TGTATTATGG CTCCATTGTC 1380
CAGCTCAGCC AGTCTGTCAC TGCCTATATG GTGTCTGCCG CAGGCCTGGG TCTGGTCCGC 1440
ATTTACTTTG CTACACAGGT AGTATTTGAC AAGAGCGACT TGGCCAAATA CTCAGCGggt 1500
ggacaccatc accatcacca ttaa 1524

```

Construct 3 - Coding sequence of natssP501₁₋₃₄ P501₅₁₋₅₅₃ HIS (yeast strain Y1800)

Protein sequence (SEQ ID NO:31)

```

                                R1      R2
MAAVQRLWVSRLLRHRKAQLLLVNLLTFGLEVCLAAAYVHSDGSYPKDKFEKINGTW
                                R3      R4      R5
YYFDSSGYMLADRWRKHTDGNWYWFDNSGEMATGWKKIADKWYYFNEEGAMKTGWVK
                                P2      R6
YKDTWYYLDAKEGAMQYIKANSKFIGITEGVMVSNAFIQSADGTGWYYLKPDGTLADRPEKFMY
MVLGIGPVLGLVCVPLLGSASDHWRGRYGRRRPFIWALSGLLSLFLIPRAGWLAGLLCPDPRPLEL
ALLILGVGLLDFCGQVCFTPLEALLSDLFRDPDHCRQAYSVYAFMISLGGCLGYLLPAIDWDTSALAP
YLGTQEECLFGLLTLIFLTCVAATLLVAEEAALGPTEPAEGLSAPSLSPHCCPCRARLAFRNLGALLPR
LHQLCCRMPTLRLRFV AELCSWMALMTFTLFYTFDFVGEGLYQGVPRAEPTARRHYDEGVRMG
SLGLFLQCAISLVFSLVMDRLVQRFGTRAVYLASVAAPVAAGATCLSHSVAVVTASAALTGFTFSA
LQILPYTLASLYHREKQVFLPKYRGDTGGASSEDLSMTSFLPGPKPGAPFPNGHV GAGGSGLPPPPA
LCGASACDVSVRVVVGEPTARVVPGRGICLDLAILDSAFLLSQVAPSLFMGSIVQLSQSVTAYMVS
AAGLGLVAIFYFATQVVFDKSDLAKYSAGGHHHHHH

```

R1 (plain): aa38-42 (fragment)

R4 (bold): aa77-106

P2 (underline): 130-143

R2 (bold): aa43-64

R5 (plain): aa107-126

R3 (plain): aa65-76

R6a (bold): aa127-128

R6b (bold): aa146-166

natss stands for native signal sequence

Nucleotide sequence (SEQ ID NO:32)

ATGgcGGCCGTGCAGAGGCTATGGGTATCGAGACTGCTAAGACACCGCAAAGCTCAGTTGTTGTTGGTTAACT
 TGTGACCTTCGGGCTGGAAGTCTGTTTGGCg9ccgctTACGTACATTCCGACGGCTCTTATCCAAAAGACAA
 GTTTGAGAAAATCAATGGCACTTGGTACTACTTTGACAGTTCAGGCTATATGCTTGACAGCCGCTGGAGGAAG
 CACACAGACGGCAACTGGTACTGGTTCGACAACCTCAGGCGAAATGGCTACAGGCTGGAAGAAAATCGCTGATA
 AGTGGTACTATTTCAACGAAGAAGGTGCCATGAAGACAGGCTGGGTCAAGTACAAGGACACTTGGTACTACTT
 AGACGCTAAAGAAGGCGCCatgcaatacatcaaggctaactctaagttcattggtatcactgaaggcgctcATG
 GTATCAAATGCCTTTATCCAGTCAGCGGACGGAACAGGCTGGTACTACCTCAAACCAGACGGAACACTGGCAG
 ACAGGCCAGAAaagttcatgtaCatgGTGCTGGGCATTGGTCCAGTGCTGGGCCCTGGTCTGTGTCCCGCTCCT
 AGGCTCAGCCAGTGACCACTGGCGTGGACGCTATGGCCGCCCGGCCCTTCATCTGGGCACTGTCTTGGGC
 ATCCTGCTGAGCCTCTTTCTCATCCCAAGGGCCGGCTGGCTAGCAGGGCTGCTGTGCCCGGATCCCAGGCCCC
 TGGAGCTGGCACTGCTCATCTGGGCGTGGGGCTGCTGGACTTCTGTGGCCAGGTGTCTTCACTCCACTGGA
 GGCCCTGCTCTCTGACCTCTTCCGGGACCCGGACCACTGTGCGCAGGCCTACTCTGTCTATGCCTTCATGATC
 AGTCTTGGGGGCTGCCTGGGCTACCTCCTGCCTGCCATTGACTGGGACACCAGTGCCCTGGCCCCCTACCTGG
 GCACCCAGGAGGAGTGCCCTCTTTGGCCTGCTCACCTCATCTTCTCACCTGCGTAGCAGCCACACTGCTGGT
 GGCTGAGGAGGCAGCGCTGGGCCCCACCGAGCCAGCAGAAGGGCTGTGGCCCCCTCCTTGTGCCCCACTGC
 TGTCATGCCGGGCCCCGCTTGGCTTTCCGGAACCTGGGCGCCCTGCTTCCCCGGCTGCACCAGCTGTGCTGCC
 GCATGCCCCGCACCCTGCGCCGGCTCTTCGTGGCTGAGCTGTGCAGCTGGATGGCACTCATGACCTTCACGCT
 GTTTTACACGGATTTCTGTGGGCGAGGGGCTGTACCAGGGCGTGCCAGAGCTGAGCCGGGCACCGAGGCCCCGG
 AGACACTATGATGAAGGCGTTTCGGATGGGCAGCCTGGGGCTGTTCCCTGCAGTGCGCCATCTCCCTGGTCTTCT
 CTCTGGTTCATGGACCGGCTGGTGCAGCGATTCCGGCACTCGAGCAGTCTATTTGGCCAGTGTGGCAGCTTTCCC
 TGTGGCTGCCGGTGCCACATGCCTGTCCACAGTGTTGGCCGTGGTGACAGCTTCAGCCGCCCTCACCGGGTTC
 ACCTTCTCAGCCCTGCAGATCCTGCCCTACACACTGGCCTCCCTCTACCACCGGAGAAGCAGGTGTTCTCTGC
 CCAAATACCGAGGGGACACTGGAGGTGCTAGCAGTGAGGACAGCCTGATGACCAGCTTCTGCCAGGCCCTAA
 GCCTGGAGCTCCCTTCCCTAATGGACACGTGGGTGCTGGAGGAGTGCCCTGCTCCACCTCCACCGCGCTC
 TGCGGGGCTCTGCTGTGAtGTCTCCGTACGTGTGGTGGTGGGTGAGCCACCGAGGCCAGGGTGGTTCCGG
 GCCGGGGCATCTGCTGGACCTCGCCATCCTGGATAGTGCTTCTGCTGTCCCAGGTGGCCCCATCCCTGTT
 TATGGGCTCCATTGTCCAGCTCAGCCAGTCTGTCACTGCCTATATGGTGTCTGCCGAGGCCTGGGTCTGGTC
 GCCATTTACTTTGCTACACAGGTAGTATTTGACAAGAGCGACTTGGCCAAATACTCAGCGggtggacaccatc
 accatcaccattaa

Construct 4 - Coding sequence of alphapreCPC-P501₅₁₋₅₅₃ HIS (yeast strain Y1802)

Protein sequence (SEQ ID NO:33)

Alpha-pre	signal	R1	R2	R3
MAARFPSIFTAVLFAASSALAAAYVHSDGSYPKDKFEKINGTWYIFDSSGYMLADRWRKHTDGNWYWFD				
R4		R5	P2	
NSGEMATGWKKIADKWYFFNEEGAMKTGWVKYKDTWYYLDAKEGAMQYIKANSKFIGITEGVMVSNAPF				

R6

QSADGTGWYLYLKPDGTLADRPEKFMVMVLGIGPVLGLVCVPLLGSASDHWGRYGRRRPFIWALSGLILLSLF
 LIPRAGWLAGLLCPDPRPLELALLILGVGLLDFCGQVCFTPLEALLSDLFRDPDHCRQAYSVYAFMISLGGCL
 GYLLPAIDWDTSALAPYLGTQECLFGLLTLIFLTCVAATLLVAEEAALGPTEPAEGLSAPSLSPHCCPCRAR
 LAFRNLGALLPRLHQLCCRMPTLRRLFVAELCSWMALMTFTLFYTFVGEGLYQGVPRAEFGTEARRHYDEG
 VRMGSGLFLQCAISLVFSLVMDRLVQRFQTRAVYLASVAAFPVAAGATCLSHSVAVVTASAALTGFTFSALQ
 ILPYTLASLYHREKQVFLPKYRGDTGGASEDSLMTSFLPGPKPGAPFPNGHVGAGGSGLLPPPPALCGASAC
 DVSVRVVVGEPTEARVVPGRGICLDLAILDSAFLLSQVAPSLFMGSIVQLSQSVTAYMVAAGLGLVAIYFAT
 QVVFDKSDLAKYSAGGHHHHHH

Alpha-pre signal (bold): aa4-22

R1 (plain): aa24-28 (fragment)

R4 (bold): aa72-91

P2 (underline): 116-129

R2 (bold): aa29-49

R5 (plain): aa92-112

R3 (plain): aa50-71

R6a (bold): aa113-114

R6b (bold): aa132-152

Alphapre stands for alpha pre signal sequence

Nucleotide sequence (SEQ ID NO:34)

TACGTACATTCCGACGGCTCTTATCCAAAAGACAAGTTTGAGAAAATCAATGGCACTTGGTACTACTTTGACA
 GTTCAGGCTATATGCTTGCAGACCGCTGGAGGAAGCACACAGACGGCAACTGGTACTGGTTCGACAACCTCAGG
 CGAAATGGCTACAGGCTGGAAGAAAATCGCTGATAAGTGGTACTATTTCAACGAAGAAGGTGCCATGAAGACA
 GGCTGGGTCAAGTACAAGGACACTTGGTACTACTTAGACGCTAAAGAAGGCGCCatgcaatacatcaaggcta
 actctaagttcattggtatcactgaaggcgctcATGGTATCAAATGCCTTTATCCAGTCAGCGGACGGAACAGG
 CTGGTACTACCTCAAACCAGACGGAACACTGGCAGACAGGCCAGAA

ATGgcGGCCAGATTTCCTTCAATTTTACTGCAGTTTATTTCGCAGCATCCTCCGCATTAGCggccgctTACG
 TACATTCCGACGGCTCTTATCCAAAAGACAAGTTTGAGAAAATCAATGGCACTTGGTACTACTTTGACAGTTC
 AGGCTATATGCTTGCAGACCGCTGGAGGAAGCACACAGACGGCAACTGGTACTGGTTCGACAACCTCAGGCGAA
 ATGGCTACAGGCTGGAAGAAAATCGCTGATAAGTGGTACTATTTCAACGAAGAAGGTGCCATGAAGACAGGCT
 GGGTCAAGTACAAGGACACTTGGTACTACTTAGACGCTAAAGAAGGCGCCatgcaatacatcaaggctaactc
 taagttcattggtatcactgaaggcgctcATGGTATCAAATGCCTTTATCCAGTCAGCGGACGGAACAGGCTGG
 TACTACCTCAAACCAGACGGAACACTGGCAGACAGGCCAGAAgctggtattacttacgttcaccattggtgt
 tggaggttggtgtgaagaaaagttcatgtaCatgGTGCTGGGCATTGGTCCAGTGCTGGGCCTGGTCTGTGT
 CCGCTCCTAGGCTCAGCCAGTGACCACTGGCGTGGACGCTATGGCCGCCCGGCCCTTCATCTGGGCACTG
 TCCTTGGGCATCCTGCTGAGCCTCTTCTCATCCCAAGGGCCGGCTGGCTAGCAGGGCTGCTGTGCCCCGATC
 CCAGGCCCTGGAGCTGGCACTGCTCATCTGGGCGTGGGGCTGCTGGACTTCTGTGGCCAGGTGTGCTTCAC
 TCCACTGGAGGCCCTGCTCTCTGACCTCTTCCGGGACCCGGACCACTGTGCGCCAGGCCTACTCTGTCTATGCT
 TCATGATCAGTCTTGGGGGCTGCCTGGGCTACCTCCTGCCTGCCATTGACTGGGACACCAGTGCCCTGGCCCC
 CTACCTGGGCACCCAGGAGGAGTGCTCTTTGGCCTGCTCACCTCATCTTCTCACCTGCGTAGCAGCCACA

CTGCTGGTGGCTGAGGAGGCAGCGCTGGGCCCCACCGAGCCAGCAGAAGGGCTGTGCGCCCCCTCCTTGTGCGC
 CCCACTGTGTCCATGCCGGGCCCCGCTTGGCTTTCGGGAACCTGGGCGCCCTGCTTCCCCGGCTGCACCAGCT
 GTGTGCGCCGATGCCCCGCACCCTGCGCCGGCTCTTCGTGGCTGAGCTGTGCAGCTGGATGGCACTCATGACC
 TTCACGCTGTTTTACACGGATTTCTGTGGGCGAGGGGCTGTACCAGGGCGTGCCAGAGCTGAGCCGGGCACCG
 AGGCCCCGAGACACTATGATGAAGGCGTTCGGATGGGCAGCCTGGGGCTGTTCCTGCAGTGCGCCATCTCCCT
 GGTCTTCTCTCTGGTCATGGACCGGCTGGTGCAGCGATTCCGGCACTCGAGCAGTCTATTTCGCCAGTGTGGCA
 GCTTTCCTGTGGCTGCCGGTGCCACATGCCTGTCCACAGTGTGGCCGTGGTGACAGCTTCAGCCGCCCTCA
 CCGGGTTACCTTCTCAGCCCTGCAGATCCTGCCCTACACACTGGCCTCCCTCTACCACCGGGAGAAGCAGGT
 GTTCCTGCCCAAATACCGAGGGGACACTGGAGGTGCTAGCAGTGAGGACAGCCTGATGACCAGCTTCTGCCA
 GGCCCTAAGCCTGGAGCTCCCTTCCCTAATGGACACGTGGGTGCTGGAGGCAGTGGCCTGTCCACCTCCAC
 CCGCGCTCTGCGGGGCCCTCTGCCTGTGATGTCTCCGTACGTGTGGTGGTGGGTGAGCCACCGAGGCCAGGGT
 GGTTCCGGGCCGGGGCATCTGCCTGGACCTCGCCATCCTGGATAGTGCCCTTCCTGCTGTCCAGGTGGCCCCA
 TCCCTGTTTATGGGCTCCATTGTCCAGCTCAGCCAGTCTGTCACTGCCTATATGGTGTCTGCCGAGGCCTGG
 GTCTGGTCCGCATTTACTTTGCTACACAGGTAGTATTTGACAAGAGCGACTTGGCCAAATACTCAGCGggtgg
 acaccatcaccatcaccattaa

Construct 5 - Coding sequence of alphaprepro-P501₅₁₋₅₅₃ HIS (in plasmid pRIT 15068 and yeast strain Y1790)

Protein sequence (SEQ ID NO:35)

MSFLNFTAVL FAASSALAAP VNTTTEDETA QIPAEAVIGY SDLEGDFDVA VLPFSNSTNN 60
 GLLFINTTIA SIAAKEEGVS LEKREAEAMV LGIGPVLGLV CVPLLGSASD HWRGRYGRRR 120
 PFIWALSIGI LLSLFLIPRA GWLAGLLCPD PRPLELALLI LGVGLLDFCG QVCFTPLEAL 180
 LSDLFRDPDH CRQAYSVYAF MISLGGCLGY LLPADWDTS ALAPYLGTQE ECLFGLLTLI 240
 FLTCVAATLL VAEEAALGPT EPAEGLSAPS LSPHCCPCRA RLAFRNLGAL LPRHLQLCCR 300
 MPRTLRLRFV AELCSWMALM TFTLFYTDFV GEGLYQGVPR AEPGTEARRH YDEGVRMGSL 360
 GLFLQCAISL VFSLVMDRLV QRFGTRAVYL ASVAAFPVAA GATCLSHSVA VVTASAALTG 420
 FTFSALQILP YTLASLYHRE KQVFLPKYRG DTGGASSEDS LMTSFLPGPK PGAPFPNGHV 480
 GAGGSGLLPP PPALCGASAC DVSVRVVVE PTEARVVPGR GICLDLAILD SAFLLSQVAP 540
 SLFMGSIVQL SQSVTAYMVS AAGLGLVAIY FATQVVFDDK DLAKYSAGGH HHHHH 595

Nucleotide sequence (SEQ ID NO:36)

ATGAGTTTCC TCAATTTTAC TGCAGTTTAA TTCGCAGCAT CCTCCGCATT AGCTGCTCCA 60
 GTCAACACTA CAACAGAAGA TGAAACGGCA CAAATTCCGG CTGAAGCTGT CATCGGTTAC 120
 TCAGATTTAG AAGGGGATTT CGATGTTGCT GTTTTGCCAT TTTCCAACAG CACAAATAAC 180
 GGGTTATGTG TTATAAATAC TACTATTGCC AGCATTGCTG CTAAGAAGA AGGGGTATCT 240
 CTCGAGAAAA GAGAGGCTGA AGCCatgGTG CTGGGCATTG GTCCAGTGCT GGGCCTGGTC 300
 TGTGTCCCGC TCCTAGGCTC AGCCAGTGAC CACTGGCGTG GACGCTATGG CCGCCGCCGG 360

CCCTTCATCT GGGCACTGTC CTTGGGCATC CTGCTGAGCC TCTTTCTCAT CCCAAGGGCC 420
 GGCTGGCTAG CAGGGCTGCT GTGCCCAGAT CCCAGGCCCC TGGAGCTGGC ACTGCTCATC 480
 CTGGGCGTGG GGCTGCTGGA CTTCTGTGGC CAGGTGTGCT TCACTCCACT GGAGGCCCTG 540
 CTCTCTGACC TCTTCCGGGA CCCGGACCAC TGTCGCCAGG CCTACTCTGT CTATGCCTTC 600
 ATGATCAGTC TTGGGGGCTG CCTGGGCTAC CTCCTGCCTG CCATTGACTG GGACACCAGT 660
 GCCCTGGCCC CCTACCTGGG CACCCAGGAG GAGTGCCTCT TTGGCCTGCT CACCCTCATC 720
 TTCCTCACCT GCGTAGCAGC CACACTGCTG GTGGCTGAGG AGGCAGCGCT GGGCCCCACC 780
 GAGCCAGCAG AAGGGCTGTC GGCCCCCTCC TTGTCGCCCC ACTGCTGTCC ATGCCGGGCC 840
 CGCTTGGCTT TCCGGAACCT GGGCGCCCTG CTTCCTCCGC TGCACCAGCT GTGCTGCCGC 900
 ATGCCCCGCA CCCTGCGCCG GCTCTTCGTG GCTGAGCTGT GCAGCTGGAT GGCACTCATG 960
 ACCTTCACGC TGTTTTACAC GGATTTCTGT GCGGAGGGGC TGTACCAGGG CGTGCCCGA 1020
 GCTGAGCCGG GCACCGAGGC CCGGAGACAC TATGATGAAG GCGTTCGGAT GGGCAGCCTG 1080
 GGGCTGTTCC TGCAGTGCGC CATCTCCCTG GTCTTCTCTC TGGTCATGGA CCGGCTGGTG 1140
 CAGCGATTCT GCACTCGAGC AGTCTATTG GCCAGTGTGG CAGCTTTCCC TGTGGCTGCC 1200
 GGTGCCACAT GCCTGTCCCA CAGTGTGGCC GTGGTGACAG CTTTCAGCCGC CCTCACCAGG 1260
 TTCACCTTCT CAGCCCTGCA GATCCTGCCC TACACACTGG CCTCCCTCTA CCACCGGGAG 1320
 AAGCAGGTGT TCCTGCCCAA ATACCGAGGG GACACTGGAG GTGCTAGCAG TGAGGACAGC 1380
 CTGATGACCA GCTTCCTGCC AGGCCCTAAG CCTGGAGCTC CCTTCCCTAA TGGACACGTG 1440
 GGTGCTGGAG GCAGTGGCCT GCTCCACCT CCACCCGCGC TCTGCGGGGC CTCTGCCTGT 1500
 GATGTCTCCG TACGTGTGGT GGTGGGTGAG CCCACCGAGG CCAGGCTGGT TCCGGGCCGG 1560
 GGCATCTGCC TGGACCTCGC CATCCTGGAT AGTGCCTTCC TGCTGTCCCA GGTGGCCCCA 1620
 TCCCTGTTTA TGGGCTCCAT TGTCCAGCTC AGCCAGTCTG TCACTGCCCTA TATGGTGTCT 1680
 GCCGCAGGCC TGGGTCTGGT CGCCATTTAC TTTGCTACAC AGGTAGTATT TGACAAGAGC 1740
 GACTTGGCCA AATACTCAGC Gggtggacac catcaccatc accattaa 1788

FIG. 3. Structure of CPC-p501 His fusion protein expressed in *S. cerevisiae*




FIG. 4. Primary structure of CPC-P501 His fusion protein (SEQ ID NO.41)

```

MAAAYVHSDG SYPKDKFEKI NGTWYFDSS GYMLADRWRK HTDGNWYWFD NSGEMATGWK 60
KIADKWYYFN EEGAMKTGWV KYKDTWYYLD AKEGAMQYIK ANSKFIGITE GVMVSNAPIQ 120
SADGTGWYYL KPDGTLADRP EKFMVMVLGI GPVLGLVCVP LLGSASDHWR GRYGRRRPFI 180
WALSLGILLS LFLIPRAGWL AGLLCPDPRP LELALLILGV GLLDFCGQVC FTPLEALLSD 240
LFRDPDHCRQ AYSVYAFMIS LGGCLGYLLP AIDWDTSALA PYLGTQEECL FGLLTLIFLT 300
CVAATLLVAE EAALGPTEPA EGLSAPSLSP HCCPCRARLA FRNLGALLPR LHQLCCRMPR 360
TLRRLFVAEL CSWMALMTFT LFYTDFVGEG LYQGVPRAEF GTEARRHYDE GVRMGSLGLF 420
LQCAISLVFS LVMDRLVQRF GTRAVYLASV AAFPVAAGAT CLSHSVAVVT ASAALTGFTF 480
SALQILPYTL ASLYHREKQV FLPKYRGDTG GASSEDSLMT SFLPGPKPGA PFPNGHVAG 540
GSGLLPPPPA LCGASACDVS VRVVVGEPTE ARVVPGRGIC LDLAILDSAF LLSQVAPSLF 600
MGSIVQLSQS VTAYMVSAAG LGLVAIYFAT QVVFDKSDLA KYSAGGHHHH HH 652

```

FIG. 5. Nucleotide sequence of CPC P501 His(pRIT15201) (SEQ ID NO.42)

```

ATGGCGGCCG CTTACGTACA TTCCGACGGC TCTTATCCAA AAGACAAGTT TGAGAAAATC 60
AATGGCACTT GGTACTACTT TGACAGTTCA GGCTATATGC TTGCAGACCG CTGGAGGAAG 120
CACACAGACG GCAACTGGTA CTGGTTTCGAC AACTCAGGCG AAATGGCTAC AGGCTGGAAG 180
AAAATCGCTG ATAAGTGGTA CTATTTCAAC GAAGAAGGTG CCATGAAGAC AGGCTGGGTC 240
AAGTACAAGG ACACTTGGTA CTACTTAGAC GCTAAAGAAG GCGCCATGCA ATACATCAAG 300
GCTAACTCTA AGTTCATTGG TACTACTGAA GGCGTCATGG TATCAAATGC CTTTATCCAG 360
TCAGCGGACG GAACAGGCTG GTACTACCTC AAACCAGACG GAACACTGGC AGACAGGCCA 420
GAAAAGTTCA TGTACATGGT GCTGGGCATT GGTCCAGTGC TGGGCCTGGT CTGTGTCCCG 480
CTCCTAGGCT CAGCCAGTGA CCACTGGCGT GGACGCTATG GCCGCCGCCG GCCCTTCATC 540
TGGGCACTGT CCTTGGGCAT CCTGCTGAGC CTCTTTCTCA TCCAAGGGC CGGCTGGCTA 600
GCAGGGCTGC TGTCCCCGGA TCCCAGGCCC CTGGAGCTGG CACTGCTCAT CCTGGGCGTG 660
GGGCTGCTGG ACTTCTGTGG CCAGGTGTGC TTCCTCCAC TGGAGGCCCT GCTCTCTGAC 720
CTCTTCCGGG ACCCGGACCA CTGTCGCCAG GCCTACTCTG TCTATGCCTT CATGATCAGT 780
CTTGGGGGCT GCCTGGGCTA CCTCCTGCCT GCCATTGACT GGGACACCAG TGCCCTGGCC 840
CCCTACCTGG GCACCCAGGA GGAGTGCCTC TTTGGCCTGC TCACCCTCAT CTTCTCACC 900
TGCGTAGCAG CCACACTGCT GGTGGCTGAG GAGGCAGCGC TGGGCCCCAC CGAGCCAGCA 960
GAAGGGCTGT CGGCCCCCTC CTTGTCGCCC CACTGCTGTC CATGCCGGGC CCGCTTGGCT 1020
TTCCGGAACC TGGGCGCCCT GCTTCCCCGG CTGCACCAGC TGTGCTGCCG CATGCCCCGC 1080
ACCTTGCGCC GGCTCTTCGT GGCTGAGCTG TGCAGCTGGA TGGCACTCAT GACCTTCACG 1140
CTGTTTTACA CGGATTTCTG GGGCGAGGGG CTGTACCAGG GCGTGCCCAG AGCTGAGCCG 1200
GGCACCGAGG CCCGGAGACA CTATGATGAA GGCGTTCGGA TGGGCAGCCT GGGGCTGTTC 1260
CTGCAGTGCG CCATCTCCCT GGTCTTCTCT CTGGTCATGG ACCGGCTGGT GCAGCGATTC 1320
GGCACTCGAG CAGTCTATTT GGCCAGTGTG GCAGCTTTCC CTGTGGCTGC CGGTGCCACA 1380
TGCCTGTCCC ACAGTGTGGC CGTGGTGACA GCTTCAGCCG CCCTCACCAG GTTCACCTTC 1440
TCAGCCCTGC AGATCCTGCC CTACACACTG GCCTCCCTCT ACCACCGGGA GAAGCAGGTG 1500
TTCTGCCCCA AATACCGAGG GGACACTGGA GGTGCTAGCA GTGAGGACAG CCTGATGACC 1560
AGCTTCCTGC CAGGCCCTAA GCCTGGAGCT CCCTTCCCTA ATGGACACGT GGGTGTCTGGA 1620
GGCAGTGGCC TGCTCCCACC TCCACCCGCG CTCTGCGGGG CCTCTGCCTG TGATGTCTCC 1680
GTACGTGTGG TGGTGGGTGA GCCCACCGAG GCCAGGGTGG TTCCGGGCCG GGGCATCTGC 1740
CTGGACCTCG CCATCCTGGA TAGTGCCTTC CTGCTGTCCC AGGTGGCCCC ATCCCTGTTT 1800
ATGGGCTCCA TTGTCCAGCT CAGCCAGTCT GTCAGTGCCT ATATGGTGTC TGCCGCAGGC 1860
CTGGGTCTGG TCGCCATTTA CTTTGCTACA CAGGTAGTAT TTGACAAGAG CGACTTGGCC 1920
AAATACTCAG CGGGTGGACA CCATCACCAT CACCATTAA 1959

```

FIG. 6. Cloning strategy for generation of plasmid pRIT 15201




FIG. 7. Plasmid map of pRIT15201





FIG. 8. Comparative expression of CPC P501 and P501 in *S.cerevisiae* strain DC5 (gel Laemmli 10%)



- 1 MW Biolabs (175/83/62/47.5/32.5/16.5 Kda)
- 2 Y1796 purified
- 3 Y1795 Crude Extract (negative control)
- 4 SC333 Crude Extract
- 5 Y1796 Crude Extract
- 6 Y1790 Crude Extract
- 7 Y1802 Crude Extract

FIG. 9A.





FIG. 9B.



- 1 - Molecular Weight Marker (Biolabs - Grow Range) 175; 83; 62; 47.5; 32.5; 25; 16.5; 6.5 kD - 10
- 2 - Purified Reference CP2CP501S/12 135 ng
- 3 - Purified Reference CP2CP501S/12 67.8 ng
- 4 - Purified Reference CP2CP501S/12 33.9 ng
- 5 - Purified Reference CP2CP501S/12 16.9 ng
- 6 - Fermentation PRO119-21h30
- 7 - Fermentation PRO124-21h30
- 8 - Fermentation PRO124-22h30
- 9 - Fermentation PRO127-0 h
- 10 - Fermentation PRO127-4 h
- 11 - Fermentation PRO127-6 h
- 12 - Fermentation PRO127-22h20
- 13 - Fermentation PRO127-22h45

FIG. 10. Purification scheme of CPC-P501-His produced by Y1796.

<i>S. Cerevisiae</i> cells	
↓	
Dyno-mill disruption	OD 120 / 2 passes / 20 mM Tris pH 8.5 - 5 mM EDTA
↓	
Centrifugation	12.000 g / RT / 90 min (supernatant discarded)
↓	
Pellet washing step 1	20 mM Tris pH 8.5 - 0.15 M NaCl - 2.0 M Guanidine.HCl - 0.1% Empigen (30 min / RT)
↓	
Centrifugation	12.000 g / RT / 60 min (supernatant discarded)
↓	
Pellet washing step 2	20 mM Tris pH 8.5 - 0.15 M NaCl - 4.0 M Urea
↓	
Centrifugation	12.000 g / RT / 30 min (supernatant discarded)
↓	
Solubilisation / Reduction	20 mM Tris pH 8.5 - 0.15 M NaCl - 8.0 M Urea - 1% SDS - 0.2 M Glutathion (60 min / RT)
↓	
Centrifugation	12.000 g / RT / 30 min (pellet discarded)
↓	
Carbamidomethylation	0.3 M Iodoacetamide (30 min / RT / in the dark) / pH adjusted to 8.5 (with 5 M NaOH solution) before incubation
↓	
R/C Supernatant	
↓	
10-fold dilution and pH adjustment (8.5)	<u>Dilution buffer</u> : 20 mM Tris pH 8.5 - 1 M NaCl - 8.0 M Urea
↓	
Immobilised metal ion affinity chromatography on Ni⁺⁺-Chelating Sepharose FF (Amersham) (10x25 cm column – 2000 ml)	<u>Equilibration buffer</u> : 20 mM Tris pH 8.5 - 0.9 M NaCl - 8.0 M Urea - 0.1% SDS <u>Washing buffers</u> : 1) Equilibration buffer 2) 20 mM Tris pH 8.5 - 0.15 M NaCl - 8.0 M Urea - 0.1% SDS 3) 20 mM Tris pH 8.5 - 8.0 M Urea - 0.1% Tween 80

	<u>Elution buffer:</u> 20 mM Tris pH 8.5 - 8.0 M Urea - 0.1% Tween 80 - 0.5 M Imidazole
↓	
2-fold dilution and pH adjustment (10.0)	20 mM Piperazine pH 10.0 - 8.0 M Urea - 0.1% Tween 80
↓	
Anion exchange chromatography on Q Sepharose FF (Amersham) (2,6 x 6.5 cm column - 35 ml)	<u>Equilibration buffer:</u> 20 mM Piperazine pH 10.0 - 8.0 M Urea - 0.1% Tween 80 <u>Washing buffers:</u> 1) Equilibration buffer 2) 20 mM Tris pH 8.5 - 8.0 M Urea - 0.1% Tween 80 <u>Elution buffer:</u> 20 mM Tris pH 7.5 - 8.0 M Urea - 0.1% Tween 80 - 0.5 M NaCl
↓	
Concentration/Diafiltration (Pall - Omega 10 kDa - 200 cm ²)	+/- 3-fold concentration <u>Diafiltration buffer:</u> Tris 20 mM pH 7.5
↓	
Sterile filtration (Millipore - Millex GV 0.22µm)	
↓	
Purified bulk	<u>Final buffer:</u> 20 mM Tris pH 7.5 - +/- 0.3% Tween 80
↓	
Storage -20°C	

FIG. 11. Pattern of CPC P501 His purified protein (4-12% Novex Nu-Page polyacrylamide precasted gels)




FIG. 12. Native full-length P501S sequence (SEQ ID NO:17 & 43)

Nucleotide sequence: SEQ ID NO.17

Polypeptide sequence: SEQ ID NO.43

```

#####
GCCACCATGGTCCAGAGGCTGTGGGTGAGCCGCTGCTGCGGCACCGG
      M V Q R L W V S R L L R H R   14

AAAGCCCAGCTCTTGCTGGTCAACCTGCTAACCTTTGGCCTGGAGGTGTGTTTGGCCGCA
K A Q L L L V N L L T F G L E V C L A A   34

GGCATCACCTATGTGCCGCTCTGCTGCTGGAAGTGGGGGTAGAGGAGAAGTTCATGACC
G I T Y V P P L L L E V G V E E K F M T   54

ATGGTGTGCGGCATTGGTCCAGTGTGGGCTGGTCTGTGTCCCGCTCCTAGGCTCAGCC
M V L G I G P V L G L V C V P L L G S A   74

AGTGACCACTGGCGTGGACGCTATGGCCGCCGCCGCCCTTCATCTGGGCACTGTCTTTG
S D H W R G R Y G R R R P F I W A L S L   94

GGCATCTGTGAGCCTCTTTCTCATCCCAAGGGCCGGCTGGCTAGCAGGGCTGCTGTGC
G I L L S L F L I P R A G W L A G L L C   114

CCGGATCCCAGGCCCTGGAGCTGGCACTGCTCATCTGGGCGTGGGGCTGCTGGACTTC
P D P R P L E L A L L I L G V G L L D F   134

TGTGGCCAGGTGTGCTTCACTCCACTGGAGGCCCTGCTCTCTGACCTCTTCCGGGACCCG
C G Q V C F T P L E A L L S D L F R D P   154

GACCACTGTGCCCAGGCCTACTCTGTCTATGCCTTCATGATCAGTCTTGGGGGCTGCCTG
D H C R Q A Y S V Y A F M I S L G G C L   174

GGCTACCTCCTGCCTGCCATTGACTGGGACACCAGTGGCCTGGCCCCCTACCTGGGCACC
G Y L L P A I D W D T S A L A P Y L G T   194

CAGGAGGAGTGCCTCTTTGGCCTGCTCACCCTCATCTTCCTCACCTGCGTAGCAGCCACA
Q E E C L F G L L T L I F L T C V A A T   214

CTGCTGGTGGCTGAGGAGGCAGCGCTGGGCCCCACCGAGCCAGCAGAAGGGCTGTGCGGC
L L V A E E A A L G P T E P A E G L S A   234

CCCTCCTTGTGCGCCCACTGCTGTCCATGCCGGGCCCGCTTGGCTTTCCGGAACCTGGGC
P S L S P H C C P C R A R L A F R N L G   254

GCCCTGCTTCCCCGCTGCACCAGCTGTGCTGCCGCATGCCCGCACCCCTGCGCCGGCTC
A L L P R L H Q L C C R M P R T L R R L   274

TTCGTGGCTGAGCTGTGCAGCTGGATGGCACTCATGACCTTCACGCTGTGTTTACACGGAT
F V A E L C S W M A L M T F T L F Y T D   294

TTCGTGGGCGAGGGGCTGTACCAGGGCGTGCCAGAGCTGAGCCGGGCACCGAGGCCCGG
F V G E G L Y Q G V P R A E P G T E A R   314

AGACACTATGATGAAGGCGTTCCGATGGGCAGCCTGGGGCTGTTCTGTCAGTGCGCCATC
R H Y D E G V R M G S L G L F L Q C A I   334

TCCCTGGTCTTCTCTCTGTCATGGACCGGCTGGTGCAGCGATTCCGGCACTCGAGCAGTC
S L V F S L V M D R L V Q R F G T R A V   354

```

TATTTGGCCAGTGTGGCAGCTTTCCCTGTGGCTGCCGGTGCCACATGCCTGTCCCACAGT
 Y L A S V A A F P V A A G A T C L S H S 374

 GTGGCCGTGGTGACAGCTTCAGCCGCCCTCACC GGTTACCTTCTCAGCCCTGCAGATC
 V A V V T A S A A L T G F T F S A L Q I 394

 CTGCCCTACACACTGGCCTCCCTCTACCACCGGAGAAGCAGGTGTTCTGCCCAAATAC
 L P Y T L A S L Y H R E K Q V F L P K Y 414

 CGAGGGGACACTGGAGGTGCTAGCAGTGAGGACAGCCTGATGACCAGCTTCCTGCCAGGC
 R G D T G G A S S E D S L M T S F L P G 434

 CCTAAGCCTGGAGCTCCCTTCCCTAATGGACACGTGGGTGCTGGAGGCAGTGGCCTGCTC
 P K P G A P F P N G H V G A G G S G L L 454

 CCACCTCCACCCGCGCTCTGCGGGGCCTCTGCCTGTGATGTCTCCGTACGTGTGGTGGTG
 P P P P A L C G A S A C D V S V R V V V 474

 GGTGAGCCCACCGAGGCCAGGGTGGTTCCGGGCCGGGCATCTGCCTGGACCTCGCCATC
 G E P T E A R V V P G R G I C L D L A I 494

 CTGGATAGTGCCTTCCTGCTGTCCCAGGTGGCCCCATCCCTGTTTATGGGCTCCATTGTC
 L D S A F L L S Q V A P S L F M G S I V 514

 CAGCTCAGCCAGTCTGTCACTGCCTATATGGTGTCTGCCGCAGGCCTGGGTCTGGTGCCTC
 Q L S Q S V T A Y M V S A A G L G L V A 534

 ATTTACTTTTGCTACACAGGTAGTATTTGACAAGAGCGACTTGGCCAAATACTCAGCGTAG
 I Y F A T Q V V F D K S D L A K Y S A * 554

 GTCGAG

FIG. 13. Sequence of the CPC-P501S expression cassette of JNW735 (SEQ ID NO:18 & 44)

Nucleotide sequence: SEQ ID NO.18

Polypeptide sequence: SEQ ID NO.44

```

#####
GCCACCATGGCGGCCGCTTACGTACATTCCGACGGCTCTTATCCAAAA
      M A A A Y V H S D G S Y P K 14

GACAAGTTTGTAGAAAAATCAATGGCACTTGGTACTACTTTGACAGTTTCAGGCTATATGCTT
D K F E K I N G T W Y Y F D S S G Y M L 34

GCAGACCGCTGGAGGAAGCACACAGACGGCAACTGGTACTGGTTCGACAACTCAGGCGAA
A D R W R K H T D G N W Y W F D N S G E 54

ATGGCTACAGGCTGGAAGAAAATCGCTGATAAGTGGTACTATTTCAACGAAGAAGGTGCC
M A T G W K K I A D K W Y Y F N E E G A 74

ATGAAGACAGGCTGGGTCAAGTACAAGGACACTTGGTACTACTTAGACGCTAAAGAAGGC
M K T G W V K Y K D T W Y Y L D A K E G 94

GCCATGCAATACATCAAGGCTAACTCTAAGTTTCATTGGTATCACTGAAGGCGTCATGGTA
A M Q Y I K A N S K F I G I T E G V M V 114

TCAAATGCCTTTATCCAGTCAGCGGACGGAACAGGCTGGTACTACCTCAAACCAGACGGA
S N A F I Q S A D G T G W Y Y L K P D G 134

ACACTGGCAGACAGGCCAGAAAAGTTTCATGTACATGGTGTGCTGGGCATTGGTCCAGTGCTG
T L A D R P E K F M Y M V L G I G P V L 154

GGCCTGGTCTGTGTCCCGCTCCTAGGCTCAGCCAGTGACCACTGGCGTGGACGCTATGGC
G L V C V P L L G S A S D H W R G R Y G 174

CGCCGCCGCCCTTCATCTGGGCACTGTCTTGGGCATCCTGCTGAGCCTCTTTCTCATC
R R R P F I W A L S L G I L L S L F L I 194

CCAAGGGCCGGCTGGCTAGCAGGCTGCTGTGCCCCGATCCCAGGCCCTTGGAGCTGGCA
P R A G W L A G L L C P D P R P L E L A 214

CTGCTCATCCTGGGCGTGGGGCTGCTGGACTTCTGTGGCCAGGTGTGCTTCACTCCACTG
L L I L G V G L L D F C G Q V C F T P L 234

GAGGCCCTGCTCTCTGACCTCTTCCGGGACCCGACCACTGTGCGCCAGGCCTACTCTGTC
E A L L S D L F R D P D H C R Q A Y S V 254

TATGCCTTCATGATCAGTCTTGGGGCTGCCTGGGCTACCTCCTGCCTGCCATTGACTGG
Y A F M I S L G G C L G Y L L P A I D W 274

GACACCACTGCCCTGGCCCCCTACCTGGGCACCCAGGAGGAGTGCTCTTTGGCCTGCTC
D T S A L A P Y L G T Q E E C L F G L L 294

ACCTCATCTTCTCACTGCGTAGCAGCCACACTGCTGGTGGCTGAGGAGGCAGCGCTG
T L I F L T C V A A T L L V A E E A A L 314

GGCCCCACCGAGCCAGCAGAAGGGCTGTGCGCCCCCTCCTTGTGCCCCCACTGCTGTCCA
G P T E P A E G L S A P S L S P H C C P 334

```

TGCCGGGCGCTTGGCTTTCCGGAACCTGGGCGCCCTGCTTCCCCGGCTGCACCAGCTG
 C R A R L A F R N L G A L L P R L H Q L 354
 TGCTGCCGCATGCCCCGCACCCTGCGCCGGCTCTTCGTGGCTGAGCTGTGCAGCTGGATG
 C C R M P R T L R R L F V A E L C S W M 374
 GCACTCATGACCTTCACGCTGTTTTACACGGATTTTCGTGGGCGAGGGGCTGTACCAGGGC
 A L M T F T L F Y T D F V G E G L Y Q G 394
 GTGCCCAGAGCTGAGCCGGGCACCGAGGCCCGGAGACACTATGATGAAGGCGTTCCGGATG
 V P R A E P G T E A R R H Y D E G V R M 414
 GGCAGCCTGGGGCTGTTCTGTCAGTGCGCCATCTCCCTGGTCTTCTCTCTGGTCATGGAC
 G S L G L F L Q C A I S L V F S L V M D 434
 CGGCTGGTGCAGCGATTCCGGCACTCGAGCAGTCTATTTGGCCAGTGTGGCAGCTTTCCCT
 R L V Q R F G T R A V Y L A S V A A F P 454
 GTGGCTGCCGGTGCCACATGCCTGTCCACAGTGTGGCCGTGGTGACAGCTTCAGCCGCC
 V A A G A T C L S H S V A V V T A S A A 474
 CTCACCGGGTTACCTTCTCAGCCCTGCAGATCCTGCCCTACACACTGGCCTCCCTCTAC
 L T G F T F S A L Q I L P Y T L A S L Y 494
 CACCGGGAGAAGCAGGTGTTCTGCCCCAAATACCGAGGGGACACTGGAGGTGCTAGCAGT
 H R E K Q V F L P K Y R G D T G G A S S 514
 GAGGACAGCCTGATGACCAGCTTCTGCCCAGGCCCTAAGCCTGGAGCTCCCTTCCCTAAT
 E D S L M T S F L P G P K P G A P F P N 534
 GGACACGTGGGTGCTGGAGGCAGTGGCCTGCTCCACCTCCACCCGCGCTCTGCGGGGCC
 G H V G A G G S G L L P P P P A L C G A 554
 TCTGCCTGTGATGTCTCCGTACGTGTGGTGGTGGGTGAGCCCACCGAGGCCAGGGTGGTT
 S A C D V S V R V V V G E P T E A R V V 574
 CCGGGCCGGGGCATCTGCCTGGACCTCGCCATCCTGGATAGTGCCTTCTGCTGTCCCAG
 P G R G I C L D L A I L D S A F L L S Q 594
 GTGGCCCCATCCCTGTTTATGGGCTCCATTGTCCAGCTCAGCCAGTCTGTCACTGCCTAT
 V A P S L F M G S I V Q L S Q S V T A Y 614
 ATGGTGTCTGCCGAGGCCTGGGTCTGGTGCCTTTACTTTGCTACACAGGTAGTATTT
 M V S A A G L G L V A I Y F A T Q V V F 634
 GACAAGAGCGACTTGGCCAAATACTCAGCGTAGGTCGAG
 D K S D L A K Y S A * 645

FIG. 14 – Codon optimised P501S sequences (SEQ ID NO:19-20)**SEQ ID NO:19**

ATGGTGCAGCGGCTCTGGGTGAGCCGCTCCTGCGGCATCGCAAGGCCAGCTCCTGCTGGTGAATCTGCTCA
 CATTGCGCCTGGAGGTGTGCTGGCCGCGGCATCACCTACGTGCCCCCTCCTGCTGGAGGTGGGAGTCGA
 GGAGAAGTTCATGACCATGGTGTGGGCATTGGGCCCCGTCTGGGCCTCGTGTGCGTGCCCTCTCCTCGGCAGC
 GCTTCGACCATTTGGCGCGGCCGTATGGCCGAGGAGACCCCTTCATCTGGGCTCTGAGTCTCGGCATCCTGC
 TGAGCCTGTTCTGATCCCTCGGGCCGGCTGGCTGGCCGGGCTGCTGTGCCCCGATCCTCGGCCCTGGAGCT
 GGCCCTGCTGATCCTCGGCGTGGGCTGCTGGACTTCTGCGGCCAGGTGTGCTTCACGCCCCCTGGAGGCACTG
 CTGAGCGACCTGTTCCGGGACCCGACCATTGCCGCCAGGCGTACAGCGTGTACGCCCTTCATGATCTCCCTGG
 GAGGCTGCTGGGCTACCTGCTCCCCGCCATCGATTGGGACACCAGCGCACTCGCCCCCTATCTCGGAACACA
 GGAGGAATGCCCTGTTTCGGATTGTTGACGCTCATCTTCCTCACGTGCGTCGCGGCCACCCTGTTGGTGGCCGAG
 GAGGCCGCCCTGGGGCCACCGAGCCGGCCGAGGGACTGAGCGCCCCGAGCCTGAGTCCCACTGCTGCCCTT
 GCCGGGCCCCGCTGGCCCTTCGTAATCTGGGCGCCCTCCTGCCTCGGCTCCATCAGCTGTGTTGCAGAATGCC
 TAGGACGCTGCGGCGCCTGTTCTGTCGCTGAGTTGTGCTCCTGGATGGCTCTCATGACCTTCACCCTGTTTTAT
 ACGGACTTCGTCGGGGAGGGCCTGTACCAGGGGTGCCGCGCGCCGAGCCCGGGACAGAGGCGCGCCGCCACT
 ACGACGAGGGAGTGCATGAGGCTCCCTGGGCCTCTTCTTGCACTGCGCCATCAGTCTGGTTTTCTCTCTGGT
 CATGGACAGGCTGGTGCAGCGCTTCGGAACCCGGGCGGTGTACCTGGCGAGCGTGGCCGCCCTTCCCCGTGGCT
 GCCGGCGCCACCTGCCTCTCTCACTCGGTGGCCGTGGTACCGCCAGCGCCGCCCTGACCGGGTTACCTTCT
 CTGCCCTGCAGATTCTGCCTTACACCCTGGCCAGCCTGTACCATCGCGAGAAACAGGTGTTTCTCCCAAGTA
 CAGAGGCGACACCGGGGGCGCTCCAGCGAGGACAGCCTCATGACCTCCTTCTGCTGGCCCCAAGCCCGGC
 GCCCCCTTCCCAACGGGCACGTGGGCGCGGCGGGAGTGGGCTCCTGCCCCCCCCCTCTGCGCTGTGCGGGG
 CCAGCGCCTGCGACGTGAGCGTGGCGGTGGTGGTGGGCGAGCCACCGAGGCCCGCGTGGTGGCGGGCAGAGG
 CATTTGTCTGGACCTGGCCATCCTCGACTCCGCCCTTCTCCTCAGCCAGGTGGCCCCCTCCCTCTTCATGGGC
 TCTATCGTCCAGCTGTCTCAGAGCGTCACCGCTTACATGGTGTCCGCTGCTGGACTGGGCTTGGTGGCTATTT
 ATTTGCCACCCAGGTGGTGTTCGACAAGAGCGACCTGGCCAAATACTCCGCCTGA

SEQ ID NO:20

ATGGTGCAGCGGCTGTGGGTGTCCCGCTGCTGCGCCATAGAAAGGCCAGTTGCTGCTGGTGAACCTGCTGA
 CTTTTCGGACTGGAGGTGTGCTGGCTGCCGGGATCACGTACGTGCCCCCTCCTGCTGCTGGAGGTGGGCGTGA
 GGAGAAGTTCATGACAATGGTGTGGGCATCGGCCCGCTCCTGGGCCTCGTGTGTGTGCCCTCCTCGGGAGT
 GCGTCCGATCATTTGGCGGGGCCGTACGGCCGCCGAGACCGTTTCATCTGGGCCCTGAGCCTGGGGATCCTGC
 TCTCTCTCTCCTGATCCCCGGGCGGCTGGCTGGCCGGCCTGCTGTGTCCGACCCCCGCCCTCTGGAGCT
 GGCCCTCCTGATCCTGGGCGTGGGCTTGTGGACTTCTGCGGCCAGGTGTGTTTCACTCCCCCTGGAGGCTCTG
 CTCTCCGACCTCTTCCGCGACCCGACCCTGTAGGCAGGCTTACAGCGTGTACGCCCTTCATGATCAGTCTGG

GGGGATGCCTGGGCTATCTGCTGCCCCGTATCGACTGGGACACCAGCGCCCTGGCCCCCTACCTGGGGACTCA
GGAGGAGTGCCCTGTTCCGGCCTGCTCACCTTGATCTTCCTGACGTGCGTCGCCGCCACCCTGCTGGTGGCCGAG
GAGGCGGCCCTGGGGCCACCGAGCCCGCCGAGGGCCTGAGCGCTCCCAGCCTGAGCCCCCATTGCTGCCCCGT
GCAGGGCTAGGCTCGCCTTCAGGAATCTGGGCGCTTTGCTGCCCCCGCTGCATCAGCTGTGCTGTGCGCATGCC
TCGCACCCTGCGCCGCTGTTTCGTGCTGAGCTCTGTTCCCTGGATGGCCCTGATGACGTTACCCCTCTTCTAC
ACCGACTTCGTGGGGAGGGCCTGTACCAGGGCGTGCCAGGGCCGAGCCCGGCACCGAGGCTAGGCGCCATT
ACGACGAGGGCGTCAGGATGGGCTCTCTGGGCCTCTTCCTGCAGTGCGCCATCAGTCTGGTGTCTCTCTGGT
GATGGACCGGCTGGTGCAGCGCTTCGGCACCCGGGCGGTGTACCTCGCCTCTGTGGCGGCTTTCCCCGTGCC
GCCGGCGCGACCTGCCTGTCTCATTCTGTGCGCGTGGTGACCGCCAGCGCCGCCCTGACCGGCTTCACCTTCA
GTGCGCTCCAGATTCTGCCCTACACCCTGGCGTCTCTGTACCATCGCGAGAAGCAGGTGTTCTGCCCAAGTA
CCGCGGGGACACAGGGGGAGCTTCCTCTGAGGACAGCCTGATGACCAGCTTCCTGCCCCGGCCCCAAGCCGGG
GCCCCCTTCCCCAACGGCCATGTGCGGGCGGGCGGCAGCGGCCTGCTCCCTCCCCCCCCCGCCCTGTGCGGCG
CTAGTGCTGCGACGTGAGCGTGCGGGTGGTGGTGGGGAGCCCACCGAGGCTAGGGTCGTGCCTGGCCGGG
GATCTGCCTGGACCTGGCCATCCTCGACTCCGCCTTCCTGCTCTCCAGGTGGCGCCAGCCTGTTTCATGGGC
AGTATCGTGCGAGCTGAGCCAGAGCGTGACCGCCTACATGGTGAGCGCCGCCGCTGGGGTTGGTGGCCATCT
ACTTTGCCACCCAGGTCGTGTTTCGACAAGAGCGATCTCGCCAAGTATAGCGCCTGA

FIG. 15 – Re-engineered codon optimised sequence 19 (SEQ ID NO:21)

GACGGCTAGCGCCACCATGGTGCAGCGGCTCTGGGTGAGCCGCCCTCTGCGGCATCGCAAGGCCAGCTCCTG
 CTGGTGAATCTGCTCACATTTCGGCCTGGAGGTGTGCTGGCCGCCGGCATCACCTACGTGCCCCCTCCTGC
 TGGAGGTGGGAGTCGAGGAGAAGTTCATGACCATGGTGTCTGGGCATTGGGCCCCGTCTGGGCCCTCGTGTGCGT
 GCCTCTCCTCGGCAGCGCTTCCGACCATTGGCGCGGCCGGTATGGCCGCAGGAGACCCTTCATCTGGGCTCTG
 AGTCTCGGCATCCTGCTGAGCCTGTTCTGATCCCTCGGGCCGGCTGGCTGGCCGGGCTGCTGTGCCCCGATC
 CTCGGCCCCCTGGAGCTGGCCCTGCTGATCCTCGGCGTGGGCCTGCTGGACTTCTGCGGCCAGGTGTGCTTCAC
 GCCCCCTGGAGGCACTGCTGAGCGACCTGTTCCGGGACCCCGACCATTGCCGCCAGGCGTACAGCGTGTACGCC
 TTCATGATCTCCCTGGGAGGCTGCCTGGGCTACCTGCTCCCCGCCATCGATTGGGACACCAGCGCACTCGCCC
 CCTATCTCGGAACACAGGAGGAATGCCTGTTTCGGA[]TG[]TGACGCTCATCTTCCTCACGTGCGTCGCGGCCAC
 CCTGTTGGTGGCCGAGGAGGCCGCCCTGGGGCCCCAGAGCCGGCCGAGGGACTGAGCGCCCCGAGCCTGAGT
 CCACACTGCTGCCCCTGCGGGGCCCGCCTGGCCTTCCGTAATCTGGGCGCCCTCCTGCCTCGGCTCCATCAGC
 TGTGTTGCAGAATGCCTAGGACGCTGCGGCGCCTGTTCTGTCGCTGAGTTGTGCTCCTGGATGGCTCTCATGAC
 CTTACCCCTGTTTTATACGGA[]TTCGTCGGGGAGGGCCTGTACAGGGGGTGCCGCGCGCCGAGCCCCGGGACA
 GAGGCGCGCCGCACTACGACGAGGGAGTGCATGAGGCTCCCTGGGCTCTTCTTGCAGTGCGCCATCAGTC
 TGGTTTTCTCTCTGGTCATGGACAGGCTGGTGCAGCGCTTCGGAACCCGGGCGGTGTACCTGGCGAGCGTGGC
 CGCCTTCCCCGTGGCTGCCGGCGCCACCTGCCTCTCTCACTCGGTGGCCGTGGTCACCGCCAGCGCCGCCCTG
 ACCGGGTTACCTTCTCTGCCCTGCAGATTCTGCCTTACACCTGGCCAGCCTGTACCATCGCGAGAAACAGG
 TGTTTTCTCCCAAGTACAGAGGCGACACCGGGGGCGCCTCCAGCGAGGACAGCCTCATGACCTCCTTCCTGCC
 TGGCCCCAAGCCCGGCGCCCCCTTCCCAACGGGCACGTGGGCGCCGGCGGGAGTGGGCTCCTGCCCCCCCCCT
 CCTGCGCTGTGCGGGGCCAGCGCCTGCGACGTGAGCGTGC[]CGTGGTGGTGGGCGAGCCCACCGAGGCCCGCG
 TGGTGCCGGGCAGAGGCATTTGTCTGGACCTGGCCATCCTCGACTCCGCTTCTCCTCAGCCAGGTGGCCCC
 GTCCCTCTTCATGGGCTCTATCGTCCAGCTGTCTCAGAGCGTCACCGCTTACATGGTGTCCGCTGCTGGACTG
 GGCTTGGTGGCTATTTATTTGCGCACCCAGGTGGTGTTCGACAAGAGCGACCTGGCCAAATACTCCGCTGAC
 TCGAGGCAG

FIG. 16 – Re-engineered codon optimised sequence 20 (SEQ ID NO:22)

GACGGCTAGCGCCACCATGGTGCAGCGGCTGTGGGTGTCCCGGCTGCTGCGCCATAGAAAGGCCCCAGTTGCTG
 CTGGTGAACCTGCTGACTTTCGGACTGGAGGTGTGCCTGGCTGCCGGGATCACGTACGTGCCCCCCTGCTGC
 TGGAGGTGGGCGTGGAGGAGAAGTTCATGACAATGGTGTGGGCATCGGCCCCGTCTGGGCCTCGTGTGTGT
 GCCCCCTCCTCGGGAGTGCCTCCGATCATTGGCGGGGCCGCTACGGCCGCCGACACCGTTTCATCTGGGCCCTG
 AGCCTGGGCTATCCTGCTCTCTCTCTCCTGATCCCCCGGGCCGGCTGGCTGGCCGGCCTGCTGTGTCCCCGACC
 CCCCCCTCTGGAGCTGGCCCTCCTGATCCTGGGCGTGGGCTGCTGGACTTCTGCGGCCAGGTGTGTTTCAC
 TCCCCCTGGAGGCTCTGCTCTCCGACCTCTTCCGCGACCCGACCACTGTAGGCAGGCTTACAGCGTGTACGCC
 TTCATGATCAGTCTGGGGGGATGCCTGGGCTATCTGCTGCCCCGCTATCGACTGGGACACCAGCGCCCTGGCCC
 CCTACCTGGGGACTCAGGAGGAGTGCCTGTTCCGGCCTGCTCACCTTGATCTTCTGACGTGCGTCGCCGCCAC
 CCTGCTGGTGGCCGAGGAGGCGGCCCTGGGGCCACCGAGCCCGCCGAGGGCCTGAGCGCTCCCAGCCTGAGC
 CCCCATTGCTGCCCCGTGCAGGGCTAGGCTCGCCTTCAGGAATCTGGGCGCTTTGCTGCCCCGCCTGCATCAGC
 TGTGCTGTGCGATGCCCTGCACCTGCGCCGCTGTTCTGCTGAGCTCTGTTCTGGATGGCCCTGATGAC
 GTTACCCCTCTTCTACACCGACTTCGTGGGGGAGGGCCTGTACCAGGGCGTGCCAGGGCCGAGCCCGGCACC
 GAGGCTAGGCGCCATTACGACGAGGGCGTCAGGATGGGCTCTCTGGGCCTCTTCTGTCAGTGCGCCATCAGTC
 TGGTGTCTCTCTGCTGATGGACCGGCTGGTGCAGCGCTTCGGCACCCGGGCGGTGTACCTCGCCTCTGTGGC
 GGCTTTCCCCGTGCGCCGCGGCGGACCTGCCTGTCTCATTTCTGTCGCCGTGGTGACCGCCAGCGCCGCCCTG
 ACCGGCTTCACCTTCAGTGCCTCCAGATTCTGCCCTACACCTTGGCGTCTCTGTACCATCGCGAGAAGCAGG
 TGTTCTTGCCTCAAGTACCGCGGGGACACAGGGGGAGCTTCTCTGAGGACAGCCTGATGACCAGCTTCTTGCC
 CGGCCCCAAGCCGGGGGCCCCCTTCCCCAACGGCCATGTGGGGCGGGCGGCGAGCGGCCTGCTCCCTCCCCC
 CCGCCCTGTGCGGCGCTAGTGCCTGCGACGTGAGCGTGGGGTGGTGGTGGGGAGCCCCACCGAGGCTAGGG
 TCGTGCCTGGCCGGGGATCTGCCTGGACCTGGCCATCCTCGACTCCGCCTTCTGCTCTCCCAGGTGGCGCC
 CAGCCTGTTTCATGGGCAGTATCGTGCAGCTGAGCCAGAGCGTGACCGCCTACATGGTGAGCGCCGCCGGCCTG
 GGGTTGGTGGCCATCTACTTTGCCACCCAGGTGCTGTTTCGACAAGAGCGATCTCGCCAAGTATAGCGCCTGAC
 TCGAGGCAG

FIG. 17 – The starting sequence for the optimisation of CPC (SEQ ID NO:23)

Four amino acids of P501S sequence are boxed.

ATGGCGCCCGCTTACGTACATTCCGACGGCTCTTATCCAAAAGACAAGTTTGAGAAAATCAATGGCACTTGGT
 ACTACTTTGACAGTTTCAGGCTATATGCTTGACAGCCGCTGGAGGAAGCACACAGACGGCAACTGGTACTGGTT
 CGACAACTCAGGCGAAATGGCTACAGGCTGGAAGAAAATCGCTGATAAGTGGTACTATTTCAACGAAGAAGGT
 GCCATGAAGACAGGCTGGGTCAAGTACAAGGACACTTGGTACTACTTAGACGCTAAAGAAGGCGCCATGCAAT
 ACATCAAGGCTAACTCTAAGTTCATTGGTATCACTGAAGGCGTCATGGTATCAAATGCCTTTATCCAGTCAGC
 GGACGGAACAGGCTGGTACTACCTCAAACCAGACGGAACACTGGCAGACAGGCCAGAAAGTTCATGTAC

FIG. 18 – Representative codon optimised CPC sequences (SEQ ID NO:24-25)**SEQ ID NO:24**


ATGGCCCGCCCTACGTGCATAGCGACGGGAGCTACCCCAAGGACAAGTTCGAGAAGATCAACGGGACATGGT
 ACTACTTCGACTCCTCCGGCTACATGCTCGCCGACCGCTGGCGGAAGCACACCGACGGCAACTGGTACTGGTT
 CGATAACTCGGGAGAGATGGCCACCGGCTGGAAGAAGATCGCGGACAAGTGGTACTATTTCAACGAGGAGGGC
 GCCATGAAGACCGGCTGGGTGAAGTATAAGGACACCTGGTACTACCTCGACGCCAAGGAGGGCGCCATGCAGT
 ATATCAAGGCCAACAGCAAGTTCATCGGCATCACCGAGGGAGTGATGGTCAGCAACGCCTTTATCCAGAGCGC
 CGACGGCACCGGATGGTACTACTTGAAGCCGACGGCACCCCTCGCGGATCGGCCCCGAGAAGTTCATGTAC

SEQ ID NO:25

ATGGCCCGCCCTACGTGCACAGCGACGGGTCTTACCCAAAGGACAAGTTCGAGAAGATCAACGGCACGTGGT
 ACTATTTGACAGCAGCGGCTACATGCTCGCCGATCGCTGGCGCAAGCACACCGACGGGAAGTGGTACTGGTT
 CGACAACTCTGGCGAGATGGCTACGGGGTGAAGAAGATCGCCGACAAGTGGTACTACTTCAACGAGGAGGGC
 GCCATGAAGACCGGCTGGGTGAAGTACAAGGACACCTGGTACTACCTGGACGCTAAGGAGGGCGCCATGCAGT
 ACATCAAGGCCAACTCGAAGTTCATCGGGATCACCGAGGGCGTGATGGTCAGTAACGCCTTTATCCAGAGCGC
 GGACGGCACAGGCTGGTATTACCTGAAGCCCGATGGCACCCCTGGCGGACAGACCTGAGAAATTCATGTAC

FIG. 19 – Engineered CPC codon optimised sequence (SEQ ID NO:26)**SEQ ID NO:26**

GACGGCTAGCGCCACCATGGCCCGCCCTACGTGCATAGCGACGGGAGCTACCCCAAGGACAAGTTCGAGAAG
 ATCAACGGGACATGGTACTACTTCGACTCCTCCGGCTACATGCTCGCCGACCGCTGGCGGAAGCACACCGACG
 GCAACTGGTACTGGTTCGATAACTCGGGAGAGATGGCCACCGGCTGGAAGAAGATCGCGGACAAGTGGTACTA
 TTTCAACGAGGAGGGCGCCATGAAGACCGGCTGGGTGAAGTATAAGGACACCTGGTACTACCTCGACGCCAAG
 GAGGGCGCCATGCAGTATATCAAGGCCAACAGCAAGTTCATCGGCATCACCGAGGGAGTGATGGTCAGCAACG
 CCTTTATCCAGAGCGCCGACGGCACCGGATGGTACTACTTGAAGCCGGACGGCACCCCTCGCGGATCGGCCCCG
GAAGTTCATGTACTGACTCGAGGCAG

FIG. 20 – P501S CPC fusion candidate constructs and sequences**Construct A = SEQ ID NO:37 (nucleotide) & 45 (polypeptide)**

GCGGCCGCGCCACCATGGCCGCGCCTACGTGCATAGCGACGGGAGCTACCCCAAGGACA
 M A A A Y V H S D G S Y P K D K
 AGTTCGAGAAGATCAACGGGACATGGTACTACTTCGACTCCTCCGGCTACATGCTCGCCG
 F E K I N G T W Y Y F D S S G Y M L A D
 ACCGCTGGCGGAAGCACACCGACGGCAACTGGTACTGGTTCGATAACTCGGGAGAGATGG
 R W R K H T D G N W Y W F D N S G E M A
 CCACCGGCTGGAAGAAGATCGCGGACAAGTGGTACTATTTCAACGAGGAGGGCGCCATGA
 T G W K K I A D K W Y Y F N E E G A M K
 AGACCGGCTGGGTGAAGTATAAGGACACCTGGTACTACCTCGACGCCAAGGAGGGCGCCA
 T G W V K Y K D T W Y Y L D A K E G A M
 TGCAGTATATCAAGGCCAACAGCAAGTTCATCGGCATCACCGAGGGAGTGATGGTCAGCA
 Q Y I K A N S K F I G I T E G V M V S N
 ACGCCTTTATCCAGAGCGCCGACGGCACCGGATGGTACTACTTGAAGCCGGACGGCACCC
 A F I Q S A D G T G W Y Y L K P D G T L
 TCGCGGATCGGCCCCGAGAAGTTCATGTACATGGTGCTGGGCATCGGCCCCGTCTGGGCC
 A D R P E K F M Y M V L G I G P V L G L
 TCGTGTGTGTGCCCCCTCCTCGGGAGTGCGTCCGATCATTGGCGGGGCGCTACGGCCGCC
 V C V P L L G S A S D H W R G R Y G R R
 GCAGACCGTTCATCTGGGCCCTGAGCCTGGGCATCCTGCTCTCTCTCTCCTGATCCCCC
 R P F I W A L S L G I L L S L F L I P R
 GGGCCGGCTGGCTGGCCGGCCTGCTGTGTCCCGACCCCCGCCCTCTGGAGCTGGCCCTCC
 A G W L A G L L C P D P R P L E L A L L
 TGATCCTGGGCGTGGGCCTGCTGGACTTCTGCGGCCAGGTGTGTTTCACTCCCCTGGAGG

I L G V G L L D F C G Q V C F T P L E A
 CTCTGCTCTCCGACCTCTTCCGCGACCCCGACCACTGTAGGCAGGCTTACAGCGTGACG
 L L S D L F R D P D H C R Q A Y S V Y A
 CCTTCATGATCAGTCTGGGGGATGCCTGGGCTATCTGCTGCCCCGCTATCGACTGGGACA
 F M I S L G G C L G Y L L P A I D W D T
 CCAGCGCCCTGGCCCCCTACCTGGGGACTCAGGAGGAGTGCCTGTTCCGGCCTGCTCACCT
 S A L A P Y L G T Q E E C L F G L L T L
 TGATCTTCCTGACGTGCGTCGCCGCCACCCTGCTGGTGGCCGAGGAGGCGGCCCTGGGGC
 I F L T C V A A T L L V A E E A A L G P
 CCACCGAGCCCGCCGAGGGCCTGAGCGCTCCCAGCCTGAGCCCCATTGCTGCCCGTGCA
 T E P A E G L S A P S L S P H C C P C R
 GGGCTAGGCTCGCCTTCAGGAATCTGGGCGCTTTGCTGCCCCGCTGCATCAGCTGTGCT
 A R L A F R N L G A L L P R L H Q L C C
 GTCGCATGCCTCGCACCCCTGCGCCGCTGTTGCTGCTGAGCTCTGTTCTGGATGGCCCC
 R M P R T L R R L F V A E L C S W M A L
 TGATGACGTTACCCCTCTTCTACACCGACTTCGTGGGGGAGGGCCTGTACCAGGGCGTGC
 M T F T L F Y T D F V G E G L Y Q G V P
 CCAGGGCCGAGCCCGGCACCGAGGCTAGGCGCCATTACGACGAGGGCGTCAGGATGGGCT
 R A E P G T E A R R H Y D E G V R M G S
 CTCTGGGCCTCTTCTGCGAGTGCGCCATCAGTCTGGTGTCTCTCTGCTGATGGACCGGC
 L G L F L Q C A I S L V F S L V M D R L
 TGGTGACGCGCTTCGGCACCCGGGCGGTGTACCTCGCCTCTGTGGCGGCTTTCCCCGTCG
 V Q R F G T R A V Y L A S V A A F P V A
 CGCCGGGCGCGACCTGCCTGTCTCATTCTGTGCGCGTGGTGACCGCCAGCGCCGCCCTGA
 A G A T C L S H S V A V V T A S A A L T
 CCGGCTTCACCTTCAGTGCCTCCAGATTCTGCCCTACACCCTGGCGTCTCTGTACCATC
 G F T F S A L Q I L P Y T L A S L Y H R
 GCGAGAAGCAGGTGTTCTGCCCCAAGTACCGCGGGGACACAGGGGGAGCTTCCTCTGAGG
 E K Q V F L P K Y R G D T G G A S S E D
 ACAGCCTGATGACCAGCTTCTTGCCCGGCCCAAGCCGGGGGGCCCTTTCCCCAACGGCC
 S L M T S F L P G P K P G A P F P N G H
 ATGTGCGGGGCGGGCGGCAGCGGCCTGCTCCCTCCCCCCCCCGCCTGTGCGGCGCTAGTG
 V G A G G S G L L P P P P A L C G A S A
 CCTGCGACGTGAGCGTGCGGGTGGTGGTGGGGGAGCCCCACCGAGGCTAGGGTCTGCTGCTG
 C D V S V R V V V G E P T E A R V V P G
 GCCGGGGGATCTGCCTGGACCTGGCCATCCTCGACTCCGCCTTCCTGCTCTCCAGGTGG
 R G I C L D L A I L D S A F L L S Q V A
 CGCCAGCCTGTTTCATGGGCGAGTATCGTGCAGCTGAGCCAGAGCGTGACCGCTACATGG
 P S L F M G S I V Q L S Q S V T A Y M V

TGAGCGCCGCCCGCCTGGGGTTGGTGGCCATCTACTTTGCCACCCAGGTGCTGTTTCGACA
 S A A G L G L V A I Y F A T Q V V F D K

AGAGCGATCTCGCCAAGTATAGCGCCTGAGGATCC
 S D L A K Y S A *

Construct B = SEQ ID NO:38 (nucleotide) & 46 (polypeptide)

GCGGCCGCGCCACCATGGCCGCCCTACGTGCATAGCGACGGGAGCTACCCCAAGGACA
 M A A A Y V H S D G S Y P K D K

AGTTCGAGAAGATCAACGGGACATGGTACTACTTTCGACTCCTCCGGCTACATGCTCGCCG
 F E K I N G T W Y Y F D S S G Y M L A D

ACCGCTGGCGGAAGCACACCGACGGCAACTGGTACTGGTTCGATAACTCGGGAGAGATGG
 R W R K H T D G N W Y W F D N S G E M A

CCACCGGCTGGAAGAAGATCGCGGACAAGTGGTACTATTTCAACGAGGAGGGCGCCATGA
 T G W K K I A D K W Y Y F N E E G A M K

AGACCGGCTGGGTGAAGTATAAGGACACCTGGTACTACCTCGACGCCAAGGAGGGCGCCA
 T G W V K Y K D T W Y Y L D A K E G A M

TGCAGTATATCAAGGCCAACAGCAAGTTCATCGGCATCACCAGGGAGTGATGGTCAGCA
 Q Y I K A N S K F I G I T E G V M V S N

ACGCCTTTATCCAGAGCGCGGACCGGATGGTACTACTTGAAGCCGGACGGCACCC
 A F I Q S A D G T G W Y Y L K P D G T L

TCGCGGATCGGCCCCGAGATGGTGCAGCGGCTGTGGGTGTCCCGGCTGCTGCGCCATAGAA
 A D R P E M V Q R L W V S R L L R H R K

AGGCCCCAGTTGCTGCTGCTGAACCTGCTGACTTTCGGACTGGAGGTGTGCCTGGCTGCCG
 A Q L L L V N L L T F G L E V C L A A G

GGATCACGTACGTGCCCCCCTGCTGCTGGAGGTGGGCGTGGAGGAGAAGTTTCATGACAA
 I T Y V P P L L L E V G V E E K F M T M

TGGTGCTGGGCATCGGCCCCGTCCTGGGCCTCGTGTGTGTGCCCTCCTCGGGAGTGCGT
 V L G I G P V L G L V C V P L L G S A S

CCGATCATTGGCGGGGCGCTACGGCCGCCGAGACCGTTCATCTGGGCCCTGAGCCTGG
 D H W R G R Y G R R R P F I W A L S L G

GCATCCTGCTCTCTCTCTTCTGATCCCCGGGCGGCTGGCTGGCCGGCCTGCTGTGTC
 I L L S L F L I P R A G W L A G L L C P

CCGACCCCGGCCCTCTGGAGCTGGCCCTCCTGATCCTGGGCGTGGGCCTGCTGGACTTCT
 D P R P L E L A L L I L G V G L L D F C

GCGGCCAGGTGTGTTTCACTCCCTGGAGGCTCTGCTCTCCGACCTCTTCCGCGACCCCG
 G Q V C F T P L E A L L S D L F R D P D

ACCACTGTAGGCAGGCTTACAGCGTGTACGCCCTTCATGATCAGTCTGGGGGGATGCCTGG
 H C R Q A Y S V Y A F M I S L G G C L G

GCTATCTGCTGCCCCGCTATCGACTGGGACACCAGCGCCCTGGCCCCCTACCTGGGGACTC
 Y L L P A I D W D T S A L A P Y L G T Q

AGGAGGAGTGCCTGTTTCGGCCTGCTCACCTTGATCTTCCTGACGTGCGTCGCCGCCACCC
 E E C L F G L L T L I F L T C V A A T L
 TGCTGGTGGCCGAGGAGGCGGCCCTGGGGCCACCGAGCCCGCGAGGGCCTGAGCGCTC
 L V A E E A A L G P T E P A E G L S A P
 CCAGCCTGAGCCCCATTGCTGCCCCGTGCAGGGCTAGGCTCGCCTTCAGGAATCTGGGCG
 S L S P H C C P C R A R L A F R N L G A
 CTTTGCTGCCCCGCCTGCATCAGCTGTGCTGTGCGATGCCTCGCACCTGCGCCGCCTGT
 L L P R L H Q L C C R M P R T L R R L F
 TCGTCGCTGAGCTCTGTTCTGGATGGCCCTGATGACGTTACCCCTCTTCTACACCGACT
 V A E L C S W M A L M T F T L F Y T D F
 TCGTGGGGGAGGGCCTGTACCAGGGCGTGCCAGGGCCGAGCCCGGCACCGAGGCTAGGC
 V G E G L Y Q G V P R A E P G T E A R R
 GCCATTACGACGAGGGCGTCAGGATGGGCTCTCTGGGCCTCTTCTGCACTGCCCATCA
 H Y D E G V R M G S L G L F L Q C A I S
 GTCTGGTGTCTCTCTGTTGATGGACCGCTGGTGCAGCGCTTCGGCACCCGGGCGCTGT
 L V F S L V M D R L V Q R F G T R A V Y
 ACCTCGCCTCTGTGGCGGCTTTCCCCGTGCGCGCCGGCGCGACCTGCCTGTCTCATTCTG
 L A S V A A F P V A A G A T C L S H S V
 TCGCCGTGGTGACCGCCAGCGCCGCCCTGACCGGCTTCACCTTCAGTGCGCTCCAGATTG
 A V V T A S A A L T G F T F S A L Q I L
 TGCCCTACACCTGGCGTCTCTGTACCATCGCGAGAAGCAGGTGTTCTGCCAAGTACC
 P Y T L A S L Y H R E K Q V F L P K Y R
 GCGGGGACACAGGGGAGCTTCTCTGAGGACAGCCTGATGACCAGCTTCTTGCCCGGCC
 G D T G G A S S E D S L M T S F L P G P
 CCAAGCCGGGGCCCCCTTTCCCCAACGCCATGTGCGGGCGGGCGGCAGCGGCTGCTCC
 K P G A P F P N G H V G A G G S G L L P
 CTCCCCCCCCCGCCTGTGCGGCGCTAGTGCCTGCGACGTGAGCGTGCGGGTGGTGGTGG
 P P P A L C G A S A C D V S V R V V V G
 GGGAGCCACCGAGGCTAGGGTCGTGCCTGGCCGGGGGATCTGCCTGGACCTGGCCATCC
 E P T E A R V V P G R G I C L D L A I L
 TCGACTCCGCCTTCCTGCTCTCCAGGTGGCGCCAGCCTGTTTCATGGGCAGTATCGTGC
 D S A F L L S Q V A P S L F M G S I V Q
 AGCTGAGCCAGAGCGTGACCGCCTACATGGTGAGCGCCGCCGCTGGGGTTGGTGGCCA
 L S Q S V T A Y M V S A A G L G L V A I
 TCTACTTTGCCACCCAGGTGCTGTTTCGACAAGAGCGATCTCGCCAAGTATAGCGCCTGAG
 Y F A T Q V V F D K S D L A K Y S A *
 GATCC

Construct C = SEQ ID NO:39 (nucleotide) & 47 (polypeptide)

GCGGCCGCGCCACCATGGCCGCGCCTACGTGCATAGCGACGGGAGCTACCCCAAGGACA
 M A A A Y V H S D G S Y P K D K
 AGTTCGAGAAGATCAACGGGACATGGTACTACTTCGACTCCTCCGGCTACATGCTCGCCG
 F E K I N G T W Y Y F D S S G Y M L A D
 ACCGCTGGCGGAAGCACACCGACGGCAACTGGTACTGGTTCGATAACTCGGGAGAGATGG
 R W R K H T D G N W Y W F D N S G E M A
 CCACCGGCTGGAAGAAGATCGCGGACAAGTGGTACTATTTCAACGAGGAGGGCGCCATGA
 T G W K K I A D K W Y Y F N E E G A M K
 AGACCGGCTGGGTGAAGTATAAGGACACCTGGTACTACCTCGACGCCAAGGAGGGCGCCA
 T G W V K Y K D T W Y Y L D A K E G A M
 TGCAGTATATCAAGGCCAACAGCAAGTTCATCGGCATCACCGAGGGAGTGATGGTCAGCA
 Q Y I K A N S K F I G I T E G V M V S N
 ACGCCTTTATCCAGAGCGCCGACCGGACCGGATGGTACTACTTGAAGCCGGACGGCACCC
 A F I Q S A D G T G W Y Y L K P D G T L
 TCGCGGATCGGCCCCGAGAAGTTCATGTACATGGTGTCTGGGCATCGGCCCCGTCCTGGGCC
 A D R P E K F M Y M V L G I G P V L G L
 TCGTGTGTGTGCCCTCCTCGGGAGTGGCTCCGATCATTGGCGGGCCGCTACGGCCGCC
 V C V P L L G S A S D H W R G R Y G R R
 GCAGACCGTTTCATCTGGGCCCTGAGCCTGGGCATCCTGCTCTCTCTCTTCTGATCCCCC
 R P F I W A L S L G I L L S L F L I P R
 GGGCCGGCTGGCTGGCCGGCCTGCTGTGTCCCGACCCCCGCCCTCTGGAGCTGGCCCTCC
 A G W L A G L L C P D P R P L E L A L L
 TGATCCTGGGCGTGGGCCTGCTGGACTTCTGCGGCCAGGTGTGTTTCACTCCCCTGGAGG
 I L G V G L L D F C G Q V C F T P L E A
 CTCTGCTCTCCGACCTCTTCCGCGACCCCGACCACTGTAGGCAGGCTTACAGCGGTACG
 L L S D L F R D P D H C R Q A Y S V Y A
 CCTTCATGATCAGTCTGGGGGGATGCCTGGGCTATCTGCTGCCCGCTATCGACTGGGACA
 F M I S L G G C L G Y L L P A I D W D T
 CCAGCGCCCTGGCCCCCTACCTGGGGACTCAGGAGGAGTGCCTGTTTCGGCCTGCTACCT
 S A L A P Y L G T Q E E C L F G L L T L
 TGATCTTCTGACGTGCGTCGCGGCCACCCTGCTGGTGGCCGAGGAGGCGGCCCTGGGGC
 I F L T C V A A T L L V A E E A A L G P
 CCACCGAGCCCCGCGAGGGCCTGAGCGCTCCCAGCCTGAGCCCCCATTGCTGCCCGTGCA
 T E P A E G L S A P S L S P H C C P C R
 GGGCTAGGCTCGCCTTCAGGAATCTGGGCGCTTTGCTGCCCCGCTGCATCAGTGTGCT
 A R L A F R N L G A L L P R L H Q L C C
 GTCGCATGCCTCGCACCCCTGCGCCGCTGTTCTGCTGAGCTCTGTTTCTGGATGGCCC
 R M P R T L R R L F V A E L C S W M A L
 TGATGACGTTACCCCTCTTCTACACCGACTTCGTGGGGGAGGGCCTGTACCAGGGCGTGC
 M T F T L F Y T D F V G E G L Y Q G V P

CCAGGGCCGAGCCCGGCACCGAGGCTAGGCGCCATTACGACGAGGGCGTCAGGATGGGCT
 R A E P G T E A R R H Y D E G V R M G S
 CTCTGGGCCTCTTCTGTCAGTGCGCCATCAGTCTGGTGTTCTCTCTGGTGATGGACCGGC
 L G L F L Q C A I S L V F S L V M D R L
 TGGTGCAGCGCTTCGGCACC CGGGCCGTGTACCTCGCCTCTGTGGCGGCTTTCCCCGTCG
 V Q R F G T R A V Y L A S V A A F P V A
 CCGCCGGCGCGACCTGCCTGTCTCATTCTGTGCGCGTGGTGACCGCCAGCGCCGCCCTGA
 A G A T C L S H S V A V V T A S A A L T
 CCGGCTTCACCTTCAGTGCGCTCCAGATTCTGCCCTACACCCTGGCGTCTCTGTACCATC
 G F T F S A L Q I L P Y T L A S L Y H R
 GCGAGAAGCAGGTGTTCTGTCCTGCCCCAAGTACCGCGGGGACACAGGGGGAGCTTCCTCTGAGG
 E K Q V F L P K Y R G D T G G A S S E D
 ACAGCCTGATGACCGAGCTTCTTGCCCCGGCCCCAAGCCGGGGGCCCTTTCCCCAACGGCC
 S L M T S F L P G P K P G A P F P N G H
 ATGTCGGGGCGGGCGGCAGCGGCTGCTCCCTCCCCCCCCCGCCCTGTGCGGCGCTAGTG
 V G A G G S G L L P P P P A L C G A S A
 CCTGCGACGTGAGCGTGCGGGTGGTGGTGGGGAGCCACCGAGGCTAGGGTTCGTGCCTG
 C D V S V R V V V G E P T E A R V V P G
 GCCGGGGGATCTGCCTGGACCTGGCCATCCTCGACTCCGCTTCCTGCTCTCCAGGTGG
 R G I C L D L A I L D S A F L L S Q V A
 CGCCAGCCTGTTTCATGGGCAGTATCGTGCAGCTGAGCCAGAGCGTGACCGCCTACATGG
 P S L F M G S I V Q L S Q S V T A Y M V
 TGAGCGCCGCGCGCCTGGGGTGGTGGCCATCTACTTTGCCACCCAGGTTCGTGTTTCGACA
 S A A G L G L V A I Y F A T Q V V F D K
 AGAGCGATCTCGCCAAGTATAGCGCCATGGTGCAGCGGCTGTGGGTGTCCCGGCTGCTGC
 S D L A K Y S A M V Q R L W V S R L L R
 GCCATAGAAAGGCCAGTTGCTGCTGGTGAACCTGCTGACTTTCGGACTGGAGGTGTGCC
 H R K A Q L L L V N L L T F G L E V C L
 TGGCTGCCGGGATCACGTACGTGCCCCCCTGCTGCTGGAGGTGGGCGTGGAGGAGTGAG
 A A G I T Y V P P L L L E V G V E E *
 GATCC

Construct D = SEQ ID NO:40 (nucleotide) & 48 (polypeptide)

GCGGCCGCGCCACCATGGTGCAGCGGCTGTGGGTGTCCCGGCTGCTGCGCCATAGAAAGG
 M V Q R L W V S R L L R H R K A
 CCCAGTTGCTGCTGGTGAACCTGCTGACTTTCGGACTGGAGGTGTGCCTGGCTGCCGGGA
 Q L L L V N L L T F G L E V C L A A G I
 TCACGTACGTGCCCCCCTGCTGCTGGAGGTGGGCGTGGAGGAGATGGCCGCCGCTACG
 T Y V P P L L L E V G V E E M A A A Y V

TGCATAGCGACGGGAGCTACCCCAAGGACAAGTTCGAGAAGATCAACGGGACATGGTACT
 H S D G S Y P K D K F E K I N G T W Y Y
 ACTTCGACTCCTCCGGCTACATGCTCGCCGACCGCTGGCGGAAGCACACCGACGGCAACT
 F D S S G Y M L A D R W R K H T D G N W
 GGTACTGGTTCGATAACTCGGGAGAGATGGCCACCGGCTGGAAGAAGATCGCGGACAAGT
 Y W F D N S G E M A T G W K K I A D K W
 GGTACTATTTCAACGAGGAGGGCGCCATGAAGACCGGCTGGGTGAAGTATAAGGACACCT
 Y Y F N E E G A M K T G W V K Y K D T W
 GGTACTACCTCGACGCCAAGGAGGGCGCCATGCAGTATATCAAGGCCAACAGCAAGTTCA
 Y Y L D A K E G A M Q Y I K A N S K F I
 TCGGCATCACCGAGGGAGTGATGGTCAGCAACGCCTTTATCCAGAGCGCCGACGGCACCG
 G I T E G V M V S N A F I Q S A D G T G
 GATGGTACTACTTGAAGCCGGACGGCACCCCTCGCGGATCGGCCCGAGAAGTTCATGTACA
 W Y Y L K P D G T L A D R P E K F M Y M
 TGGTGCTGGGCATCGGCCCCGCTCCTGGGCCTCGTGTGTGTGCCCCCTCCTCGGGAGTGCCT
 V L G I G P V L G L V C V P L L G S A S
 CCGATCATTGGCGGGGCGGCTACGGCCGCGCAGACCGTTCATCTGGGCCCTGAGCCTGG
 D H W R G R Y G R R R P F I W A L S L G
 GCATCCTGCTCTCTCTCTTCTGATCCCCCGGGCGGCTGGCTGGCCGGCCTGCTGTGTC
 I L L S L F L I P R A G W L A G L L C P
 CCGACCCCCGCCCCTCTGGAGCTGGCCCTCCTGATCCTGGGCGTGGGCCTGCTGGACTTCT
 D P R P L E L A L L I L G V G L L D F C
 GCGGCCAGGTGTGTTTCACTCCCCCTGGAGGCTCTGCTCTCCGACCTCTTCCGCGACCCCCG
 G Q V C F T P L E A L L S D L F R D P D
 ACCACTGTAGGCAGGCTTACAGCGTGTACGCCTTCATGATCAGTCTGGGGGGATGCCTGG
 H C R Q A Y S V Y A F M I S L G G C L G
 GCTATCTGCTGCCCGCTATCGACTGGGACACCAGCGCCCTGGCCCCCTACCTGGGGACTC
 Y L L P A I D W D T S A L A P Y L G T Q
 AGGAGGAGTGCCTGTTCGGCCTGCTCACCTTGATCTTCCTGACGTGCGTCGCGGCCACCC
 E E C L F G L L T L I F L T C V A A T L
 TGCTGGTGGCCGAGGAGGCGGCCCTGGGGCCCACCGAGCCCGCGAGGGCCTGAGCGCTC
 L V A E E A A L G P T E P A E G L S A P
 CCAGCCTGAGCCCCCATTTGCTGCCCCGTGCAGGGCTAGGCTCGCCTTCAGGAATCTGGGCG
 S L S P H C C P C R A R L A F R N L G A
 CTTTGCTGCCCCGCTGCATCAGCTGTGCTGTGCGATGCCTCGCACCCCTGCGCCGCTGT
 L L P R L H Q L C C R M P R T L R R L F
 TCGTCGCTGAGCTCTGTTCTGGATGGCCCTGATGACGTTACCCCTCTTCTACACCGACT
 V A E L C S W M A L M T F T L F Y T D F
 TCGTGGGGGAGGGCCTGTACCAGGGCGTGCCAGGGCCGAGCCCGGCACCGAGGCTAGGC

V G E G L Y Q G V P R A E P G T E A R R
 GCCATTACGACGAGGGCGTCAGGATGGGCTCTCTGGGCCTCTTCCTGCAGTGCGCCATCA
 H Y D E G V R M G S L G L F L Q C A I S
 GTCTGGTGTCTCTCTGGTGATGGACCGGCTGGTGCAGCGCTTCGGCACC CGGGCCGTGT
 L V F S L V M D R L V Q R F G T R A V Y
 ACCTCGCCTCTGTGGCGGCTTTCCCGCTCGCCGCCGGCGCGACCTGCCTGTCTCATTCTG
 L A S V A A F P V A A G A T C L S H S V
 TCGCCGTGGTGACCGCCAGCGCCGCCCTGACCGGCTTCACCTTCAGTGCCTCCAGATTC
 A V V T A S A A L T G F T F S A L Q I L
 TGCCCTACACCCTGGCGTCTCTGTACCATCGCGAGAAGCAGGTGTTCCCTGCCCAAGTACC
 P Y T L A S L Y H R E K Q V F L P K Y R
 GCGGGGACACAGGGGGAGCTTCCTCTGAGGACAGCCTGATGACCAGCTTCTTGCCCGGCC
 G D T G G A S S E D S L M T S F L P G P
 CCAAGCCGGGGGGCCCCCTTTCCCCAACGGCCATGTGCGGGCGGGCGGCAGCGCCTGCTCC
 K P G A P F P N G H V G A G G S G L L P
 CTCCCCCCCCCGCCCTGTGCGGCGCTAGTGCCCTGCGACGTGAGCGTGCGGGTGGTGGTGG
 P P P A L C G A S A C D V S V R V V V G
 GGGAGCCACCGAGGCTAGGGTCGTGCCTGGCCGGGGGATCTGCCTGGACCTGGCCATCC
 E P T E A R V V P G R G I C L D L A I L
 TCGACTCCGCCTTCCTGCTCTCCCAGGTGGCGCCCAGCCTGTTTCATGGGCAGTATCGTGC
 D S A F L L S Q V A P S L F M G S I V Q
 AGCTGAGCCAGAGCGTGACCGCCTACATGGTGAGCGCCGCCCGCCTGGGGTTGGTGGCCA
 L S Q S V T A Y M V S A A G L G L V A I
 TCTACTTTGCCACCCAGGTGCTGTTTCGACAAGAGCGATCTCGCCAAGTATAGCGCCTGAG
 Y F A T Q V V F D K S D L A K Y S A *
 GATCC

FIG. 21 – Western blot analysis of CHO cells following transient transfection with P501S (JNW680), CPC-P501S (JNW735) and empty vector control.




FIG. 22 – Anti-P501S antibody responses following immunisation at day0, 21 & 42 with pVAC-P501S (JNW680, mice B1-9) or Empty vector (pVAC, mice A1-6).




FIG. 23 – Peptide library screen using C57BL/6 mice immunised at day 0, 21, 42, and 70 with pVAC-P501S (JNW680).




FIG. 24 – Cellular responses by ELISPOT at day 77 following PMID immunisation at day 0, 21, 42, and 70 with pVAC-P501S (JNW680, B6-9) and pVAC empty (A4-6).

Graph A shows the IFN- γ responses whilst Graph B shows the IL-2 responses.




FIG. 25 – Comparison of P501S and CPC-P501S.




FIG. 26 – Immune response (lymphoproliferation on spleen cells) following protein immunisation with CPC-P501S.





FIG. 27 – Evaluation of the immune response to different CPC-P501S constructs

FIG.28. MUC1-CPC DNA and polypeptide sequences**FIG. 28A. DNA sequence (SEQ ID NO.49)**

ATGACACCGGGCACCCAGTCTCCTTTCTTCTGCTGCTGCTCCTCACAGTGCTTACAGTTGTTACAGGTTCTG
 GTCATGCAAGCTCTACCCAGGTGGAGAAAAGGAGACTTCGGCTACCCAGAGAAGTTCAGTGCCAGCTCTAC
 TGAGAAGAATGCTGTGAGTATGACCAGCAGCGTACTCTCCAGCCACAGCCCCGGTTCAGGCTCCTCCACCACT
 CAGGGACAGGATGTCACTCTGGCCCCGGCCACGGAACCAGCTTCAGGTTACAGTGCCACCTGGGGACAGGATG
 TCACCTCGGTCCCAGTCACCAGGCCAGCCCTGGGCTCCACCACCCCGCCAGCCCACGATGTACCTCAGCCCC
 GGACAACAAGCCAGCCCCGGGCTCCACCGCCCCCAGCCCACGGTGTACCTCGGCCCCGGACACCAGGCCGCC
 CCCCCGGGCTCCACCGCCCCCAGCCCACGGTGTACCTCGGCCCCGGACACCAGGCCGCCCGGGCTCCA
 CCGCGCCCCGAGCCCCACGGTGTACCTCGGCCCCGGACACCAGGCCGCCCGGGCTCCACCGCCCCCAGC
 CCATGGTGTACCTCGGCCCCGGACAACAGGCCCGCTTGGCGTCCACCGCCCCCTCAGTCCACAATGTACCC
 TCGGCCTCAGGCTCTGCATCAGGCTCAGCTTCTACTCTGGTGCACAACGGCACCTCTGCCAGGGCTACCACAA
 CCCCAGCCAGCAAGAGCACTCCATTCTCAATCCCAGCCACCACTCTGATACTCCTACCACCCTTGCCAGCCA
 TAGCACCAAGACTGATGCCAGTAGCACTACCATAGCAGGTACCTCCTCTCACCTCCTCCAATCACAGCACT
 TCTCCCCAGTTGTCTACTGGGGTCTCTTTCTTTTCTGTCTTTTCACATTTCAAACCTCCAGTTTAAATCTCT
 CTCTGGAAGATCCCAGCACCGACTACTACCAAGAGCTGCAGAGAGACATTTCTGAAATGTTTTTGCAGATTTA
 TAAACAAGGGGGTTTTCTGGGCTCTCCAATATTAAGTTCAGGCCAGGATCTGTGGTGGTACAATTGACTCTG
 GCCTTCCGAGAAGGTACCATCAATGTCCACGACGTGGAGACACAGTTCAATCAGTATAAAACGGAAGCAGCCT
 CTCGATATAACCTGACGATCTCAGACGTACGCGTGAAGTATGTGCCATTTCTTTCTCTGCCAGTCTGGGGC
 TGGGGTGCCAGGCTGGGGCATCGCGCTGCTGGTGTCTGTGTTCTGGTTGCGCTGGCCATTGTCTATCTC
 ATTGCCTTGGCTGTCTGTCAAGTCCGCGCGAAAGAACTACGGGCAGCTGGACATCTTTCCAGCCCGGGATACCT
 ACCATCCTATGAGCGAGTACCCACCTACCACACCCATGGGCGCTATGTGCCCCCTAGCAGTACCGATCGTAG
 CCCCTATGAGAAGGTTTCTGCAGGTAATGGTGGCAGCAGCCTCTCTTACACAAACCCAGCAGTGGCAGCCACT
 TCTGCCAATTGATGGCGGCGCTTACGTACATTCGACGGCTCTTATCCAAAAGACAAGTTTGAGAAAATCA
 ATGGCACTTGGTACTACTTTGACAGTTTACGGCTATATGCTTGCAGACCGCTGGAGGAAGCACACAGACGGCAA
 CTGGTACTGGTTCGACAACCTCAGGCGAAATGGCTACAGGCTGGGAAGAAAATCGCTGATAAGTGGTACTATTTT
 AACGAAGAAGTGCCATGAAGACAGGCTGGGTCAAGTACAAGGACACTTGGTACTACTTAGACGCTAAAGAAG
 GCGCCATGCAATACATCAAGGCTAACTCTAAGTTCAATGGTATCACTGAAGGCGTCATGGTATCAAATGCCTT
 TATCCAGTCAGCGGACGGAACAGGCTGGTACTACCTCAAACCAGACGGAACACTGGCAGACAGGCCAGAATGA

FIG. 28B. MUC1-CPC polypeptide sequence (SEQ ID NO.50)

MTPGTQSPFFLLLLLVLTVTVTGSGHASSTPGGEKETSATQRSSVPSSTEKNAVSMSTSSVLSSHSPGSGSSTT
 QQQDVTLPATEPASGSAATWGQDVTSVPVTRPALGSTTPPAHDVTSAPDNKPAPGSTAPPAHGVTSAPDTRP
 PPGSTAPPAHGVTSAPDTRPPPGSTAPAAHGVTSAPDTRPAPGSTAPPAHGVTSAPDNRPALASTAPPVHNVT
 SASGSASGSASTLVHNGTSARATTTASKSTPFSIPSHSDTPTTLASHSTKTDASSTHHSTVPPLTSSNHST
 SPQLSTGVSFFLSFHISNLQFNSSLEDPSDYYQELQRDISEMFLQIYKQGGFLGLSNIKFRPGSVVQLTL

AFREGTINVHDTVETQFNQYKTEAASRYNLTISDVSVSDVPFPFSAQSGAGVPGWGIALLVLCVLVALAIVYL
IALAVCQCRRKNYGQLDIFPARDTYHPMSEYPTYHTHGRYVPPSSTDRSPYEKVSAGNGGSSLSYTNPAVAAT
SANLMAAAYVHSDGSYPKDKFEKINGTWYYFDSSGYMLADRWRKHTDGNWYWFNDSGEMATGWKKIADKWYF
NEEGAMKTGWVKYKDTWYYLDAKEGAMQYIKANSKFIGITEGVMVSNAFIQSADGTGWYYLKPDGTLADRPE

FIG.29. ss-CPC-MUC1 construct and sequence

FIG. 29A. DNA sequence (SEQ ID NO.51)

ATGGGATGGAGCTGTATCATCCTCTTCTTGGTAGCAACAGCTACAGGTGTCCACTCCCAGGTCCAAATGGCGG
CCGCTTACGTACATTCGACGGCTCTTATCCAAAAGACAAGTTTGAGAAAATCAATGGCACTTGGTACTACTT
TGACAGTTTCAGGCTATATGCTTGACAGACCGCTGGAGGAAGCACACAGACGGCAACTGGTACTGGTTCGACAA
TCAGGCGAAATGGCTACAGGCTGGAAGAAAATCGCTGATAAGTGGTACTATTTCAACGAAGAAGGTGCCATGA
AGACAGGCTGGGTCAAGTACAAGGACACTTGGTACTACTTAGACGCTAAAGAAGGCGCCATGCAATACATCAA
GGCTAACTCTAAGTTCATTGGTATCACTGAAGGCGTCATGGTATCAAATGCCTTTATCCAGTCAGCGGACGGA
ACAGGCTGGTACTACCTCAAACAGACGGAACACTGGCAGACAGGCCAGAAATGACACCGGGCAGCCAGTCTC
CTTCTTCTCTGCTGCTGCTCCTCACAGTGCTTACAGTTGTTACAGGTTCTGGTTCATGCAAGCTCTACCCAGG
TGGAGAAAAGGAGACTTCGGCTACCCAGAGAAGTTCAGTGCCCGAGCTCTACTGAGAAGAATGCTGTGAGTATG
ACCAGCAGCGTACTCTCCAGCCACAGCCCCGGTTCAGGCTCCTCCACCACTCAGGGACAGGATGTCACTCTGG
CCCCGGCCACGGAACAGCTTCAGGTTACAGTGCCACCTGGGGACAGGATGTACCTCGGTCCCAGTCACCGAG
GCCAGCCCTGGGCTCCACCACCCCGCCAGCCACGATGTACCTCAGCCCCGACAAACAAGCCAGCCCCGGGC
TCCACCGCCCCCCCCAGCCACGGTGTACCTCGGCCCGGACACCAGGCCGCCCCCGGGCTCCACCGCCCCG
CAGCCACGGTGTACCTCGGCCCGGACACCAGGCCGCCCCCGGGCTCCACCGCGCCCGCAGCCACGGTGT
CACCTCGGCCCGGACACCAGGCCGCCCCCGGGCTCCACCGCCCCCCCCAGCCATGGTGTACCTCGGCCCG
GACAAAGAGCGCCCTTGGCGTCCACCGCCCCCTCAGTCCACAATGTACCTCGGCCTCAGGCTCTGCATCAG
GCTCAGCTTCTACTCTGGTGCAACGGCACCTCTGCCAGGGCTACCACAACCCAGCCAGCAAGAGCACTCC
ATTCTCAATTCCCAGCCACCACTCTGATACTCCTACCACCTTGCCAGCCATAGCACCAAGACTGATGCCAGT
AGCACTCACCATAGCAGGTACCTCCTCTCACCTCCTCCAATCACAGCACTTCTCCCCAGTTGTCTACTGGGG
TCTCTTTCTTTTTCTGTCTTTTACATTTCAAACCTCCAGTTTAATTCCTCTCTGGAAGATCCCAGCACCGA
CTACTACCAAGAGCTGCAGAGAGACATTTCTGAAATGTTTTTGAGATTATAAACAAGGGGGTTTTCTGGGC
CTCTCCAATATTAAGTTCAGGCCAGGATCTGTGGTGGTACAATTGACTCTGGCCTCCGAGAAGGTACCATCA
ATGTCCACGACGTGGAGACACAGTTCAATCAGTATAAACGGAAGCAGCCTCTCGATATAACCTGACGATCTC
AGACGTCAGCGTGAGTGATGTGCCATTTCCCTTCTCTGCCAGTCTGGGGCTGGGGTGCCAGGCTGGGGCATC
GCGCTGCTGGTGTGTCTGTGTTCTGGTTGCGCTGGCCATTGTCTATCTCATTGCCTTGGCTGTCTGTCACT
GCCGCCGAAAGAACTACGGGCAGCTGGACATCTTTCAGCCCCGGATACCTACCATCCTATGAGCGAGTACCC
CACCTACCACACCCATGGGCGCTATGTGCCCCCTAGCAGTACCGATCGTAGCCCTATGAGAAGGTTTCTGCA
GGTAATGGTGGCAGCAGCCTCTCTTACACAAACCCAGCAGTGGCAGCCACTTCTGCCAACTTGTAG

FIG. 29B. ss-CPC-MUC1 protein sequence Polypeptide sequence (SEQ ID NO.52)

MGWSCIILFLVATATGVHSQVQMAAAYVHSDGSYPKDKFEKINGTWYYFDSSGYMLADRWRKHTDGNWYWFDN
 SGEMATGWKKIADKWYFNEEGAMKTGWVKYKDTWYYLDAKEGAMQYIKANSKFIGITEGVMVSNAFIQSADG
 TGWYYLKPDGTLADRPEMTPGTQSPFFLLLLLTVLTVVTGSGHASSTPGGEKETSATQRSSVPSSTEKNAVSM
 TSSVLSSHSPGSGSSTTQGDVTLAPATEPASGSAATWGQDVTSVPVTRPALGSTTPPAHDVTSAPDNKPAPG
 STAPPAHGVTSAPDTRPPPGSTAPPAHGVTSAPDTRPPPGSTAPAAHGVTSAPDTRPAPGSTAPPAHGVTSAP
 DNRPALASTAPPVHNVTASGSASGSASTLVHNGTSARATTTTPASKSTPFSIPSHHSDTPTTLASHSTKTDAS
 STHHSTVPPLTSSNHSTSPQLSTGVSFFFLSFHISNLQFNSSLEDPSTDYYQELQORDISEMFLQIYKQGGFLG
 LSNIKFRPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISDVSVSDVPFPFSAQSGAGVPGWGI
 ALLVLVCVLVALAIVYLIALAVCQCRRKNYGQLDIFPARDTYHPMSEYPTYHTHGRYVPPSSSTRSPYEKVSA
 GNGGSSLSYTNPAVAATSANL